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This thesis concerns an under-researched and, until recently, neglected category of 
schizophrenia described as “Treatment Resistant Schizophrenia” (TRS).   This applies to 
individuals who have not clinically responded to at least two trials of chemically different 
antipsychotics, at an adequate dose and duration, yet respond to clozapine.  This unique 
drug has, potentially, many therapeutic actions and is notable for its lack of extra-pyramidal 
side effects associated with antagonism at the Dopamine (D2) receptor - the target of 
conventional antipsychotics.  Consequently, the fundamental question pervading research in 
this area is whether TRS represents a distinctive aetiopathological category or whether it 
reflects greater illness severity?   
 
Epidemiological research indicates TRS may affect around 21% of individuals with 
schizophrenia, therefore, there is an urgent need to study the neurobiological substrates of 
TRS to facilitate identification and optimal treatment.   
 
AIMS AND HYPOTHESES: 
The primary aim of this research was to characterize TRS through clinical assessment, 
neuropsychological tests and an exploration of task evoked changes in the blood-oxygen-
level-dependent (BOLD) signal at different levels of cognitive load during a verbal n-back 
working memory task, using functional magnetic resonance imaging along with the 
exploration of the association between the BOLD signal and clinical correlates.  
It was hypothesised that:   
1)  TRS individuals would show attenuated engagement of an “executive” fronto-parietal 
network during working memory processing compared to controls. 
2) Brain areas exhibiting altered haemodynamic response would include the cingulate 
gyrus and would be associated with task performance and symptom severity. 
 
Secondary aims included the exploration of the association between clinical and cognitive 
variables and between BOLD signal, clinical and cognitive outcome measures. 
 
METHODS:   
Twenty-six individuals with TRS, medicated with clozapine, and 21 healthy control 
participants performed a verbal n-back working memory task in a 3-Tesla GE Signa 
Neurovascular MR system.  This task had three levels of cognitive load (1-, 2-, 3-back).  
TRS participants were assessed with the Positive and Negative Syndrome Scale (PANSS) to 
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measure symptom severity, the Wechsler Abbreviated Scale of Intelligence (WASI) and 
MATRICS Consensus Cognitive Battery (MCCB).  Functional MRI data were analysed 
using XBAM_v4.1 software which uses a non-parametric approach. The interaction of 
group and task condition (cognitive load) was explored using ANCOVA.  Groups 
comprised: a) TRS participants and controls; b) TRS divided according to PANNS scores 
(lower PANNS:  median total score=41; higher PANNS:  median total score=66).  Age was 
a covariate in all imaging analyses. 
 
RESULTS:   
The group with the higher level of pathology (TRS participants relative to controls) 
displayed attenuated haemodynamic responses with increasing cognitive load in the  
right middle frontal gyrus and left frontal gyrus, left middle temporal gyrus and 
parahippocampal gyri bilaterally, the right thalamus, right parietal lobe, right precuneus and 
left lingual gyrus.  They also showed increased haemodynamic responses in the left 
superior/medial frontal gyrus, left cingulate (anteriorly and posteriorly), the right putamen 
and left paracentral lobule. 
 
Similarly, the higher PANSS group exhibited an attenuated haemodynamic response with 
increasing cognitive load in the left claustrum and left frontal gyrus relative to the lower 
PANSS group, as well as increased haemodynamic responses in left superior frontal, right 
medial frontal and right postcentral gyri. 
 
The behavioural and neuropsychological analyses in the TRS group revealed estimated IQ 
scores clustered around the peak of the normal distribution yet scores on the MCCB tests 
were consistently depressed relative to standardisation norms for the general population.  
Also, scores were superior in the lower PANSS group on the speed of processing composite, 
the test of visual learning, and for attention and vigilance, all at trend level significance.  
Further, exploratory correlations revealed negative symptoms were strongly associated with 
decrements in attention and with estimated full-scale IQ and verbal IQ scores.   
 
CONCLUSIONS: 
Clozapine can ameliorate long-standing symptoms in TRS and has been demonstrated to 
have a wide range of biological effects.  This study showed that with increasing working 
memory load there was a pattern of attenuation in the haemodynamic response during the 
working memory task in the groups with the higher level of pathology (i.e. TRS relative to 
control participants and higher PANSS relative to lower PANSS participants) which 
implicated “connector hubs” which is suggestive of a pathology affecting long range 
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communication.  The altered haemodynamic response included brain areas which are part of 
an “executive” network as well as a “default mode network”.  This pattern of activity might 
reflect hyperactivity in the default mode network undermining activity in the cognitive 
control fronto-parietal executive network, possibly through microlapses in attention.   
 
At a cognitive level, the lower PANSS group performed better than the higher PANSS 
group on tests of learning and attention. On the basis of these findings, a tentative 
conclusion is proposed that clozapine may help to restore function in the prefrontal cortex 
and other areas involved in working memory and further aspects of higher cognition. The 
results are subject to qualification by several limitations including participant selection, the 
likelihood that lower vs higher PANSS comparisons may be under-powered and the cross-
sectional design of the study.  In spite of these limitations, this study provides a framework 
that may contribute to understanding the neuroanatomical alterations associated with TRS. 
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Abbreviations and Definitions 
 
1H-MRS:  Proton magnetic resonance spectroscopy - a neuroimaging method that enables 
the measurement of metabolite concentrations in a noninvasive way. 
 
ACC:  Anterior Cingulate Cortex. 
Forms part of the medial wall of the frontal lobe and lies medially to the dorsolateral 
prefrontal cortex and superiorly to the corpus callosum which it follows anteriorly around 
the curve of the genu to the rostral area below.   
 
ADHD:  Attention deficit hyperactivity disorder. 
 
AST:  Associative Striatum.  
Lies within the pre and post-commissural areas of the caudate and putamen, not readily 
localised, rather it is defined by its cortical afferents associated with higher cognition, 
especially the dorsolateral prefrontal cortex (DLPFC), a major hub of striatal-thalamo-
cortical circuity which also integrates inputs from other parts of the limbic system, which 
include the hippocampus, amygdala, thalamus and hypothalamus. 
 
CPT:  Continuous Performance Task;  CPT-DS (degraded stimuli version);  CPT-IP 
(identical pairs version);  CPT-X (is it’ X’?) 
 
CATIE: Clinical Antipsychotic Trials of Intervention Effectiveness.  Conducted at 57 sites 
this study compared the efficacy of atypicals compared with a first-generation antipsychotic 
in chronic schizophrenia as measured by any/all-cause discontinuation rates over an 18-
month period.  
 
Conventional Antipsychotics: also known as “first generation”, “neuroleptic medication”, 
“typicals.” medication which have clinical efficacy through antagonism at the dopamine D2 
receptor.  Clozapine may also be described as a first generation antipsychotic but has 
atypical actions. 
 
CAR: Cortisol awakening response - a sharp increase in cortisol associated with awakening. 
 




DA:  Dopamine. 
 
DLPFC:  Dorsolateral Prefrontal Cortex.   
 
DMN:  Default Mode Network 
 
DS-CPT:  Degraded stimulus version of a continuous performance task. 
 
DSM-5: Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, 2013. 
 
DUP:  Duration of untreated psychosis.  Criteria vary but usually refers to the period from 
the onset of symptoms during the prodrome before diagnosis. 
 
EOS:  Early onset schizophrenia. 
 
EPSE:  Extra-pyramidal side effects. 
 
FA:  fractional anisotropy - a measure of white matter integrity. 
 
FEP:  First episode of psychosis (usually the first admission of psychiatric hospital). 
 
FLRS:  First Line Responsive Schizophrenia- a term borrowed from Anderson et al., 2015,  
to differentiate individuals who clinically respond to first line antipsychotic treatments. 
 
fMRI BOLD signal:  Functional magnetic resonance blood-oxygen-level-dependent signal 
exploits differences in magnetic susceptibility of oxyhaemoglobin and deoxyhaemoglobin to 
provide a measure of oxygen delivery to local neural tissue 
 
GABA:  Gamma-aminobutyric acid is the major inhibitory neurotransmitter of the 
mammalian central nervous system. 
 
GAD:  Glutamic acid decarboxylase synthesises GABA from glutamate. The isoform 
GAD65 concentrated around the synapses is transiently active.  GAD67 which produces 
most of the GABA in the brain is constitutively active and is more widely distributed in 
neurons (e.g. in the cytosol and around axons).   
 




HVA:  Homovanillic acid. 
 
HVLT-R: The Hopkins Verbal Learning Test - Revised™. 
 
MAM:  mitotoxin methylazoxymethanol acetate is used in a rodent developmental model of 
schizophrenia. Administered to a pregnant rat on gestational day 17 this stimulates a 
maternal immune response and a schizophrenia-like phenotype in offspring which emerges 
around puberty. 
 
MCCB:  The MATRICS Consensus Cognitive Battery. 
 
MDMA:  3,4-Methylenedioxymethamphetamine (Ecstasy). 
 
NMDA / NMDAR:  N-methyl-D-aspartate receptor.  An ionotropic glutamate receptor 
which will only admit (chloride) ions if the cell bearing the receptor is in a depolarised/ 
firing state as this removes a magnesium block from the ion channel. 
 
NAA: Cr ratio: N-acetylaspartate: Creatine.  NAA is a marker of neuronal integrity and 
associated with lipid synthesis for myelination and, possibly, mitochondrial energy 
production. 
  
NAc (Nucleus Accumbens)/ Ventral Striatum:  A key part of the circuitry mediating 
reward.  The NAc lies medial to the caudate, and rostral to the preoptic area of the 
hypothalamus where it “leans against” the septum.  Haber (2016) describes the NAc as 
being part of ventral striatum.  It is also part of the amygdaloid complex. 
 
PCC:  posterior cingulate cortex - comprises several areas (Vogt and Laureys, 2005, 2006); 
can include the precuneus (e.g. Andrews-Hanna et al., 2014; Leech et al. (2011). 
 
PCP:  phencyclidine. 
 
PD:  Parkinson’s disease. 
 
PET:  Positron Emission Tomography. 
 




PPI:  Pre-pulse inhibition.   
 
PVI and PV+:  Parvalbumin containing interneurons.  PV+ stain positively for parvalbumin, 
a calcium binding protein expressed by fast spiking interneurons (a sub-category of 
interneuron).   
 
PFC:  Prefrontal cortex - frontal cortex anterior to the agranular cortex of Brodmann area 6 
and parts of the paracentral gyrus.   
 
PSZ:  People with schizophrenia, i.e. the wider population, not necessarily including TRS. 
 
RCT:  Randomized control trial. 
 
rsfcMRI or rs MRI:  resting state functional connectivity MRI. 
 
ROI:  Region of interest.  
 
ROS:  Reactive Oxygen Species are negatively charged molecules (free radicals). 
 
SGAs:  Second generation antipsychotics. 
 
SSQs:  Sum of squares.  This is a goodness of fit statistic calculated at each voxel which 
indexes differences in the haemodynamic response from baseline for each of the levels of 
task difficulty.  It consists of the ratio of the sum of squares of deviations from the model 
time series mean divided by the sum of squares of deviations from residuals.  The null 
distribution of SSQs assumes no response due to the experiment, is then tested using the 
wavelet permutation method which is described by Bullmore et al. (1999, 2001). 
 
Striatum:  The component nuclei of the striatum vary across texts, but the term literally 
means “striped body” which provides an apt description of the white fibres of the external 
capsules which largely divide the main components, the caudate and putamen on the 
superior aspect.  Small white fibres (“Wilson’s pencils”) also traverse the area towards the 
globus pallidus.  The dorsal striatum comprises the caudate and putamen, while the ventral 
striatum comprises the nucleus accumbens and olfactory tubercle.  Striatal structures are 
packed with medium spiny projection neurons, the combined effect of which is to provide a 
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major GABAergic inhibitory drive to the thalamus via direct and indirect pathways as 
described in Haber (2016). 
 
SPECT: single-photon computerized emission tomography 
 
TNN:  task negative network - “identified on the basis of both spontaneous correlations 
within each network and anticorrelations between networks” using resting state functional 
connectivity MRI (Cauda et al., 2010). 
 
TPN:  task positive network.   
 
TRS:  Treatment resistant schizophrenia. 
 
Typicals:  Also known as “first generation” antipsychotics or “conventional neuroleptics.”  
These drugs are antagonists at the dopamine D2 receptor. 
 
UFM:  Unaffected family member who is a first-degree relatives of an individual with 
schizophrenia. 
 
U-TRS:  Ultra-treatment resistant schizophrenia (where individuals do not clinically 
respond to typical, atypical antipsychotics or clozapine at an adequate dose or duration). 
 
VENs: von Economo or “spindle neurons” found at high density in the core nodes of the 
salience network (ACC and insula; also in the DLPFC). 
 
VIQ:  Verbal IQ. 
 
VLPFC:  Ventrolateral prefrontal cortex. 
 
vmPFC:  Ventromedial prefrontal cortex. 
 
VTA: Ventral Tegmental Area: lies on the ventral surface of midbrain around midline and 
contains a large population of dopaminergic cells which receives afferents from the 
hippocampus and brainstem and projects to the striatum.  
 




Some Network Terminology 
 
Betweenness centrality:  In graph theory this is a measure of how frequently an area is used 
to communicate with another, so it also indicates the importance of a hub in the optimal 
organisation of pathways.  Therefore, “connector hubs” have high betweenness centrality.  
Prime examples are the ACC and insula which form the salience network 
 
LFP:  Local Field Potential: “electric potential generated in a volume of neural 
tissue by a local population of neurons. LFPs result from the flow of current in 
the extracellular space generated by electromotive forces operating across the 
cell membranes of neurons, principally at synapses” - Bressler and Menon (2010) 
 
SCP:  Slow cortical potential:  a local field potential with slow oscillatory activity for 
example, in the delta band - which correlates with fMRI BOLD measures in the resting state 
(Raichle, 2009).  
 
Task positive activity:  involves outwardly directed attention, as opposed to “task negative 
activity” involving internal mentation such as day-dreaming, self-reflection, planning and 
the prospective use of memory associated with DMN activity.    
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Chapter I - INTRODUCTION 
 
1.1   The Burden of Schizophrenia 
Schizophrenia is a devastating disorder which, for many, has an onset during adolescence or 
young adulthood, blighting the prospects of young lives.  This is evidenced by a high risk of 
suicide, which was reported to be 8.5 times higher than might be expected in western 
populations (Harris and Barraclough, 1997).  While, more recently, an epidemiological 
study of a cohort of 8624 individuals with schizophrenia from the Danish national register 
by Wimberley et al., 2016, revealed especially high levels of suicide attempt associated with 
treatment resistant schizophrenia (TRS) at 27 - 30% (depending on the definition) and 15% 
for other categories of schizophrenia. 
 
Individuals with schizophrenia are also more likely to die at a younger age from physical 
illnesses which, at first sight, appear to be unrelated to schizophrenia or its treatment 
(McGrath et al., 2008;  De Hert et al., 2011).  The adverse social and economic impact of 
chronic and disabling illness seems an inadequate explanation, although a higher prevalence 
of smoking could be a contributory factor (Salokangas et al., 2006). 
 
Schizophrenia has been ranked by the World Health Organisation as one of the top ten 
illnesses that contributes to the burden of disease (Murray and Lopez 1996).  In one 
systematic review covering 46 countries, regional estimates of the lifetime risk ranged from 
0.3 - 2.0%, with an average of 0.7% (Saha et al., 2005).  This variation may partly reflect 
differences in diagnostic criteria, however, an examination of the incidence of new cases by 
Tandon et al. (2008) pointed to urbanisation, migration and industrialisation contributing to 
higher rates.  They suggested increased exposure to environmental toxins, disease, vitamin 
D deficiency, poverty, access to drugs of abuse and a loss of social support as possible 
factors.  Moreover, all these may negatively impact upon maternal health and the prenatal 
and perinatal health of children, which might also affect the prevalence of schizophrenia 
which is now widely considered to be a neurodevelopmental disorder (Murray et al., 2017). 
 
1.2  The DSM-5 Definition of Schizophrenia 
The highly influential diagnostic manual of the American Psychiatric Association, DSM-5 
(Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, 2013) has recently 
made a number of important changes concerning the diagnosis of schizophrenia.  It is now 
stipulated that an individual must have experienced at least two symptoms, from a list of 
five, for a minimum of a month:  delusions, hallucinations, disorganised speech, 
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disorganised or catatonic behaviour, or negative symptoms.  Also, at least one of the 
symptoms should be from the first three “positive” items in the list.  The severity of 
symptoms is also considered and there is an expectation of deterioration from premorbid 
function, or underachievement where onset arises during childhood or adolescence.  Further, 
some symptomatology, with deterioration in occupation or social function must be present 
for at least 6 months, albeit in attenuated form, but including one month of “active 
symptoms - shorter if responsive to treatment.  Alternative illnesses should be ruled out1.  
Tandon, et al. (2013), commented cognitive symptoms are a common feature, however they 
are not diagnostic of schizophrenia and so were not included in DSM-5).   
 
DSM-5 has also firmly placed the diagnosis of schizo-affective disorder within 
schizophrenia by requiring that individuals must meet the criteria for schizophrenia first 
before an affective component is added.  Another important change is the removal of 
longstanding sub-categories: “paranoid”, “disorganized”, “catatonic”, “undifferentiated”, 
and “residual type” as they were deemed by the American Psychiatric Association (2013) to 
have “limited diagnostic stability, low reliability, and poor validity.”  More fundamentally, 
the abandonment of categories may reflect disillusion with the way this complex disorder 
has been conceptualised.  However, there may still be a case for sub-categories and this 
thesis sets out evidence which suggests the future inclusion of TRS as a sub-category could 
be an important step for research purposes and have implications for diagnosis and 
treatment.  First, as relatively few studies have specifically addressed TRS, this needs to be 
set within a broader context of schizophrenia research. 
 
1.3  A Diversity of Symptoms 
Schizophrenia has many manifestations involving a heterogeneous range of symptoms 
where no individual symptom is necessary or sufficient for a diagnosis.  However, the 
classification of some symptoms as “positive” or “negative” has proved useful.  Briefly 
summarised, positive symptoms describe an “excess” of behaviour or perceptions, such as 
hallucinations and delusions, whereas negative symptom suggest a deficit, for example, 
“alogia”, “anergia”, “avolition.”  These ideas were the basis of scales developed by  
Crow (1980) and Andreasen (1982, 1989) which were later incorporated into the 30-item 
Positive and Negative Syndrome Scale (PANSS) which comprises three subscales: positive, 
negative and general (Kay, Opler, and Lindenmayer 1987; Kay, Opler, and Lindenmayer 
 
1 Steiner et al. (2013; 2014) observed some individuals with antibodies to the N-methyl-D-aspartate 
receptor (NMDA receptor or NMDAR) “with disorganized and catatonic features of schizophrenia 
may be misdiagnosed encephalitis cases”, p. E6. 
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1988).  Moreover, there appears to have been an early consensus that positive symptoms 
may be associated with excessive dopamine release in the striatum during active psychosis 
(Sartorius et al., 2009).   
 
However, the basis of negative or “deficit” symptoms has been less clear, i.e. there may not 
be a simple correspondence with insufficient dopamine function.  Initially, Kay et al. (1988) 
suggested scores on the positive and negative scales might be anti-correlated.  However, this 
has not been supported, possibly because the items may reflect more than one dimension 
(Blanchard and Cohen 2006).  Indeed, just as the classification of symptoms in the DSM-5 
has not been without debate, Kay et al. (1988) may have struggled, describing some 
symptoms as “secondary negative” (e.g. disturbance of volition, motor retardation, poor 
attention, preoccupation and depression).  These were assigned to their general scale.  
Similarly, “excitement” was not classified as a positive symptom but put in the general scale 
on the basis it reflects arousal.   
 
There is now more empirical evidence to support symptom dimensions and potential 
biological substrates than was available to Kay et al. (1998) and it seems the general scale 
reliably disappears in factor analyses and not all the items are retained.  An analysis of 29 
published studies by Wallwork et al. (2012) indicated factor analysis of symptoms in the 
PANSS generally yields 5 factor solutions instead of 3 (summarised in Table 1. 1 below).  
One of the more overtly cognitive items from the negative scale, “conceptual 
disorganisation”, which relates to impairment in abstract/symbolic forms of thinking, i.e. 
beyond sensory-motor representations, was reclassified into a new “disorganized/ concrete 
factor”. Another negative item, “stereotyped thinking”, disappeared entirely.  Also, 
“attentional impairment”, which was described as a negative factor in a personal 
communication from Andreasen to Kay (Kay et al., 1988) but assigned to the PANSS 
general scale (G11), emerged as a cognitive symptom under the disorganized/ concrete 
factor.  Further new factors “excited” (comprising poor impulse control, poor attention and 
hostility) and “depressed”, were self-explanatory.  Just four items were retained on the 
positive scale: “delusions”, “hallucinatory behaviour”, “grandiosity” with the further 
addition of “unusual thought content” (formerly, G9 on the general scale).  This last item 
includes symptoms with a bizarre aspect (sometimes referred to as “passivity 
phenomenon”), such as “thought broadcast” and “thought insertion”2.  
 
2 Potentially, just as auditory hallucinations have been proposed to arise from misattribution as to the 
source of auditory stimulation, a similar explanation might apply to thought insertion and thought 
broadcast.  The faulty use of feedback against expectation (“prediction error”) provides a possible 
explanatory mechanism (Shergill et al., 2005; Tracy and Shergill, 2013; Friston, 2016). 
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Table 1. 1   A 5-factor model of the Positive and Negative Syndrome Scale - based on a 
confirmatory factor analysis of 29 models by Wallwork et al. (2012) 
POSITIVE 
P1   Delusions 
P3   Hallucinatory behaviour 
P5   Grandiosity 
G9   Unusual thought content 
NEGATIVE  
N1   Blunted affect* 
N2   Emotional withdrawal 
N3   Poor rapport 
N4   Passive/apathetic social withdrawal 
N6   Lack of spontaneity & flow of conversation* 
G7   Motor retardation 
 DISORGANIZED/ CONCRETE FACTOR 
P2   Conceptual disorganisation 
N5   Difficulty in abstract thinking 
G11 Poor attention 
EXCITED 
P4   Excitement 
P7   Hostility  
G8   Uncooperativeness 
G14 Poor impulse control 
DEPRESSED FACTOR 
G2 Anxiety 
G3 Guilt feelings 
(Codes on left represent item numbers on the PANSS Scale (Kay et al., 1987):   
N = Negative, P = Positive, G = General item). 
* Subcategory: “diminished emotional expression” (Hartmann-Riemer et al., 2015).  
 
Looking across a selection of studies (including,  Nunnally and Bernstein 1994; Rodriguez-
Jimenez et al., 2013), positive, negative and “cognitive” dimensions endure, however, items 
under the cognitive dimension vary considerably (Honey et al., 2003).  The most stable 
items on the PANSS scale are those on the negative subscale as they undergo the least 
attrition and reassignment, for example, in Wallwork et al.’s model, 5/7 items (blunted 
affect, emotional withdrawal, poor rapport, passive /apathetic social withdrawal, lack of 
spontaneity and flow of conversation) were joined by “motor retardation” from the general 
scale.  Notwithstanding challenges in classifying a heterogeneous range of symptoms, the 
PANSS has been widely used and remains a valuable research tool (for example, in a multi-
centre study, Glick et al. (2015), found a reduction of 10 points in total PANSS scores 
translated to sizeable reductions in the length of hospitalisation).  As such the PANSS was 
selected for this study (Methods, section 2.6). 
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1.4  Epidemiology 
1.4.1 Outcomes and Age of Onset 
Fortunately, not everyone who develops schizophrenia will have further episodes of 
psychosis and deterioration is not inevitable, for example, in one prospective study over 15 
years, more than 50% of affected individuals did not have a course of schizophrenia that 
was “chronic or continuous” (Harrow et al., 2005).  A meta-analysis of studies by Lally et 
al. (2017), relating to more than 12,000 individuals (including some with an affective 
psychosis) revealed remission rates after a first episode of psychosis (FEP) of around 58% at 
an average follow-up of 5.5 years.  Further, a cross-sectional study of prescribing practices 
for 5055 individuals with schizophrenia and schizo-affective disorder in England and Wales, 
estimated that 21.4% of individuals were in full remission and 50.2% were in partial 
remission with minimal symptoms.  However, 28.4% were not in remission or still had 
substantial symptoms or disability (Patel et al., 2014).   
 
These observations provide a welcome correction to the impression that schizophrenia has a 
relentlessly bleak prognosis.  Importantly, Zipursky et al. (2013) have proposed where 
illness does progress this could be due to a lack of appropriate treatment, social and 
financial poverty, so “mental health professionals need to join with patients and their 
families in understanding that schizophrenia is not a malignant disease that inevitably 
deteriorates over time but rather one from which most people can achieve a substantial 
degree of recovery.” (p.1363) 
 
Nonetheless, relapse, or the persistence of certain symptoms are major problems and 
epidemiological studies have identified subgroups; for example, one study of medical 
records in the Israeli population over three decades identified 2290 individuals with 
schizophrenia from a cohort of all those born between 1970-1988 and revealed four 
different trajectories based on the annual average number of days in hospital (Levine et al., 
2011).  The largest group (57%) had a mean age of onset of 20 years and spent an average 
of 44 days in hospital upon first admission and 48 on the last.  While another group 
comprising 15.5% had a first admission at the mean age of 17.1 years. The trajectories of 
both groups revealed substantial recovery by the age of 23 years.  (A similar stabilisation 
was observed by Lally et al. (2017).  However, 12% of the cases in Levine et al. (2011), had 
a mean age of onset around 18 years and a progressive course indicated by lengthening 
periods of hospitalisation.  Their fourth group was characterised by a later age of onset 
(mean 29 years) and comprised a significantly higher proportion of males (72.7%), although 
it was observed this may have changed with an extended age range.   
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1.4.2 Sex Differences 
This is quite possible as the distribution of onset for women is markedly different, with a 
later and broader range of onset (Abel, Drake and Goldstein 2010; Aleman, Kahn, and 
Selten, 2003).  Interestingly, there may be an increased incidence around major hormonal 
changes such as puberty, childbirth and the menopause, even across the menstrual cycle 
(Riecher-Rossler et al., 1994; Markham, 2012).  Associations between cognitive impairment 
and menstrual irregularity (or post-menopause) have also been reported, for example, in a 
sample of 242 healthy women by Gurvich et al. (2018), bolstering conjecture that some 
neural protection may be afforded by female sex hormones which are also synthesised in the 
brain as neurosteroids (Seeman 1997; Hafner et al., 1991), during development and in the 
mature brain (Cutter, Norbury, and Murphy 2003).  In one study, peak bone density (used as 
a marker of lifetime exposure to estrogen) was one standard deviation lower in women with 
schizophrenia compared with a control group matched for education, age and other 
characteristics (Maric et al., 2005).  
 
At least two estrogen hypotheses of schizophrenia has been proposed - as reviewed by 
Hayes et al. (2012):  one emphasises the potentially protective effects of estrogen and 
related sex hormones, while the other proposes a deficiency.  More specifically, Hayes et al. 
(2012) referencing Adams et al. (2004), observed “Oestradiol is known to upregulate 
NMDA receptors, change their subunit configuration, and increase NMDA agonist binding 
in the rat brain, which could presumably help reverse hypoactive glutamatergic functioning 
in schizophrenia.” (p.3)3     
 
The dopamine system may also be affected, for example, in one preclinical study, Chavez et 
al. (2010), demonstrated that following ovariectomy, estrogen treatment could completely 
reverse consequent decrements in the dopamine transporter DAT and changes in the density 
of D2 receptors in the nucleus accumbens and caudate nucleus, while leaving serotonergic 
aspects unaffected.   
 
It is also interesting that the only drug with superior efficacy for TRS, clozapine, has been 
shown to greatly increase the neurosteroid and sex hormone pregnenolone in the rat 
hippocampus (Marx et al., 2006).  Pregnenolone has been described as being 
neuroprotective and enhancing “learning and memory, myelination, and microtubule 
polymerization” and, potentially, may also have downstream effects at GABA-A and 
NMDA receptors (Marx, 2014).  The use of pregnenolone as an adjunctive treatment for 
 
3  N-methyl-D-aspartate receptor, or NMDAR. 
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schizophrenia was further explored in a randomised control trial (RCT) in a study of 120 
individual receiving first or second-generation antipsychotics.  After 8 weeks, improvements 
in functional outcomes were observed in the pregnenolone group relative to placebo, yet 
without cognitive improvement.  Nor were negative symptoms ameliorated, however, they 
were low at baseline (Marx et al., 2014), but another RCT by Ritsner et al., 2014 did report 
significant benefit.  Also, cognitive improvements, including visual attention, were observed 
in a small RCT by Kreinin et al. (2014).   
 
Group characteristics, including symptoms at baseline and the type of adjunctive 
medication, dosage and duration could all help to account for differential findings.  In 
another RCT of 12 weeks duration by Kulkarni et al. (2015) using raloxifene hydrochloride 
(a “selective estrogen receptor modulator” to prevent osteoporosis), reported significant 
reductions in symptom severity in their group of 56 individual with treatment refractory 
schizophrenia or schizo-affective disorder.  Emerging evidence therefore suggests the 
actions of sex steroids could cast some light on the pathophysiology of schizophrenia and be 
used as adjunctive medication. 
 
1.5 Can schizophrenia be treated?  The discovery of antipsychotics 
Although a biological basis for schizophrenia seemed apparent to Kraepelin, who identified 
and described the illness as a dementia of youth (1887), there was a long period during the 
last century when psychological theories were to the fore, as exemplified by the judgemental 
sounding notion of the “schizophrenogenic mother” which gained currency during the 
1970’s (Harrington, 2012;  Neill, 1990).  By that time however, the first antipsychotic, 
chlorpromazine, a chlorinated phenothiazine, had been trialled in Paris after an army 
surgeon, Henri Laborit, had noted the calming effect of this anaesthetic.  When eventually 
tested in psychiatric patients, it was observed to attenuate the symptoms of psychosis within 
just three days (Delay and Deniker 1952).  Another drug, haloperidol - a butyrophenone 
synthesised in 1958 in Paul Janssen’s laboratory as an analgesic, was observed in rodent 
studies to have similar effects to chlorpromazine (Granger and Albu 2005).  Carlson and 
Lindqvist (1963) proposed these drugs blocked monoamine transmission, preparing the 
ground for van Rossum’s insight that the efficacy of antipsychotics might arise from their 
ability to suppress dopaminergic activity (van Rossum, 1966; Madras, 2013).  
 
In the same era, there was another serendipitous discovery when clozapine, which had been 
synthesised in 1958 as a tricyclic antidepressant, was found to have antipsychotic properties.  
According to Crilly (2007), by 1966 clozapine had been trialled in 100 individuals with 
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schizophrenia and in 1973 it was being marketed in several European countries.  Clozapine 
greatly benefitted some patients who did not respond to conventional antipsychotics, or 
those who were developing extra-pyramidal side effects (EPSE) such as irreversible tardive 
dyskinesia4.  In 1974, clinical trial data in the USA indicated clozapine could cause 
hypotension in healthy individuals, informing titration regimes (Honigfeld, 2005)5. 
However, progress was abruptly halted when clozapine was withdrawn from several 
countries in 1975 after a cluster of deaths in Finland from agranulocytosis.  The 
pharmaceutical company, Sandoz, ended its research program the following year but 
continued to supply clozapine on compassionate grounds.  Eventually, incentivised by 
legislative changes, including repatenting (Crilly, 2007), a double-blind comparison with 
chlorpromazine was conducted which established clozapine’s superior efficacy for positive 
and negative symptoms in individuals “refractory to neuroleptics” (Kane et al., 1988). 
Clozapine was reintroduced under licence in the UK in 1990 and also in North America and 
is now prescribed according to a protocol which requires regular monitoring of white blood 
cell counts. 
 
In the years that followed, a second generation of drugs (often called “atypicals”) were 
developed which were partly inspired by the low liability for EPSE of clozapine.  They were 
successful in so far as the drugs were effective antipsychotics and had different side-effect 
profiles from the first generation.  However, an unexpected finding of a multi-centre study 
(the CATIE6 trials) was that overall clinical efficacy of the four comparison drugs (as 
measured by “any-/all cause treatment discontinuation” was not superior to a first generation 
antipsychotic perphenazine which tends to cause fewer EPSE than haloperidol.  Only 
olanzapine, chemically more similar to clozapine, had lower rates of discontinuation despite 
a marked liability for weight gain and other metabolic side effects (Liebermann et al., 2005; 
Stip et al., 2007).   
 
 
4 The margin between clinical efficacy and side effects seems quite narrow - the appearance of EPSE 
was regarded by some as a sign that an adequate dose had been achieved: “The more pronounced the 
extrapyramidal symptoms, the better the antipsychotic effect” (Crilly, 2007, pp.41, 42).  In support a 
double-blind study of first-episode participants indicated: “The likelihood of clinical response, 
hyperprolactinemia, and extrapyramidal side effects increased significantly as D (2) occupancy 
exceeded 65%, 72%, and 78%, respectively.” - Kapur, 2000.   
 
5 Personal interview by John Crilly, 1–2 Aug. 2005, referenced in Crilly, 2007. 
 




Therefore, it seems there have been no major drug discoveries on a par with those of 
clozapine and the first generation.  More recently, pharmaceutical companies have largely 
discontinued their costly investments (an account is provided in Bullmore, 2018).  
Nonetheless, some research initiatives continue, such as the RCTs into progesterone, 
estrogen, related hormones and metabolites by Marx and colleagues mentioned above.  
Advances across many areas of science, including genetics are also facilitating integrative 
and systems approaches to understanding schizophrenia, which may lead to better 
treatments. 
 
1.5.1  The Dopamine Hypothesis - “the fuel that stokes the psychotic fire”7 
Support for van Rossum’s idea (1966) that dopamine might have an important role in the 
symptoms of schizophrenia came from Seeman and Lee (1975; 1995) who demonstrated an 
impressive correlation between the average doses at which various antipsychotic drugs have 
clinical efficacy and their ability to block the release of dopamine upon electrical 
stimulation of the rodent striatum. Further support came from observations that 
psychostimulants like amphetamine, which increases dopamine availability in the striatum8, 
could worsen or precipitate the transient emergence of positive symptoms in individuals 
with schizophrenia (Laruelle and Abi-Dargham, 1999). 
Hall et al. (1994) provided useful information about the distribution of Dopamine D1 and 
D2 receptors throughout the human brain, but observations from postmortem studies 
concerning the density of D2 and D2-like receptors in schizophrenia, where antipsychotics 
are thought to exert their main therapeutic effect (Steeds et al., 2015), have been difficult to 
interpret because antipsychotic treatment is known to upregulate these (Laruelle and Abi-
Dargham, 1999, Muller and Seeman, 1978).  However, non-invasive in vivo neuroimaging 
methods such as single-photon computerized emission tomography (SPECT) and positron 
emission tomography (PET) have provided clear evidence of dopamine dysregulation: for 
example, one early SPECT study that used a dopamine depletion paradigm to “unmask” 
receptors observed elevations in striatal D2 receptor availability (indexed by increased 
binding of a radioligand) in participants with schizophrenia who were either antipsychotic 
naïve or newly relapsed and untreated (Abi-Dargham et al., 2000).  The upregulation of 
 
7 From Kapur (2003), echoes the imagery of Laruelle and Abi-Dargham’s (1999) paper ‘Dopamine as 
the wind of the psychotic fire: new evidence from brain imaging studies’, and alludes to the intensity 
and, perhaps also destructive aspects of the psychotic experience. Similarly, Kay Redfield-Jamieson’s 
(1993) book “Touched by fire” concerns creativity in people who have experienced mental illness. 
 
8 According to Slifstein et al. (2015) amphetamine increases synaptic concentrations by reversing the 
dopamine transporter.  (Their ref:  Sulzer D, Maidment NT, Rayport S, 1993). 
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receptors, relative to healthy controls, was tentatively interpreted as a sign of increased 
availability of synaptic dopamine, higher affinity for D2 receptors or a combination of both 
(p.8108).  (Although upregulation might also occur where there is a lack of stimulation, as 
proposed by Abi-Dargham et al., 2002 concerning increases in D1 receptor in the prefrontal 
cortex in medication free or neuroleptic naïve individuals with schizophrenia).   
Compatible with the idea that striatal hyperdopaminergia underlies positive symptoms, high 
baseline levels of dopamine predicted “better or faster” clinical responses.  Notwithstanding 
the lower risk of EPSE, it was concluded D2 antagonism at an early stage is an important 
mode of action of atypicals, however, it was acknowledged there were some individuals 
who exhibited positive symptoms yet did not show alterations in dopamine levels:  “In these 
patients, psychotic symptoms may reflect a non-dopaminergic chemical imbalance, such as 
a deficiency in glutamatergic function.” (Abi-Dargham et al., 2000, p.8109).  It is possible 
these participants had TRS or ultra-TRS (the latter appear non-responsive to clozapine). 
 
Several PET studies have reported increases in the synthesis capacity of pre-synaptic 
dopamine in individuals acutely unwell with schizophrenia, relative to healthy controls (as 
described by Howes and Kapur, 2009 and Egerton et al., 2013).  The methodology involves 
radiolabelling the dopamine precursor L-dopa and measuring its accumulation in synaptic 
vesicles (Hietala et al., 1995).  Importantly, these findings have been extended to unaffected 
first-degree relatives (Huttunen et al., 2008) and individuals experiencing prodromal signs 
of schizophrenia (Howes et al., 2009).  Moreover, in the latter study, the increase in 
dopamine synthesis capacity correlated positively with the severity of symptoms on the 
PANSS but not with measures of anxiety or depression.  Negative correlations were also 
observed between striatal synthesis capacity and measures of semantic and phonological 
fluency (assumed to measure executive function)9 indicating cognitive processes may be 
compromised by abnormal striatal dopamine function in the prodrome.  On this point, a 
meta-analysis of 19 studies (Fusar-Poli et al., 2012) involving 1188 individuals at clinical 
high risk of psychosis, confirmed decrements in performance on tests of general intelligence 
and cognition across several domains with the greatest impairment being observed in 
relation to tests of short-term verbal and visual memory.  By contrast, decrements in 
processing speed did not reach significance which is, perhaps, surprising if cognitive deficits 
are characterised by indecision or processing inefficiency, however, it is possible this may 
be linked with the progression of disease, indeed deficits in the volume or ultra-structure of 
myelin might be predicted to slow conductance speeds (Joyce, 2013).  
 




Egerton et al. (2013) subsequently replicated the finding of increases dopamine synthesis 
capacity during the prodrome and then combined their PET data with Howes et al. (2009).  
This enabled the increases to be localised to the associative striatum (AST) and 
sensorimotor striatum but not in the limbic striatum.  This was also in agreement with a 
prospective study by Howes et al., 2011, which again observed elevations in dopamine 
synthesis capacity in the AST of 30 individuals at “ultra-high risk” of developing psychosis, 
relative to healthy controls.  Elevations were even higher in those who subsequently 
transitioned to psychosis.10 
 
Possibly the first study localising abnormal dopamine function to the AST (Kegeles et al., 
2010) compared unmedicated in-patients with healthy controls using an acute dopamine 
depletion paradigm and observed the highest increase in D2 receptor availability in the 
precommissural dorsal caudate of the schizophrenia group (as compared with the 
postcommissural caudate, precommissural and postcommissural putamen and ventral 
striatum where D2 receptor availability didn’t differ between the groups).  Similarly, 
Demjaha et al. (2012) noted the highest uptake of [18F] DOPA in individuals who had 
responded to first line antipsychotics (FLRS) was in the AST. 
 
The AST is defined by its reciprocal connections with cortical areas associated with higher 
cognitive processing, especially the DLPFC, the cortical apex and major hub of the striatal-
thalamo-cortical network which also integrates inputs from other parts of the limbic system, 
which include the hippocampus, amygdala, thalamus and hypothalamus.  Therefore, 
isolating striatal dysregulation to this area may advance understanding concerning aspects of 
cognitive dysfunction observed in schizophrenia.  This circuitry has been proposed to 
provide a critical role in integrating diverse information flows (Haber, 2016) and is 
important for monitoring performance and other forms of feedback, learning, action section 
and adaptive behaviour (Ullsperger et al., 2014) and other aspects of executive function.   
The flow of information through the striatal-thalamo-cortical loops is very complex and not 
completely understood but Haber has made a major contribution in this area (e.g. Haber et 
al., 2000, Haber, 2011, Haber, 2016) and promoted the view that this circuitry permits 
integration at various points, which is contrary to the traditional view that the loops function 
to maintain segregation.  One way both separation and integration may be achieved is in the 
iterative flow of activity through the loops, tracking across areas of the striatum (caudate 
 





and putamen) via collaterals while retaining topological organisation of sensory inputs.  In 
this updated view, separation is still apparent.  within the traditional divisions of the striatum 
(limbic, cognitive and sensorimotor).  
 
Using resting state functional connectivity MRI (rsfcMRI) seven striatal networks were 
estimated by selecting the 25 most correlated vertices which, for example, determined 
whether striatal voxels belonged to the default mode network or the motor network. Using 
this approach “the posterior putamen was assigned to the motor network laterally and the 
ventral attention network medially......The 7-network parcellation shows that corticostriatal 
circuits, in particular the association circuits, couple to zones of the striatum that extend 
along its longitudinal extent, consistent with anatomical studies.”  (Choi, Yeo and Buckner, 
2012, p.2250). 
 
Kegeles et al. (2010), commenting on role of the dorsal striatum/ precommissural dorsal 
caudate noted it is “involved in learning, habituation, memory, attention, motivation 
emotion, and volitional behavior.”  It may have been with some irony they further observed 
the lack of difference between the control and schizophrenia groups in the ventral striatum 
also challenged the “widely-held” assumption that this area is an important target for 
antipsychotic action (e.g. Lidsky, 1995) and, presumably, drug design.   
 
As noted above, an increase in synthetic capacity in the AST can precede the onset of 
psychosis and before antipsychotic treatment, however, psychosis is not an inevitable end-
point as not everyone transitions to psychosis and presynaptic DA function may vary during 
the disease (Laruelle (2013).  However, there may be a case for giving antipsychotic 
medication to ultra-high risk individuals who show elevations in dopamine synthesis 
capacity but there may also be hazards, for example, Jauhar et al. (2017) commented 
reductions in presynaptic dopamine synthesis capacity have been observed in ADHD 
(Ludolph et al., 2008) and also in Parkinson’s Disease (Dhawan et al., 2002) - consistent 
with reduced dopaminergic transmission.  Apart from cognitive problems, psychosis is not 
uncommon in both ADHD and PD (Watson and Leverenz, 2010, Levy et al., 2015, Zahodne 
and Fernandez, 2008) so it is suggested here this spectrum of conditions, including 
schizophrenia, might possibly be associated with the inverted-U shape of dopamine function 
whereby optimal function is achieved when dopamine is neither too high nor too low 
(similarly, see section 1.5.5 on synaptic plasticity). 
 
One of the most recent chapters in the dopamine hypothesis concerns the unexpected 
observation of hypo-dopaminergia in regions outside the striatum in drug naïve or drug-free 
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individuals with schizophrenia relative to healthy controls (Slifstein et al., 2015).  Indeed, 
relatively blunted DA release was observed across all 14 preselected regions of interest:  in 
the DLPFC, orbitofrontal cortex, medial frontal cortex, anterior cingulate and subgenu of 
the cingulate; also, the insula, parietal cortex, temporal cortex and occipital cortex; and 
subcortically, in the amygdala, hippocampus, substantia and ventral tegmental areas, 
thalamus and uncus.  Moreover, when the percentage changes in dopamine binding potential 
were regressed onto fMRI BOLD activation during a working memory task performed by 
the same participants, it was apparent amphetamine-induced dopamine release in the 
DLPFC correlated positively with the magnitude of the fMRI BOLD signal, to the same 
degree in both the healthy controls and schizophrenia participants, although the intercept of 
the line of best fit was lower in the schizophrenia group indicating lower amounts dopamine 
were released.  In addition, there was a positive correlation between baseline levels of 
dopamine in the DLPFC and working memory performance at higher levels of cognitive 
load in the healthy control group which was not present in the schizophrenia group (where 
perhaps maximum sensitivity to dopamine had been achieved already).  Moreover, this 
pattern extended to the other regions of interest analysed.  Slifstein et al. (2015) proposed 
the availability of D1 receptors in the PFC may modulate working memory performance.   
 
It is further observed here that an analogy might be made between hypodopaminergia and 
blunted release of hormones following excessive activity as might, for example, following 
the chronic and sustained release of cortisol in Cushing’s which may produce long-term 
changes such as reductions in hippocampal volume and reductions in the grey matter of the  
anterior cingulate cortex (ACC) (Andela et al., 2013, 2015), this may also affect resting state 
connectivity (van der Werff, 2015). Similarly, abnormalities have been observed in pituitary 
volumes in association with psychosis (Pariante, 2004, 2008; Garner et al., 2005, 2009).  
Evidence of hormonal dysregulation is apparent in the blunted release of cortisol during the 
first hour of waking (CAR) which has been observed in individuals at high risk of  
psychosis (Day et al., 2014) and unaffected first-degree relatives which was interpreted as a 
possible genetic predisposition towards HPA hyper-responsiveness (Mondelli et al., 2008).  
If the co-release of dopamine and cortisol may support cognition, then hormonal 
dysregulation could weaken this link, possibly contributing to the observations of Slifstein 
et al. (2015).  A downregulation in dopamine release might occur for other reasons so it 
does not necessarily follow an endocrine explanation underlies their result.  Yet it might, for 
example, if it is further considered that interactions between immune, endocrine and central 
nervous system are orchestrated by the hypothalamus, a collection of nuclei at the base of 
the brain, (Herman and Cullinan, 1997; Silverman and Sternberg, 2012).  Not only are 
hormones released into the circulation from the pituitary to reach target glands such as the 
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thyroid and adrenal glands, they are synthesised within the brain where there are some direct 
connections, including a very strong connection from the lateral hypothalamus to the ventral 
tegmental area (VTA), Tyree and de Lecea (2017).  Further, there are close links between 
the immune, endocrine and central nervous system which may be relevant to the 
pathophysiology of schizophrenia as demonstrated by associations with childhood adversity 
(Egerton et al., 2016), maternal stress and immune activation models (Modinos et al., 2015). 
Therefore, this recent development in the dopamine hypothesis may lead to further research 
on interactions between these systems and better control of related variables in the future. 
 
1.5.2 The Glutamate NMDA Receptor Hypofunction Theory of Schizophrenia 
Olney et al. (1995, 1999), recognised that while antagonism at the dopamine D2 receptor 
was an effective treatment for the “positive” symptoms of psychosis, the persistence of 
symptoms in some individuals could not be accommodated by dopamine theories at the 
time.  It was, however, known that NMDA receptor antagonists like the former anaesthetic 
phencyclidine (PCP) could induce psychosis (Luby et al., 1959).  Also, that their preclinical 
studies with rodents had demonstrated neurons could be damaged by excessive 
glutamatergic transmission which might be consequent upon failures of inhibition.  In 
particular, at the NMDA receptor where antagonism or other forms of NMDAR 
hypofunction could lead to the release of damaging quantities of glutamate and 
overstimulation at post-synaptic neurons.  Also, depending on the duration and severity, this 
could promote reversible and irreversible morphological changes at post-synaptic neurons 
even neuronal death (Olney and Farber, 1995).  It was further recognised this could be 
prevented by clozapine (also, the atypicals olanzapine and fluperlapine) and by many types 
of drugs which implicated different kinds of neurotransmitter receptors11 where an important 
insight was that the major excitatory neurotransmitter glutamate regulates inhibitory tone 
“by tonically activating NMDA receptors on GABAergic, serotonergic and noradrenergic 
neurons” Olney et al., 1999, p.526.  These, they proposed formed part of an NMDA 
network, however: 
Conspicuously absent from the list of intrinsic components is the D2 dopamine receptor …. 
Does this signify that D2 receptors play no role in the NRHypo model?  No, quite the 
contrary. We have found no evidence that D2 receptors function internally within the 
network, but we postulate that they may be exceedingly important extrinsic regulators of the 
network.” (p.527) 
 
11 “NMDA Glu, nonNMDA Glu, m3-muscarinic, a2-adrenergic, GABAA, sigma and 5HT2A”, Olney 
et al., 1999, p.526, i.e. incuding, muscarinic receptor antagonists, GABA-A “receptor facilitators”, 




It was further proposed dopamine may be involved in the release of glutamate but pathology 
might arise if dopamine resulted in too much inhibition. Twenty years on this awaits 
confirmation, however, as above, there is good evidence of striatal dysregulation.  Also, 
Grace (2012, 2016) discussed further below, has demonstrated through preclinical studies 
that midbrain DA cells in the VTA may themselves be influenced by NMDAR 
hypofunction. (Also see Slifstein et al., 2015, above, on extrastriatal hypodopaminergia). 
 
More recent support for a glutamatergic hypothesis comes from PCP and ketamine models 
of schizophrenia which induce NMDA receptor hypofunction, now widely regarded as 
being superior to those involving amphetamine challenge which increases synaptic 
dopamine availability (Kantrowitz and Javitt 2010).  NMDA receptor antagonists can induce 
schizophrenia-like symptoms at low dose in healthy individuals, while exacerbating or 
prompting relapse in individuals diagnosed with schizophrenia (Newcomer et al., 1999, 
Coyle et al., 2012, Krystal et al., 1994).  One PET study of chronic ketamine users revealed 
an upregulation of D1 receptor availability in the DLFPC, consistent with upregulations in 
animal studies after long-term dopamine depletion (Narendran et al., 2005).  Moreover, 
Olney et al. (1995), proposed that NMDA receptor hypofunction might arise under other 
circumstances without recourse to a dopaminergic explanation as primary factor, for 
example, if GABAergic interneurons which bear them are missing (Benes et al., 1991).   
 
1.5.3  GABA During Development and in the Mature brain 
Many of the associations observed in schizophrenia appear to have a developmental aspect 
so part of the liability to schizophrenia may lie in the early foundations of the nervous 
system when, for example, electrical communication between cells via gap junctions is 
pervasive during embryonic development. In the neocortex, the patterns of oscillations “are 
thought to play important roles in wiring essential connections notably cortical maps and in 
other important functions including migration and proliferation” (section F in Ben-Ari et al. 
(2007).  By the post-natal period oscillatory activity has given way to chemical 
communication in most neuronal populations although communication via gap junctions 
remains a feature of glial cells (Venance et al., 2000).  Without the pruning of gap junctions, 
Hameroff (2010), has observed the entire brain could be “one uninterrupted synchronized 
syncytium.”  However, a sparser distribution enables a capacity for many “conversations” to 
arise through rhythms at different frequencies which may occur virtually simultaneously at 




An important neurotransmitter in the generation of oscillations is gamma-aminobutyric acid 
(GABA), (Whittington and Traub 2003; Traub et al., 2003) which serves many roles during 
early development as discussed in detail by Ben-Ari et al. (2007).  These include an 
excitatory role, which following Hebbian principles, they suggest may enable neurons 
which fire together to also “wire together.”  Also, GABA receptors are active in the 
hippocampus, and possibly other areas, even before most synapses are functional.  GABA’s 
role as an inhibitory neurotransmitter, may be delayed until afferents to GABAergic 
interneurons have developed.  Nonetheless, they observe, even at this stage there is a need to 
maintain a balance between GABA and the major excitatory neurotransmitter, glutamate, to 
avoid excitotoxicity.  
 
Oscillatory activity remains an important feature in the mature brain where the synchronized 
activity of interneurons can induce synchronous activity in cortical neurons (Traub et al., 
2001;  Schmizt, 2001;  Lytton and Sejnowski 1991) and is increasingly recognised as being 
relevant to schizophrenia (Hunt et al., 2017;  Rowland et al., 2013;  Sorman et al., 2011)12 
and the efficient function of working memory in healthy individuals (Yoon, Grandelis, and 
Maddock, 2016). 
 
1.5.4  GABA Deficits in Schizophrenia 
Widespread deficits in the GABA synthesising enzymes (glutamic acid decarboxylase) 
GAD 65 and 67 have been frequently observed in postmortem studies of schizophrenia (de 
Jonge et al., 2017).  The isoform GAD 65 is concentrated around the synapses where its 
transcription is activity-dependent and so may be especially involved in dendrite to dendrite 
communication, whereas GAD 67, which is responsible for synthesising 80-90% of GABA 
is more widely distributed in the extracellular cytoplasm and believed to be involved in 
maintaining basal levels of GABA and therefore is a source of tonic inhibition.  GABA is 
the major inhibitory neurotransmitter, capable of putting inhibition into excitatory 
glutamatergic circuits.  While GABAergic interneurons also appear to be involved in the 
generation of oscillatory rhythms (section 1.5.5). 
 
12 It would appear the dopamine cells in the ventral tegmental area of the midbrain respond to a 
phasic signal (burst firing) from the pedunculopontine area, as described by Grace (2016) and can be 
entrained to produce a similar phasic signal: “Burst firing of DA neurons in the VTA is potently 
driven by glutamate from the pedunculopontine nucleus (PPTg) ….. acting on NMDA receptors.” 
A proportion of these cells are already firing as a result of release from GABA-ergic inhibition (via a 
process that starts with increased activity in the hippocampus) which is necessary for transmission at 
the NMDA receptor, so it is wondered whether the burst firing confers a specificity to the signal that 
in some way is related to the “meaning” of the stimulus? 
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Oscillations in the gamma band (a broad range) are particularly suited to long-range 
communication and emerging evidence indicates these may prove highly important in 
supporting complex mental processes that require the integration of information across and 
within large scale networks.  It is suggested here, on the basis of evidence from recent 
connectivity studies which indicated reduced connectivity in TRS individuals (Wang et al., 
2015; Ganella et al., 2017, 2018) oscillatory behaviours may be especially relevant to TRS, 
although it is a matter for empirical research whether GAD deficits may be present in TRS 
and, if they are, whether they may be primary or secondary indicators of pathology.   
Similar questions apply to mitochondria which supply cellular energy and increase and 
decrease in number according to energy requirements, thereby supplying a marker of 
cellular metabolic activity and have been observed to be reduced in people with 
schizophrenia (PSZ) in the caudate and putamen (Somerville et al., 2011) and, distinctively, 
not in TRS (Roberts, 2017). 
 
1.5.5 The Glutamate, GABA and Dopamine Neurotransmitter Systems Interact:  
- Oligodendrocytes 
There is now an extensive literature relating to myelin integrity, which may be vulnerable 
glutamatergic/ GABAergic dysfunction, for example, with observations of increased 
glutamate and increased lipid membrane metabolism coinciding in the frontal cortex and 
ACC of individuals with schizophrenia (Smesny et al., 2015).  It has been observed 
“oligodendrocytes are highly vulnerable to glutamate” (Matute et al., 2006, p.215) and a 
lethal influx of calcium ions can follow brief agonism of the glutamate AMPA or kainate 
receptors expressed on oligodendrocytes.  Moreover, excitatory activity at microglia can 
cause a damaging release of inflammatory cytokines, including tumour necrosis factor- 
(TNF-).  The depletion of the antioxidant  glutathione may also render cells vulnerable to 
oxidative damage (Matute et al., 2006).  The particular vulnerability of oligodendrocytes to 
oxidative stress has also been commented upon by Vostrikov and Uranova, 2011 (p.6).  The 
ways in which inflammatory, glutamatergic and oxidative processes may interact in 
schizophrenia are elaborated upon in a model advanced by Steullet et al. (2016), who 
propose an imbalance in one “hub” system (immune, glutamatergic, redox) can affect 
another.    
 
In one postmortem study involving 7 PSZ and 7 age-matched control individuals, a 28% 
reduction in the number of oligodendrocytes in cortical layer 3 of the superior frontal gyrus, 
BA9 was observed.  In addition, the spatial arrangements of the oligodendrocytes appeared 
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more dispersed (Hof et al., 2003).  Similarly, Natalya Uranova has published a series of 
papers on schizophrenia reporting substantial reductions in oligodendrocytes:  a 25% 
decrement in layer V1 and adjacent white matter of BA 9 (Uranova, et al. 2004);  a 23% 
reduction in the number of pericapillary oligodendrocytes in prefrontal BA10 tissue 
(Vostrikov et al., 2008) and a decrease in the number of mitochondria in oligodendroglia in 
the caudate nucleus and BA10 along with signs of necrosis and apoptosis of 
oligodendrocytes in these areas (Uranova et al, 2001).  With white matter decrements in 
schizophrenia potentially on such a scale it might be predicted these could reduce resting 
state connectivity (Koch et al., 2012), the conductance of axon potentials and perhaps even 
communication via oscillatory rhythms.   
 
The diverse roles of other types of glia continue to be elucidated and extended, rising to a 
prominence and importance that may rival that of neurons.  Bernstein et al. (2015), for 
example, observe that astrocytes “are now accepted as having crucial roles in brain 
functions, supplying neurons and oligodendrocytes (OLs) with substrates for energy 
metabolism, controlling extracellular water and electrolyte homeostasis, expressing 
neuromodulators, regulating neurotransmitter release, modulating immune responses.” (p.6).  
Therefore, it is clear all these cell types, glia and neurons, are closely related and inter-
dependent (Orthmann-Murphy, et al., 2008; Fields et al., 2015; Paolicelli et al., 2011).  
Interestingly, one aspect of clozapine’s therapeutic efficacy might be an ability to protect 
against glutamate excitotoxicity or oxidative damage as demonstrated by Steiner et al. 
(2011) when the application of clozapine to immature oligodendrocytes (from the OLN-93 
cell line) in vitro prevented excitotoxic damage that would have otherwise arisen in an 
energy-deprived medium (also see Ozcelik-Eroglu et al., 2014).13   
 
- Synaptic Plasticity 
Many theories have been generated during decades of schizophrenia research, however, 
separating out primary from secondary pathology is a major challenge, not least because 
neurotransmitter systems interact where they converge upon the same circuitry.  Some 
examples, are provided below, including one concerning modifications in synaptic plasticity 
which may also readily translate to the idea of short-term memory as “activated LTM”.  It 
may be relevant to further note here that dopaminergic innervation of the DLPFC may be 
reduced in schizophrenia (Akil et al, 1999), however, understanding the effects of dopamine 
 
13 Relevant here might be the demonstration that clozapine can inhibit synaptic transmission at 
GABA A receptors by inhibiting post synaptic excitatory currents in isolated GABAergic neurons 
(Michel and Trudeau, 2000; also see Zink, 2004). 
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at D1 receptors is complicated by the inverted-U pattern of the post-synaptic response - 
where too little or too much stimulation can fail to produce an effect (Zahrt et al., 1997; 
Cools and D’Esposito, 2011; Colzato and Hommel, 2014).  This pattern is not uncommon 
among neurotransmitters (Bentley et al., 2011) and so might provide a means, along with 
alterations in receptor density and neuromodulatory influences, of maintaining sensitivity 
(Vijayraghavan et al., 2007) and making fine adjustments as demonstrated below. 
 
Dopamine neurons can modulate the excitability of glutamatergic cortical pyramidal 
neurons either directly at D1 receptors, or indirectly by synapsing upon GABAergic 
interneurons which bear D2 and D4 receptors where they may serve to stimulate 
GABAergic inhibition (Laruelle, 2014).  Moreover, dopamine can act with exquisite 
precision in small populations at pre and post-synaptic circuits at glutamatergic synapses 
where receptors are not co-localised yet can co-operate to modify excitatory circuits through 
Hebbian plasticity, by creating a temporal window in which tonic GABAergic inhibition is 
lifted to enable synaptic transmission to occur.   
 
Xu and Yao (2010) demonstrated this in layer V pyramidal neurons from PFC slices 
(prepared from C57BL/6J mice), where the inhibition was lifted presynaptically by 
dopamine acting at D2 receptors on GABAergic interneurons.  In addition, the duration of 
the temporal window could be extended from 30ms by dopamine acting at D1 receptors 
postsynaptically.  Timing is critical for spike timing–dependent long-term potentiation       
(t-LTP) to occur, “t-LTP is induced when presynaptic spiking precedes postsynaptic spiking 
within a narrow temporal window” (p.16366).  A minimum 30ms period is required (Pawlak 
and Kerr 2008).   Whether there are long-term alterations in synaptic plasticity, with 
possible related changes in long-term memory involving protein synthesis, may also be 
subject to other modulatory inputs from other neurotransmitters and neurohormones 
(Stephan et al., 2009). 
 
- Parvalbumin-Containing GABAergic Interneurons 
Deficits in GABAergic interneuron have been reported in post-mortem studies of 
schizophrenia (Benes et al., 1991) which could compromise the generation of gamma 
oscillations in recurrent micro-circuits and the related ability to synchronise different 
streams of information which is an important aspect of cognitive function (e.g. Lodge et al., 
2009; Andersson et al., 2012; Lewis et al., 2012; Whittington and Traub, 2003).  The 
integration and “binding” of information is hypothesised to arise through observable 
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synchronisation of oscillatory rhythms.  Moreover, deficits in PVIs may lead to disinhibition 
of the pyramidal cells (Lewis and Gonzalez-Burgos, 2006; Lisman et al., 2008). 
 
There is also a literature in schizophrenia on PVI deficits arising in context of maternal 
stress and maternal immune activation (Uchida et al., 2014, Canetta et al., 2016, 
respectively), also, through increased vulnerability to redox dysregulation in a model where 
vulnerability to oxidative stress (through reduced levels of antioxidant)14 was increased with 
decrements arising early in postnatal development and during the equivalent of adolescence 
but not in older animals (Cabungcal et al., 2013a). 
 
1.5.6  The many actions of Clozapine 
“The failure of current science to explain the unique mechanism of action of clozapine is 
one of the most humbling aspects of the current situation.” (Nutt & Need, 2014, p.1183) 
 
Clozapine has a range of potentially beneficial therapeutic actions and so could benefit 
individuals in different ways and, perhaps, at different stages of the illness.  Some support 
may come from the variation in time courses demonstrated in a prospective 1-year study by 
Fabrazzo et al. (2002) where some participants responded only towards the end of the trial. 
Despite its low liability for ESPE, clozapine does have affinity for D2 receptors (Seeman 
and Lee, 1975), however it is distinguished by fast on/ fast off binding, for possibly 12-24 
hours, whereas some conventional antipsychotics may bind for days (Seeman, 2011).    
 
Clozapine also has especially high affinity for the dopamine 4 (D4) receptor, described by 
Seeman (2011) as having a potency that is about 10 times than for D2 receptors.  The D4 
receptor is present at high density in some areas implicated in schizophrenia, for example, in 
the hippocampus and striatum (Brady et al., 2012, page 1005).  Similarly, it is enriched in 
the anterior cingulate cortex (ACC) where a novel role has been proposed “in gating 
responses to reward-salient stimuli” (Cocker et al., 2016, p.191).  mRNA analysis by  
De Almeida and Mengod (2010) revealed the D4 receptor is more densely represented than 
the D2 receptor in layer V of the monkey PFC where layer V has likely projections to the 
striatum.   This differential expression in the PFC is summarised in Table 1. 2 and it is 
proposed here that one of the many potential reasons for clozapine’s efficacy could lie in the 
high density of D4 neurons on parvalbumin containing interneurons (PVIs) which are 
 
14 i.e. redox dysregulation:  “ Oxidative and nitrosative stress result from an imbalance between 
overproduction of reactive oxygen species (ROS), and reactive nitrogen species (RNS) on one side 
and deficiency of enzymatic and nonenzymatic antioxidants on the other side” (Do et al, 2009, p.220) 
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vulnerable to damage from calcium influx due to slow kinetics, which, however, facilitate 
sustained activity in the prefrontal cortex (PFC), thereby prolonging depolarization and 
increasing synaptic summation, which brings a neuron closer to its threshold for spike-
firing.  This promotes synaptic plasticity and cognition (Cabungcal et al., 2013 (b); Steullet, 
2016;  Monaco et al., 2015).    
 
Table 1. 2   Clozapine has high affinity for D4 receptors which are expressed at high 
density in the Prefrontal Cortex, Anterior Cingulate Cortex, Hippocampus and 
Striatum  
Percentage of neurons in the 





Glutamatergic Neurons* 52% 75% 
GAD¬ + interneurons 34% 47% 
Parvalbumin interneurons 
(chandelier morphology)  
15-20%  
antipsychotics act here 
65%  
clozapine may act here. 
Calbindin interneurons 
(double bouquet morphology) 
37% 37% 
* These percentages imply some co-localisation of D2 and D4 receptors on glutamatergic 
neurons. 
¬ Glutamic acid decarboxylase. 
After de Almeida and Mengod, (2010) 
 
Preclinical studies have shown clozapine increases dopamine in the prefrontal cortex and 
may restore dopamine turnover after chronic exposure to the NMDA receptor antagonist 
phencyclidine.  Elsworth et al., 2008 (p.495) suggested this might be attributed to the role of 
clozapine as a selective D4 antagonist, which would be compatible with the proposal based 
on the obsevations of de Almeida and Mengod (2010) above. 
 
Clozapine also has high affinity for serotonin receptors, especially of the 5-HT2 type.   
Farber (1998) presented evidence that clozapine has actions at the 5HT2A receptor 
proposing this may be a reason for clozapine’s superior’s efficacy as it exhibits strong 
binding affinity for the 5HT2A receptor where it acts as an antagonist.15  It has been 
suggested that 5-HT2A antagonists may ameliorate negative symptoms and cognition in 
schizophrenia (Roth et al., 2004; Akhondzadeh et al., 2008 cited in Steeds et al., 2015).  
Interestingly, LSD is a serotoninergic agonist at several 5-HT2 subtypes and has been 
 
15 This is not unique to clozapine as chronic treatment with atypicals at clinically relevant doses, 
including clozapine, may antagonise 5HT-2A while stimulating 5HT-1A receptors (Meltzer and 
Massey, 2011).  In the prefrontal network described by Sumiyoshi et al., 2013, both 5-HT1A and 5-




associated with psychosis.16  NMDA receptor hypofunction was also proposed to affect 
serotonergic neurons (Olney et al., 1999).  In a study of knock-out mice that lacked markers 
for the presynaptic serotonergic system, Yadav et al. (2011), observed the pre-synaptic 
serotonin system must be intact for clozapine to normalise NMDAR function.   
 
As discussed at the end of the section 1.5.2, clozapine is very effective against NMDA 
receptor hypofunction induced excitotoxicity and prevents psychotomimetic symptoms 
(Farber et al., 1998).  Clozapine and olanzapine were included in a list of agents by Olney et 
al. (1999, page 1001) with efficacy against NMDAR antagonism.17  Farber et al. (1999) 
added glycine and D-cycloserine, indicating the latter might be more suitable. (p.13)           
D-cycloserine is a partial agonist at the glycine site on NMDARs, while glycine is a full 
agonist at the same receptor so both agents may promote glutamatergic transmission.  
Clozapine may achieve this by inhibiting system A-type glycine transporters (Javitt et al, 
2004).  It also appears to be an agonist at the glycine site (Moghaddam & Javitt, 2012, p.12).  
 
Interestingly, clozapine at therapeutically relevant doses, may be capable of reversing 
hypermethylation associated with epigenetic changes (Guidotti and Grayson, 2013; 
Gillespie et al., 2017), as might be incurred in prenatal immune activation and prenatal 
stress models of schizophrenia.  Gene expression of the GABAergic system in the adult 
prefrontal cortex and medial prefrontal cortex has been observed to be especially vulnerable 
in these models (Richetto et al., 2014, 2017;  Matrisciano et al., 2013).   
 
Taken together these observations suggest that clozapine’s therapeutic actions may work on 
several levels, for example, it may improve both cognitive and negative symptoms through 
serotonergic actions, protect against neurotoxicity consequent upon NMDAR hypofunction 
or energetic failures, and it may, through its high affinity at the D4 receptor help to 
compensate for impaired dopamine transmission in the prefrontal cortex. 
 
The origins of TRS may be neurodevelopmental, however, as Olney et al. (1999) proposed, 
pathology may only arise as circuitry matures.  Recent evidence of a common 
 
16 Farber et al. (1998) observed LSD may effectively counter neurotoxicity caused by NMDAR 
antagonism: “Among the 5HT2A agonists examined and found to be neuroprotective are LSD and 
related hallucinogens. The apparent contradiction in proposing that these agents might have 
antipsychotic properties is resolved by evidence linking their hallucinogenic activity to agonist action 
at 5HT2C receptors, whereas antipsychotic activity would be attributable to agonist action at 5HT2A 
receptors”, p.57.   
 
17 Clozapine and olanzapine are “an order of magnitude more effective” than conventional 
antipsychotics (Farber et al., 1998, p.58 cite their earlier studies) 
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endophenotype with unaffected siblings (as identified by Wang et al., 2015) suggests the 
emergence of TRS is not inevitable but perhaps may require further insults or conditions of 
vulnerability.  Moreover, Wang et al., 2015 identified some patterns of connectivity which 
were not shared with healthy controls or TRS individuals, but were unique to the  
unaffected relative which, they proposed, might represent resilience. 
 
The lack of sex difference in the incidence of TRS cases identified by Wimberley et al., 
2016, may provide a further clue to the nature of TRS, as this is a marked difference from 
most studies of schizophrenia where there is a greater proportion of males at the younger 
end of the spectrum. This might suggest that TRS pathology becomes active before the 
potentially protective effects of female hormones are fully available, whether due to an 
earlier onset or perhaps because of maturational delays at the menarche.  Sex hormones are 
also synthesised in the brain, and it has been observed for example, that ovarian hormones 
may help to limit damage from excitotoxicity following a stroke or delay the onset of 
neurological disorders like Parkinson’s disease.  A circumstantial argument might also be 
constructed for clozapine because it greatly upregulates the production of allopregnenolone, 
a metabolite of pregnenolone which has shown promise in the treatment of schizophrenia in 
randomised controlled trials (e.g. Marx et al., 2014;  Kreinin et al., 2014;  Ritsner et al., 
2014).  A large randomised control trial of estradiol for TRS has also been conducted in 
female participants, demonstrating dose response effects on the reduction of symptoms 
measured on the PANSS (Kulkarni et al., 2015).   
 
It is concluded clozapine works on many levels and may benefit individuals in different 
ways.  A better understanding of the nature of pathology, disease stage, interactions with 
ageing and other factors in the individual may lead to more personalised treatment and 
perhaps it may be possible to use adjunctives or move on from clozapine once stability has 
been restored. 
 
1.5.7  A Reconciliation 
Following the unexpected observations of Slifstein et al. (2015) concerning hypofunction of 
dopamine in extrastriatal areas in schizophrenia, Abi-Dargham (2017) proposed dopamine 
might modulate the excitability of gamma-aminobutyric acid-ergic (GABA-ergic) cells in 
the hippocampus “as it does in the cortex” and lead to a dysregulation of midbrain dopamine 
firing.  In support, she referred to the work of Anthony Grace (2017), who has conducted 
extensive work on the methylazoxymethanol acetate (MAM) mouse developmental model 
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of schizophrenia18.  Grace (2012, 2016) has proposed the hippocampus is the primary site of 
pathology in schizophrenia, possibly, several synapses up (via the ventral pallidum and 
nucleus accumbens) from dopamine cells in the ventral tegmental area (VTA) which are 
mostly kept under tonic inhibition.  However, those active VTA cells will be capable of 
responding to glutamatergic transmission at their NMDA receptors since depolarisation 
removes a magnesium block in the ion channel.  Grace (2012) observed the hippocampus, 
by determining the number of active dopamine neurons, can control the strength of the 
signal that is then sent to the striatum in response to a behaviourally relevant stimulus.   
 
In addition, Abi-Dargham (2017) provided an “overarching model for a “dual hit” on DA 
function in schizophrenia”:  the first “hit” concerns dopamine-related genes which may bias 
developmental trajectories, as illustrated by another impressive model, the D2R-OE 
transgenic mouse model (Simpson and Kellendonk, 2017, 2010; Kellendonk et al., 2006).  
This has demonstrated how a transient over-expression of D2 receptors in the striatum late 
in embryonic development can also lead to the emergence of a schizophrenia-like phenotype 
with maturation around the mouse “adolescence”.  The second “hit” relates to 
environmental risk factors, e.g. “drugs, stress, urbanicity, diet, and inflammation.”  In both 
the MAM and D2R-OE models, the schizophrenia phenotype emerges during the adolescent 
period when Olney et al. (1999) proposed maturation of circuitry permitted the development 
of psychosis.  Pertinent to the second “hit”, Du and Grace (2016) were able to restore stress 
responses in their MAM model to resemble controls and avert damage to the hippocampus 
by administering diazepam for 10 days during the adolescent period.  This also appeared to 
prevent the emergence of a psychosis-like phenotype as the adult rats did not exhibit 
hyperactive DA neuron firing, hyperactivity in the amygdala, increased anxiety behaviours 
or hyperlocomotion to amphetamine. 
  
 
18 Mitotoxin methylazoxymethanol acetate administered to a pregnant rat on gestational day 17 
stimulates a maternal immune response, followed by a schizophrenia-like phenotype in offspring 
which emerges around puberty: with exaggerated responses to amphetamine and PCP; deficits in pre-
pulse inhibition, latent inhibition and reversal learning and set shifting; atrophy and increased cell 
packing throughout the ventral hippocampus (analogous to the anterior hippocampus in humans) and 
medial prefrontal cortex. The number of spontaneously firing dopaminergic cells in the Ventral 
Tegmental Area (VTA) of the midbrain, approximately doubles. 
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1.5.8  Genetic Evidence  
Schizophrenia is a highly heritable disease, for example, Wray and Gottesman (2012) 
derived a heritability estimate of .67 from their study of the Danish register, which is 
perhaps surprising because according to classical argument schizophrenia might be expected 
to be under negative selection pressure and disappear since a lower rate of reproduction is 
associated with this disorder.  This does not appear to be the case so either de novo 
mutations in families are very common or the disorder involves polymorphisms which 
individually carry very little risk.  Indeed, both arguments may apply.  The most recent 
evidence emerging from GWAS studies that have merged databases supports the view that 
the origins of schizophrenia probably involve many genes of small effect.  These have also 
supported the major theories relating to dopamine, glutamate and GABA referred to in this 
introduction, for example, an enrichment of genes has been observed concerning 
GABAergic transmission, glutamatergic signalling and synaptic proteins (particularly, 
NMDARs).  Many had already concluded multiple genes were involved after years of non-
significant genetic associations (Pocklington et al. 2015; Ohi et al., 2015). 
 
However, while the results of the CRESTAR study on the genetics of TRS19 are awaited 
Gillespie et al., 2017 identified a study by Joober et al., (2005) which indicated TRS may 
have a higher familial loading than non-TRS.  Another study indicated first-degree relatives 
of TRS individuals had a higher risk of developing a schizophreniform disorder (Silverman 
et al., 1987). 
  
Moreover, there is a growing list of studies involving unaffected first-degree relatives of 
individuals with schizophrenia which have been finding evidence of similarities which, 
while not pathological by themselves, may be indicative of a shared endophenotype.   This 
has been proposed for the rare early onset schizophrenia (by the age of 12 years).  Using 
morphometry analysis, Gogtay et al. (2012) observed slower white matter development 
trajectories, relative to healthy controls, in the left parietal lobes of unaffected siblings of 
individuals with early onset schizophrenia (EOS) between the ages of 7 and 14 years, 
however, this normalised by the age of 18 years. In an earlier study, grey matter growth 
trajectories, which followed an inverted-U pattern reflecting synaptic pruning after puberty, 
were also altered in unaffected siblings who exhibited early deficits in the PFC and temporal  
  
 
19 Research to identify pharmocogenomic biomarkers of TRS is currently being conducted at King’s 




cortex but not in the parietal cortex, unlike their EOS siblings, which prompted a proposal 
that changes there might involve a non-genetic stimulus.  The deficits were normalised in 
the unaffected siblings by the age of 20 years (Gogtay et al., 2010).  While these studies do 
not address TRS, they do reveal developmental trajectories and raise the possibility of 
deficits in unaffected siblings which subsequently normalise with maturation. 
  
Decrements have been observed in ACC volumes for first-degree relatives and those at 
high-risk (Ohi et al., 2017 (a), Fornito et al., 2009).  Moreover, Wang et al. (2005) observed 
abnormal connectivity in the healthy siblings of TRS individuals.  Further, in a review of 58 
studies, cognitive deficits, were observed in unaffected siblings particularly affecting 
executive/ cognitive control and auditory verbal learning (Snitz et al., 2006);  intellectual 
asymmetry favouring the verbal subscale over the performance subscale was reported in 
unaffected first-degree relatives of PSZ (Karvariti et al., 2006). Perceptual deficits have also 
been observed (Keri et al., 2005, 2004; Gracitelli et al., 2015, 2013).  In addition, using 
fMRI, de Leeuw et al. (2015) observed reduced activation in the ventral striatum, 
supplementary motor area (SMA) and insula during reward anticipation relative to healthy 
controls.  Further this correlated with negative symptoms. Finally, there is some limited 
evidence that there may be an increased predisposition towards hyperglycaemia in 
schizophrenia which is independent of medication.  This may also apply to unaffected first-
degree relatives who have also exhibited glucose dysregulation which might, perhaps, affect 
energy homeostasis and  undermine cognitive function (Thakore et al., 2002; Fernandez-
Egea et al., 2008; Henderson et al., 2005; Guest et al., 2011).  However, it is difficult to 
separate genetic from shared environmental factors. 
 
After major advances in the last couple of decades, genetic research has entered a new 
exciting phase where molecular and metabolic pathways associated with genes are being 
explored in great detail.  Further, metabolic profiles can be generated and collated. 
However, Horvath et al. (2015) have cautioned “These are monumental tasks and they will 
many years to complete.”  In the meantime, integrative and systems approaches may be used 




1.6 Treatment Resistant Schizophrenia 
Kapur (2003) proposed that antipsychotic treatments “do not erase the symptoms but 
provide the platform for a process of psychological resolution”, but unfortunately this does 
not always happen.  While positive symptoms usually abate, cognitive and negative 
symptoms may remain. A widely repeated observation is that around 30% of individuals 
with schizophrenia do not respond to treatment with conventional antipsychotics (Meltzer 
1997; Nakajima et al., 2015; Mouchlianitis, McCutcheon, and Howes, 2016 (a).  However, 
Kane et al. (1988) demonstrated clozapine brought symptomatic relief to a sizeable 
proportion of their “severely ill schizophrenic patients, previously considered by many to be 
beyond the reach of conventional therapy.”  This has been repeatedly observed since, so 
clozapine is frequently described as the “gold standard” for TRS (Meltzer, 2012).  However, 
not everyone who may be eligible for a trial of clozapine will receive it and TRS is 
associated with residual symptoms and worse outcomes (Iasevoli et al., 2016).   In addition, 
there are other individuals, perhaps 5-10% of all cases, who derive no benefit from 
antipsychotic medication (Pantelis and Barnes, 1996) and might be described as “clozapine-
resistant”, “treatment refractory” (Kelly et al., 2010), or “ultra-treatment resistant” (U-TRS), 
for whom polypharmacy is the remaining option although the evidence base appears weak20 
(Cipriani, Boso, and Barbui 2009; Wimberley et al., 2016).   
 
Since the inception of this study, the evidence for TRS as distinctive aetiopathological 
subgroup has advanced in important ways, for example, an epidemiological study of 8044 
individual with a diagnosis of schizophrenia in the Danish national register with the aim of 
identifying predictors of TRS has been published by Wimberley et al. (2016).  As clozapine 
may be under-prescribed, two criteria were employed to identify TRS individuals: one based 
on the prescription of clozapine; also a broader proxy definition based on a hospital 
admission after two courses of monotherapy with different types of antipsychotic - modelled 
in so far as possible on the criteria proposed by Kane et al. (1988).  Using this approach, 
21% of 8044 individuals in this study fulfilled either criteria for TRS - confirming some 
earlier estimates (Kerwin and Bolonna 2005).  
 
This is, of course, a sizeable subgroup within a disorder that affects millions of people 
worldwide.  Wimberley et al. (2016) identified some biological differences from the main 
sample of those who did not show signs of treatment resistance, for example, the TRS group 
had an earlier age of onset and were more likely to have already been an inpatient when they 
 
20 In the epidemiological study of the Danish national registry by Wimberley et al. (2016), over a 10-
year period, 44% individuals had received polypharmacy continuously for at least 90 days. 
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were diagnosed with schizophrenia21. The well-established risk factor of being male was 
also absent in the TRS group (one meta-analysis by Aleman et al. (2003) indicated an 
incidence risk ratio of 1.42).  Urbanicity was associated with TRS, but in the opposite to 
direction to usually associated with schizophrenia (possibly indicating environmental 
stresses and toxins were less likely to be involved in the development of TRS).  It is also 
interesting the TRS broader definition group (extending to those who were eligible for a trial 
of clozapine) did not differ from responsive individuals on the basis of family history, 
season of birth, early parental loss or paternal age.  Just over half were living alone and 
around 30% were employed.  The levels of long-term disability benefit were similar across 
the groups, around 14%.  These latter figures, while perhaps reflecting aspects of Danish 
society, could indicate better functional outcomes for some than might have been expected. 
 
Importantly, two longitudinal studies (Demjaha et al., 2017; Lally et al., 2016) have reported 
most cases of TRS are present at the point of FEP (usually defined as a first hospital 
admission or diagnosis relating to schizophrenia).  Demjaha et al. (2017), reported treatment 
resistance was present from an early stage in 84% of those in their sample who were 
subsequently identified as having TRS.  Their analysis also supported the observation made 
by Wimberley et al. (2016) of a younger age of onset (the mean age of the TRS at first 
diagnosis was 25.4 years compared to 30.1 years for responders).  While Lally et al. (2016) 
concluded TRS was present from the outset in 70% of those who subsequently met the 
criteria for TRS in their sample.  In the remaining 30%, symptoms had initially appeared to 
remit with first-line antipsychotics for a minimum of six months but failed to respond 
subsequently to another first line antipsychotic.  They observed it has been estimated that 
50% of TRS cases might arise from an upregulation of D2 receptors in response to 
pharmacological blockade leading to the development of supersensitivity to dopamine in the 
striatum (Chouinard and Chouinard 2008).  The idea of “breakthrough” DA supersensitivity 
leading to a form of TRS is also given credence by Demjaha et al. (2012) and Seeman 
(2013).  Consistent with Wimberley et al. (2016), both studies reported a prevalence of TRS 
in 23% of their samples. 
  
The study by Demjaha et al. (2017) further revealed a higher level of negative symptoms 
and a longer duration of untreated psychosis independently predicted TRS.  (The nature of 
negative symptoms and whether they are related to cognitive deficits in TRS will be further 
explored below).  The question of whether the duration of untreated psychosis (DUP) might 
 
21 Researchers from the same team (Schneider et al., 2015), have noted the beneficial use of clozapine 
in childhood onset schizophrenia. 
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be related to outcomes and/or illness progression has been of great interest in the wider 
literature where findings have been mixed.  In a prospective 10-year longitudinal by Barder 
et al. (2015), a subgroup exhibited a significant decline in scores on the working memory 
test of digit span, but this was associated with duration of psychosis after the start of 
treatment and not DUP in the prodrome.  This group also had a lower IQ than the group 
with the shortest duration of psychosis after the start of treatment (a mean IQ of 96 
compared with 105), thereby highlighting another potential vulnerability.  In a systematic 
review, Rund (2014) identified only 6 studies out of 35 where there were significant 
correlations between DUP and changes in brain structure, however, this could not settle the 
question as to whether active psychosis might have the potential to be neurotoxic.   
 
This is of particular concern in the case of TRS where there may be delays in accessing 
clozapine, and perhaps an increased risk of non-compliance issues with ineffective 
treatments.  A concern shared by Harvey and Rosenthal (2016), who in their review of TRS 
refer to Boonstra et al. (2011), where the duration of untreated illness (DUP) preceding the 
first episode was unrelated to changes in brain volumes after 5 years, whereas the level of 
symptoms at baseline during the first episode were.  This would be compatible with a 
hypothesis that symptoms in an attenuated form are not neurotoxic whereas the intensity 
associated with psychosis itself might be.  In support, a longitudinal study over an average 
period of 7 years, reported decreases in whole and frontal brain volumes and reductions in 
white matter in the frontal and temporal lobes were associated with the duration of relapses 
(Andreasen et al., 2013).  Moreover, in a study of 162 individuals medicated with clozapine, 
Ucok et al. (2015) reported a more favourable response to clozapine was likely if the 
duration of illness was shorter before the initiation of clozapine, the number of antipsychotic 
trials were fewer and individuals were younger.   
 
Side-effects from inappropriate treatments could be a factor in deterioration, for example, 
one PET study with 6 TRS individuals receiving neuroleptic medication observed a 
blockade of 95% of D2 receptors in the striatum (Coppens et al., 1991).  This helpfully 
excluded the possibility that a D2 blockade was not being achieved in these chronically 
unwell participants, but its extent would now be regarded as exceeding therapeutic limits.   
 
However, as observed in the SPECT study of Abi-Dargham et al. (2000) above, striatal 
dopamine dysregulation may not be characteristic of all cases of schizophrenia.  This has 
been reinforced by a seminal PET study by Demjaha et al. (2012) where TRS participants 
did not exhibit elevations in striatal dopamine synthesis capacity relative to healthy controls, 
unlike matched FLRS participants. While all the clinical participants were receiving 
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antipsychotic medication, none were taking clozapine and the TRS group exhibited a high 
level of symptoms (with total PANSS scores greater or equal to 75), whereas the FLRS 
group were described as having mild or absent symptoms on all PANSS items.  Kim et al. 
(2017) subsequently addressed this imbalance by repeating the experimental design but also  
matching the TRS and FLRS groups with respect to symptom severity (presumably, this 
was now possible because the TRS participants were taking clozapine).  Again, DA 
synthesis capacity was significantly lower in the TRS group relative to the FLRS group, 
across the whole striatum (and also the subdivisions), thereby affirming this important 
distinction and its potential as a biomarker of treatment responsiveness. 
 
1.6.1 Considerations Concerning the use of Clozapine 
In 2008, in the US, clozapine was used to treat just 4.4% of individuals with schizophrenia, 
indicating it is under-prescribed in some countries and not accessed by many who could 
benefit from it (Meltzer, 2012).  The situation in England and Wales appears more 
reassuring as a recent audit of prescribing for 5,055 individuals with a diagnosis of 
schizophrenia, or schizoaffective disorder, revealed 23.7% were receiving clozapine, similar 
to the estimated prevalence of TRS by Wimberley et al. (2016).  However, Patel et al. 
(2014) also identified cases of treatment resistance where in 8.5% where “no clear reason” 
was documented as to why a trial of clozapine had not been undertaken. 
 
 One consideration may involve the requirement of regular monitoring as clozapine requires 
titration to therapeutic levels as there is no direct relationship between oral dosage and the 
achievement of stable therapeutic levels of clozapine and its major metabolites in plasma.  
These are influenced by rates of metabolism in the liver, associated with allelic variation in 
the cytochrome P450 system (Aitchison et al., 2000).  Moreover, smoking can speed up 
clozapine clearance considerably so care needs to be taken upon cessation as this could lead 
to excessive sedation or seizure (Maccall et al., 2009, Rostami- Hodjegan et al., 2004).  
Regular measurement of white blood cell counts is also required to identify developing 
agranulocytosis which is life-threatening (Kelly et al., 2007).   
 
More common side-effects may also deter, for example hyper-salivation, a high risk of 
considerable weight gain, hyperglycaemia, dyslipidaemia, diabetes, hypertension and further 
problems which may be related to these, including myocarditis (Whitney, et al., 2014).  In 
one study of 84 patients taking clozapine, 46.4% had metabolic syndrome and, possibly, 
only olanzapine rivals clozapine for this liability (Ahmed et al., 2008; Wu et al., 2008).  
However, such concerns are eclipsed by the considerable clinical benefit it can bring.  
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Clozapine also has the advantage of a very low liability for distressing and potentially 
irreversible extra pyramidal side effects (EPSE) such as involuntary “pill-rolling” 
movements of the fingers, dyskinesias and distorted movements of the tongue and mouth.  
For research and clinical purposes, it is also important to note that unlike other 
antipsychotics, it may take some considerable time to produce a therapeutic effect: in a one-
year prospective study of the response to clozapine at a fixed dose with TRS individuals 
who, apart from one, met the Kane criteria for TRS, some individuals converted to a clinical 
a response at six months and, impressively, 71.8% of the 32 participants had responded by 
12 months (Fabrazzo et al., 2002). 
 
1.6.2 A Challenge to Clozapine’s Superior Efficacy 
Clozapine’s primacy as the “gold standard” in the treatment of TRS and for reducing 
suicidal behaviour (Meltzer, 2012), has recently been questioned as a result of a meta-
analysis conducted by Samara et al. (2016), who observed the evidence base involves 
comparisons with first-generation antipsychotics.  Also, that the large effect size of the 
original study (Kane et al., 1988) has never been replicated while more recently a Cochrane 
review involving simple pair-wise comparisons with “atypical” antipsychotics did not find 
clozapine to be superior (Asenjo Lobos et al., 2010).  Their own meta-analysis of 40 single 
or double-blind randomised control trials involving more than 5,000 participants, with 
changes in symptom levels as the main outcome measure, revealed a surprising result: 
clozapine was not significantly better than most other drugs, atypical and typical, including 
olanzapine and risperidone.   
 
One possible explanation advanced by Samara et al. (2016), is the extra contact with 
services required for clozapine may introduce a form of bias when research is not blinded 
and it is further observed here, by the time a patient considers clozapine they may be more 
reconciled with their condition, more compliant and accepting of the need for treatment. 
However, as Samara et al. (2016) acknowledged it is difficult to blind research involving 
clozapine because of monitoring protocols; also, they had excluded three large non-blinded 
studies which supported clozapine’s superiority.  Taylor (2017) described the first trial 
conducted by Kane as “perhaps one of the last truly blind studies of clozapine” as staff and 
investigators were unfamiliar with it.  Kane and Correll (2016) writing in the editorial of the 
issue where the meta-analysis appears, further noted patients who are severely ill are less 
likely to enrol in demanding and complex randomised control studies; also the identification 
of TRS may be less stringent than in earlier studies.  Moreover, individuals may be less 
responsive to clozapine if it is introduced at a later stage of illness (Nielsen, Nielsen, and 
65 
 
Correll, 2012;  Ucok et al. 2015) and some of the subgroup and post hoc sensitivity analyses 
conducted by Samara et al. (2016) had low statistical power.   
 
The meta-analysis was “unarguably well conducted” (Taylor, 2017) and revealed 
differences in dosage across studies which were described by Kane and Correll (2016) as 
“potentially very important” because, as discussed above, clozapine is the only 
antipsychotic where an association has been reliably observed between drug plasma levels 
and the clinical response:  the meta-analysis revealed a mean dose of 392 mg/d had been 
administered in the studies involving comparisons with the atypicals - well below the 
average of 511 mg/d in the earlier studies using first generation antipsychotics.  Recognising 
this as an issue, Samara et al. (2016) comment “the likely underdosing in industry-funded 
trials could constitute a serious problem that could have affected the results.” (p.207) 
 
Kane and Correll (2016) agreed more research is needed, but some comfort might be taken 
from a study by Agid et al. (2011) who applied an algorithm to trials that involved switching 
treatment between the chemically different22 antipsychotics risperidone or olanzapine if 
there was no clinical response to the first; and then switching to clozapine if there was no 
response to either of these.  They reported that 74.5% of 244 participants responded to 
treatment after 12 weeks, and among the non-responders who were switched to the other 
drug, 16.6% responded.  However, among the treatment resistant individuals who then 
agreed to try clozapine, the response rate rose again to 75%.  A further striking example of 
clozapine’s efficacy, was observed by Rodriguez et al. (1997), discussed further below, 
where there was marked improvement in 17/39 participants who had been severely unwell 




22 Risperidone and Olanzapine are both “atypicals” in that they have a higher affinity for 5-HT2A 
serotonin receptors than D2 dopamine receptors and thereby minimise the risk of EPSE.  Olanzapine 
a selective monoaminergic antagonist with high affinity binding to Serotonin 5-HT, Dopamine, 
muscarinic, H1 and alpha receptors so perhaps it is here some efficacy lies).  (Incepta 
Pharmaceuticals).   
 
The pharmacological profiles of Olanzapine and Risperidone are quite different; for example, 
Olanzapine exerts strong antagonism at the muscarinic acetylcholine M2 and M3 receptors, while 
Risperidone does not (Lavalaye et al., 2001).  Risperidone also has the interesting property of being a 
“qualitative” atypical because at lower doses it has greater serotonin antagonism than dopamine 




1.6.3 The Need for the Consistent use of a Consensus Definition 
One of the observations to emerge from the debate around the meta-analysis, is that 
judgements determining TRS are inadequate if based on clinical judgement alone.  The 
terms “poor outcome schizophrenia”, “deficit schizophrenia”, “ultra-high resistant 
schizophrenia” and “Kraepelinian” schizophrenia” are all used in the literature but apart 
from those studies which state they have followed the Kane criteria, or a “modified” 
version, it is not always clear whether individuals have been given adequate trials of at least 
two antipsychotics and met other criteria for TRS or, alternatively, might be clozapine-
resistant.  This problem had been described two decades earlier by Conley and Buchanan 
(1997) who commented studies of TRS “have long been hampered by a lack of consistency 
in definition.”   
 
A working group on diagnostic guidelines and terminology for application in drug trials, led 
by Oliver Howes and including John Kane, was published in March 2017 (Howes et al., 
2017).  It presented the results of a systematic review of 42 randomized antipsychotic trials 
relating to TRS.  This revealed that half did not provide details of operationalized criteria 
and in the remaining 21 studies, the criteria varied considerably to the extent that they were 
identical only in 2 instances.  New guidelines have been presented for defining and 
reporting treatment resistance, what determines adequate treatment and represents treatment 
response: “Three key elements define the concept of treatment resistant schizophrenia:  
1) a confirmed diagnosis of schizophrenia based on validated criteria, 2) adequate 
pharmacological treatment, and 3) persistence of significant symptoms despite adequate 
treatment.” (p.217)  These principles distil the essence of criteria used by Kane et al. 
(1988)23. 
 
TRS may also have been under-researched because it is prone to confounds relating to 
chronicity, age, co-morbidities and concerns about the effects of exposure to other 
antipsychotics and treatments.  Associations between antipsychotics and structural changes 
have since been confirmed through regression in meta-analyses (Radua et al., 2012;  Fusar-
Poli et al., 2013).  Interestingly, 7 years after a first episode, those individuals who had 
 
23 In this seminal study, TRS was defined using historical, cross-sectional (actual) and prospective 
outcomes:  no good period of function in the previous 5 years;  at least three treatments of different 
antipsychotics from at least two chemically different classes, at doses equivalent of 1000mg 
chlorpromazine for a minimum of 6 weeks;  a high severity of symptoms (greater than 44 on the 
British Psychiatric Rating Scale), including two of the following:  unusual thought content, 
conceptual disorganisation, hallucinatory behaviour, suspiciousness.  That there should be no 
improvement, defined by a 20% reduction in symptoms after 6 weeks on haloperidol. 
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discontinued antipsychotic medication had double the recovery rate compared with those 
who had continued “maintenance” treatment (Wunderink et al., 2013).  This is just one 
study but adds to concerns about antipsychotic treatment, but as discussed above, relapse 
may be neurotoxic (quite apart from other ramifications), and this is the clinician’s 
“troublesome dilemma” (Andreasen et al., 2013).  If the general effect of antipsychotics is to 
lower glutamate transmission (Egerton et al., 2017) and further downregulation in 
glutamatergic transmission occurs during the disease process, or with age, perhaps timing 
and duration is important.    
 
On the evidence above, it is now clear TRS represents a sizeable subgroup who need a 
distinctive treatment strategy unless they are to run the risk of side-effects with ineffective 
treatments.  A further implication is that disregard for the distinction between FLRS and 
TRS may have led to a potentially important confound pervading the literature, affecting 
well-conceived and carefully conducted studies especially those involving small groups, as 
might be found in pathology and molecular biology studies, contributing to mixed results, 
perhaps, for example, Beasley et al. (2001, 2002).  There could also be an over-
representation of TRS among altruistic donors because of a higher suicide rate and disease 
severity. 
 
1.7 Brain alterations in TRS 
1.7.1 Brain morphology in TRS 
Even though few studies have been conducted with participants who meet the consensus 
guidelines definition of TRS, an extensive systematic review has been conducted by 
Mouchlianitis et al., 2016 (b) which identified 11 structural MRI studies that compared TRS 
individuals with healthy controls. In four of these, grey matter deficits were identified in at 
least 25 areas.  The most commonly implicated areas being the left middle frontal gyrus, 
right middle temporal gyrus and right precentral gyrus.  
 
Extensive reductions in GM were observed in TRS relative to FLRS groups by Anderson et 
al. 2015 (a), in the “superior, middle, and inferior temporal gyri, pre- and post-central gyri, 
middle and superior frontal gyri, right supramarginal gyrus, and right lateral occipital 
cortex”.  The U-TRS group showed reduced GM compared with FLRS in the right parietal 
operculum and left cerebellum. However, no differences were observed between the TRS 
group and ultra-TRS groups.  This might possibly suggest that TRS and U-TRS are on a 
continuum, where in the latter the disease is too advanced to be helped by clozapine (a 




Replicated reductions were observed by Mouchlianitis et al., 2016 (b) in the volume of the 
caudate nucleus consequent upon clozapine treatment, although it is suggested here this 
could reflect a reversal of the effects of treatment with conventional antipsychotics which 
have been observed to cause enlargement in this area.  Progressive reductions in striatal 
volume might arise in “poor outcome” individuals (Mitelman et al., 2009; Li et al. 2018). 
 
In a further systematic review (Nakajima et al., 2015) several studies were identified where 
structural predictors of the TRS had been reported.  However, they were unaware of any 
prospective studies involving structural changes following treatment with clozapine.  
However, this review may have been conducted before Ahmed et al. (2015) reported 
progressive reductions in grey matter during the first 6-9 months after commencing 
clozapine. It was inferred grey matter loss might not necessarily be pathological as 
symptoms remitted and could, perhaps, reflect the pruning of aberrant connections.   
In addition, lesser decrements in the left medial prefrontal and right middle temporal 
cortices were associated with a greater likelihood of treatment response. 
 
Looking beyond TRS, alterations have been observed in the gross anatomy of the 
orbitofrontal cortex in “deficit schizophrenia” which might include some TRS individuals.  
This is characterised by abnormalities in the patterns of sulci and gyri (Takahashi et al., 
2017).   A consortium meta-analysis led by Walton (2017) of PSZ, observed a correlation 
between negative symptoms and reductions in cortical thickness in the left medial 
orbitofrontal cortex which is implicated in an extensive network, including the thalamus, 
amygdala and ventral striatum relating to reward, identified by Menon (2011) as part of the 
Salience Network which includes the fronto-insular cortex and dorsal anterior cingulate as 
major nodes and may be influenced by the HPA-axis (Porcelli, Lewis, and Delgado 2012).   
 
Palaniyappan et al. (2011), observed areal contraction of the surface area in schizophrenia in 
regions associated with the three major networks, as described by Menon (2011):  the DMN, 
Central Executive and Salience Networks (especially in the left hemisphere).  Residual 
negative symptoms in their clinically stable participants correlated with the degree of 
contraction in the DMN and SN, but not in the CEN.  Also see Palaniyappan et al. (2013, a).  





1.7.2 Brain function in TRS - A Dearth of Functional Neuroimaging Studies 
Advances in computer power and the understanding of neural architecture, has also enabled 
the ongoing development and testing connectionist models of neural function that have been 
under way for around 40 years. More recently, fMRI has been used to distinguish between 
evoked and spontaneous intrinsic activity in the brain (Lu et al., 2007).  Commenting on this 
distinction, Raichle (2009) observed a paradigm shift could be under way.  Importantly, “the 
conclusion of several perspectives, is that the fMRI BOLD signal is best correlated with 
local field potentials” around pre and post-synaptic terminals.  Moreover, those falling in the 
gamma band frequency (24- 80+) and those exhibiting much slower frequencies (described 
as slow cortical potentials (SCPs), including the delta band (1-4 Hz) bear the greatest 
similarity to those of intrinsic activity. Raichle proposed the correlation between the BOLD 
signal and SCPs, thereby provides a “bridge to highly relevant, rich and diverse 
neurophysiologic literature.” (p.12732)  This is also considered here to be highly relevant to 
understanding the anatomy of working memory in schizophrenia.   
 
Since the inception of this project, the systematic review by Nakajima et al. (2015) on 
neuroimaging studies involving TRS has been timely.  Using search criteria that include the 
definition of TRS as involving “a failure to respond to at least two antipsychotic 
medications” (p.171), they identified 25 articles suitable for review, however, only 3 used 
fMRI and only 5 directly compared TRS and non-TRS, nor did they find any replication of 
results.  Another valuable systematic review of TRS, and related terms, conducted by 
Mouchlianitis et al., 2016 (b), above, involved a different database.  Five functional MRI 
studies were identified (three resting-state MRI studies).  Another used arterial spin 
labelling “in individuals with resistant auditory hallucinations showed increased cerebral 
blood flow in areas involved in speech processing” (p.452)24.  The fifth was a small fMRI 
BOLD study by Fitzgerald et al., 2007 concerning 3 participants described as having 
treatment resistant auditory verbal hallucinations.  
 
The diversity of the studies was commented upon which may be one reason this extensive 
analysis found few findings that had been replicated.  Contrasting changes in the caudate 
were interesting as this might reflect dysregulation in the AST which might be expected 
differ between TRS and FLRS in the light of the observations concerning normal 
presynaptic synthesis of dopamine in TRS (Demjaha et al, 2012 and Kim et al, 2017), 
however as Mouchlianitis et al., 2016 (b) observed volumetric changes may be attributed to 
clozapine and atypicals having contrasting effects, which may be further complicated by sex 
 
24 Wolf et al. (2012) cited in Mouchlianitis et al., 2016(b).  Also see McGuire et al., 1993. 
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differences (Scheepers et al., 2001; Heitmiller et al., 2004).  The observation with the 
greatest replication was that of “a greater reduction in grey matter in resistant patients, 
predominantly in frontal areas.” (p.458)  This was a main finding of the impressive study by 
Anderson et al., (2015,a) who compared TRS with FLRS, clozapine non-responders (or  
U-TRS) and a healthy control group, however, evidence of replication was still modest.  
 
There is perhaps, at least one fMRI BOLD study that may have escaped the searches in the 
above reviews, as it was not specifically concerned with treatment resistance or related 
terms, but which may be relevant to the research reported here:  a cross-sectional n-back 
study conducted by Jansma et al. (2004) where 8/10 clinical participants were receiving 
treatment with clozapine.  However, both reviews did identify one peer-reviewed fMRI 
BOLD study.  This involved 3 participants meeting the TRS definition and 4 healthy control 
participants (Fitzgerald et al., 2007).  Apart from the very small size of the sample, it should 
be noted that one of the participants was not receiving clozapine at the time.  Mixing 
participants who are taking, or not taking, clozapine seems less than ideal.   
 
This raises another important aspect of TRS research, which is the possibility that, in 
responders, treatment with clozapine may go some way towards “normalising” aspects of 
function.  This highlights the value of prospective studies in this area and might also help to 
reconcile mixed observations.  Also, while Fitzgerald et al. (2007), had a prospective design, 
the independent variable was treatment with rTMS.  However, in retrospect, it did identify 
areas of differential contrasts with healthy controls which may be relevant to TRS - if not 
the direction, and that might not, in any case, reliably translate across methodologies or the 
stage of illness of participants. Fitzgerald et al. (2007), notably reported relative 
hypoactvation in the TRS group before treatment in the medial frontal cortex, extending to 
the inferior frontal cortex, anterior cingulate, left superior frontal gyrus and parietal areas.  
Greater activation in the left caudate and precentral gyrus was also observed. 
 
1.7.3  Evidence Concerning TRS from Molecular Neuroimaging  
Similarly, in one of the rare PET studies of TRS individuals who had responded to six 
months of clozapine treatment compared with conventional antipsychotic treatment for six 
months, Molina et al. (2007) observed “clear hypofrontality”.  An earlier study by Molina 
using single proton emission computed tomography (SPECT) compared participants after 6 
months’ treatment with conventional antipsychotics with a subsequent 6-month course of 
clozapine (Rodriguez et al., 1997; 1998).  The possibility of hypofrontality had been 
indicated by reference to a normative database but not confirmed.  However, comparisons 
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between the treatment groups indicated the non-responders to clozapine (which might be 
equated with ultra-treatment resistance) generally exhibited less perfusion with significant 
differences with the clozapine responders in the left inferior dorsolateral prefrontal cortex, 
right superior dorsolateral prefrontal cortex, thalamus and basal ganglia – resembling part of 
the thalamo-cortical loop circuitry.  It is tentatively suggested here the lack of response 
might possibly reflect the endpoint of a more severe form of illness where structural deficits 
may have met their limits, (for example, through widespread dendritic atrophy). 
 
Interestingly, a therapeutic response to clozapine was associated with a significant lowering 
of perfusion values in within-subject comparisons with conventional antipsychotic treatment  
in the basal ganglia bilaterally, thalamus and right superior dorsolateral prefrontal cortex 
and the left anterior prefrontal cortex.  A further lowering of perfusion in the context of a 
therapeutic response seems counter-intuitive unless, perhaps, further brain changes occur in 
that time.  This is quite possible since, as mentioned above (p.68), grey matter loss was 
observed by Ahmed et al. (2015), 6-9 months after treatment with clozapine had begun.  
Irrespective of the response, this was marked in the medial prefrontal cortex and also the 
periventricular area which is presumed to reflect atrophy in overlying structures (and so 
might include the basal ganglia).   
 
The early SPECT study is important in several respects: firstly, for its rarity value and the 
relatively large number of participants (39 “treatment-refractory”), also selection of the 
clinical participants used criteria similar to Kane et al. (1988) and they defined the treatment 
response as being a 50% decrease on clinical rating scales for positive and negative 
symptoms. It was designed to look at the clinical response to clozapine after medication was 
switched from conventional neuroleptics with the differences between responders and non-
responders providing outcome measures.  Treatment with clozapine had the effect of 
lowering metabolism in responders to clozapine while, as indicated above, hypometabolism 
in TRS was affirmed in the prospective study by Molina et al. (2007). 
 
Molina et al. (2007) also referred to research which demonstrates clozapine can raise 
concentrations of extracellular dopamine in the prefrontal cortex (Yamamoto, Pehek, and 
Meltzer, 1994; Moghaddam and Bunney, 1990).  The overall effect of this may be to 
increase GABA release, thereby providing inhibition into this area: “this GABA release 
being coherent with a lower metabolic rate.” (p.60)  In support, they referred to a preclinical 
study by Grobin and Deutch (1998) that demonstrated dopamine can regulate levels of 
GABA in the prefrontal cortex, possibly through the actions of D2 agonism on interneurons.  
Laruelle (2005; 2014) has also highlighted the interaction between glutamatergic and 
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dopaminergic pathways and the potential consequences of a dopamine imbalance (between 
D1 and D2 receptors) upon NMDA glutamate receptor mediated function.   
 
A study by Abi-Dargham et al. (2012) replicated and extended the observations of an earlier 
study that dopamine 1 (D1) receptors were increased in medication naïve individuals in the 
DLPFC, orbito-frontal cortex (OFC) and medial prefrontal cortex (mPFC) and normalised 
through antipsychotic treatment - the inference being that an ineffective upregulation occurs 
because of a loss of sensitivity to dopamine (Abi-Dargham et al., 2002; Rao et al., 2018).  
The 2012 study also demonstrated that prior exposure to anti-psychotics may have reversed 
this in a separate group of individuals who were drug-free at the time of scanning.   
 
More recently, ACC hyperactivity has been observed in individuals who meet the Kane 
criteria for TRS, or a modified version, using proton magnetic resonance spectroscopy 
(Egerton et al., 2012;  Demjaha et al., 2014;  Mouchlianitis et al., 2016 (a) but not in 
participants who are being medicated with clozapine, raising the possibility that treatment 
may have normalised glutamatergic function although causality cannot be inferred given the 
cross-sectional nature of the studies (Goldstein et al., 2015).  Moreover, it is important to 
emphasise, even if this were the case, the haemodynamic response to executive tasks in 
fMRI studies, may still be influenced to the by individual differences with respect to “the 
inverted-U” of sensitivity to dopamine which helps to inhibit or modulate glutamatergic 
transmission.    
 
1.7.4  Evidence Concerning TRS from Connectivity Studies 
At the point of writing, only three resting state connectivity studies exploring whole brain 
connectivity appear to have been published concerning TRS (Ganella et al., 2017, 2018; 
Wang et al., 2015), however, the preliminary impression is this approach may yield valuable 
biomarkers that may help diagnose TRS an early stage if, for example, TRS is well-
characterised as a disorder principally affecting connector hubs in large-scale networks.  
The study by Ganella et al. (2017) explored and compared whole-brain functional 
connectivity in TRS participants who were taking clozapine with healthy controls. This 
involved 70 nodal pairings but the efficiency of a network is “inversely related to the 
number of intermediate regions that must be traversed for a pair of brain regions to 
communicate with each other.” (p.74)   
 
Possibly the most important observations concern a potential biomarker of TRS in the 
highly significant observations of reduced global efficiency along with increased local 
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efficiency in TRS participants relative to controls.  Ganella et al. (2017) posed the important 
question as to:   
“whether the findings in our study of TRS provide evidence to a unique pattern of 
connectivity in comparison to the extant literature in schizophrenia.” (p.76)   
 
It was further observed the mean duration of illness in the TRS group was 17.9 years and no 
relationship was found with global network properties.  However, the authors commented 
this could reflect a ceiling effect on connectivity and perhaps also medication effects.  
Specifically, Ganella et al. (2017) observed reductions in connectivity strength in 228 
functional connections (3.4%), while none of the regional pairings in the TRS group 
exhibited increases in connectivity strength relative to the control group.  It was further 
established these reductions occurred across all six brain lobes25, but were concentrated in 
the frontal, occipital and temporal lobes (also see Palaniyappan et al., 2013 (b), p.1813).  
The majority of reductions occurred between the frontal lobe and cuneus in the occipital 
lobe and between the occipital lobe and the paracentral lobule; also, between the fusiform 
gyrus in the temporal lobe and the occipital lobe, further, between Heschl’s gyrus in the 
temporal lobe and the frontal lobe.  There were some lesser decrements involving the 
parietal lobe and connections with the occipital and temporal lobes which were not 
commented upon.  This might suggest these connections are relatively unaffected, 
alternatively, parietal connections are so important they are highly protected or maintained, 
for example, it has been proposed the posterior cingulate cortex (PCC) may have a role in 
the fine-tuning of the connectivity of intrinsic networks in the service of attentional focus 
(Leech et al., 2011; Leech and Sharp, 2014).   
 
Further, the strong implication of areas involved in audition and visual perception lends 
strength to proposals made elsewhere in this thesis that TRS individuals may have early 
sensory processing deficits which may adversely impact upon the efficiency of encoding, 
short term learning of auditorily presented verbal material and executive task performance.  
 
Interestingly, in the study by Wang et al. (2015) a group of unaffected siblings appeared to 
have some potentially compensatory connections which were increased relative to controls, 
but “moderately reduced” in the TRS group.  These were “widespread, especially between 
the occipital and frontal lobes and between the parietal and temporal lobes.” (p.101)   
 
 
25 Occipital, Temporal, Parietal, Frontal, Subcortical and Posterior. 
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Observations on the connectivity between the occipital and frontal lobes were supported 
when Ganella et al. (2018) expanded their earlier study to include rs connectivity 
measurements with unaffected siblings. It was observed brain networks exhibited increased 
local efficiency in both unaffected siblings and TRS compared with the control group.  This 
confers greater resilience with respect to local network disruption and was present in all 
areas when the network was decomposed into four modules (i.e. distinct brain areas) but 
was significant only for the visual and cerebellar modules but not for the salience or default 
modules.  It was further observed there were significant reductions in global efficiency for 
both groups relative to the control group, while there were no significant differences 
between the TRS and sibling groups.   
 
1.8 Multiple Risk Factors and Integrative Approaches 
Just as many scientists have broadened their perspectives on schizophrenia there has been  
an acceleration in research. This progress is reflected in Figure 1. 1 based on simple search 
terms applied to the Public Medicine database of the National Institute of Mental Health 
(U.S).  This revealed more than 125,000 peer reviewed articles have been published on 
“schizophrenia” and in 2017 the number of articles was 6495, while 148 papers were 
published on “treatment resistant schizophrenia.”  
 
Many genes of small effect have been implicated in the pathogenesis of schizophrenia, 
along with a range of environmental and psychosocial influences which may be risk factors 
or precipitants of psychosis.  As mentioned in section 1.1, these include poverty, 
urbanisation, migration, industrialisation and a loss of social support; also, exposure to 
toxins, disease, vitamin D deficiency, poverty and drugs of abuse.  All of which might also 
have perinatal effects.  An impressive accumulation of knowledge indicates various paths 
might lead to schizophrenia, impacting different individuals in different ways, contributing 
to the heterogeneity of the condition.   
 
A useful way of organising and understanding the accumulation of knowledge has been 
achieved in integrative and bio-social models, e.g. Keshavan (1999, 2011), Maynard et al. 
(2001), Howes and Kapur (2009), Howes and Murray (2014), Murray et al. (2017), Abi-
Dargham (2017).  By accommodating the timing of insults and different pathological 




Figure 1. 1   Exponential Growth in Publications on Schizophrenia since 1966  
Compared with those referencing Clozapine (b) and Treatment Resistant Schizophrenia (c).
 
where the burden of pathology overwhelms the processes of adaptation and repair.  One of 
the achievements of an integrative approach is that has helped a range of seemingly 
disparate and odd associations with schizophrenia, such as season of birth, cannabis use and 
neurological “soft signs”, to be reconciled with the realisation that schizophrenia may, 
perhaps, be best characterised as a “developmental risk factor model of psychosis” (Murray 
et al., 2017) instead of the neurodegenerative theories which have prevailed historically. 
 
One highly detailed and impressive contribution has been Keshavan’s (1999) ‘three hit’ 
model, which reconciled genetic and environmental factors with a glutamatergic explanation 
of pathology occurring during early and late development with possible neurodegenerative 
changes.  A brain state was proposed where there was a reduction in tonic glutamatergic 
transmission consequent upon early neuronal loss and a subsequent pathological excess of 











phasic activity after illness onset.  It was also noted dopaminergic activity in the striatum is 
under the control of glutamatergic neurons, so dysregulation might predispose to hyper- and 
hypo-dopaminergia.  More recently, Grace (2012, 2016), has described how tonic 
glutamatergic activity sets the responsivity of dopamine neurons in the ventral tegmental 
area (VTA) to phasic glutamatergic signals.  
 
Further, Keshavan (1999) described periods of sensitivity across the lifespan when 
pathological factors might be especially potent as “windows of vulnerability.”  The first 
window concerned the perinatal period, for example, Keshavan highlighted the importance 
of glutamatergic transmission to neuronal migration.  In the years since, evidence has 
accrued to suggest the fetus during the second or third trimesters may be vulnerable 
maternal stress (Yehuda et al. 2005), infection, malnutrition or intoxication which may 
degrade or overwhelm defences, including the placental barrier enzyme, 11beta-
hydroxysteroid dehydrogenase.  There may also be long-lasting effects on immune and 
endocrine function which continue into adulthood and may be reflected in associations with 
weight, blood pressure, stress reactivity, behaviour and brain alterations (reviewed by 
Reynolds, 2012).    Moreover, associations between schizophrenia with the season of birth 
might be interpreted from an endocrine or immune perspective concerning the availability of 
food or increased risk of maternal infection during the winter (Bullmore, 2018).  
 
Other risk factors include obstetric complications such as hypoxia during delivery, being 
born preterm and treatments associated with this;  for example, the potentially life-saving 
administration of glucocorticoids (for example, to aid fetal lung maturation) may incur 
oxidative damage (Camm et al., 2011), while, a preclinical study by Virdee et al. (2016) 
found that antenatal exposure to dexamethasone “dramatically” increased mesencephalic 
dopamine neurons in the offspring, while, in a possible compensatory response, D1 
receptors were downregulated in the adult ACC, prelimbic areas and striatum. 
 
Keshavan proposed adolescence was a second window when a major reorganisation and 
pruning of synapses occurs (Keshavan 1999; Keshavan, Anderson, and Pettergrew 1994; 
Feinberg, 1982) along with unique “psychosocial stresses.”  There might be an association 
with immune regulation as microglia have a role in synaptic pruning (Paolicelli, et al., 2011; 
Perry and Teeling, 2013) where, for example, around 40-50% of excitatory synapses are lost 
in the DLPFC alone (Gonzalez-Burgos, et al., 2008).  Around this time, as learning 
capabilities mature, for example, Monaco et al. (2015), citing Dumas (2005), observed that 
many NR2B subunits in NMDA receptors are switched from the NR2B to the NR2A form, 
thereby changing the slow kinetics on the post-synaptic spine which enable sustained firing 
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and support working memory.  However, this also reduces the risk of excessive and 
damaging influxes of calcium ions.  (This trade-off is described as a “double edged sword”). 
A third “window” related to disease progression with neurodegenerative changes observed 
in some individuals (Theberge et al., 2007; Aoyama et al., 2011) which might cause or 
exacerbate cognitive deficits.  In view of sex differences in epidemiology (discussed above), 
parturition and the menopause could represent further windows of vulnerability, when the 
neuroprotection of ovarian hormones and neurotropins such as BDNF may also decline - 
e.g. Pluchino et al., 2009; Komulainen et al., 2008. 
 
Integrative approaches such as that of Keshavan (1999) have apparent “face validity” by 
recognising schizophrenia is a complex and multifactorial disorder, involving interactions 
across different systems.  Each re-articulation of major integrative theories reflects that so 
much more has been learned.  This will continue as the “common language” of 
neurotransmitters, hormones and immune factors is decoded and more is learned regarding 
communication at the level of the networks - between local and global and through the 
various frequencies of oscillatory rhythms.   
 
An example of the inter-relatedness of biological functions was provided by Brattsand and 
Linden (1996) when describing the interplay of the immune system and the HPA-axis: 
 
Glucocorticoids inhibit the expression and action of most cytokines. This is part of the in 
vivo feed-back system between inflammation-derived cytokines and CNS-adrenal produced 
corticosteroids with the probable physiological relevance to balance parts of the host 
defence and anti-inflammatory systems of the body. (p.81) 
  
Moreover, it is apparent, NMDA-receptor antagonism can increase the number of 
circulating immune cells and cytokines, e.g. see review by Colucci et al. (2017).  These 
observations illustrate how the endocrine, immune and central nervous systems can work 
together, and also provides one mechanism by which NMDAR hypothesis of schizophrenia 
could be expanded to accommodate immunological features.  It is proposed below that an 
immunological explanation of negative symptoms seems also possible and may be 





1.9 STM, WM, Executive Function and Fluid Intelligence  
A variety of models and terms have been used in relation to working memory and attention.  
Therefore, this section will examine the overlapping concepts of STM, WM, executive 
function and fluid intelligence.  It also highlights cognitive control and selective attention 
exercised by a central executive or central executive network (CEN).  In some accounts 
cognitive control seems synonymous with “attention” (not necessarily selective attention) 
or, perhaps, a “controlled processing capability” exercised by the DLPFC and similar to 
fluid intelligence (Engle et al., 1999).  Finally, this section introduces the idea of STM as 
“activated LTM” and how this may relate to processes involved in synaptic plasticity.   
 
1.9.1 Short-Term Memory, Working Memory and Executive Function 
The terms working memory (WM) and short-term memory (STM) are sometimes used 
interchangeably in the literature, but STM as a construct may be best viewed as a subset of 
working memory (Engle et al., 1999).  Also, while there appears to be a large degree of 
overlap between “working memory” and “executive function” some executive functions 
may place no or minimal demands upon memory, for example, the inhibition of pre-potent 
responses.  The meta-analysis by Minzenberg et al. (2009), which included a wide range of 
paradigms26 observed a similar network is activated across tasks requiring executive 
function.27   Working memory processes specifically associated with the n-back task involve 
the maintenance, manipulation and updating of remembered information, along with on-line 
monitoring of operations (Glahn et al., 2005, p.62; Owen et al., 2005, p.47). 
 
Executive function has been broadly defined as: “processes necessary to control or regulate 
other cognitive processes in the service of goal-directed behaviour” (Minzenberg et. al., 
2009, p.812).   Maintaining task goals and following necessary processing steps is clearly 
vital and may be under the control of attention - as assigned to the limited capacity central 
executive in the multicomponent model which originated with Baddeley and Hitch (1974).  
Since then, further executive functions have been added to the central executive, as 
 
26 The meta-analysis comprised 19 n-back studies and 21 other studies of executive function:  
Oddball paradigm, sequence recall, Stroop, Wisconsin Card Sorting and Word Generation.  While not 
all medication details were available, clozapine use appears to have been very limited with the 
exception of a study by Jansma et al., 2004 where 8/10 participants received clozapine and 2 received 
olanzapine.  
 
27 “Within-group analysis of all of the 41 studies indicated that healthy controls and schizophrenic 
patients activated a similarly distributed cortical-subcortical network while performing executive 
tasks, including the DLPFC, ACC, VLPFC, premotor cortex, lateral temporal cortical areas, parietal 
areas, cerebellum, and thalamus.” Minzenberg et al., 2010, p.818. 
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enumerated by St. Clair-Thompson and Gathercole (2007), these include:  temporary 
activations in LTM, scheduling multiple tasks, switching between tasks, the operation of 
selective attention along with the ability to inhibit information.  Miyake (2000) suggested 
the following were particularly important:  shifting between tasks and information sets, 
monitoring performance and updating information in working memory, inhibiting dominant 
or automatic responses.   
 
Following Menon and Uddin (2010) and Crittenden et al. (2015), it is suggested here that 
shifting between tasks and information sets is likely to involve the dynamic interaction of 
three large-scale networks:  the central executive network, salience network and default 
mode network.  Further, it seems widely accepted task monitoring is likely to engage the 
ACC in a fairly automatic way using feedback processes and prediction error until an error, 
or a salient stimulus, engages the attentional processes of the central executive network 
(Kerns et al., 2005;  Carter and van Veen, 2007;  Heilbronner et al., 2016).  The updating 
function is classically required by the n-back task, although there may be a debate about 
how this is achieved:  this might be through rehearsal using the phonological loop or the 
visuo-spatial sketch-pad;  alternatively, it might involve maintaining representations through 
focused attention boosting activations above threshold (Engle et al., 1991).  If none of these 
strategies are efficient, then it is suggested here a mix of strategies could be tried, including 
reliance on familiarity, possibly based on trace decay.  The inhibition of dominant 
responses, discussed by Miyake (2000), may gain greater prominence at a later stage of 
processing, however, it is inhibition of distractors and partially activated representations at 
the encoding and maintenance stages that was regarded as “critical” to WM capacity by 
Engle et al. (1991).  An example of the potentially deleterious impact upon working 
memory of failing to inhibit distractors and selectively attend to relevant information can be 
found in Conway et al. 2001 (section 1.10.3), with the caveat this may not be problematic 
when task demands are within capacity.  
 
1.9.2 Multicomponent Approaches to Working Memory/ Executive Function 
One of the strengths of the components approach of Baddeley (2010; 2012) and Baddeley 
and Hitch, (1974) is its simplicity.  This has highlighted processes and capacity limitations, 
while assessing compatibility with emerging evidence.  The original concept of Baddeley 
and Hitch (along with a visuo-spatial sketch-pad and phonological loop) involved a central 
executive, representing the well-learned/automatic and controlled aspects of attention, 
particularly, in relation to actions which built upon the work of Norman and Shallice (1986).  
More recently Baddeley (2012) has commented it is “increasingly clear that the loop can 
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also provide a means of action control.”  When the association with action is considered, 
this may help to explain why so much of the premotor cortex, BA6, is activated bilaterally 
in n-back tasks which require a simple button press.  Afterall, the brain continually receives 
information from internal and external sources.  It has been proposed this information may 
cascade in both directions (top-down, bottom up), possibly, in the manner of distributed 
interactive activation where there are inhibitory links between competing features or 
representations at different levels (e.g. letter features,  letters, words), also between levels 
(McClelland and Rumelhart, 1981; McClelland and Rogers, 2003) to prime perception, 
understanding and potential responses.  Processing may also be facilitated by the “top-
down” biasing of filters through cognitive control (Miller and Cohen, 2001).   
 
These models suggest the links between perception, thought and action may be very close 
indeed.  However, it is also the case that BA 6 is proximal to the DLPFC so activations may 
be related to this area which in earlier studies was directly associated with short-term 
memory, for example, “memory fields” were inferred on the basis of cellular recordings in 
monkeys during delayed response paradigms (Goldman-Rakic, 1995).  The DLPFC in 
conjunction with parietal areas is now more generally conceived as a “multiple-demand 
system” which is closely allied to fluid intelligence (Duncan, 2010).  
 
Baddeley (2000) added a fourth component to the Baddeley and Hitch (1974) model to 
account for prose comprehension in the form of an “episodic buffer” which enables the 
integration of information represented in different codes, for example, spatial and verbal 
codes from the visuo-spatial sketch-pad and phonological loop, or from LTM.  It was further 
proposed this might be used to model the environment and construct new representations.  
However, the episodic buffer was subsequently described as an “essentially passive 
structure on which bindings achieved elsewhere can be displayed” but where “executive 
processes” can manipulate information (Baddeley, 2012, p.17).  One view of the evidence 
from visual perception is that the brain samples the environment and largely “constructs” 
what it perceives by drawing upon longer term representations (Cohen et al., 2016), so 
something like an episodic buffer could be involved.  Baddeley has generally been 
constrained in mapping functions and structures to anatomy although, it was proposed the 
phonological loop was associated with BA 40 and BA 44, while the visuospatial sketchpad 
might involve BA 6, 19, 40 and 47 in the right hemisphere (Baddeley, 2000).  It is ventured 
here, the functions “episodic buffer” and the processing of multiple codes, might be 
conducted in the striatal-thalamo-cortical loops, involving the AST and DLPFC.  However, 




1.9.3 Short-Term Memory as Activated Long-Term Synaptic Representations 
Some leading theorists appear aligned with the proposal that STM may be instantiated 
through activated long-term representations (Cowan, 1995; 2005; Engle et al., 1999).  This 
may have originated with Ruchkin et al., 2003, after co-activations were observed in the 
posterior areas associated with comprehension, visual cortex and prefrontal cortex.  The 
idea, however, was explicitly rejected by Baddeley (2000), along with a proposal “that the 
slave systems merely represent activations within the processes of visual and verbal 
perception and production” p.422.  Baddeley did assimilate the observations of Gathercole 
(1995) who demonstrated long-term lexical knowledge influenced the immediate recall of 
nonwords, commenting this suggested that “information flows from LTM to the 
[phonological] loop as well as the reverse” (Baddeley, 2012, p.11).  However, the role of 
LTM in STM was circumscribed:  
  
For example, memory for a telephone number spoken in your native language is 
substantially better than that for a number spoken in a foreign language, reflecting the 
importance of long-term phonological knowledge in short-term verbal memory. The 
capacity to remember and repeat a string of unrelated words is about five items, but if they 
comprise a meaningful sentence, the span is around 15 words, reflecting a contribution from 
grammar and meaning, both depending on different aspects of long-term memory. 
(Baddeley, 2010, p.140).  
 
Nonetheless, the idea of STM as “reactivated LTM” could map readily onto biological 
substrates at the synaptic level, for example, with short-term plasticity and transient 
activation of existing representations reflected in inhibitory and excitatory postsynaptic 
potentials;  for example, Cowan (1995) defined working memory as “the set of activated 
memory elements.” (p.100) and in their model elements (or microfeatures) are at different 
stages of activation and are subject to trace decay if they are not boosted, for example, 
through the application of capacity-limited attention.  Further, as discussed by Engle et al. 
(1999), even when activations are outside conscious awareness, they may influence 
perceptual and semantic processing.  Also, Eriksson et al. (2015) observe, working memory 
“may involve short-term plasticity ... it works by recruiting already existing synapses and 
ion channels (“activated LTM”).” (p.34)  By contrast, longer term changes to memory 
involve protein synthesis and occur over a longer time-course (Friston, 2002).  In section  
1. 5. 5 on synaptic plasticity an example of the precision that may be required can be found 
by reference to Xu and Yao (2010) who described how changes may be achieved through 
the temporary lifting of tonic inhibition in pre- and post-synaptic circuits. 
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1.9.4 The Relationship between Working Memory and Fluid Intelligence   
A distinction between crystallised and fluid intelligence is reflected in the subscales of the 
WASI (section 2.7.1).  It is also clearly made in Baddeley’s (2012) model with crystallized 
knowledge segregating with visual semantics, language and episodic LTM, while the 
sketch-pad, phonological loop, and episodic buffer, along with the central executive, form 
the working memory system which aligns with fluid intelligence (Figure 3 in Baddeley, 
2012, p.16). Consistent with this, it is further observed that WM is “represented by a series 
of fluid systems that require only temporary activation” while LTM represents “more 
permanent crystallized skills and knowledge.” p.11.  Examples of “fluid” operations include 
planning, chunking or aggregating information, perceptual grouping, the use of imagery, 
updating and temporal sequencing.  Importantly, this division was also supported by a latent 
variable analysis conducted by Engle et al. (1999), whose study of 133 healthy participants 
affirmed STM as a subcomponent of working memory and observed working memory was 
strongly related to fluid intelligence, whereas short-term memory was not. The point was 
reinforced in Joyce (2013), who observed “The cognitive requirements of tests of fluid 
intelligence overlap considerably with those of executive function.” (p.162).  Moreover, 
functional neuroimaging studies have indicated the areas involved in cognitive control are 
also active in tests of fluid intelligence (Gray et al., 2003; Duncan, 2010).  Therefore, when 
considering the correlates of performance IQ in this study, the terms “executive function”, 
“cognitive control” and “fluid intelligence”, refer to a similar underlying construct.  Further, 
applying Baddeley (2012), it is assumed VIQ scores will be strongly influenced by lexical 
knowledge in LTM, while PIQ scores will be strongly associated with fluid intelligence. 
 
1.10   Translating Neurobiology to Symptoms 
Kapur’s (2003) conception of dopamine as a learning signal which confers “motivational 
salience” upon internal representations and external stimuli and events, may have resonated 
with thousands of clinicians who have witnessed the increased drive into sensory and motor 
circuits during an episode of psychosis as reflected in “pressure of speech”, flight of ideas, 
hyperlocomotion and agitation.  Consistent with the idea of “salience”, phenomenological 
experiences of visual and auditory hyperacuity have also been reported (Kelemen et al., 
2013). Even more pertinent, perhaps, is Grace’s (2010; 2016) observation that chronic 
hyperactivity in the dopaminergic cells of the VTA would mean that exaggerated responses 
would be given to stimuli, thereby conferring salience. 
 
Many accounts are now attributing symptoms to impaired connectivity.  This found 
eloquent expression in Friston and Frith (1995), who proposed that while pathology 
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localised to areas like the DLPFC might explain some symptoms of schizophrenia, 
“abnormal interactions or the integration between different cortical areas” may also have 
explanatory power. (p.92)  Further, it was assumed that “the frontal cortices are necessary 
for intrinsically generated behaviour.” (p.93)  In doing so they drew upon a wealth of 
neurological, neuropsychological and preclinical studies; for example, analogies were made 
between “psychomotor poverty” in schizophrenia which may include decrements in 
vocalisation, flat vocal expression, social withdrawal or diminished facial expression, with 
the kinds of symptoms observed in degenerative or acquired frontal lobe damage involving 
the ACC and/or supplementary motor area.  Also, deficits in executive function have been 
observed following frontal lobe damage: for example, in a study that compared 26 
individuals with unilateral or bilateral lesions with age and IQ matched controls, individuals 
with frontal lobe lesions needed more time and were more impaired on a test of spatial 
working memory (Owen et al., 1990).  Further, in this study, individuals with frontal lobe 
lesions appeared less able to improve performance through the use of strategy which might 
be related to the impaired monitoring of behaviour as proposed by Frith (2008). 
 
However, negative and other symptoms might be also explained by deficits in the 
functioning of frontal-striatal loops where information is integrated and the willed initiation 
of behaviour (which might be informed after consultation with long-term memory  
involving other networks e.g. Frith, 1987;  Davey et al., 2016;  Kaminiski et al., 2017;  
also reviewed by Robbins, 1990).  Frith (1987) had suggested both positive and negative 
symptoms might arise from impairments in willed intentions which are not correctly 
monitored and can lead to behavioural symptoms.  “Either a patient fails to recognise  
that an action is the consequence of his own will (positive symptoms), or else the will  
fails to generate the actions altogether (negative symptoms).” (p.634)   
Moreover, this will act as a barrier to better performance in future if it is not possible to 
recognise what kind  of error has been made. 
 
1.10.1 Dysconnectivity and Different forms of Dysconnection 
The idea of prediction error, working automatically and continuously below conscious 
awareness for much of the time, shows how behaviour can be informed and finessed, for 
example, it can use proprioceptive information to guide and smooth movement.  A failure 
might only be noticed, for example, by missing the last step on the stairs (Marsh, 2014).  It 
may also apply to higher cognitive processes with schizophrenic symptoms being a possible 
consequence of faulty prediction error and monitoring (Peterburs and Desmond, 2016).  
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The mechanism for this aberration was proposed by Friston and Frith (1995) to be 
disconnection.  This also finds application to higher cognitive processes as well and, as 
discussed later, it may lead to failures in error detection which diminishes the prospects of 
improvement.  Other examples might include premature decision making on the basis of 
inadequate information (“jumping to conclusions”), delusions (where, perhaps, the logic of a 
situation goes awry); hallucinations (where the source of sensory stimulation may be 
misattributed).  Possibly all served by a strong drive for the brain to interpret sensory inputs, 
which may be further influenced by cognitive biases and emotional aspects.   
 
Friston and Frith (1995) observed while dysconnectivity may accommodate the diversity of 
symptoms in schizophrenia, the impaired use of prediction error arising from this need not 
be incompatible with other explanations (e.g. auditory-visual hallucinations may have more 
than one cause). Since then, amongst many functions, evidence has mounted that the ACC 
serves an important role in monitoring for conflict and errors (Carter and van Veen 2007; 
Ullsperger, Danielmeier, and Jocham, 2014).   
 
The literature on oscillatory rhythms, as applied to schizophrenia, has burgeoned since it has 
become evident that electrophysiological recordings of local field potentials are not just of 
interest to sleep researchers and clinicians looking for signs of pathology but reflect an 
important form of communication that synchronizes and integrates different information 
streams:  oscillatory rhythms may also facilitate long range communication across and 
between networks, for example, by stimulating and “entraining” patterns of activity in cell 
populations downstream.  Gamma oscillations which represent a broad range of frequencies, 
may be involved in selective attention (Fries, 2001) and support working memory at 
increasing levels of cognitive load: for example, Lewis et al. (2004) observed “Studies in 
non-human primates indicate that normal working memory function depends upon 
appropriate GABA neurotransmission in the DLPFC, and alterations in markers of GABA 
neurotransmitters are well documented in the DLPFC of subjects with schizophrenia.” 
(p.143)  Further evidence that oscillatory rhythms support working memory performance 
has come from:  Basar-Eroglu et al. (2007), Menzies et al. (2007), Haenschel et al. (2009), 
Michels et al. (2012), Chen et al. (2014), Roux and Uhlhaas (2014), Senkowski and Gallinat 





Central to dysregulation may be hypofunction of the NMDA receptors on parvalbumin 
containing interneurons which act together to generate gamma oscillations through feedback 
inhibition on pyramidal neuron networks.  The NMDA receptor antagonist ketamine can 
elicit positive and negative symptoms at subanaesthetic doses, and also induce deficits in 
free recall and recognition along with disturbance in attention (Krystal et al., 1994; Xu et al., 
2015), which in Malhotra et al. (1996), seemed to be independent of the psychotic 
symptoms (p.305).  Low levels of GABA in the DLPFC of healthy human participants have 
been associated with a faster deterioration in working memory performance with increasing 
cognitive load (Yoon, Grandelis, and Maddock 2016); yet studies with ketamine, PCP, MK-
801 and other NMDA receptor antagonists have produced dose-dependent increases in 
baseline gamma in rodents and healthy humans  (Driesen et al., 2013). 
 
However, this could be understood in terms of a lack glutamatergic transmission leading to 
an imbalance with GABA.  It might also be compatible with Gandal et al.’s (2012) proposal 
that increases in baseline activity might increase background noise in processing, making 
signal detection more difficult.  A further aspect to consider are the contrasting gradients of 
expression of makers of GABA and glutamate in a caudal to rostral direction that have been 
observed, postmortem in humans, in areas associated with visuo-spatial working memory: 
where GABA concentrations are at their highest in the primary visual cortex and at their 
lowest in the DLPFC, while glutamate shows the opposite pattern (Hoftman et al., 2018).  
Perhaps, GABAergic interneurons help to segment, transmit and integrate information, but 
processing in the prefrontal cortex is more nuanced, involving a greater role for other 
neuromodulators, including dopamine.  Some convergent support for this view might come 
from the observation of another gradient which concerns a relatively greater amount of 
arborisation and dendritic density in the prefrontal cortex.  However, this may be a delicate 
balance as a lack of inhibition may also mean a lack of protection in excitatory networks and 
decrements in the spine density of pyramidal neurons (rather than neuron loss), especially in 
deep layer 3 (which along with layer 4 is the main target of excitatory projections from the 
thalamus), is a well-established observation in schizophrenia (Glausier and Lewis, 2013), 
for example, in the DLPFC and the auditory association cortex (Pierri et al., 2003; Lewis et 
al., 2003).  Consequential to dendritic loss there will be less glutamatergic transmission.  In 
their comparison of 7 studies of postmortem tissue, Moyer et al. (2015) observed that 
significant reductions in spine density had been observed in the areas studied in 
schizophrenia relative to control subjects with a median decrease of 23% (range 6.5 - 66%). 




This is also supported by Hoftman et al. (2018) who observed measures for glutamate in 
postmortem samples were reduced in individuals with schizophrenia, while GABA was 
elevated.  The alterations were in layer 3 which carries glutamatergic projections from 
pyramidal neurons from region to region: from the primary visual and association cortices 
(V1, V2) in the occipital lobe to the posterior parietal cortex (PPC) and DLPFC.  By 
contrast, local GABAergic interneurons influence the activity of pyramidal neurons and also 
generate gamma frequency oscillations.  Hoftman et al. (2017) reviewing the literature on 
layer 3 circuitry of the DLPFC affirmed its importance to working memory.  Taking an 
integrative approach, they concluded alterations may occur during development but many 
associations with environmental factors suggesting there may be “multiple sensitive 
periods” when this circuitry may be disturbed because it takes so long to mature.  However, 
Moyer et al. (2015) observed it is the excitatory synapses onto dendritic spines in layer 3 
which undergo the greatest pruning during adolescence and proposed this may contribute to 
early disease onset.  Hoftman et al. (2018) tentatively proposed a resolution involving 
regional differences, so that deficits “in both glutamate and GABA neurotransmission in the 
DLPFC might impair the ability of layer 3 microcircuitry to increase the power of gamma 
oscillations required” for visuo-spatial working memory function, whereas increases “in 
glutamate and GABA neurotransmission in layer 3 of  V1 [primary visual cortex], might 
contribute to the elevated levels of visual gamma power reported in psychosis” p. 676  (see 
Brealy et al., 2015).   
 
However, further regional specificity is required to accommodate observations made by 
Kegeles et al. (2010) of elevated GABA and Glx (glutamate and glycine combined) in the 
medial prefrontal cortex of unmedicated patients compared with controls, which were not 
present in medicated participants, possibly indicating a normalisation of glutamatergic 
function with antipsychotic treatment.  Moreover, no alterations in the DLPFC were 
observed in either group, which is at odds with Hoftman et al.’s (2017) postmortem study.  
The elevation in GABA described by Kegeles et al. (2010) was “unexpected”, while in a 
comprehensive review of GABAergic mechanisms in schizophrenia, (de Jonge et al., 2017) 
it was acknowledged “the current literature is inconsistent regarding the measured GABA 
levels in different brain regions.”  Perhaps inconsistency should be expected if basal 
concentrations of GABA vary across the brain.  A further consideration might be local 
metabolic demands which may be excessive in certain condition and whether processes 




1.10.2 Stress, Learning, Executive Function and Memory 
A range of neuropsychological and cognitive impairments have been observed in 
schizophrenia including “executive function” which may underpin aspects of performance 
in certain cognitive tasks.  Closely allied to this, and often referred to interchangeably, is 
working memory, which enables representations of external stimuli or internally generated 
representations to be temporarily held in readily accessible form while other cognitive 
operations are conducted.  These might include operations upon the representations 
themselves, for example, re-ordering items in a sequential list or, perhaps, the rotation of 
mental images.   
 
Yerkes and Dodson (1908) in their experiments with “dancing mice” correctly noted the 
effects of stress varied with task difficulty, so that simple tasks were unimpaired at high 
levels of arousal, as illustrated in the graph below.   
 
Figure 1. 2   Differential Effects of Stress on Simple and Complex Task 
Performance (Yerkes and Dodson, 1908).  
 
Source:  https://upload.wikimedia.org/wikipedia/commons/b/ba/OriginalYerkesDodson.JPG  Also 
see Diamond et al. (2007):  The temporal dynamics model of emotional memory processing.   
 
Arnsten (2009) vividly discusses differential effects of stress upon task performance in 
humans observing that “Some of the first studies on the effects of stress on cognition began 
after the Second World War, based on observations that pilots who were highly skilled 
during peacetime often crashed their planes in the stress of battle owing to mental errors”.  
Further, that early studies in this area revealed stress can impair task performance where 
complex and flexible thinking is required but that it can also improve the performance of 




those that involved the influence of PFC operations (Arnsten, 1998), “whereas engrained 
habits that rely on basal ganglia circuits were spared or enhanced.” p.410  These also 
indicated the locus of control had an effect so that if individuals felt (sometimes wrongly) 
they were in control of the situation they were often unaffected by the stress.  Considering 
stress/arousal (as shown on the horizontal axis of the Yerkes-Dodson graph above), cortisol 
or ACTH could replace the label, but it suggested that any of the catecholamines that are 
released in response to the activation of the HPA might also be substituted, i.e. dopamine, 
norepinephrine, epinephrine.  A further consequence of HPA activation is the release of 
energy resources into the circulation in the form of triglycerides (lipids) and glucose, but 
dysregulation in the form of hyperglycaemia or insulin resistance might, perhaps, undermine 
the efficiency of HPA activation at the cognitive and behavioural levels. 
 
 
1.10.3 The Category of Symptoms is not Closed:  Perception and Cognition 
Notwithstanding the extensive symptoms described above, the list is incomplete as 
perceptual problems are frequently omitted from discussion, even though they could 
potentially impact upon higher processing - including the quality of representations, for 
example decreasing visual contrast or components of the orthographic structure can prolong 
naming times (Frederiksen and Kroll 1976; Mechelli et al., 2000).  Ophthalmology issues 
have been reviewed by Gracitelli et al. (2015) who noted decrements in the thickness of 
retinal nerve fibre layer and macular areas have been observed in schizophrenia,  
Alzheimer’s Disease and Parkinson’s Disease.  In addition, Lee et al. (2013) found a 
positive correlation between the extent of thinning and illness duration.  Citing their own 
work, Gracitelli et al. (2015) commented that abnormalities in the magnocellular pathway, 
which conveys lower spatial frequency information from the retina to the visual cortex, are 
well-established in schizophrenia and “the neurophysiology of these processes involves 
deregulation of glutamatergic activity to dopamine receptors and interactions between 
magnocellular and parvocellular pathways.” p.10 
 
The parallel and complementary nature of these pathways has been described by Denison et 
al. (2014):  the magnocellular neurons of the lateral geniculate nucleus are suited for motion 
detection and “other rapid visual changes occurring at large spatial scales” while 
parvocellular neurons are specialised for “detailed form and color processing,” p.1053 
Gracitelli et al. (2015) elaborate further observing the magnocellular pathway is suited to 
low light conditions, “stereopsis, spatial localization, depth perception, hyperacuity, figural 
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grouping, illusory border perception, and figure/ground separation” while the parvocellular 
pathway conveys detailed, high frequency information about static objects.   
 
It follows that abnormalities in the magnocellular pathway may deprive the brain of useful 
information and, as processing is faster along this route, it may also normally help to 
“prime” other processes.  Some support for this may be found in Nunez et al. (2013) who 
describe priming as “highlighting of relevant information” and suggest it is “critical for 
orienting attention in space preferentially to parieto-occipital and other dorsal stream visual 
areas.”  Electrophysiological measurement of the N80 amplitude indicated participants with 
an early age of onset of schizophrenia (mean 16 years; 13-18) did not benefit from a priming 
effect from the magnocellular pathway in their pattern reversal paradigm, however, a group 
with a later age of onset (mean 32 years; 26-38) and controls did.  The difference in the 
early onset group was interpreted as being compatible with a neurodevelopmental 
hypothesis of schizophrenia. 
 
Magnocellular abnormalities have also been inferred in schizophrenia concerning the 
perception of motion (Kandil et al., 2013); reading (Martinez et al., 2012); and the 
perception of facial emotion (Jahshan et al., 2017), which might surely impact, in turn, upon 
the development of skills related to social cognition?  Shared perceptual deficits in 
individuals with schizophrenia and unaffected siblings have been observed (Keri et al., 
2004; Keri et al., 2005) and also in unaffected parents (Gracitelli et al., 2013), thereby 
indicating these may reflect a heritable endophenotype of schizophrenia. 
 
Perceptual deficits of a different kind have been reported by Yoon et al. (2010) who 
observed a 10% reduction in the major inhibitory transmitter GABA in the visual cortex of 
medicated individuals with schizophrenia of a recent onset in conjunction with reduced 
contrast discrimination (indexed by orientation-specific, surround suppression of contrast 
gratings).  Kelemen et al. (2013) also found reductions in GABA levels, relative to healthy 
controls, in 28 FEP participants before medication and 8 weeks after treatment with 
antipsychotics (only 3 were treated with conventional antipsychotics).  Contrast sensitivity 
improved with treatment (sensitivity was actually reduced but it was inferred there had been 
hyperactivity in the magnocellular retino-geniculo-cortical pathways).  “Anomalous 
perceptual experiences” were also reduced - these were not hallucinations but involved 
“disturbingly high intensity of environmental stimuli”, possibly equating to sensory 
hyperacuity where stimuli present with a higher level of detail and intensity than normally 
experienced.  However, treatment failed to normalise performance on a test of motion 




Kelemen et al. (2013) had expected to replicate the correlation between changes in visual 
function and GABA levels in the occipital cortex observed by Yoon et al. (2010), thinking 
this would be consistent with deficits in gamma oscillations observed in schizophrenia and 
their potential relationship with glutamatergic hypofunction and working memory deficits  
(Lewis and Gonzalez-Burgos 2006), however, this was not supported.  It was suggested a 
methodological difference may have accounted for the correlation in Yoon et al. (2010).  
Also, the participants in Yoon et al. varied on some parameters and illness stage as well as 
medication or region could be important, for examples, elevations in GABA had been 
observed in the parieto-occipital cortex of individuals with chronic schizophrenia by Ongur 
et al. (2010), who found no difference between individuals taking atypical and typical 
antipsychotics; while in a study by Kegeles (2012), 16 participants with long-standing 
illness who were unmedicated (9 were medication naïve) exhibited elevations in GABA, 
along with glycine and glutamate in the medial prefrontal cortex, but not the DSFPC.  
Whereas those who were medicated (n =16) with atypicals for at least 4 weeks, did not show 
increases.  The FEP participants in the study by Kelemen et al. (2013) had reduced levels of 
GABA in the visual cortex relative to controls both at baseline and after antipsychotic 
treatment). 
 
The focus on medication is important as antipsychotics can have pronounced effect on D2 
receptors in the retina and affect sensitivity to contrast gratings (Harris et al., 1990), 
enhancing sensitivity to low spatial frequency while reducing sensitivity to medium and 
high spatial frequency information.  This mirrors the pattern with hypodopaminergia in 
Parkinson’s Disease which is reversed for medium spatial frequencies by dopaminergic 
drugs (Domenici et al., 1985).  It is interesting that only 3/28 of the clinical participants in 
the study by Kelemen et al. (2013) were receiving treatment with conventional neuroleptics 
(and 1/13 in the study by Yoon et al., 2010) yet there may have been an effect on dopamine 
function in the retina). 
 
While antipsychotic treatment may be a complicating factor, such research could lead to the 
development of “state” or “trait” biomarkers based on perceptual tests, as explored by 
Koychev et al. (2011).  However, the attribution of such observations to the magnocellular 
pathway has been challenged by Herzog and Brand (2015) on the basis this is unproven.  
(They also criticised the methodology of Keri et al., 2004, 2005 above).  Kelemen et al. 
(2013) agree “the exact psychophysiological distinction of the M and P pathways has been 
debated.”  However, the evidence of dysfunction in the magnocellular pathway reviewed by 
Gracitelli et al. (2015) is derived from more than one methodology.  Nonetheless, Herzog 
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and Brand point to a rich evidence on masking paradigms in schizophrenia research, 
including, observations made by Slaghuis et al. (1995) that individuals with a higher level of 
negative symptoms needed a longer period to process target stimuli and were more sensitive 
to backward masking.  Indeed, backward masking may bear a relationship to sensory gating 
- an issue explored by Wynn et al. (2004) who wondered if they index a common factor.  
Individuals with schizophrenia exhibit slower recovery from backward masking and deficits 
in pre-pulse inhibition (PPI).  Wynn et al. (2004) suggested higher levels of PPI may help to 
“gate out” the disruptive effects of backward masking so clinical participants would be 
disadvantaged.  
 
At the end of this complicated story where it might be wondered if medication effects on 
retinal dopamine cells might explain deficits in backward masking, or imbalances between 
the magnocellular and parvocellular streams of information, there is still the evidence 
relating to perceptual abnormalities in first-degree relatives, also, the phenomenological 
accounts of non-hallucinatory perceptual distortions before any medication is taken.  The 
observations of abnormal levels of GABA in different brain regions and at different stages 
of the illness also needs to be explained.  In addition, there is interest in considering the role 
of GABA in sensory gating (Cheng et al., 2016). 
 
Moreover, corresponding deficits in PPI have been observed in the auditory realm, for 
example, correlations between auditory and visual PPI were observed in the study by Wynn 
et al. (2004).  As described for putative abnormalities in the magnocellular pathway, deficits 
in auditory sensory gating might affect higher level processing; for example, difficulty in the 
pre-attentive detection of subtle alterations in speech sounds was observed in schizophrenia 
by Kasai et al. (2002).  These issues may assume greater relevance to TRS, when the 
performance of participants in this study on a Continuous Performance Task and also the 
Hopkins Verbal Learning Task are considered. 
 
It was proposed above that deficits in early sensory processing in various modalities, 
including those potentially related to abnormalities in GABAergic transmission, are usually 
overlooked although they form part of the symptomatology of schizophrenia.  However, 
there may be further ramifications which affect higher level processes;  for example, upon 
the efficiency of encoding which might, in turn, affect the number of items that can be held 
in capacity-limited stores such as working memory.  This may underlie the phonological 
similarity effect (Conrad 1964), visual similarity effects (Saito et al., 2008) and the word 
length effect (Baddeley, Thomson, and Buchanan 1975) where the quality and parsimony of 




The clarity of an auditory signal against background noise will affect the quality of the 
information that converges for processing in the striatal-thalamo-cortical loops, but before it 
even enters neural pathways, the quality of the signal will also be influenced by the way 
attention is deployed, filtering out or inhibiting some aspects and selectively attending to 
others.  This was illustrated by a study by Conway et al. (2001) which simulated “the 
cocktail party phenomenon” and observed that individuals with higher working memory 
spans were less likely to detect their names in an unattended stream of information than 
those with lower spans.  This was interpreted as indirect evidence of more effective 
inhibition of irrelevant information by individuals with higher spans, however, it was 
observed the result could so easily have gone in the opposite direction, with individuals with 
spare capacity being better able to monitor the environment.   
 
1.10.4  Do Negative Symptoms Resemble Sickness Behaviour? 
Immune activation has been observed to affect behaviour, for example, during 
immunotherapy in cancer treatment. Capuron et al. (2005) commented “a rich database has 
been developed that substantiates the capacity of proinflammatory cytokines, including 
tumour necrosis factor α, interleukin (IL-1 and IL-6), to induce behavioural symptoms 
referred to as "sickness behavior.” p.2  This is typified by social withdrawal, fatigue, 
anhedonia and, perhaps, depression.  There is some debate as to whether withdrawal is 
about finding a place of safety, away from predators while energy resources are directed 
toward recuperation and repair, or whether this confers benefit to a group by containing the 
risk of disease transmission.  Quite possibly both arguments might apply.  
 
These behaviours were observed in sick animals by Hart (1988) and has subsequently been 
extended to humans, especially in relation to depression (e.g. Raison, Capuron, and Miller 
2006;  Dantzer 2009).  Sickness behaviour may include a lack of appetite, activation of the 
HPA axis, a reduction in parasympathetic tone, disrupted sleep with less REM and more 
slow-wave sleep, a flattening of diurnal rhythms (for example of cortisol production), 
impaired learning and memory for recent events (Dantzer et al., 2008).   It is unclear 
whether this has been directly commented upon, apart from Smith (1992) below, but, at first 
sight (with the possible exception of reduced appetite), surely there is similarity between 
“sickness behaviour” and the negative symptoms of schizophrenia?   
 
The theory that immune activation might have psychological effects originated with Smith 
(1991) and Maes et al. (1995), based on observations of elevations in cytokines in depressed 
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individuals.  Dantzer et al. (2008) commented on the originality of the hypothesis 
“especially at a time when depression was thought to be associated with decreased rather 
than increased immunity.” p.4  Then, Smith (1992) extended the theory to schizophrenia: 
 
Recently I proposed excessive production of interleukin-2 (IL-2) and IL-2 receptors (IL-
2Rs) by gastrointestinal (GI) T-lymphocytes as the cause of schizophrenia (10, 11). The idea 
for the hypothesis was initiated by the well documented, but profoundly ignored, 
observation that IL-2, when given to psychiatrically normal human volunteers, produces 
severe positive and negative symptoms of active phase schizophrenia in the majority of 
subjects (12). Once the importance of this clinical observation is realized, then an 
astonishing amount of previously unexplained information on schizophrenia becomes 
coherent.  The negative symptoms (apathy, avolition. alogia, emotional flattening, 
asociality), which are identical to symptoms of depression, usually occur throughout the 
disease.  (p.249) 
 
Consideration of such aspects has been slow to gain traction.  Indeed, the eminent 
neuroscientist, Ed Bullmore (2018) has commented that psychoimmunology has only 
recently started to gain acceptance (after refutation of an established idea that the brain has 
“immune privilege”, which virtually prevents all such activity beyond the blood-brain-
barrier).  The book highlights the similarities between depressive symptoms and those of 
sickness behaviour and points to evidence that immunotherapy may have great potential in 
their treatment.  It is not suggested explicitly there is overlap between the symptoms of 
sickness behaviour and negative symptoms but closing pages indicate immunotherapy could 
be successfully applied in schizophrenia. The book is essentially a “call to arms” with 
Bullmore warning “it may never happen” unless these ideas are followed up.  Fortunately, it 
has received many commendations. 
 
But what of TRS?  If there is indeed a link then the persistence of negative symptoms would 
suggest TRS should be a good candidate for this approach.  Recent studies have reported 
elevations in inflammatory cytokines in FEP individuals, also in individuals with long-
standing psychosis (Di Nicola et al., 2013; Mondelli et al., 2011).  Moreover, in a study 
which combined measures of inflammatory markers with waking cortisol levels, Mondelli et 
al. (2015) observed reductions in cortisol and inflammatory cytokines after 12 weeks of 
treatment with antipsychotic medication in participants who responded to this treatment but 
not in non-responders.  Interferon gamma (IFN-γ) was strongly related to the severity of 




1.10.5 Might Negative Symptoms and Cognition be Related? 
Several studies have observed that negative symptoms may persist along with cognitive 
deficits.  Impaired cognitive function and psychosocial adjustment have been associated 
with worse functional outcomes in the community (Green, Kern, and Heaton, 2004;  
Iasevoli et al., 2016).  However, one study observed attention, working memory and verbal 
fluency predicted functional outcomes in schizophrenia even when negative symptoms were 
controlled for (Jaeger et al., 2003).  Cognitive deficits are so common they are regarded by 
some as a core symptom of schizophrenia; however, they were not regarded sufficiently 
specific for diagnostic purposes in DSM-5 (Tandon et al., 2013).  This might be revisited if 
TRS is accepted as a sub-category, for example, de Bartolomeis et al. (2013) observed 
worse performance on a verbal memory task in their TRS participants than “non-TRS” 
participants.  In addition, worse performance was associated with a higher level of negative 
symptoms in the TRS group, leading them to suggest cognitive deficits in TRS might be 
related to negative symptoms (also see Jaeger et al., 2003). 
 
Some researchers have divided negative symptoms into further dimensions described as 
“diminished emotional expression” (blunted affect and alogia28) and “apathy” (anhedonia, 
avolition and asociality) - which may also be referred to as diminished emotional 
experience.  Hartmann-Riemer et al. (2015) found diminished emotional expression was 
significantly associated with verbal learning and memory, planning and a composite 
cognitive score when variation relating to severity of apathy was held constant.  While none 
of the cognitive measures correlated with apathy when diminished emotion expression was 
held constant.  By contrast, Harvey et al. (2017) , found that apathy predicted social 
outcomes better than DEE or negative symptoms.  Therefore, associations between negative 
symptoms and cognition or psychosocial outcomes may be influenced by the precise nature 
of the symptoms. 
 
Improvements in negative and cognitive symptoms (especially those relating to executive 
functions) have been observed in case reports when antipsychotic treatment has been 
augmented by the antibiotic minocycline, as reviewed by Zhang and Zhao (2014):  in an 
open-label study using minocycline as an adjunctive, Miyaoka et al. (2008) observed 
 
28 Blunted Affect:  diminished emotional expression - reduction in facial expression and 
communicative gestures.  If present, these may seem “forced, artificial or lacking in modulation”. 
    Alogia: poverty of speech (or, as Blanchard and Cohen (2006) prefer “poverty of content of 
speech” which aligns this with “lack of spontaneity and flow of conversation” (item N6 on the 
PANSS), and not G7, motor retardation. 
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improvements in 22 participants on all PANSS subscales after 4 weeks without adverse 
effects.  (The participants had been unwell for a mean of 4.9 years (1-15 years).  
 
These results are also consistent with a randomized, double-blind, placebo-controlled study 
investigating the effects of minocycline augmentation which started in 2003 and was 
reported by Levkovitz et al. (2010).  With further corroboration from a parallel study which 
concerned 78 individuals with “early-phase” schizophrenia, receiving atypical antipsychotic 
medication (including clozapine), of whom 54 also received minocycline.  After six months 
of adjunctive treatment, improvements in general outcome (global impression), negative 
symptoms, working memory and other cognitive aspects were observed.  These results have 
been replicated in a larger double-blind randomised placebo-controlled study with respect to 
improvement in negative symptomatology.  The evidence concerning cognitive symptoms 
was less clear, but difficulties in finding equivalent tests with appropriate standardisation 
may have been a factor as the research was conducted in Pakistan and Brazil (Chaudhry et 
al., 2012), while the study by Levkovitz et al.(2010) was conducted with Israeli participants. 
 
Following, their earlier 2014 review, Zhang et al. (2018) have published a double-blind 
randomised placebo-controlled trial with 75 schizophrenia participants with elevated 
negative symptoms, conducted in China.  After 3 months of treatment with risperidone and 
minocycline, greater improvements for negative symptoms were observed in participants 
who had received a high dose of minocycline than those who had received a lower dose or 
placebo.  It also correlated with reductions in interleukin-1beta and IL-6 in serum.  While 
the evidence in relation to cognitive symptoms may be weaker, all these studies provide 
persuasive evidence of inflammatory cytokines being related to negative symptoms. 
 
Associations between negative symptoms and specific inflammatory cytokines may be 
especially pertinent to TRS in view of the persistence of negative symptoms and higher 
level of suicide attempt.  Moreover, Zhang, Zhao et al. (2005) cited studies which indicated 
that abnormalities in inflammatory cytokines had been “particularly prominent” in TRS.  
This was supported by their own research with Chinese participants considered to be TRS 
where elevations in interleukin 6 were observed after a 2-week washout period relative to 
healthy controls.  Elevations were also observed in cortisol at baseline and correlated with 
negative symptoms.  They were also correlated after 12 weeks of antipsychotic treatment 
with haloperidol or risperidone, when significant reductions in cortisol and negative 
symptoms were seen.  The interpretation of IL-2 and IL-6 was more complicated as they 
were not detected in some participants and intercorrelations were not significant.  
Interestingly, elevations in IL-2 were associated with positive symptoms although this was 
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not reported in a study of 68 FEP participants by Mondelli et al. (2015) who did however 
find persistent elevations in Interleukin-6 were associated with non-responsiveness to first 
line antipsychotics.  Decrements in the cortisol awakening response (CAR) and higher 
interferon-gamma were also observed in the non-responders from the outset.  Mondelli et al. 
(2015) observed, “The blunted CAR and the reduced HPA axis reactivity to stress have also 
been associated with more severe symptoms and worse cognitive function in patients with 
psychosis.  Furthermore, the blunted CAR is not normalized by antipsychotic treatment, 
indicating that it may represent a stable biological feature of psychosis.” (p.2)  Therefore, 
their suggestion that cortisol and inflammatory cytokines could serve as biomarkers to 
predict treatment response and point to new therapies appears well-founded.     
 
This set of results is also interesting from an endocrine perspective, as according to Rotter et 
al. (2003) associations between IL-6 and insulin resistance have been demonstrated in 
several studies.  Fat cells appear to be targets for Il-6 and TNF-alpha which both appear to 
decrease “insulin-stimulated glucose transport.”   In a study of cultures of human fat cells, 
Rotter et al. (2003) observed TNF-alpha amplified IL-6 production.  Moreover, there was 
also a 15-fold elevation in TNF-alpha and IL-6 cells from a subgroup non-obese of insulin-
resistant individuals.  Given the metabolic liability of clozapine, this surely highlights the 
importance of attempting to control hyperglycaemia even in the absence of overt diabetes.  
Moreover, it would be interesting to ascertain if immune treatments might improve insulin 
sensitivity as well as bringing about an amelioration in negative and cognitive symptoms. 
Further evidence for an association between immune activation and cognitive deficits comes 
from preclinical studies where behavioural responses to the endotoxin lipopolysaccharide, 
found on the membrane of gram-negative bacteria, have been reported to include a reduction 
in social interactions and worse memory for objects by adult rats that had been injected with 
a toxin when pups (Zhu et al., 2014).  “Dramatic” elevations in microglia were observed in 
the hippocampus, thalamus and cerebral cortex of the adult rat, but reductions were 
observed if they were subsequently treated with minocycline, risperidone, or in 
combination.  Moreover, there were corresponding improvements in behavioural measures 
of prepulse inhibition, memory for novel objects and social interaction. 
 
In one functional neuroimaging study of patients receiving interferon-alpha therapy, which 
“is notorious for causing behavioural symptoms, including depression, fatigue and cognitive 
dysfunction” (p.190), increased activity was observed in the dorsal ACC relative to control 
patients who were not receiving this treatment.  There were no significant differences in 
performance of visuospatial attention task but there was a strong correlation between ACC 
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activation and the number of errors in the immunotherapy group who may have been having 
to work harder (Capuron et al., 2005) 
 
This simple interpretation is based on a view that various negative symptoms are not 
conducive to learning or the energy expenditure associated with cognitive effort.  Another 
might be related to weaker connectivity with the reward circuitry which could undermine 
motivation.   
 
1.10.6 Are Negative Symptoms related to Default Mode Activity? 
Another association with negative symptoms could relate to hyperactivity in the default 
mode network which has been observed in some medical conditions for example, 
instantiated in increased strength of connectivity in the resting state.  Under these 
circumstances, the “default” position might be a heightened tendency for attention and 
cognition to revert to the inner world.  
 
The relationship between the DMN and CEN appears to be influenced by NMDAR 
function.  Anticevic et al. (2012) demonstrated the connectivity and strength during a 
delayed working memory task was altered by the administration of ketamine to healthy 
participants.  The extent of this disruption predicted task performance and transient 
symptoms were observed that resembled schizophrenia (although only the relationship 
between the degree of DMN deactivation and negative symptoms was significant, indicating 
greater DMN activity/failure to supress was associated with a higher level of negative 
symptoms).   It is suggested here, the weakening of segregation between major networks, 
might help to explain aspects of abnormal states which describe an increased “oneness” with 
the universe - where boundaries between the external and inner worlds disappear.29 
 
The idea of major networks relating the inner and outward worlds (for example the DMN 
and CEN respectively), also finds resonance with Nekovarova et al. (2014), who have 
proposed Menon’s triple network theory might be applied to diverse symptoms of 
schizophrenia.  Choosing as the bedrock of their model, the ability to construct 
 
29 This idea finds expression in studies concerning the psychedelic drug psilocybin (e.g. Carhart-
Harris et al., 2012; Tagliazucchi et al., 2016).  A pharmacological description by de Gregorio et al. 
(2016) indicated different effects according to dose: “LSD’s mechanism of action is pleiotropic, 
primarily mediated by the serotonergic system in the Dorsal Raphe, binding the 5-HT2A receptor as a 
partial agonist and 5-HT1A as an agonist. LSD also modulates the Ventral Tegmental Area, at higher 




representations of ourselves and others to understand mental states, they regard emotional 
flattening “a core negative symptom of schizophrenia” which interferes with this process,  
affecting inward aspects (anhedonia) blunted affect/ diminished emotional expression (N1) 
and outward aspects relating to a lack of empathy or poor rapport (N3).  They propose the 
domains of the “self” and feelings of pleasure are associated with an inward direction of 
reference, while those of empathy and perspective taking/ “theory of mind” (ToM) are 
related to an outward orientation.  Also, self-awareness, involves the representation of one’s 
own mind and self-reflection enables inferences concerning the thoughts of others.  
Similarly, autobiographical memory may inform, including anticipation of the future and 
“underlies representations of one’s own mental states, a process parallel to … ToM.” (p.2) 
Nekovarova et al. (2014) propose that in schizophrenia “deficits in coordination” of the 
triple network may underlie functions related to the “self” leading to impaired social 
cognition.  Their model, only superficially described here, and reflected in the diagram 
below30, extends understanding of the potential nature of negative symptoms, especially in 
relation to social cognition by highlighting differences in perceptions relating to the inner 
and outer world.  
 
Figure 1. 3   Perspectives from Inner and Outer Worlds    
 
 
30 Figure 1 .3 depicts a “cognitive dimension” (self : theory of mind) and a second 
dimension “with stronger motivational accent” (empathy :  hedonia).  Nekovarova et al. 
(2014) propose the co-ordination of “these two axes can create a mental representation of 




                                          
















Hedonia                                                              
                                        
 
                                          
                                       
Self                                                                              T o M 









An alternative, although compatible suggestion is that perceptual problems in schizophrenia 
(as discussed above) could contribute to deficits in empathy and theory of mind, for 
example, by impairing the interpretation of facial expressions. 
 
From the foregoing, it might be predicted that negative symptomatology might be associated 
with a reluctance to respond, so this could be reflected in positive correlations with slower 
reaction times and a greater level of omission errors.  Also, perhaps, a negative correlation 
with false positive responses - although unexpected in this data set since 50% false positive 
responses were made 3 individuals.  Negative symptoms might also confer some resistance 
to distraction unless the distractor is of personal or emotional nature. 
 
1.11  Summary of the Introduction 
Considerable progress has been made concerning the identification of brain areas and 
pathophysiological processes associated with schizophrenia. Some evidence is substantive, 
for example, concerning pathophysiological cascades associated with NMDAR 
hypofunction states and the particular vulnerability of white matter to excitatory and 
oxidative damage.  Other aspects may have less support in the form of replication or 
convergence but have been demonstrated in the laboratory and delineated in clear and 
exquisite detail, for example, the conditions under which long-term potentiation and long-
term depression may occur.  Yet in other areas, neural processes and the associated 
anatomical substrates may be poorly understood, for example, the function of the claustrum 
or aspects of processing within the striatal-thalamo-cortical loops.  Consequently, the 
introduction has sought to take an integrative approach towards pertinent evidence and 
provide a context for the discussion of TRS.   
 
TRS appears to be a distinctive category representing around 21-23% of individuals with a 
diagnosis of schizophrenia.  This is distinguished clinically by the persistence of negative 
and cognitive symptoms and also biologically with a younger age of onset, no sex difference 
in prevalence and an absence of elevations in the presynaptic synthetic capacity for striatal 
dopamine which characterises FLRS individuals.  It appears to be present at the first episode 
in about 84% of individuals, however, around 30% respond to conventional antipsychotic 
treatment initially but not subsequently, possibly due to an upregulation in D2 receptors in 
response to conventional antipsychotic medication and the development of dopamine 




Predictors of TRS appear to include a higher level of negative symptoms and a longer 
duration of untreated psychosis in the prodrome.  However, one longitudinal study over a 
10-year period observed deterioration in working memory digit span in a subgroup who had 
experienced psychosis over a longer period after diagnosis. Indeed, concerns have been 
raised that acute psychosis might be neurotoxic whereas there could be a lesser risk during 
the prodrome which has been the focus of research into DUP and has produced mixed 
observations. 
 
The literature concerning TRS has suffered from a dearth of research and the lack of a 
consistently used definition.  Recent reviews of the neuroimaging evidence did not identify 
an fMRI BOLD study comparable to the one here, and the diversity of studies on TRS may 
have contributed to a near-absence of replicated findings of any substance.  However, some 
excellent PET and 1H-MRS studies on TRS have been conducted and there are, by now, 
some well-developed theories which may be compatible with this emerging evidence, both 
with respect to symptoms and possible neurobiological substrates.  The introduction 
reviewed the major theories of schizophrenia and posed a question that has been asked by 
others (for example, Egerton et al., 2012; Gillespie et al., 2017)31 as to whether a 
glutamatergic hypothesis might be more appropriate for TRS?  Glutamatergic dysfunction, 
for example, caused by NMDAR antagonists, can precipitate or reinstate the symptoms of 
psychosis along with cognitive symptoms similar to those observed in schizophrenia.  Also, 
decrements in GABAergic interneurons (or GABA synthesising enzymes), consequent upon 
glutamate of excitotoxicity could result in the loss of tonic inhibition in excitatory networks 
and lead to further glutamate excitotoxicity with diverse impacts upon symptoms and 
cognitive function. 
 
The glutamate and GABAergic theories are therefore closely related and different aspects 
could gain prominence during the course of disease.  One well-founded theory proposes 
primary pathology may lie in the hippocampus consequent upon decrements in a certain 
class of GABAergic interneuron (PVIs), possibly starting with hypofunction at the 
NMDARs they bear.  This leads to hyperactivity in the dopamine cells of the VTA 
downstream which projects to the striatum (Grace, 2012; 2016).  However, as outlined in 
the seminal hypothesis of NMDAR hypofunction, losses may occur in other brain areas as 
 
31 Egerton et al. (2012) raised the possibility that “clinical status following antipsychotic treatment in 
schizophrenia is linked to glutamate dysfunction.”   Similarly, Gillespie et al. (2017), concluded: 
“treatment-resistant schizophrenia appears to be characterised by a relatively normal dopamine 




PVIs are highly numerous and widely distributed along with the glutamatergic pyramidal 
neurons which they innervate (Goldman-Rakic et al., 1989; also see Stone et al., 2010). 
 
Moreover, a substantive body of preclinical evidence indicates how a selective loss of 
GABAergic parvalbumin containing interneurons in schizophrenia might arise.  This has 
been demonstrated in rodent studies involving maternal stress, maternal immune activation 
and redox dysregulation.   Also, white matter appears to be particularly susceptible to 
excitotoxic and oxidative damage, but neuronal atrophy or loss is also possible.  Indeed, 
Gillespie et al. (2017) observed significant decrements in grey matter volumes relative to 
controls and treatment responsive-schizophrenia may be specific to TRS and U-TRS, noting 
the alternative position of Mouchlianitis et al. (2016, b) that the reductions may be along a 
continuum reflecting illness severity.  It is suggested here that reductions in PVIs could 
contribute to such decrements, as they may also bear NMDARs which may be particularly 
susceptible to damage when they have a greater preponderance of the NR2B subunit 
because these confer slow ion channel kinetics which allow more calcium ions to enter, 
increasing a cell’s excitability at the risk of excitotoxicity and cell loss.  (Further, not  
only are synaptic connections are “pruned” and reorganised during adolescence, but NR2B 
subunits on NMDARs may be substituted by other kinds). Interestingly, as commented in 
section 1.7.1, Ahmed et al. (2015) observed progressive reductions in grey matter during the 
first 6-9 months after commencing clozapine, inferring that grey matter loss might not 
necessarily be pathological as symptoms remitted and could, perhaps, reflect the pruning of 
aberrant connections. Moreover, lesser decrements in the left medial prefrontal and right 
middle temporal cortices were associated with a greater likelihood of treatment response. 
 
Recent evidence suggests GABAergic deficits may compromise the ability to generate 
oscillations in the gamma range through reverberating microcircuits.  This is an emerging 
area of science and the detection of GABA levels is still at the limits of what is technically 
possible but may prove to be important, for example, in one study working memory 
performance in healthy participants was observed to correlate positively with GABA levels 
in the DLPFC.  Moreover, in another study by the same team, a 10% reduction in GABA 
was observed in the visual cortex of medicated PSZ relative to healthy controls. When 
observations were combined there was a strong correlation between GABA levels and a 
visual test of cortical inhibition (measured by orientation-specific, surround suppression) but 
not contrast sensitivity per se.  This might have implications for selective attention certainly 
from a “bottom up” perspective where GABA may have a role in suppressing irrelevant 
activity, potentially affecting the specificity of encoding or signal to noise ratio.  Some 
evidence indicates clozapine may reverse sensory gating deficits.  It was also suggested 
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here, clozapine may help to compensate for the loss of PVIs through its high binding affinity 
for D4 receptors which are found at high density in the PFC, ACC and hippocampus, as 
discussed in section 1. 5. 6. 
 
Towards the end of the introduction potential associations between hyperactivity in the 
DMN and negative symptoms were explored since it was proposed that negative symptoms 
might be associated with introspection and DMN activity which, in turn, my interfere with 
the performance of cognitive tasks.  However, it was the evidence from preclinical studies 
on NMDAR hypofunction conducted by Olney and colleagues (1999, 1995) which 
highlighted the potential vulnerability of medial areas, including the anterior and posterior 
cingulate, which in humans are strongly associated with the DMN  that helped to inform the 
second hypothesis of this study.  
 
1.12  Aims and Hypotheses 
As TRS has been under-researched and there were no comparable fMRI studies, this study 
was largely exploratory and intended as a preliminary characterization of the neurobiology 
of TRS.  The primary aim of this research was to characterize TRS through clinical 
assessment, neuropsychological tests and an exploration of task evoked changes in the 
blood-oxygen-level-dependent (BOLD) signal at different levels of cognitive load during a 
verbal n-back working memory task, using functional magnetic resonance imaging along 
with the exploration of the association between the BOLD signal and clinical correlates.  
It was hypothesised that:   
a) TRS individuals would show attenuated engagement of an “executive” fronto-
parietal network during working memory processing compared to controls. 
b) Brain areas exhibiting altered haemodynamic response would include the cingulate 
gyrus and would be associated with task performance and symptom severity. 
Secondary aims included the exploration of the association between clinical and cognitive 




Chapter II - Methods 
 
   Participants 
Participants for this study were recruited from within the catchment area of the South 
London and Maudsley NHS Foundation Trust (SLaM) and neighbouring area of Oxleas 
which is slightly less urban and more prosperous.  All clinical participants had a confirmed 
diagnosis of schizophrenia or schizo-affective disorder and met modified criteria for TRS 
(based on those used in Kane et al., 1988) as they had been treated with at least two 
chemically different antipsychotics, at an adequate dose and for sufficient duration (of at 
least six months) but had not clinically responded before a trial of clozapine was tried.  
 
A group of healthy control participants was also recruited, usually at short notice as “stand-
ins” for scanning appointments that could not be filled by TRS participants.  It was therefore 
not possible to carefully match the characteristics of this group with the TRS group with 
respect to social and demographic characteristics which are shown in Table 3. 1.  
 
   Description of Recruitment Procedure 
Several people, helped with the recruitment of TRS participants during visits to clozapine 
clinics which are run for the purposes of regular monitoring for the risk of agranulocytosis, 
titration of clozapine and the dispensing of medicine and advice.  Attendees who expressed 
an interest in the study were provided with a Participant Information Sheet which outlined 
the purpose of the study and what it entailed.  They were encouraged to make an 
appointment, or ‘phone to discuss aspects of research.   
 
Written informed consent was required to take part in the study and permitting access to 
medical records and for radiographers to contact a participant’s GP if necessary.  Consent 
was also sought for neuroimaging data to be used in other studies.  Where participants were 
willing to provide blood for genetic research, consent was again sought, but it was made 
clear this was not a requirement for participation in the neuroimaging study.  Copies of the 





2.2.1   Screening and Exclusions 
Neurological trauma, psychiatric co-morbidity (including drug addiction) and left-
handedness32 were exclusion criteria, along with other conditions that might interfere with 
the ability to perform the experiment task:  for example, claustrophobia, glaucoma and 
finger stiffness (a possible legacy of treatment with conventional antipsychotics) which was 
tested by tapping out sequences with the right hand.  For control participants, a personal or 
family history of any major psychiatric disorder were further exclusion criteria, if known.   
 
An unforeseen de facto exclusion was body size, as weight gain is a common side-effect of 
antipsychotic medication and many individuals appeared too large to be comfortable within 
the narrow space of the fMRI scanner and so were not generally approached.  MRI safety 
questions and medical checks to assess suitability were also conducted.   
 
A diagnosis of TRS was confirmed by reference to medical records by the clinical 
consultant nurse, Tracey Collier. 
 
  Ethical Approval 
Ethical approval was provided by Wandsworth (REC 09/H0803/81).  The study was 
conducted in accordance with the World Medical Association Declaration of Helsinki and 
subsequent amendments (World-Medical-Association, 1965, 1996, 2008, 2013). 
 
   The Design of this Study and Procedure 
The study was of cross-sectional design.  All participants performed a verbal n-back task for 
the fMRI study, which also provided behavioural data.  However, individuals in the control 
group did not participate in other aspects of the study, including neuropsychological 
assessments as they were recruited under a different protocol as part of a BRC “cluster 
study”.  
 
TRS individuals took part in a clinical interview on the day of the scanning appointment, 
whereas the collection of demographic information and neuropsychological testing was 
usually conducted at least a couple of weeks before to minimise fatigue.  A further 
difference was that TRS participants had practice and familiarisation with the n-back task 
during the preliminary visit, partly to ensure they could perform the task and to minimise 
 
32 The Annett Handedness Questions were asked if there was any doubt (Annett 1970). 
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stress during the scan.  This may have conferred an advantage relative to the control group 
but the practice sequence differed from that in the study.  
 
   Social and Demographic Questions 
Relatively few questions were asked to minimise demands made upon participants 
(questions relating to socioeconomic status were dropped at the first interview after the  
participant appeared distressed;  also, it was not part of the protocol to collect this 
information from the control group (2.4 above), similarly for years of education and other 
social and demographic aspects. 
 
Some information was also obtained from medical records, for example, the duration of 
time between first diagnosis and receiving a trial of clozapine, and how many years had 
elapsed since the first episode.  As illicit drugs, as well as smoking nicotine, are known to 
affect the same neural circuitry implicated in schizophrenia (e.g. Steeds et al., 2015; Moran 
et al., 2018), TRS participants were asked whether they had ever tried a particular drug 
(from a list) and, if so, whether they could remember how old they were at the time.  It was 
emphasised there was no need to answer the questions, however, participants seemed 
generally forthcoming and perhaps, “first ever” experiences tend to be recalled more easily 
even though the chronology might be doubted33.  The information was subsequently related 
to the age of the first psychiatric admission for psychosis obtained from clinical records.  
Information about subsequent or current drug use (apart from nicotine) was not sought.  
Social and demographic data is presented in Section 3.1.1 and Appendix 1. 
 
   Clinical Assessment 
This involved a semi-structured interview by a trained interviewer using the Positive and 
Negative Syndrome Scale (PANSS) (Kay et al., 1987).  The PANSS interviews were 
conducted by clinical nurse consultant Tracy Collier.  Also, at least one interview was 
conducted under her supervision by master’s student James Hurley and, another, by Dr. 
James Gilleen.34  It was considered unnecessary to evaluate inter-rater reliability.   
 
33 There may not be a “classic paper” on primacy effects in long-term memory, possibly, because 
these might be difficult to verify. However, by definition, “first ever” experiences should be less 
susceptible to proactive interference from similar representations.  Moreover, they may be more 
likely to be remembered because of their novelty and the co-release of dopamine (the “learning 
signal” described by Abi-Dargham, 2017).  Further, drug-taking may have enhanced this by 
stimulating processes associated with reward.  
34 The subscale scores for this participant, whose total score was in the middle of the group’s 




The development of the PANSS scale and analysis of its factors are referred to in section 1.3 
of the introduction.  Clinically, it is useful because it has been widely used and considers a 
broad range of symptoms and provides a global measure of symptom severity which is 
useful for comparisons across studies.  There is no predetermined script and questions 
addressing the items (listed in Table 2. 1), can be raised in any order, thereby providing 
useful flexibility during interview.  Each item is rated on a scale from 1 to 7, corresponding 
to:  absent, minimal, mild, moderate, moderate-severe, severe or extreme.  The minimum 
score is 30 (as the scale comprises 16 items in the General Scale and 7 items in each of the 
Positive and Negative Scale).  However, the PANSS is not a continuous scale as the items 
are qualitatively different. 
 
 
Table 2. 1   List of Items in the Positive and Negative Syndrome Scale (PANSS) 
Positive Scale General Scale 
P1 Delusions 
P2 Conceptual disorganisation  
P3 Hallucinatory behaviour  
P4 Excitement  
P5 Grandiosity  
P6 Suspiciousness/persecution  
P7 Hostility  
G1 Somatic concern  
G2 Anxiety  
G3 Guilt feelings  
G4 Tension  
G5 Mannerisms & posturing  
G6 Depression  
G7 Motor retardation  
G8 Uncooperativeness  
G9 Unusual thought content  
G10 Disorientation  
G11 Poor attention  
G12 Lack of judgement & insight  
G13 Disturbance of volition  
G14 Poor impulse control  
G15 Preoccupation  
G16 Active social avoidance 
Negative Scale 
N1 Blunted affect  
N2 Emotional withdrawal  
N3 Poor rapport  
N4 Passive/apathetic social withdrawal  
N5 Difficulty in abstract thinking  
N6 Lack of spontaneity & 
flow of conversation  






2.6.1   Analysis of the Clinical Data and Creation of Symptom Groups 
As indicated in the introduction, the classification of symptoms remains an active area of 
research and debate.  Items on the general scale usually disappear or are reassigned to other 
dimensions in factor analyses so correlations were not conducted with the general scale in 
this study.  Also, a third of the items on the PANSS disappeared in Wallwork et al.’s (2012) 
confirmatory factor analysis which might cast doubt on usefulness of individual items, also 
given the relatively small number of TRS participants in this study, analyses were not 
conducted with individual items.  Further, the diversity of symptom profiles across patients 
presents another issue for schizophrenia research, as Howes et al. (2017) observe “It may 
not be appropriate to compare groups of patients in whom the illness is predominantly 
resistant in another domain.” p.219 (Treatment-Resistant Schizophrenia: Treatment Response and 
Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology). 
 
It was therefore decided to focus on overall symptom severity so various analyses are 
presented where the TRS participants have been divided into two groups (referred to as 
Lower PANSS and Higher PANSS) according to their level of symptoms.  The term 
“Higher” is preferred to “High” as the latter might imply a greater level of symptoms than 
generally indicated by the scores.   A median split of the distribution of total scores was not 
possible as three participants had identical scores in the middle of the distribution, however, 
it was possible to achieve two groups with a minimum of 6 points of separation between 
them by assigning 14 participants to the lower PANSS group and 12 to the higher PANSS, 
with median total scores of 41 and 66 respectively35. 
 
   Neuropsychological Assessment 
2.7.1   The Wechsler Abbreviated Scale of Intelligence (WASI) 
Intellectual aptitude was assessed using the Wechsler Abbreviated Scale of Intelligence 
(WASI) which provides estimates that correlate highly with the more extensive Wechsler 
Adult Intelligence Scale (WAIS-III) Full-scale Intelligence Quotient which has been 
standardised in the general population and enables scores to be adjusted for age and gender.  
The two subscales of performance IQ (PIQ) and verbal IQ (VIQ) reflect two factors which 
equate to “fluid” and “crystallised” intelligence (Cattell 1963) and have strong coefficients 
of congruence “suggesting factorial equivalence across the standardization and clinical 
 
35  The minimum gap between the groups widened to 9 points in some analyses when one participant 
(ID32), who had a total PANSS score was not included as scores on the Negative and Positive scales 
were unavailable. Perhaps, serendipitously, their total score was in the middle of the distribution and 
this was the only assessment not conducted or supervised by TC. 
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samples” (Ryan et al., 2003).  The WASI comprises four tests: two addressing performance 
(Block Design and Matrix Reasoning) and two for verbal aptitude (Similarities and 
Vocabulary).  The results from these are combined to produce an estimated Full-Scale 
Intelligence Quotient (FIQ). In this study, the scores were adjusted for age and gender; 
percentiles were also obtained for comparisons with population norms and those on the test 
battery.  However, standard IQ scores are expressed elsewhere because these are normally 
used in the literature (also, to avoid confusion, for example, the t-score at the 50th percentile 
is 50, whereas for the standard score IQ scores it is 100). 
 
Further investigations were conducted concerning an unexpected asymmetry between the 
WASI subscales for some individuals (illustrated in the results at Figure 3. 2).  This was 
fairly sizeable, exceeding 10 points in 52% of the participants, with the majority showing an 
imbalance which favoured performance IQ (PIQ).  Whereas verbal IQ (VIQ) scores were 
superior only in a small group of 4 participants.  Apart from potentially being an interesting 
observation in its own right, the presence of these sub-groups could present a confound in 
the data. Therefore, further descriptive and exploratory correlational analyses were 
conducted concerning the groupings of “superior PIQ” (PIQ>VIQ), “no asymmetry” and 
“superior VIQ” (VIQ>PIQ), in order to assist the interpretation of results.  
 
A descriptive characterisation of the VIQ>PIQ individuals is presented in Table 3. 19  (also 
Appendix 5) and appeared so distinctive that some analyses were repeated in a reduced set 
of 20 TRS participants which excluded their scores.  These concerned correlations involving 
negative symptoms and variables associated with attention (Table 3. 17: 0-Back SDs, CPT-
IP scores and percentage of omission errors in the n-back task); also, between all these with 
estimates of IQ (Table 3. 18).  All these correlations in the reduced set are reported in 
Appendix 5:  Table Appx. 5. 1 and Table Appx 5. 2  
 
2.7.2   The MATRICS Consensus Cognitive Battery (MCCB)  
The MCCB arose from a U.S. funded collaborative project at five academic sites: “the 
Measurement and Treatment Research to Improve Cognition in Schizophrenia 
(MATRICS)” and has been standardised and validated with 300 community residents and 
176 individuals with schizophrenia or schizoaffective disorder (Green, Harris, and 
Nuechterlein 2014; Kern et al., 2011).  Specifically developed for schizophrenia research 
and drug trials, it was recently described as “the gold standard” (Lees et al., 2015).  Many of 
its tests are well-established and were selected by consensus from more than 90 tests in a 
process that considered test-retest reliability, usefulness regarding functional outcomes, 
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tolerability and practicality (Nuechterlein et al., 2008; Kern et al., 2011).   A computer was 
necessary for scoring overall composite scores and for administering the Continuous 
Performance Task - Identical Pairs (CPT-IP), however, a traditional “paper and pencil” 
approach with a stopwatch was used for other aspects of administration and data collection. 
 
Seven separable domains of function were identified during the MCCB process, which are 
summarised in Table 2. 2 along with the ten tests chosen to assess them and a brief 
description of testing procedures.  These concerned aspects of executive function, working 
memory, verbal fluency, measures of verbal learning and memory, visual learning and 
memory, processing speed, sensorimotor aspects, attention and emotional 
understanding/social cognition (Nuechterlein et al., 2004).   
 
The MCCB generated a number of variables for exploratory analysis, including comparisons 
between lower and higher PANSS groups.   Correlations have been observed between 
different domains and intelligence scores (e.g. August et al., 2012; Mohn et al., 2014), 
therefore in summary charts of the WASI and MCCB results in sections 3.2 and 3.4 scores 
are also expressed as percentiles as these are readily comprehensible in relation to 
population norms from standardisation studies (Crawford, 2003).    
 
As this study lacked a FLRS group for comparison, the T-scores for the domains in this 
study are displayed alongside others from published studies (Table Appx. 4. 8, Figure Appx. 
4. 1).   However, in order to evaluate heterogeneity amongst the MCCB tests in this study a 
series of within-participant comparisons were conducted using the Wilcoxon Signed Rank 
Test with scores on category fluency (animal name generation) which had the best 
performance at the 38th percentile.  Uniquely, the scores were virtually identical for lower 
and higher PANSS groups thereby strengthening the case for its suitability as a baseline.  
These are reported in section 3.4.1, Table 3. 8.   
 
Further, as the processes that underlie verbal and visual learning may largely differ from the 
executive processes of verbal and visual working memory, some exploratory correlations 
were conducted between these and variables assumed to reflect higher cognition and 





Table 2. 2   MCCB Tests and Domains 
Cognitive domain  MCCB test Dependent Variable 
Speed of 
Processing  
Trail Making Test, part A (TMT -
A). 
Time taken to draw a line 
connecting 25 circles 
according to numeric order 
indicated by labels.  
Brief Assessment of Cognition in 
Schizophrenia (BACS) Symbol 
Coding.  (A digit symbol 
substitution test) 
Total number of correct 
pairings within 90 seconds. 
Category Fluency  
(A verbal fluency test similar to 
one used by Brenda Milner 
(1964). 
The number of animal names 
generated in 60 seconds. 
Verbal Learning The Hopkins Verbal Learning 
Test - Revised™ (HVLT-R™) 
Total number of words 
correctly recalled from a 12-
item list presented 3 times. 
Visual Learning The Brief Visuospatial Memory 
Test-Revised™ (BVMT-R™) 
Recall and reproduction of six 
2-dimensional abstract figures 
(with geometric elements) 
presented together for 10 
seconds, repeated 3 times. 
Working Memory Wechsler Memory Scale (WMS-
III) Spatial Span.  
(Similar to “Corsi Blocks”) 
Total number of correct 
reproductions of tapped 
sequences (forward and 
backwards), presented at 
increasing length. 
Letter-Number Span (LNS) 
(University of Maryland) 
Number of letter-number 
sequences correctly re-ordered 
(numbers first, then letters) 





Assessment Battery (NABs): 
Mazes 
Total score based on time to 





Emotional Intelligence Test 
(MSCEIT): Managing Emotions 
Scoring determined by a 
consensus method about “the 
effectiveness of solutions 
about regulating emotions in 
oneself and interactions with 
others” (Kern et al., 2011). 
Attention/Vigilance  Continuous Performance Task - 
Identical Pairs (CPT-IP) 
Mean d-prime values for 2-, 
3-, and 4-digit conditions 
 
Exploratory correlations were also conducted between selected variables and the duration of 
treatment with clozapine and also, the elapse of time from diagnosis until treatment with 
clozapine since, as Table 3. 3 shows, the lower PANSS group had received it for a median 
of 9.5 years, a significantly longer duration than in the higher PANSS group where the 
median duration of treatment was 4.5 years.  Individuals in the lower PANSS had also 
started a trial of clozapine a median 4 years after their initial diagnosis (assumed to be the 
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FEP), compared with 7 years in the higher PANSS group (a difference which, arguably, had 
“trend significance).   
 
The variables for correlation were chosen on the basis they appeared to distinguish four 
participants with an intellectual asymmetry that favoured VIQ (Table 3. 19 and Appendix 5) 
and who had waited to receive clozapine for a mean average of 2.5 years, compared to 6.6 
years for the group as a whole (Table 3. 3).  These concerned total PANSS score, the 
number of negative symptoms, 0-Back SDs and 0-Back RTs, WASI estimates and the 
percentage of omission errors to targets in the n-back study, category fluency and sustained 
attention/vigilance scores and the MCCB Overall Composite.  Verbal learning (HVLT-R) 
and total free recall on the first trial of the HVLT-R were also selected in the light of an 
observation on recency (below).  A corresponding correlation was conducted with visual 
learning (BVMT).  These correlations are reported in Table Appx. 4. 7 (a, b).    
 
The possibility that visual and verbal learning might deteriorate during the time between 
diagnosis and a trial of clozapine led to a further decision to conduct partial correlations 
with age as a covariable.  The time between first episode/diagnosis and receiving a trial of 
clozapine was slightly positively skewed (skewness = 1.007, standard error = .464, with a 
kurtosis of .640) and had initially been treated as non-parametrically distributed variable, 
however, this marginal decision was revised as partial correlation was only available for 
parametrically distributed variables in SPSS (these are reported at the end of section 3.4.3). 
 
An unplanned analysis was also conducted with data from one of the MCCB tests.  This 
concerned free recall on the first trial the HVLT-R.  This was done because the 12-item list 
is presented auditorily and requires immediate recall, yet few participants appeared to 
demonstrate recency36 by recalling the most recently presented items first, notwithstanding, 
clear instructions that the words could be recalled in any order37.  This seemed surprising as 
individuals might be expected to seize upon the last two or three items held in a transient 
auditory store after the presentation of a long list that is likely to exceed their short-term 
memory span.  The results are presented in section 3.5.  
    
 
36 The recency effect reflects a common strategy that appears to take advantage of items held in a 
limited capacity, transient, auditory store.  Noted by Hermann Ebbinghaus in the 19 th century 
(Baddeley, 1976).   
 
37  “I am going to read a list of words to you. Listen carefully, because when I’m through, I’d like 





FUNCTIONAL MAGNETIC RESONANCE IMAGING 
 
    Magnetic Resonance Imaging 
2.8.1   Equipment and Image Acquisition Parameters 
Functional and structural MRI data were collected at the Centre for Neuroimaging Sciences, 
King’s College London using a Signa HDx 3.0 Tesla MR scanner (GE Medical Systems, 
Milwaukee, WI, USA), with an 8-channel head-coil.  
 
2.8.2   Functional MRI parameters:  
One hundred and eighty-six T2*-weighted images depicting the BOLD contrast during the 
n-back were acquired in the axial plane, parallel to the anterior commissure–posterior 
commissure (AC–PC) line using echoplanar imaging.  The parameters are described in 
Table 2. 3 
 
Table 2. 3   fMRI Image Acquisition Parameters for the Verbal N-Back Task 
Number of slices: 39 
Slice thickness (mm) 3.5 
Inter-slice gap (mm) 4 
Number of functional images  186 
Echo time (TE) (ms) 30 
Repetition time (TR) (ms) 2000 
Flip angle (degrees) 75 
Matrix size 64 x 64 
Pulse Sequence  epiRT 
Field of View (FOV) (cm) 24 x 24    
Scan time (seconds) 372 
 
2.8.3   Structural MRI parameters:  
To enable accurate normalisation of the images for individuals into standard stereotactic 
space (prior to mapping on to the Talairach template), high resolution GE-EPI whole brain 
volumes were acquired with axial slices parallel to the plane of the AC-PC line:  TE=40ms, 
TR = 3000ms, excitation flip angle 90 degrees, number of slices 43, thickness/gap 3.0/0.3, 





   The Experimental Paradigm:  A Verbal N-Back Task 
The n-back task in various forms (visuospatial and verbal), has been widely used in 
neuroimaging as a task of working memory and executive function.  It was used for the 
neuroimaging part of this study while on-line recording of responses also generated 
behavioural data which could be useful in the characterisation of performance by participant 
groups and, perhaps, providing some convergent support for neuropsychological assessment 
which generally occurred on different days.38  
 
The verbal n-back task involves holding in memory a temporary sequence of items (usually 
1 to 3) and updating them as the list of to-be-remembered items progresses.  Responses are 
made when a stimulus reoccurs at the designated position in the sequence, e.g. upon 
immediate repetition (1-Back), after another stimulus has intervened (2-Back) or after two 
stimuli have intervened (3-Back).  This last condition represents the highest level of task 
difficulty/cognitive load and is frequently omitted in studies with clinical participants.   
 
The baseline condition (0-Back) is assumed to evoke the same haemodynamic responses 
apart from those relating to aspects of working memory itself, thereby, providing the 
substrate against which changes in the haemodynamic response are compared.  The “verbal 
0-Back” used here, required a button to be pressed with the right index finger when the 
letter “X” appeared.  Overall, the n-back task requires sustained attention along with the 
ability to remember items stored temporarily and, presumably, the ability to inhibit 
“activated” representations or, at least ignore them through selective attention as new 
stimuli take their place (part of the updating function).  It is also necessary to apply task 
rules and demonstrate flexibility to cope with changing task demands between blocks.  
Successful performance, therefore, requires a considerable amount of attention, continuous 
monitoring, also, the inhibition of erroneous prepotent responses.   
 
A short practice session on the n-back task was given off-line to all participants during the 
hour before their scan, when they were further assessed for safety by the radiographer.  
Once settled in the scanner, participants lay supine and wore ear-phones to partially shield 
the noise from the scanner and to enable communication with the experimenter and the 
radiographers.  A panic button was held in the left hand, and the button pad for the response 
in the right (usually resting upon the thigh).  Visual stimuli were projected onto a large 
screen at the foot of the trolley where participants lay and were clearly visible from inside 
the borehole of the scanner via a two-mirror system. 
 




At the start of the experiment, instructions were read aloud by the experimenter while a 
fixation cross was displayed on the screen.  These included a request that the participant 
should keep their heads as still as possible and not to talk out loud.  The different levels of 
the task were described and participants were requested to press the button in their right 
hand whenever they saw the target letter.  (However, this cannot be described as a speeded 
reaction time paradigm as they were not asked to respond “as quickly as possible”).   
There were 3 experimental blocks for each condition, presented in a pseudo-random order 
that was held constant for all participants.  Each block comprised 14 trials of individual 
letters, including 3 targets.  Response latencies, correct responses and errors were recorded 





Figure 2. 1  Illustration of partial sequences in the Verbal N-Back Paradigm  
 
 
Shown from back to front:  each experimental block started with an instruction denoting 
the condition.  The first appearance of a target in the 1, 2 and 3-back conditions is 
highlighted in this figure in pale grey, with repeated occurrences requiring a response in 





   Behavioural Variables from the N-Back Task  
Reaction times (RTs) for correct responses to target letters, omission errors and false 
positive responses, also standard deviations (SDs) at different levels of cognitive load offer 
an array of potentially interesting variables.  However, as many processes are likely to 
contribute to these measures, the simplicity and ease of the 0-Back condition (as evidenced 
by faster reaction times and excellent accuracy), offered the best prospect of providing 
useful variables, with the exception of error data where the frequencies were too low.  
Further, it was hoped that the simple measures of mean RTs and SDs in the baseline task by 
individual participants might, to some extent, capture “state” or possibly “trait-like” 
characteristics prevailing around the time of scan 
 
2.10.1   Error Data 
In every experimental block there was an opportunity to make 3 omission errors to the target 
and 11 omission errors (amounting to 9 target errors and 33 omission errors in each 
condition and 36 target errors and 132 omission errors across the experiment as a whole).  It 
is proposed omission errors could provide an index of sustained attention as they may occur 
during lapses in attention.  As discussed in the introduction, it is further proposed attentional 
lapses might be mediated by negative symptoms such as apathy or anergia, or even be 
related to hyperactivity in the DMN acting as a “pull factor” which constantly draws 
attention back to the inner world. 
 
By contrast, false positives might reflect the influence of entirely different factors, for 
example, decision-making in the presence of insufficient, or degraded information.  There 
is, for example, a literature with several theories (described in Rausch et al., 2016) on 
“jumping to conclusions” in schizophrenia - a robust phenomenon where individuals make 
probabilistic judgments prematurely on the basis of limited information while appearing 
confident about their responses.  One explanation, might extend to failures of inhibition of 
prepotent motor responses, possibly fuelled by an elevated dopaminergic state which 
confers aberrant salience.  This generates a prediction that false positive errors might 
correlate with positive symptoms.  However, irrespective of whether it is possible to 
progress these questions within the scope of this study, error rates offer an interesting source 
of data providing different kinds are analysed separately. 




2.10.2   Standard Deviations as a Proxy Measure of Attention 
In Miller and Cohen’s (2001) influential “theory of prefrontal cortex function” top-down 
attentional control is required in situations demanding flexibility in responding, for example, 
in the context of changing task demands, or in response to the detection of performance 
errors (Carter and van Veen, 2007).   As a result, it is proposed mean standard deviations in 
the 0-Back task could provide a simple measure of the ability to sustain attention under 
cognitive control.  Also, the 0-Back task (pressing a button every time an “X” appears) 
resembles the first continuous performance task (CPT) by Rosvold et al. (1956), which was 
designed to assess “attention or alertness” and was subsequently adopted to measure 
sustained attention in classic tasks like the Conner’s CPT-3. These will be more extensive 
than the 0-Back task and parameters such the presentation rate, the number of trials and 
proportion of targets are manipulated, however, there is some face validity in proposing this 
behavioural data might provide a measure of sustained attention.   
 
The Conner’s CPT paradigm has been demonstrated in healthy participants to activate a 
network that is similarly activated in other studies of sustained attention, for example,  Tana 
et al. (2010) observed activity in a large-scale network that involved the frontal, temporal, 
insular and occipital cortices and cerebellum with the greatest activation observed in the 
right ACC.  This appears to be consistent with the engagement of the central executive and 
salience networks as described by Menon and Uddin (2010).  The Continuous Performance 
Task - Identical Pairs is included in the MCCB, however, this is more perceptually 
demanding as the stimuli (comprising 2,3 or 4 digits) are presented at a relatively fast rate of 
1 per second for long blocks and participants are required to respond if the stimulus on the 
current trial matches the previous one, which may be perceptually similar. As Rapisarda et 
al. (2014) observe “subjects need to decode each stimulus carefully and keep it in working 
memory until it can be compared with the one immediately following.” (p.234) 
Lopez-Luengo et al. (2016) suggest the literature on the CPT is divergent because “more 
difficult CPTs can place additional processing demands on the subject.”   
 
The creators of the MCCB will have been well aware of such issues, for example, 
Nuechterlein et al. (2015) describe the CPT-IP as involving “sustained attention in a 
situation demanding working memory.” (p.5)  However, it has good test-retest reliability 
and attention, as measured on this test, “is a reliable, stable trait that reflects a biological 
stability to schizophrenia” (Cornblatt and Malhotra, 2001, p.14).  Nuechterlein et al. (2015) 
have since compared performance on the CPT-IP with the degraded stimulus version  
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(DS-CPT) where the digits are blurred, at five different sites with a sample of 972 healthy 
controls and 1140 participants with schizophrenia.  No relationship was found between 
visual acuity and discrimination performance on the DS-CPT, and only a slight relationship 
with the CPT-IP, while worse performance on the both tasks was associated with poor 
cognitive function and fewer years in education.  Moreover, only a weak relationship with 
negative symptoms was found, if at all, as levels varied across sites.  Yet, while 
Nuechterlein et al.’s (2015) study did not specifically identify TRS or U-TRS individuals, 
those receiving a combination of atypical and typical antipsychotics exhibited significantly 
worse performance on the CPT-IP than while the decrement on the DS-CPT was described 
as showing “a similar but nonsignificant tendency”.   
 
As the CPT-IP was not tested on a TRS population, and the CPT-IP places demands on 
perception and working memory, a “purer” and simpler measure of sustained attention 
might help to provide convergent or supplementary evidence.   
 
2.10.3   Reaction Times 
As shown in Table 2. 2, the domain of processing speed is measured by the composite of 
three tests in the MCCB where response times are the end point of the integration of 
different sources of information and stages of processing, for example, involving perception 
and encoding, response selection and the inhibition of competing responses.  Again, it is 
proposed RTs in the 0-Back condition might provide a simpler measure of processing speed 
than more complicated or demanding tasks, and perhaps convergent evidence if the MCCB 
measure is questioned in some way.  Further, this measure might reflect “state”-like 
characteristics (including arousal and responding contingencies such as speed/error trade-
offs) that may have prevailed for the duration of the experiment.  (Table Appx. 4. 2 reports 
correlations between measures of speed and the MCCB overall composite).    
 
While RTs and SDs are usually highly correlated and difficult to separate.  SDs in the 0-
back condition are proposed to provide a proxy measure of attention (defined for these 
purposes as reflecting aspects of attention that are largely accessible to conscious control - 
the ability to maintain attention and resist distraction, i.e. sustained attention and selective 
attention respectively).  This proposition was tested in correlations between SDs in the 0-
back condition and measures which might be associated with attention:  Negative 





   Statistical Analysis of Non-Imaging Data 
The IBM SPSS Statistics software package was used to analyse neuropsychological and 
behavioural measures and to chart scatterplots.  Fisher’s exact test was used to determine if 
there was a significant difference between expected and observed frequencies for gender39.  
The parametric Pearson product moment correlation coefficient or non-parametric 
Spearman’s rho were selected according to assumptions.  Between-group comparisons used 
the independent-samples t-test for normally distributed variables, or the non-parametric 
Mann-Whitney U-test, again, according to assumptions.  All comparisons were two-tailed. 
Significance levels were rounded up to p = .001 where SPSS stated p = .000, with the 
exception of Table Appx. 4. 2 concerning correlations involving MCCB domain and 
composite scores where there was a meaningful difference between p values at .001 and 
others specified as p = .000.   The latter were labelled as p < .0005.     
 
A decision to use, potentially less sensitive, non-parametric tests for comparisons involving 
continuous variables between the lower and higher PANSS symptom groups was made, 
even though skewness ranged from 0.501 to 0.661 for the majority of the variables, because 
the number of participants were judged too few (below 15); also, the shapes of the 
distributions often varied between lower and PANSS groups.  This was a subjective decision 
that follows Saroj et al. (2016).40   McDonald (2014) has observed “there don't seem to be 
any objective rules on how much non-normality is too much for a parametric test.” (pp 133-
136 on “non-normality”).  Even, for larger groups in the behavioural data, it was necessary 
to be circumspect where, for example, the Kolmogorov-Smirnov Test of Normality 
confirmed there was heterogeneity in the distributions across the different experimental 
conditions of both controls and TRS participants (Table 3. 11).    
 
It is further noted partial regression for non-parametric data is not available in SPSS and 
regression with small datasets is inadvisable so these techniques were not used in 
exploratory analyses of asymmetries between the WASI subscales.  
 
 
39 The chi-square test for independence (χ2) was not used as the expected frequency of female 
participants in some cells was too low. 
40 “Nonparametric tests make no or very minimal assumptions about the probability density from 
which the data are derived. They are used when the sample size is small, when the data are not 
normally distributed and cannot be approximated as normal, and when using non numerical (rank, 
categorical) data. The nonparametric tests are often a good option for small sample sizes (n < 




The on-line behavioural data (RTs) was screened twice for outliers, once using a cut-off of 3 
standard deviations above the mean for each condition in each group, which resulted in no 
exclusions and again using a limit of 2.5 SDs above the mean.  As variability in responding 
is of interest and there was a need to conserve data (the experiment provided a maximum of 
9 correct responses to target stimuli per participant in each condition), a screening limit of 3 
standard deviations was chosen except where stated.  This may have had minimal effect as 
only 5 scores in the control group (0.66% of correct response) and 2 in the TRS group 
(0.21% of correct responses) fell within this band.   
 
2.11.1   Multiple Comparisons 
The nature of this study was largely exploratory given the dearth of evidence on TRS, and 
the collection of clinical, cognitive and behavioural measures leads to an accumulation of 
variables.  This raises the problem of multiple comparisons because it increases the 
likelihood of Type I Error, i.e. deeming a finding is significant when it is not.  However, a 
common criticism of correction techniques which adjust the alpha level is that they are 
overly strict and undermine power. This may lead to the neglect of potentially useful 
observations and even publication bias (Nakagawa 2004).  One way of circumventing this is 
to be highly selective but this stifles exploration and may also lead to “cherry picking” 
where significant results are more likely and, therefore, also risks bias.  In any case, it may 
be remiss not to conduct some analyses when the data is available.  
 
The approach taken in these analyses seeks to find a balance by applying a probability value 
of 0.05 as the significance level for all non-imaging tests and to look for convergent 
evidence upon interpretation.  However, the revised alpha after Bonferroni correction, 
restricted to “families” of tests, is also provided for reference in some analyses.41  The 
results of neuropsychological, clinical and behavioural comparisons are “unadjusted” unless 
otherwise stated.  Following the recommendations of Nakagawa (2004), exact p-values are 
also reported42, often with the effect size thereby, providing some indication of potential 
biological or practical importance.  These are evaluated using Cohen’s (1988) guidelines: 
for comparisons using the Mann-Whitney U test, r =.10, .30 and .50 indicate small, medium 
and large effect sizes respectively. (Similarly, for Eta-squared = .01, .06 and .14 in t-tests). 
 
41 Had the number of variables been more extensive, the “false discovery rate” might have been 
controlled instead.   
 
42  Except where p = .000 and is rounded up to .001. 
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Cohen (1988) also proposed the strength of a correlation coefficient is small if r = .10 to .29; 
medium if r = .3 to .49; large if r = .50 to 1.0. 
    
A further reason to be cautious arises from the recognition that while neuropsychological 
assessment may be useful for descriptive purposes and comparing individual scores with 
standardised norms, large numbers of participants are usually required to establish the 
robustness of observations and inferences made at group level, even when individual studies 
report highly significant results.  Apart from methodological and recruitment differences, 
other sources of variation include intra-individual factors including transient fluctuations in 
“state”.  The primary value of this rare dataset surely lies not in disproving hypotheses but 
in highlighting potential lines of enquiry and the generation of hypotheses.43 
 
2.11.2   Correlations between Symptoms, Cognitive and Behavioural Variables 
Section 3.7 presents some intercorrelations for the TRS group between clinical measures, 
neuropsychological assessments and behavioural measures from the n-back task.  In 
particular it was proposed in the introduction that negative symptoms might interfere with 
or, in some other way, be associated with aspects of cognitive control and attention, so 
exploratory correlations were conducted between negative symptoms and measures 
proposed to be associated with attention (0-Back SDs, CPT-IP scores and the percentage of 
omission errors on the n-back task).  However, both negative and positive symptom scores 
were generally low across the TRS group (n=26) with median scores of 14 and 11, 
respectively (were the minimum score is 7 and the maximum is 49 on both scales), which 
could reduce the likelihood of significant correlations.  The results of correlations with 
negative symptoms are shown in Table 3. 17 below and depicted in Figures 3.11 and 3.12.   
 
With the exception of omission errors in the n-back task, which was considered the weakest 
correlate, a second set of exploratory correlations were conducted involving these variables 
and estimated IQ scores.  In addition, correlations were performed with a variable that 
indicated IQ asymmetry - the difference between individual scores on the WASI subscales.  
The results are shown in Table 3. 18 along with scatterplots (Figures 3.13, 3.14, 3.15, 3.16).   
  
 
43 Baddeley (2012) on Lakatos and Popper, p.4. 
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 Functional MRI Analysis Using XBAM 
The data were analysed using the XBAM (version 4.1) software, developed at King’s 
College London, Institute of Psychiatry (Brammer et al., 1997), which uses a non-
parametric approach based on permutation strategies which arose from a desire to minimize 
assumptions (Thirion et al., 2007).  A history supplied with the program explains:  
“The first innovation in XBAM was not to assume normality but to use permutation testing 
to construct the null distribution used to make inference about the probability of an 
"activation" under the null hypothesis. The statistics used were also median rather than 
mean based to give more robustness against outlier effects. The second innovation was to 
recognise the existence of correlation in the residuals after fitting a statistical model to the 
data. If not taken into account, this inflates the type I error rate leading to an unacceptable 
level of false positives. The third innovation was the adoption of a two-level approach to 
data analysis in which the response sizes computed from the model fit for each individual 
(analogous to beta coefficients in SPM) were standardised with respect to their variances 
(residual noise) before embarking on the second, multi-subject, phase of analysis. This latter 
innovation effectively permits a mixed effects analysis of group level fMRI data by taking 
into account both intra and inter subject variances.”    
 
Further detail and validation can be found in Bullmore et al. (1996) and Brammer et al. 
(1997).   Fusar-Poli et al. (2010), further demonstrated the sensitivity of XBAM 
methodology in a comparative study of techniques, for example, observing it detected the 
BOLD response in the insula, temporal lobe (including the middle and inferior temporal 
gyri) and putamen, whereas a parametric package could not44.  Also, in Thirion et al. (2007), 
whose analysis involving “more than 80” subjects, compared the validity and implications 
of parametric assumptions compared with non-parametric ones.  The most commonly used 
measure of response size (unstandardised beta) in fMRI analysis was observed to depart 
from normality in 22% of intracerebral voxels leading to the observation “Non-normality is 
very significant in wide regions of the brain.”  One of their conclusions was that “mixed 
effects tests are much more reliable than random effects tests.” This also supported 
permutation-based inference and cluster, or parcel level, as opposed to voxel level inference 
- all of which are features of XBAM.   
 
(For a full description and references see http://www.brainmap.it) 
 
 




XBAM was therefore chosen for its sensitivity as it enables the detection of small but highly 
activated clusters and, also, because the current study comprises a relatively small number 
of individuals (a minimum of 20 recommended by Thirion et al. (2007) for reliability in 
fMRI studies).  Moreover, the problem of multiple comparisons is usually addressed 
through techniques such as the Bonferroni correction but, in classical fMRI approaches to 
voxel-by-voxel tests this is especially problematic and may lead to overly conservative 
corrections, reducing the detection of true differences.  Indeed, optimal thresholds can be 
found which “are rather lower than usual corrected for multiple comparison thresholds” 
(Thirion et al., 2007).  XBAM avoids the need for correction through the generation of null 
distributions which can be generated either through permutation sampling from all the 
voxels in the brain (global technique) or through local permutation at each voxel (Bullmore 
et al., 1999).  The default (global) permutation was used in these analyses.  In addition, 
cluster thresholds were adjusted to minimise the risk of type 1 error.   
 
Age was used as a covariate in all the neuroimaging analyses as functional neuroimaging 
has demonstrated this to be an important biological variable where a sizeable a literature has 
demonstrated influences upon fMRI BOLD measurements (Heinzel et al., 2017; Rieckmann 
et al.,  2017; Keller et al., 2015).  Indeed, the TRS group was older than the control group 
(Table 3. 1).   
 
However, IQ was not used as a covariate. Within a framework that regards schizophrenia as 
a neurodevelopment disorder (Murray et al., 2017), premorbid IQ score is strongly 
associated with risk for schizophrenia (Khandaker et al 2011). Therefore, IQ is confounded 
with and/or by schizophrenia in its different forms (e.g., TRS), and as it is intrinsic to 
schizophrenia it cannot be separated from its effects. On a methodological level, IQ in 
schizophrenia does not meet the following requirements for a covariate: (a) the assignment 
to the independent variable (e.g. schizophrenia) is done randomly; (b) the covariate is 
associated with the outcome measure, but this relation is not central to the research question; 
(c) the covariate is not related to the independent variable (Huitema, 1980). This is why the 
recommendation by Dennis et al. (2009) was followed and IQ was not controlled in the 





2.12.1   Individual and Group Mapping 
Before the images could be processed by XBAM software, they were converted from their 
original format (University of North Carolina, UNC format) to ANALYZE format (Mayo 
Foundation).  This involved automated processing.  The XBAM analysis is described below. 
 
2.12.2   fMRI Pre-Processing 
Data were processed to correct motion, intensity and spin excitation history (Bullmore et al., 
1999) and were smoothed prior to statistical analysis and normalization, i.e. in native space. 
First, fMRI data were realigned in order to minimise movement artefacts (Bullmore et al., 
2001) and smoothed using a Gaussian filter (“full width at half maximum” (FWHM) 8mm) 
to improve signal-to-noise ratio over each voxel. 
 
2.12.3   IBAM module (Individual Brain Activation Mapping) 
The next step involved within-subject analysis of data for individuals in native space where 
peak responses to the experimental paradigm were detected by fitting a model to the time 
series at each voxel, at each phase of the task (0-Back, 1-Back, 2-Back, 3-Back, specified in 
the time matrix of a model file) and convolved using Poisson functions (modelling 
responses at 4 s and 8 s, to provide an estimate which allows for variability in the 
haemodynamic delay).  Then the “best fit between the weighted sum of these convolutions 
and the time series at each voxel was computed using the constrained BOLD effect model 
suggested by Friman et al (2003)”.45  This reduced the risk of physiologically unlikely 
results and enabled the further computation of a goodness of fit statistic at each voxel, the 
sum of squares ratio (SSQ), which is further described as of the ratio of the sum of squares 
of deviations from the mean image intensity (over the whole time series) due to the model to 
the sum of squares of deviations due to the residuals (SSQ ratio)”34.  The null distribution 
against which any SSQ ratio can be compared for significance was then generated using the 
wavelet-based time series resampling method described in Bullmore et al. (2001) and then 
fitting the model to the resampled data.  This enables the calculation of the SSQ ratio 
needed to threshold the statistical maps for any level of type 1 error rate (for example, SSQ 
ratio values in the observed data lying above the 99th percentile of the null distribution have 
a probability under the null hypothesis of p < 0.01).  This permutation method has been 
shown to give excellent Type I error control and has been demonstrated for suitability with 
data acquired at 3 Tesla (Bullmore, et al., 2001). 
 




2.12.4   TBAM (Talairach Brain Activation Mapping) 
In order to extend inference to the group level, the observed and randomised SSQ data for 
each individual were mapped into standard stereotactic space using a two-stage warping 
procedure implemented in the TBAM (Talairach Brain Activation Mapping) module of 
XBAM as described in Brammer et al. (1997) where the statistical maps were aligned with 
the high resolution structural image and then normalised by transformation onto a Talairach 
template ( Talairach and Tournoux., 1988)46.   
 
2.12.5   GBAM (Generic Brain Activation Mapping) 
The transformation of the statistical maps into standard Talairach space permitted statistical 
testing at a group level so that a generic brain activation map (GBAM) could be produced.  
This was achieved by calculating the median of the SSQ ratio at each voxel over all 
participants (specified in the subjects.txt file) and checking through permutation if the 
median is significant against the null distribution of the median values from the randomised 
time series.  (The use of median statistics minimised the effects of outliers).  The null 
distribution of SSQ ratios could be thresholded to produce group maps at any level of voxel, 
or cluster-level to control the risk of type 1 (false positive) error.  In the GBAM analysis, the 
default voxel-level statistical threshold was set to p < 0.05 to give maximum sensitivity and 
to avoid type II errors while the cluster level was set to p < 0.01.  This process was repeated 
with an adjusted cluster level threshold as necessary to obtain less than one expected type 1 
error per whole brain.  The combination of voxel and cluster level thresholds was not 
derived from theory but rather determined by direct permutation, giving excellent Type I 
error control (Bullmore et al., 1999).   The output files of GBAM were numbered so that 
‘a1’ denoted a noise map, ‘a2’ was the 1-Back condition compared to the 0-Back baseline 
task, ‘a3’ was the 2-Back condition vs 0-Back and ‘a4’ was 3-Back condition vs. 0-Back. 
 
2.12.6   ABAM (Analysis of Variance Brain Activation Mapping) 
The transformation of the statistics maps for each individual into standard space enabled 
non-parametric analysis of variance tests to be conducted using the second level module 
called ABAM. The data for each subject and condition was listed in a plain text file 
(subjects.txt) while the ANOVA factors were specified in the corresponding order in the 
 
46 This process involved “a rigid body trans-formation of the fMRI data onto a high-resolution 
inversion recovery image from the same subject, followed by an affine transformation onto a  
Talairach and Tournoux (1988) template” see http://www.brainmap.it 
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model DesignMatrix file.  A further file (covar.dat) listed the age of the participants on the 
day of the scan so this could be regressed as a covariate.  Group comparison maps were 
thresholded to obtain less than one false positive cluster.   
 
The second-level analyses conducted were: 
- Linear trend analyses:  
A within-subject linear trend analysis was conducted for the control and TRS groups using 
XBAM. This analysis modelled haemodynamic response increase/decrease with successive 
increase/decrease in cognitive load (i.e. 1-Back < 2-Back < 3-Back).   
 
- Within Group Activations relative to the baseline task: 
In addition to the above within subject linear trend analyses, tables for significant within-
subject group activations and deactivations (i.e. increases and decreases in the 
haemodynamic response) relative to group baselines at each level of cognitive load, are 
provided in the Appendix 2. 
 
- Factorial analysis comparing the TRS and Control groups:  
A mixed between-within subject non-parametric analysis of variance was conducted in 
XBAM where the control and TRS groups formed the between subject factor, and the 
working memory/cognitive load conditions (1-Back, 2-Back, 3-Back) comprised the within 
group factor.  In the DesignMatrix, the first column coded for the main effect of the group, 
the second column coded for the main effect of condition/task, while a third coded for the 
interaction (i.e. column 1 x column 2). 
 
For the reporting of the results, significant clusters smaller than 20 voxels were removed 
from the analyses. However, the initial analysis obtained some very large clusters.  This 
analysis was subsequently repeated using a voxel p-Value of 0.01 in an attempt to reduce 
cluster size.  However, some very large clusters remained.  (The results are shown in tables 
and figures presented in Appendix 3).  Therefore, the large clusters from the first factorial 
analysis were broken up into Brodmann areas using a declustering technique described at 
2.12.7 below and, for the purposes of charting group activations at different levels of 
cognitive load, to extract SSQs around individual peak activations by applying a relatively 




- Factorial analysis comparing the Lower and Higher PANSS groups: 
 A second mixed between-within subject non-parametric analysis of variance was conducted 
with age as a covariate which explored the interaction of group (lower PANSS vs higher 
PANSS) and task condition (cognitive load) using a 2 (group) x 3 (task condition) factorial 
analysis of covariance.  This ANCOVA was conducted with TRS participants grouped 
according to symptom level based on PANSS scores (procedure as described in section 
2.6.1 above).47  The same statistical approach was taken as above, so the analysis was 
repeated using a voxel p-Value of 0.01 in an attempt to reduce cluster size.  Again, this 
reduced the number of clusters (the results are shown in Appendix 3), and it was decided to 
decluster the original analysis.  
 
2.12.7   Declustering Significant Clusters into Brodmann Areas 
In order to achieve better localisation and identify more areas within the significant clusters, 
a “declustering” procedure that is available in the XBAM was applied to the activation maps 
that were generated after the cluster p-value had been adjusted to minimise the risk of type 1 
error (while the voxel p-value was at 0.05).  This broke up the significant clusters using 
cytoarchitectonic areas based on Brodmann Area and resulted in further, generally smaller, 
clusters of significant activation and a new set of corresponding p-values.  As intended, this 
improved localisation and confirmed the presence of significant activations in brain areas 
not labelled by XBAM in the earlier analyses.  These values are reported in Table 3. 24 and 
Table 3. 25.   
 
Declustering also produced new statistical maps, however, an option to merge these maps 
was unavailable for declustered images.  However, this actually makes it easier to inspect 
the many clusters.  The reciprocal pattern of task positive and task negative network 
activity, medially and laterally, is also apparent when presented side by side.     
 
Peaks of activation described by XBAM as being in white matter should be treated with 
some suspicion as they might arise from an artefact, however distances from the peak 
activation to the “nearest grey” of less the 5mm were not reported in the tables as they were 
within the range of normalisation error.  Peaks exceeding this were retained and reported if, 
for example, they related to a large cluster of significant differential activation and there was 
 
47 A Mann-Whitney U test indicated the difference between ages in the lower PANSS (Median = 35, 
n =14) and the higher PANSS group (Median = 33, n = 12) was non-significant, U = 65, z = -.979,  
p = .328, r = 0.19.  Under Cohen (1988) guidelines an ‘r’ value of .1 = small effect and .3 =medium 
effect so this was considered to be a small to medium effect size.  However, as these were small 
groups and the test might lack sensitivity, age was specified as a covariate. 
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no clear reason to exclude them.  Also, where more than one significant cluster had the same 
Brodmann area or had common label (e.g. the left medial frontal gyrus with peaks in BA 8 
and BA 10), these were reported because to provide a more complete description of the data; 
also, it cannot be assumed they are functionally equivalent.  
 
2.12.8   Extraction of SSQs following the Declustering Procedure 
The declustering option selected in the ABAM module produced new co-ordinates and  
p-values, however, the extraction of SSQ values for the purposes of charting the 
haemodynamic response at different levels of cognitive load, was problematic as the 
application of a mask based on entire Brodmann areas, as opposed to a cluster containing 
only statistically significant activations, might include “noise” from inactive voxels, those 
with contrary activations or perhaps increase the risk from physiological artefacts.  It was 
therefore decided to minimise these issues by sampling the immediate area around the peak 
voxel of significant activations (or deactivations) through the use of a mask.  This was 
achieved by growing spheres with a 2mm radius (34 cubic mm), around each peak co-
ordinate and applying this for the extraction of SSQ values.  As computations in XBAM use 
median values, the median value of the SSQs for each condition in each group were plotted 
in graphs, which are presented in sections 3.10 and 3.11. 
 
The size of sphere was chosen after consideration of the typical thickness of the human 
cerebral cortex which according to Fischl (2000) has an overall average of 2.5mm (1 - 4.5 
mm), with crowns being typically 0.5mm thicker than the sulci.  The choice of sphere was 
also influenced by Tong et al. (2016) who explored various ways of measuring ROIs in the 
N-back task and optimised observations by restricting selection to a small area around peak 
voxels.  In this instance, it may have been desirable to use a slightly larger mask, however, 
the program only permitted integers for this function and a sphere with a 3mm radius would 
have equated to 113 cubic mm which was considered too large for this purpose given the 
smaller size of some clusters.   
 
In the depiction of contrasts between the TRS and control groups, activation at the 
corresponding co-ordinates in the contralateral hemisphere is shown for the putamen and 
thalamus to indicate the direction and degree of activation.  Similarly, in the depiction of a 
contrast for involving the TRS participants grouped according to their general level of 
symptoms (lower and higher PANSS) involving the left claustrum, the corresponding area 
for the healthy control group is also shown for comparison to indicate the direction and 
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degree of activation in this group even though the contrast was not significantly different in 
the factorial analysis.   
 
 
 Correlations between the Haemodynamic Response and other Variables. 
BBAM is an analysis available within XBAM which enables relationships between the 
haemodynamic response in different brain areas with other variables to be explored through 
correlational analysis.  As with other XBAM analyses, the results do not require adjustment 
for multiple comparisons.  In all the BBAM analyses, the non-parametric Kendall rank 
correlation coefficient was selected and performed with two covariables:  age and mean 
reaction times in the baseline condition (Is it X?).  Mean reaction times in the least 
demanding 0-Back task for each participant were chosen as a further covariable for this 
narrow subset of analysis to limit the influence of factors related to the preparation and 
execution of motor responses which, potentially, might have been affected by earlier 
treatment with neuroleptic medication although participants had been screened by requiring 
them to produce sequences of finger movements.  Controlling individual mean reaction 
times also served to better isolate factors relating to the BBAM correlate of mean standard 
deviations in the 0-Back condition.   
 
Exploratory correlational analyses were conducted for the TRS data for each level of 
cognitive load between the haemodynamic response and: 
- the total number of positive symptoms; 
- the total number of negative symptoms; 
- mean standard deviations in the 0-Back condition (proposed as proxy for sustained 
attention) in the TRS group; 
- estimated full-scale IQ, with further correlations involving the subscales.  
 
A corresponding analysis was conducted for the control group for mean standard deviations 
in the 0-Back condition.  
 
The results of the correlations with positive and negative symptoms are reported in section 
3.12, with statistical maps and plots of significant correlations.  The remaining correlations 
are provided in Appendix 6.  Three figures concerning the control group involving 
correlations between the haemodynamic response and mean 0-Back SDs were replotted 




CHAPTER III - RESULTS   
 
Results Part I:  Demographic, Clinical, Behavioural and 
Neuropsychological Characterisation of the TRS Group 
 
3.1   Demographic and Clinical Data 
Out of 250 individuals who expressed an initial interest by taking a participant information 
sheet, only 26 participated in the fMRI study.  Some potential participants met exclusion 
criteria, or there were MRI safety concerns.  Two did not have a diagnosis of schizophrenia 
but were receiving clozapine for the treatment of bipolar disorder.  Others had expressed an 
interest “out of politeness” or excluded themselves citing claustrophobia.  Some clozapine 
clinics were s considerable distance away from the IOPPN, so the complexity of the journey 
as well as the demanding nature of the study may have been considerations.    
 
Demographic information for the TRS and healthy control groups is shown in Table 3. 1, 
where it can be seen there were no significant differences between the TRS and control 
groups with respect to gender or ethnicity, however, the TRS group was significantly older, 
by an average of 7 years. 
 
As previously stated, the control group did not participate in neuropsychological and clinical 
assessments, nor was information about years of education, smoking or historic drug use 
collected.  However, even without a comparison group, there appeared to be a very high 
prevalence of smoking among TRS participants at 76%, moreover 92% (23/25) indicated 











Table 3. 1   Demographic Information for the TRS and Control Groups 
 TRS Participants Healthy Controls Statistic 
Mean Age  
(SD, range, n) 
36 years  
(7.67, 25-54, 26) 
29 years  
(6.71, 20-46, 21) 
t (45) = -3.285, p = .002*** 
Female    8 (30.7%)   7 (33.3%)  
 (1, n=47) = .000, p = 1.000, phi = .027¬¬¬ Male  18 (69.3%) 14 (66.7%) 
Ethnicity: 




18 (85.7%) ¬ 
 
 (1, n=33) = .27 p = .602¬¬¬ 
    Black British   5 (19.2%)   1 (4.76%)  
    Afro-Caribbean/Caucasian   3 (11.5%)   
    African ¬   2 (7.7%)    
    Anglo/Indian   1 (3.9%)   
    Asian    1 (4.76%)  
    SE Asian    1 (4.76%)  
Diagnosis¬¬ 




  - 
 
    Schizo-affective disorder  3/26 (11.5%)   -  
Smokes tobacco 19/25 (76%) ¬¬¬¬   -  
 
¬ English was not the first language but was the preferred language of two TRS participants having spoken it since childhood, while one control         
participant was highly fluent in English although their first language was Russian. 
¬¬ One participant had been diagnosed with schizo-affective disorder 8 year’s previously but was currently diagnosed with paranoid schizophrenia.          
Another was taking the mood stabiliser Lithium Carbonate along with clozapine but was diagnosed with paranoid schizophrenia.      
¬¬¬  with Yates Continuity Correction;   
¬¬¬¬ 92% had been regular smokers at some point  
*** Significant after Bonferroni correction with an adjusted alpha of p = .017; the eta squared statistic (.19) for the difference in mean age indicated 







3.1.1   Characteristics of TRS groups based on Symptom Severity 
As can be seen from Table 3. 2, the age difference between the lower and higher PANSS groups was not significant, nor did the distribution of the 
sexes differ.  However, the prevalence of smoking was significantly greater in the higher PANSS group at 90.9%, compared to 64.3%.  Information 
on substance use prior to the first episode of psychosis is supplied in Table 3. 4. 
 
Table 3. 2   Demographic Information for the TRS Participants Grouped According to Symptom Severity 
 Lower PANSS Group Higher PANSS Group Statistic 
Median Age (Interquartile range, n) 35 years (10, n=14) 33 years (14, n=12) z = -1.031, r = -0.2022, U =64, p = 0.303 
Female    4 (28.6%)   4 (33.3%) p = 1.000, 
Fisher’s Exact Male  10 (67.4%)   8 (66.7%) 
Smokes tobacco   9 (64.3%) 10 (90.9%)  (1, n=25) = 6.76 p = .009** 
 
Note:  Individuals in the lower PANSS group exhibited a generally very low level of psychopathology with total scores on the PANSS scale below 
41. Two of the three participants with a diagnosis of schizo-affective disorder were in the lower PANSS group.   
 
 
3.1.2   Comparison of Clinical Variables in the Lower and Higher PANSS Groups  
Table 3. 3 supplies information concerning aspects of clinical history, treatment and symptoms.  In view of concerns that acute psychosis could be 
neurotoxic, further exploratory correlations were conducted concerning the time to access clozapine from the initial diagnosis, also with the duration 








Table 3. 3   Summary of Clinical Variables, Comparing Lower and Higher PANSS Groups  














Median z r U p 
 
Age at First Episode of Psychosis 
 
20 (6.75)  
 
17-32   21 
 
 15-28  20.0 -0.914  0.179    60.5 0.361 





0.5-11    4 
 
0.5-17    7.0 -1.864 
b 
0.366          43 0.062 
 




18 -39  25.5 
 
19-45  27.5 -0.644  0.126   71.5 0.519 
 




0.6-16   9.5 
  
0.1-15    4.5 -2.398 
 b 
 0.470    37.5 0.016* 
 




 9 -24  14 
  
7-26   10.0 -0.604  0.119   66 0.546 
 




37-45  41 
 
51-90   66.0 -4.332 
 c  
 0.850    0 0.001* 
 




 7 -12   8.5 
 
10-26   15.0 -4.021 
 c  
 0.789    4 0.001* 
 




 8 -17  11 
 
11-28   20.0 -3.518 
 c 
 0.690  13 0.001* 
 




17-26  21 
 
27-45   29.0 -4.231 
 c 
 0.830   0 0.001* 
* p < 0.05 (Bonferroni correction for 17 comparisons between higher and lower PANSS p= .003 in Tables 3.2, 3.3 and 3.4). 




3.1.3   Substance Use 
Table 3. 4 provides an overview of estimated exposure to illicit drugs or excessive alcohol 
consumption by individuals in the TRS group before their FEP between 1985 and 2003.  
The availability and variety of drugs has changed considerably since so a more 
comprehensive description and analysis concerning this unique cohort is supplied in 
Appendix 1.  
 
Only 12% of the TRS group indicated they had abstained, while a third had experienced at 
least four different kinds of drug.  The most commonly tried were cannabis (used by 64%) 
and LSD (used by 40%).  There were no significant differences regarding the type of drug 
used between the lower and higher PANSS groups.   
 
Table 3. 4   Drugs of Abuse commonly tried before the First Episode of Illness 














Statistic comparing Higher 
and Lower PANSS 
No drug use 12 12  0 
 (1, n=25) = 1.034,  
p = .309, phi =.327 ¬¬¬ 
Four or more 
types 32 20 12 
 (1, n=25) = 0.001,  
p = .986, phi = .090 ¬¬¬ 
Cannabis 64 36 28 
 (1, n=25) = 0.001,  
p = 1.000, phi = .007 ¬¬¬ 
LSD 40 16 24 
 (1, n=25) = .818,  
p = .366, phi = -.263 ¬¬¬ 
 
Notes: Based on recall of approximate age when a drug was first tried.  This was subsequently related 
to age at first admission for psychosis from records.   
4% = 1 individual.    
¬¬¬  with Yates Continuity Correction.   
Bonferroni correction for 17 comparisons between lower and higher PANSS in Tables 3.2, 3.3, 3.4 
p= .003. 
 
Figure Appx. 1. 1 depicts the above along with other drugs, while in Figure Appx. 1.2 it is 
estimated that 72% of the TRS group had pharmacological exposure to drugs which boost 
dopamine and 48% were exposed to serotonergic agents at some point prior to their first 




3.2   IQ estimated with the WASI 
One of the TRS participants was considered too unwell to take part in neuropsychological 
testing so the WASI was administered to 25 participants (8 females (31%), 17 males (69%). 
The standard scores were normally distributed, and the group means for full-scale IQ, verbal 
IQ  and performance IQ scores clustered around the population norm (100).  As shown in 
Table 3. 5, mean estimated full-scale was IQ higher in the lower compared with the higher 
PANSS group, p =.04, with a large effect size, although, group differences on the subscales 
were not significant.  
 
In addition, there was a correlation between years spent in education and full-scale IQ 
scores:  p = .573, n=25, p = .003.  Scores on the verbal and performance subscales were 
positively correlated, r = 532, n =25, p = .006.  (Again, this was no longer the case when 
split into lower and higher PANSS groups, r = .421, n=14, p = .134 and r = .497, n=11,  
p = .119, respectively). 
 
Table 3. 5   Comparison between Lower and Higher PANSS Groups for WASI 
Standard Scores and Years of Education  



























































* p < 0.05 (adjusted alpha for 4 comparisons would be p = 0.0125).  
The eta squared statistic indicates large effect sizes in this table as Cohen (1988, pp.284-7) 
proposed .01, .06 and .14 indicate small, medium and large effect sizes respectively. 
 
 
3.2.1   Comparison of Estimated IQ Scores with Population Norms 
Estimated IQ scores were also expressed in percentiles so they could be readily compared 
against a marker line in Figure 3. 1 representing the 50th percentile, for the general 
population.  Some heterogeneity became apparent as the median FIQ and PIQ scores across 
the TRS group as a whole were higher than the 50th percentile by 11 and 13 percentiles 
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respectively, while the median VIQ score was 3 percentiles below this.  Also, while scores 
in the higher PANSS group were relatively depressed, they were still within 8-11 percentiles 
of the peak of the normal distribution, so comfortably within the normal range. 
 
Figure 3. 1   Median IQ Scores for the TRS Group (expressed in percentiles)  
 
IQ Scores in 
Percentiles: 
Full-scale IQ  
(interquartile range) 




TRS Group (n=25) 61  (49) 47    (51) 63  (39) 
Lower PANSS (n=14) 66  (42) 59.5 (39) 67  (24) 
Higher PANSS (n=11) 39 (52) 42    (56) 39  (51) 
 
 
3.3   Asymmetries between the WASI Subscales 
Visual inspection of individual scores (graphically illustrated in Figure 3. 2) revealed an 
unexpected observation of marked asymmetries between the subscales for some 
participants, with most favouring performance IQ.  However, this finding could be a 
consequence of using the WASI as a measure of IQ (Ryan and Brown, 2005;  also see 
discussion at 4.2.7). Using the threshold of a 10-point difference, described in methods 
(section 2.7.1), 52% (13/25) of participants exhibited an asymmetry:  in 16% of cases 
(4/25), VIQ was superior to PIQ, while in 36% (9/25), PIQ was superior to VIQ.   The three 
groups to emerge from this procedure are described below in Table 3. 6.  Only four 
individuals comprised the superior VIQ group with standard VIQ of 104, 127, 129 and 130 




















TRS Group (n=25) Lower PANSS  (n=14)




Table 3. 6   Description of IQ asymmetry groups based on individual differences 
between verbal and performance subscales in TRS participants* 
Median of Standard IQ 
Scores 
Full-scale 



































* Asymmetry if difference in standard scores is 10 points or more. 
Figure 3. 2   Individual Asymmetries in Performance between WASI Subscales 
 
(TRS:  N = 25) 
The asymmetry between the WASI subscales was also considered in relation to overall 
symptom levels:  57.1% (8/14) of individuals in the lower PANSS and 41.7% (5/12) in the 
higher PANSS groups exhibited an asymmetry between the IQ subscales.  A Chi-square test 
for independence (with Yates Continuity Correction) confirmed there was no significant 
association between lower/higher PANSS membership and asymmetry in the subscales,  
2 (1, n= 25) =.03, p = .859, phi = .116.     
 
Subscales: Difference Asymmetry Difference
Case No Verbal Performance Standard Scores Percentiles Percentiles
15 81 104 -23  10 < 61 -51
23 78 100 -22 7 < 50 -43
44 76 96 -20 5 < 39 -34
48 111 127 -16 77 < 96 -19
27 55 70 -15 0.1 < 2 -1.9
40 91 105 -14 27 < 63 -36
25 106 118 -12 66 < 88 -22
13 99 109 -10 47 < 73 -26
24 99 109 -10 47 < 73 -26
19 106 112 -6 66 < 79 -13
12 103 106 -3 58 < 66 -8
18 99 102 -3 47 < 55 -8
26 86 89 -3 18 < 23 -5
10 113 115 -2 81 < 84 -3
22 106 108 -2 66 < 70 -4
43 120 121 -1 91 < 92 -1
41 88 87 1 21 < 19 2
46 97 96 1 42 < 39 3
8 98 96 2 45 > 39 6
11 95 93 2 37 > 32 5
14 109 107 2 73 > 68 5
17 104 88 16 61 < 21 40
9 129 110 19 97 > 75 22
38 130 105 25 98 < 63 35
45 127 84 43 96 < 14 82
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However as can be seen from Figure 3. 3 below, depicting the correlation between negative 
symptoms and the degree of asymmetry between the subscales (reported in Table 3. 18), the 
four participants with superior VIQ scores also had a low level of negative symptoms 
(scores ranging from 8-11), to the extent this approximated to a “floor effect”.  (Also see 
inset for the same correlation at 3. 3 (b). This indicates the higher the level of negative 
symptoms the more likely an individual will exhibit a decrement on the verbal subscale). 
 
Figure 3. 3   Correlation between Negative Symptoms and Asymmetry between 
the WASI subscales. 
 
 
n=4 (16%) superior scores on the verbal IQ subscale; n=9 (36%) superior scores on the performance 






Figure 3. 3 (b) (inset) 
 
Depicts the same 
correlation but without 
the marking of 
asymmetry groupings, 
while the horizontal line 







The “superior VIQ” subgroup is too small for inferences based on neuropsychological 
profiles and clinical history; however, it is noted FIQ standard scores ranged from 96 - 123 
and one participant was (unusually for the group) in regular employment and two had 
returned to higher education.  They differed in further respects (described in Table 3. 19; 
also, see Figures Appx. 5.1, 5.2, 5.3).   
 
 
3.4   The MCCB Test Battery Results 
One of the TRS participants was considered too unwell to take part and another was 
unavailable for the MCCB test battery so the following results, summarised in Figure 3. 4 
with the related data in Table 3. 7, are based on 24 participants.  The TRS group and 
subgroups (i.e. higher and lower PANSS) scores were consistently below the 50th percentile 
of the normative sample, indeed most were below the 16th percentile. This applied even to 
the lower PANSS group that had a median FIQ at the 66th percentile. The best performance 
on an individual test was for the category fluency word generation task (animal names), 
while the worst was observed for social cognition which approached 2SDs below the mean.  
On both tests, there was no difference in the median scores for the lower and higher PANSS 
subgroups.  Indeed, there were no significant differences between these symptom groups for 
any of the tests (Table 3. 7).  The only difference between lower and higher PANSS groups 
on a single test that approached significance concerned visual learning, p = .077, (the 
marked discrepancy in relative to scores for the TRS group as a whole apparent in  
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Figure 3. 4 being due to median statistics).  While the speed of processing composite had 
trend significance (p = .056) with a medium effect size.   
 
As this study does not include a group of participants who responded to first line 
antipsychotics, the T-scores on the MCCB domains are compared with those provided in 
some published studies concerning “participants with schizophrenia” (PSZ).  These are 
shown in appendix 4 (Table Appx. 4. 8, Figure Appx 4. 1) and indicate a fair degree of 
similarity across studies and participant groups, with further validation of the MCCB norms 
at the 50th percentile by the large healthy control group in Johnson et al. (2013).    
In order to further evaluate the heterogeneity in this study, a series of within-participant 
comparisons were conducted comparing their category fluency scores with performance in 
other domains (described in methods 2.7.2).  The results are shown in Table 3. 7  and reveal 
highly significant differences with medium effect sizes for most tests, although, the 
differences between category fluency and working memory (spatial span and verbal span) 
were not significant.  Appendix 4, Table 4. 2, provides further context by summarising a 
series of exploratory correlations with MCCB composite scores:  estimated FIQ and the 
subscales were highly correlated with the MCCB overall composite; neither category 
fluency nor the time taken to complete the Trail Making Test correlated with the Speed of 
Processing Composite to which they contributed, whereas RTs in the 0-Back Condition of 
the n-back task did.  Nonetheless there was a very highly significant correlation between the 
‘speed of processing composite’ with the MCCB overall composite (Table Appx. 4. 2). 
Table 3. 9 displays the results of some correlations between MCCB tests of learning and 
working memory with the WASI scores and MATRICS composite scores to explore their 










Figure 3. 4   A Comparison of Scores on the MCCB for TRS Groupings with MCCB Population Norm at the 50th percentile 
 
 
Notes: Adjusted for age and sex. 















Median Percentile Scores on the MCCB 







Table 3. 7   Scores on the MCCB:  TRS Grouped According to Symptom Level on the PANSS scale (expressed in Percentiles) 
 
 TRS Group 
n =24 
Lower PANSS 
n = 13 
Higher PANSS 
n = 11 







Min-Max Median U z p r 
Trail Making Test (TMT-A) 15.0     (29.9)   0.1 – 57.9    24 0.1 – 34   6.7 47.5 -1.394 0.163  0.285 
b 
Symbol Coding (BACS SC)   7.5     (38.6)   0.3 – 66.0  18.4 0.6 – 61.8   5.5 47.5 -1.392 0.164  0.284 
b 
Category Fluency  38.0     (46.4)   7.0 – 78.8  38.0 0.2 – 97.7 38.0 63.5 -0.465 0.642  0.095 
Verbal Learning (HVLT-R) 12.95   (21.8)   4.5 – 76.0  10.0 0.5 – 81.6 15.9 70.0 -0.087 0.931  0.018 
Visual learning (BVMT-R)   7.35   (48.8)   0.2 – 96.4  34.0 0.0 – 38.0   3.6 41.0 -1.769 0.077  0.361 
b 
Spatial Span (WMS-III) 24.1     (36.1)   2.9 – 86.0  34.4 1.1 – 94.6 24.0 57.5 -0.812 0.417  0.166 
a 
Letter-Number Span (LNS) 26.0     (30.6)   8.0 – 69.0  30.8 0.2 – 57.9 21.0 49.5 -1.276 0.202  0.261 
Reasoning and Problem Solving  
(NAB Mazes) 
 
11.25   (18.3) 
 
  0.3 – 92.0  16.0 
 
1.4 – 27.0 11.0 53.5 -1.044 0.297  0.213 
a 
Social Cognition (MSCEIT ME)   2.9     (11.2)   0.0 – 99.9    2.9 0.2 – 38.2   2.9 68.5 -0.174 0.862  0.036 
Attention and Vigilance (CPT-IP) 18.0     (31.1)   3.6 - 73.0  21.0 0.1 – 38.2   9.7 40.5 -1.798 0.072  0.367 
b 
Speed of Processing Composite  
(TMT, BACS, Fluency) 
  
10.5     (22.3) 
  
  1.4 – 46.0  14.0 
 
0.0 – 79.0   4.0 38.5 -1.914 0.056  0.391 
b 
Working Memory Composite  
(WMS-III, LNS) 
 
27.0     (30.6) 
   
  0.1 – 72.6  34.4 
 




 0.338 b 
Overall Composite   * ¬   2.3     (16.4)   0.3 – 57.9    6.7 0.0 – 30.8   1.1 32.5 -2.262 0.024  0.462 
b 
* p < 0.05   ¬ Based on a complete dataset (n=24), apart from the CPT-IP (n=18) where missing scores had to be imputed for calculation of the 
composite.  (Adjusted alpha after correction for this family of 13 comparisons: p = 0.004) 







3.4.1   Heterogeneity in MCCB Task Performance Compared with Category Fluency 




Z r p 
Letter-Number Span (LNS)    26.0 (11.5 - 42.1) -1.840 .266 
b       .066 
Spatial Span (WMS-III)    24.1 (15.9 - 52.0) -1.329 .192 
a       .184 
Attention and Vigilance CPT-IP)    18.0 (4.3 - 35.4) -2.658  .384 
b       .008** 
Trail Making Test (TMT-A)    15.0 (3.3 - 33.2) -2.920 .422 
b .004*** 
Verbal Learning (HVLT-R)    13.0 (5.5-27.3) -3.129 .452 
b .002*** 
Reasoning and Problem Solving (NAB Mazes)    11.3 (8.0 - 26.3) -2.613 .377 
b       .009** 
Symbol Coding (BACS SC)      7.5 (2.5 - 41.1) -2.783 .417 
b .005*** 
Visual learning (BVMT-R)      7.4 (1.2 - 50.0) -2.386 .344 
b       .017* 
Social Cognition (MSCEIT ME)      2.9 (0.43 - 11.6) -3.452 .498 
c .001*** 
 
Note:  The median and interquartile range of scores on the category fluency test (expressed in percentiles) were 38 (19.5-65.9), n=24. 
* = significant at p < .05.   ** = significant at p < .01. 
*** = significant after Bonferroni correction for this family of 9 comparisons with an adjusted alpha = .006 






3.4.2   Some Correlations between the MCCB Overall Composite, Learning and WASI Subscales 
 



















Pearson Correlation 1.000       
Sig. (2-tailed)                                         
N 24       
Estimated Performance 
IQ 
Pearson Correlation ¬  .689** 1      
Sig. (2-tailed) .001       
N 24 25      
Estimated Verbal IQ Pearson Correlation ¬  .536** .532** 1     
Sig. (2-tailed) .007 .006      
N 24 25 25     
Visual Learning  Pearson Correlation ¬  .818** .598** .449* 1    
Sig. (2-tailed) .001 .002 .028     
N 24 24 24 24    
Visual Working 
Memory (Spatial Span) 
Pearson Correlation ¬  .492* .475* .098 .311 1   
Sig. (2-tailed) .015 .019 .648 .139    
N 24 24 24 24 24   
Verbal Learning/ STM 
(HVLT-R) 
Pearson Correlation ¬  .415* .392 .578** .476* .148 1  
Sig. (2-tailed) .043 .058 .003 .019 .490   
N 24 24 24 24 24 24  
Verbal Span/ Working 
Memory (Letter Number 
Sequence)  
Pearson Correlation ¬  .647** .688** .593** .541** .370 .431* 1 
Sig. (2-tailed) .001 .001 .002 .006 .075 .035  
N 24 24 24 24 24 24 24 
¬   Spearman’s Rho was used in this correlation.  *   Correlation significant at the 0.05 level;  **   Correlation significant at the 0.01 level.   
Bonferroni correction for a family of 21 comparisons: p = .002.  According to Cohen (1998, pp. 79-81) a correlation coefficient is strong if it is between .5 and 1.0. 
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3.4.3   MCCB Variables and the Time to access Clozapine 
There was a negative correlation between the time to access clozapine and the overall 
MCCB composite (rho = -.549, n=23, p = .007), indicating worse scores were associated 
with longer delays.  In addition, there were significant negative correlations between the 
time to access clozapine and short-term learning/memory (visual and verbal), which 
remained significant after partial correlation controlling for age.  These are reported below 
and shown in Figures 3.5 and 3.6. 
 
Moreover, there was a negative partial correlation between the elapse of time between the 
first episode of psychosis and visual learning, controlling for age at the time of the study:   
r = -.621, n=23, p = .002.  Inspection of the zero-order correlation (r = -.521) indicates age 
had a modest effect of the strength of the relationship.   
 
In addition, there was a significant negative partial correlation between the elapse of time 
between the first episode of psychosis and verbal learning, controlling for age at the time of 
the study, r = -.531, n=23, p = .01.  Inspection of the zero-order correlation (r = -.438) 
indicates age had a modest effect of the strength of the relationship.  Further, when just the 
scores on the first trial of the HVLT-R were considered with age as a covariate, the result 
was very similar:  r = -.523, n=23, p = .012.  
 
Figure 3. 5   Negative Correlation between Verbal learning and Time to access 
Clozapine 




(b)  With lines of best fit for Lower  
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Figure 3. 6   Negative Correlation between Visual learning and Time to access 
Clozapine 




(b)  With lines of best fit for Lower  
and Higher PANSSGroups 
 
 
According to Cohen (1988, pp, 79-81), all the correlations in this section might be described 
as strong after controlling for age, since the r-values were between .5 and 1.0. 
 
3.5   A Post Hoc Analysis of Serial Position in Free Recall (HVLT-R) 
Free recall following the first presentation of the list appeared normal (Miller, 1956) ranging 
from 4 to 8 items recalled out of a possible 12.  The median number of items recalled was 6 
in both the lower and higher PANSS groups, and a Mann-Whitney U Test confirmed there 
was no significant difference:  lower PANSS (Md=6, n=13), higher PANSS (Md=6, n=11), 
U = 59.50, z = -.728, p = .494, r =  .15.  However, as referred to in Methods section 2.7.2, a 
post hoc analysis of recall on the first trail of the Hopkins Verbal Learning Test was carried 
out to examine whether there was a recency effect which is thought to reflect the contents of 
a short term store that is briefly available following auditory presentation (Vallar, 2007).  
This revealed that, behaviourally, 92% (22/24) of TRS participants did not begin their free 
recall with the last item from the list of 12 words.  Indeed, only 12.5% (3/24) started their 
recall with any item from amongst the last 3 positions. 
 
Figure 3. 7 depicts recall for items at their list positions, without reference to the order in 
which items are recalled.  As expected, a primacy effect is discernible, yet, despite the 
supra-span length of the list, recall for the last two items was modest, while recall at position 
10 resembles the asymptote.  As recall at the recency portion can exceed that of the first 
portion, this curve suggests an attenuated, or absent recency effect. 
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A more detailed description of the omissions that occurred at the last three positions for 
repeated presentations of the same list is available for reference in Table Appx. 4. 1.  By the 
third trial the number of individuals recalling all three items had risen to 42%, while 87.4% 
recalled 2 items from the last three positions, however, it is not possible to differentiate 
between the effects of learning and changes in strategy to use the recency effect. 
 
Regarding recall for items at the start of the list, it is possible some participants preferred to 
recall items in the order in which they were presented despite instructions they could recall 
the words in any order.  A description of the frequencies at which items were recalled in 
their list order at the first three positions on the first trial is provided in Table 3. 10 below.  
From this is can be seen only one individual recalled all three items in their list order, so it 
seems unlikely this was a common strategy since 3 items should be within the capacity of 
short-term memory. 
 






























































Percentage of Items Correctly Recalled upon First Presentation in the 
Auditory Verbal Free Recall Task (n=24)
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Table 3. 10   Serial Learning as a Strategy? 
 1st item: “Lion” 2nd item: “Emerald” 3rd item: “Horse” 
Lower PANSS 
(n=13) 
76.9%     10/13 61.5%     8/13 7.7%    1/13 
Higher PANSS 
(n=11) 
54.5%      6/11 36.4%     4/11  0%         - 
All TRS (n=24) 66.7%     16/24 50%       12/24 4.1%    1/24 
 
 
3.6   On-line Behavioural Data Collected during the Verbal N-Back  
The non-parametric nature of the behavioural data, including that for omission errors, was 
confirmed by the Kolmogorov-Smirnov statistic below. 
  
Table 3. 11   Kolmogorov-Smirnov Test of Normality for the Behavioural Data 
Reaction Times 0-Back 1-Back 2-Back 3-Back 
TRS (n=26) .022* .053 .200 .200 
Controls (n=21) .001* .022* .047* .200 
Standard Deviations 0-Back 1-Back 2-Back 3-Back 
TRS (n=26) .001* .200 .200 .200 
Controls (n=21) .001* .002* .024* .200 
Number of Omission Errors 0-Back 1-Back 2-Back 3-Back 
TRS (n=26) .001* .001* .001* .001* 
Controls (n=21) .001* .001* .001* .113 
*A significance value of less than .05 indicates the distribution is not normal.   
 
3.6.1   Reaction Time Data (Processing Speed) 
Mean reaction times across the entire n-back task, without intermediate computation for the 
experimental conditions, were 509.05ms (SD = 87.20) in the control group and 609.50ms 
(SD = 132.36) in the TRS group, i.e. 19.73% slower overall in the TRS group.  An 
independent-samples t-test revealed this difference was significant, t (45) = -2.990, p = .005.  
The magnitude of the difference (mean difference = 100.45, 95% CI: -168.11 - 32.77) was 
large (eta squared = .166).48 
 
 
48 Cohen (1988, pp.284-7) proposed an eta squared of .01, .06 and .14 indicated small, medium and 
large effect sizes respectively. 
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As can be seen in Figure 3. 8, reaction times were slower at each level of cognitive load.  
The differences between the groups (Table 3. 12 below) were significant at every level, 
apart from the 2-back condition where the difference approached significance at p = 0.054. 
However, most would not survive Bonferroni correction restricted to this set of comparisons 
with an alpha level of 0.0125.  Following Nakagawa (2004) above, the effect sizes reflected 
in the ‘r values’ were also considered.  Applying Cohen’s (1988) guidelines, the differences 
between median reaction times were very large in the 0-back condition and large in the  
1-back; however, in the 2-back condition there was a medium effect size and in the 3-back 
condition it was negligible.   
 
In case this pattern might be explained by a high level of errors distorting values, the scores 
of one TRS participant (who made 4/9 correct responses in the 2-Back condition) and two 
controls (who made 4/9 and 3/9 correct responses in the 3-Back condition) were removed 
and the Mann-Whitney tests were repeated.  These revealed a similar result in the 2-Back 
condition where there was no significant difference in reaction times between TRS  
(Md = 611.44ms, n = 25) and control groups (Md = 546.71ms, n = 19), U = 183, z = -1.753, 
p = .08, r =.258 (a small effect size)49; but there was a significant difference between TRS 
(Md = 753.0ms, n=25) and control groups (Md = 631.11ms, n = 19), U = 149, z = -2.097,  
p = .036, r = .316 (a medium effect size) in the 3-Back condition.  However, again these 
differences would not survive the Bonferroni correction with alpha at 0.0125, in contrast to 
those at lesser levels of cognitive load.  
 
The use of median statistics minimises the influence of more extreme scores and the pattern 
of convergence in reaction times between the two groups is clearer when the data is 
described using mean reaction times (screened for outliers 2.5 SD above the mean):   
RTs were slower in the TRS group relative to the control group, by 30.16% in the 0-Back  




49  Cohen (1988):  r =.10, .30 and .50 for small, medium and large effect sizes respectively 
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Figure 3. 8   Comparison between TRS and control groups of median reaction times at 
each level of the N-Back Task. 
 
 
Table 3. 12   Comparison of Median Reaction Times (ms) at each Level of Cognitive 
Load on the N-Back Task 
Cognitive  
Load 
TRS Group (n=26) Healthy Controls (n=21) Statistic: Mann-Whitney U Test 





496.92 297.8 -  
630.1 
385.33 -3.659 1.87 a 102 p < .0005* 
1-back 
RTs 
372.78 -  
912.00 
519.78 340.2 -  
638.2 
444.44 -3.060  .45 a 130 p = .002* 
2-back 
RTs 
378.67 -  
1204.63 
615.72 402.6 -  
760.9 
546.71 -1.926  .28 183 p = .054 
3-back 
RTs¬ 
332.43 -  
1179.60 
753.00  361.6 - 
1067.8 
642.11 -2.128  .03 166 p = .033* 
* significant at p < 0.05, but note Bonferroni correction in this family of 4 multiple comparisons at p 
= 0.0125 
 ¬ n=25: 0ne TRS participant who scored 0/9 in the 3-back condition was not included.   
Cohen (1988):  r =.10, .30 and .50 indicate small, medium and large effect sizes respectively. 
 
3.6.2   Standard Deviations 
A similar convergence to those observed for the RTs at higher levels of cognitive load 
emerged from a corresponding analysis for the standard deviations (SDs), shown in Table  
3. 14 below.  Consistent with the faster reaction times, standard deviations in the control 
group were smaller than in the TRS group in every condition.  This difference was 
significant (p < 0.05) for the 0-back and 1-back conditions, although the latter would not 
survive Bonferroni correction with alpha = 0.0125, while the differences were non-
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‘r value’ indicates a large effect size for the difference for the 0-back condition and a 
medium effect size for the 1-back, while the effect sizes were negligible and small for the 2- 
and 3-Back conditions respectively. 
 
Table 3. 13   Comparison of Median Standard Deviations (ms) at each Level of 
Cognitive Load on the N-Back Task 
Cognitive  
Load 
TRS Group (n=26) Healthy Controls (n=21) Statistic: Mann-Whitney U Test 
Min-Max Median Min-Max Median Z r U p 
0-back 
SDs 
 32.38 -  
411.82 
97.86  22.2 -  
455.4 
54.03 -3.402 0.50 a 
 
114 p = .001* 
1-back 
SDs 
 27.04 -  
274.34 
152.37  22.2 - 
386.2 
86.68 -2.290 0.33 b 
 
166 p = .022* 
2-back 
SDs 
 56.10 -  
403.59 
175.67  85.7 -  
384.6 
154.96 -.086 0.01 
 
269 p = .932 
3-back 
SDs ¬ 
 56.09 -  
436.85 
228.68  69.8 -  
448.5 
202.85 -.673 0.10 
 
232 p = .501 
* significant at p < 0.05, but only the 0-Back comparison would survive Bonferroni correction in this 
family of 4 multiple comparisons at p = 0.0125 
¬ n=25  
Cohen (1988):  r =.10, .30 and .50 indicate small, medium and large effect sizes respectively. 
 
3.6.3   Target Accuracy and False Positive Responses 
When it is considered there were 168 opportunities for an individual to make an error in the 
NBACK task (from 3 blocks of 14 stimuli for each of the four levels of cognitive load), 
overall target accuracy was high in both participant groups (96.47% for the TRS group and 
98.07% for controls).   However, when only responses to the 36 target stimuli were 
considered (omission errors), accuracy fell to 88.68% in the TRS group and 93.65% in the 
control group.  A Mann-Whitney U test confirmed there was a significant difference in 
overall target accuracy between the TRS (Md = 88.89, n = 26) and controls groups (Md = 
97.22, n = 21), U = 144.5, z = -2.775, p = .006, r = .4.  Applying Cohen’s (1988) criteria, the 
r value indicated a medium effect size.   
 
However, when accuracy was assessed for each trial when a target was present, a more 
nuanced pattern emerged. Differences in target accuracy between the groups were negligible 
in the 0-Back and 1-Back conditions with target accuracy at 99.92% in the TRS group in 
each condition while only two errors were made across the entire control group; 
accordingly, Figure 3. 9 below only shows responses for the 2-Back and 3-Back conditions.   
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The following is merely descriptive however, it demonstrates target accuracy in the TRS 
group in the 2-Back condition was similar or lagged behind the control group only slightly.  
While in the 3-Back condition, responses to the first target in the series of nine were more  
 




% Correct Block 1 Block 2 Block 3 
Target: 1st 2nd 3rd 4th 5th 6th 7th 8th 9th 
TRS 2-Back 80.8 84.6 84.6 80.8 80.8 84.6 92.3 96.2 96.2 
HC 2-Back 81.0 85.7 95.2 85.7 90.5 100.0 95.2 95.2 100.0 
TRS 3-Back 92.3 26.9 53.8 84.6 84.6 80.8 84.6 69.2 65.4 
HC 3-Back 76.2 57.1 81.0 81.0 81.0 81.0 100.0 90.5 95.2 
 
accurate in the TRS group than in the control, but were markedly worse to the second, while 
the control group also faltered. Across the middle of the experiment (targets 4-6), accuracy 
in the TRS group was similar to that of the control group.  However, it decreased to 69.2% 
and 65.4% for the last two targets.  Overall, however, these rates demonstrate that not only 
could TRS participants perform the task at the highest level of cognitive load, but most were 






































































TRS Group Control Group
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Also, accuracy levels overlapped considerably in the two groups, as 14/26 (53.9%) of TRS 
participants made 2 or fewer omissions errors out of a possible 9 during the 3-back 
condition, which compares with 16/21 (76.2%) control participants.50 
 
Group differences in the rates of omission errors, were tested at each level of cognitive load 
and the results are shown in Table 3. 14.  Significantly fewer omission errors were made by 
the control group compared to the TRS in the 0-back and 3-back conditions.  These 
differences would not survive Bonferroni correction, but had medium effect sizes. 
 
Table 3. 14   Comparison of the number of Omission Errors at each Level of Cognitive 












Median z r U p 
0-Back 
Errors   0 -- 2 0   0 -- 0 0 -2.103 0.307 b 220.5 .035* 
1-Back  
Errors   0 --  3 0   0 -- 1 0 -1.181 0.172 a 243.5 .238 
2-Back  
Errors   0 -- 5 0   0 -- 4 0 -.895 0.131 a 235.5 .371 
3-Back  
Errors    0 -- 9 2   0 -- 6 0 -2.280 0.333 b 168.5 .023* 
* significant at p < 0.05, but would not survive Bonferroni correction in this family of 4 multiple 
comparisons at p = 0.0125 
Cohen (1988):  r =.10, .30 and .50 indicate small, medium and large effect sizes respectively. 
 
 
3.6.4  False Positive Errors 
Many participants, 10/26 (39%) TRS and 13/21 (62%) controls made no false positive errors 
out of a possible 132 during the task.  As can be seen in Table 3. 15, a significant group 
difference emerged only in the 3-Back condition, which had a medium effect size (r = .40).  
However, this difference appears to have been due to 3 TRS participants who accounted for 
half of the false positive errors (one in the higher PANSS group made 8 false positive errors, 
one lower and one higher PANSS participant made 7 false positive errors each).  Figure     
3. 10 shows the relative proportion of false positive errors to omissions after the scores of 
these participants were excluded and similar false positive rates between the groups. 
 
 
50 Two TRS individuals (S17 and S24) made no omission errors during the experiment; one control 
almost did as well (S32) but made an omission error in the 1-back).    
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Table 3. 15   Comparison of Total Error (Omission and False Positives) at each Level 
of Cognitive Load in the N-Back Task. 
Cognitive  
Load 
TRS Group (n=26) Healthy Controls 
(n=21) 





z r U p 
0-Back 
Errors   0 -- 2   0   0 -- 1   0 -1.246 0.182 a 235.0 .213 
1-Back  
Errors   0 -- 3   0   0 -- 1   0 -1.892 0.276 b 204.0 .058 
2-Back  
Errors   0 -- 5   0.5   0 -- 4   0  -.900 0.131 a 234.0 .368 
3-Back  
Errors    0 -- 9   3.5   0 -- 7   1 -2.707 0.395 b 148.0 .007* 
* significant at p < 0.05, also after with Bonferroni correction with alpha at 0.0125  
Cohen (1988): r =.10, .30 and .50 indicate small, medium and large effect sizes respectively. 
 
Figure 3. 10   Comparison of Omission and False Positive Errors made by TRS and 
Control Groups Across all Trials*  
 
Percentage of Errors: 0-BACK 1-BACK 2-BACK 3-BACK 
Controls (n = 21), Omission Errors 1.06 0.53 8.46 15.34 
Controls (n = 21), False Positive Errors 0.14 0.14 0.86 1.73 
TRS (n = 23*), Omission Errors 2.56 2.14 12.81 27.76 
TRS (n = 23*), False Positive Errors 0.26 0.40 0.26 2.37 


















Controls (Omssions) TRS (Omissions)
Controls (False Positives) TRS (False Positives)*
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3.6.5   On-line Behavioural Responses of the Lower and Higher PANSS Groups 
As can be seen in Table 3. 16 below, there were no significant differences between the 
lower and higher PANSS groups for four behavioural variables obtained during the on-line 
neuroimaging across all levels of cognitive load.  These were target accuracy, omission 
errors, false positive errors, omission and false positive errors combined.  Nor was there a 
significant difference in mean reaction times during the 0-Back condition when omission 
error rates were 1.6% in the lower PANSS group and 4.6% in the higher PANSS group, a 
difference which was nonsignificant: (Md = 0, n =14) in the lower PANSS and (Md = 0, 
n=12) in the higher PANSS groups, U = 67, z = -1.192, p = .233, r = .23).  However, mean 
standard deviations in the 0-Back condition for the higher PANSS group were significantly 
smaller in the lower PANSS group (with a medium to large effect size), indicating there was 
less variation in responding than by individuals in the higher PANSS group. 
 














Median z r U p 
Accuracy for 
Targets   
(N-Back %) 
88.89  91.67  
  87.5 -1.408 0.276
b








11.11  8.33 
 
  12.5 -1.408 0.276
b
 57 0.159 








2.27  2.27    2.27 -1.407 0.276
b











  11.61 -1.718 0.337
b





















97.86  85.33  147.58 -2.469 0.484
c








     
* p < 0.05 before correction. (Adjusted alpha for six comparisons = 0.008). 
b
  = medium effect size;  
c
  = medium to large effect size.  After Cohen (1988): r =.10, .30, .50 
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3.7   Correlations between Symptoms, Cognitive and Behavioural Variables 
3.7.1   Negative Symptoms and Variables associated with Attention 
It was proposed that negative symptoms might be associated with attention so correlations 
were performed with scores on the CPT-IP and other putative markers of attention:  0-Back 
SDs and Omission Errors across all conditions of the n-back task.   The latter might 
correlate with attention or cognitive control, since failures to respond might follow 
attentional lapses, a lack of volition or working memory deficits.   
 
As can be seen in Table 3. 17 and the scatterplot in Figure 3. 11(a), there was a significant 
negative correlation between negative symptoms and 0-Back SDs, indicating that less 
variability in SDs was associated with fewer negative symptoms.  A negative correlation 
between CPT-IP scores and negative symptoms was also significant, indicating that worse 
scores on this test of “sustained attention/vigilance” were associated with more negative 
symptoms (Figure 3. 11 (b).  There was also a significant positive correlation between the 
percentage of omission errors in the n-back task (Figure 3. 11 (c) and negative symptoms.  
At first sight, these correlations appear to support the proposal that negative symptoms 
might be associated with decrements in attention. 
 
Further correlations were performed between omission errors with 0-Back SDs and CPT-IP 
scores (Table 3. 17) which both might be described as having trend significance at p = .061 
and p = .063 respectively.  Their direction was congruent with the proposal that accuracy in 
the n-back might be associated with attention or cognitive control. 
 
The series of related scatterplots (Figures 3.11 – 3.15) mark data points according to 
whether individual participants had a lower or higher level of negative symptoms.  From 
these, it can be seen that scores for the correlations associated with a lower level of negative 
symptoms tend to cluster in the area related to better performance.  However, this 
generalisation does not hold for negative symptoms and performance IQ (Figure 3. 13, c). 
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Table 3. 17   Inter-correlations between Variables Proposed to be Associated with 




















1.000    
Sig. (2-tailed)     .    






.741***     1.000   
Sig. (2-tailed)  .001           .   






-.564**     -.417*    1.000  
Sig. (2-tailed)  .006         .048      .  
N     22              23      23  
 Percentage of 
Omission Errors 
in the N-Back 
task (to 36 targets) 
Correlation 
Coefficient 
    .431*        .372  -.394   1.000 
Sig. (2-tailed)  .032     .061    .063      . 
N     25           26         23       26 
 
* Correlation is significant at the 0.05 level. 
** Correlation is significant at the 0.001 level. 
*** Correlation would survive Bonferroni correction (with alpha for 24 comparisons = .002, Tables 
3.18, 3.19). 
 






- Scatterplots for negative symptoms and “attentional” variables in Table 3. 17 
Figure 3. 11   Correlations between Negative Symptoms and Attention (SDs in the 0-Back condition, CPT-IP scores, and N-Back 
Omission Errors)  
a)    Correlation between Negative Symptoms  
        and 0-Back Standard Deviations 
b)   Correlation betweeen Negative Symptoms    
       and Continuous Performance Task Scores 
c)     Correlation between Negative Symptoms  







Vertical line indicates median of 0-Back SD’s at 
101.21ms.   
Horizontal line indicates median score of negative 
symptoms at 14. 
Vertical line indicates median score on the CPT = 
2.391. Higher scores indicate better performance.  
Horizontal line indicates median score of negative 
symptoms at 14. 
Vertical line indicates median of N-Back omission 
errors at 11.11%.  Horizontal line indicates median 
score of negative symptoms at 14. 
rho = .741, n=25, p = .001 rho = -.564, n=22, p = .006 rho = .431, n=25, p = .032 
 






Figure 3. 12   Inter-correlations between CPT-IP scores and Attention (Standard Deviations in the 0-Back condition and 
Omission Errors in the N-Back task) 
a) Correlation between Percentage of 
Omission Errors and CPT-IP Scores 
b) Correlation between Percentage of 
Omission Errors and 0-Back SDs 
c) Correlation between CPT-IP Scores 







Vertical line median CPT score at 2.391.    
Horizontal line indicates median of omission errors 
in the N-Back task at 11.11%. 
Vertical line indicates median of 0-Back SDs at 
101.21ms.   Horizontal line indicates median of 
omission errors in the N-Back task at 11.11%. 
Vertical line indicates median CPT score at 2.391.    
Horizontal line indicates median of 0-Back SDs at 
101.21ms. 
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3.7.2   Negative Symptoms and Estimated IQ 
Table 3. 18 shows significant negative correlations between FIQ and negative symptoms, 
and between VIQ and negative symptoms.  However, the correlation between PIQ and 
negative symptoms was not significant.  This pattern was repeated when the 0-Back SDs 
were substituted for negative symptoms in correlations with estimated IQ scores.  When 
CPT-IP scores were substituted, a similar pattern emerged.  Scatterplots accompanying 
Table 3. 18 concerning the IQ variables are shown in Figure 3. 13 for correlations with 
negative symptoms;  Figure 3. 14 for correlations with 0-Back SD scores and Figure 3. 15 












Table 3. 18   Correlations between Variables associated with Attention and WASI Scores including Subscale Asymmetry 
Spearman’s rho  





























Full-scale IQ Correlation Coefficient -.416* -.461* .543**¬ 1.000    
Sig. (2-tailed) .043 .021 .007 .    
N 24 25 23 25    
Verbal IQ Correlation Coefficient -.500** -.512** .546**¬ .905***¬ 1.000   
Sig. (2-tailed) .013 .009 .007 .001 .   
N 24 25 23 25 25   
Performance IQ 
subscale 
Correlation Coefficient -.153 -.244 .315¬ .838***¬ .532**¬ 1.000  
Sig. (2-tailed) .476 .240 .143 .001 .006 .  
N 24 25 23 25 25 25  
IQ Asymmetry Correlation Coefficient -.514** -.450** .237 .281 .576** -.202 1.000 
Sig. (2-tailed) .010 .024 .276 .174 .003 .333 . 
N 24 25 23 25 25 25 25 
 
* Correlation is significant at the 0.05 level. 
** Correlation is significant at the 0.01 level.  
*** would survive Bonferroni correction with an alpha = .0021 for 24 comparisons. 
¬ indicates use of the Pearson product moment correlation 
Note:  Cohen (1988, pp. 79-81) proposed the strength of a correlation coefficient is small if it is between .10 and .29, medium if it is between .30 and .49 and large 
if it is between .5 and 1.0.
 






- Scatterplots for negative symptoms and estimates of IQ in Table 3. 18 
Figure 3. 13   Correlations between Negative Symptoms and Estimated Full-Scale IQ and Subscales as measured on the WASI  
a) Correlation between Negative 
Symptoms and Full-Scale IQ 
b)  Correlation between Negative 
Symptoms and Verbal IQ 
c) Correlation between Negative Symptoms 
and Performance IQ 
   
Vertical line indicates median FIQ score at 104.   
Horizontal line indicates median negative 
symptoms score at 14. 
Vertical line indicates median standard VIQ score 
at 99.  Horizontal line indicates median negative 
symptoms score at 14. 
Vertical line indicates median standard PIQ score at 
105.  Horizontal line indicates median negative 
symptoms score at 14. 
rho = -.416, n=24, p = .043 rho = -.500, n=24, p = .013 rho = -.153, n=24, p = .476 
 
 






Figure 3. 14   Correlations between Estimated IQ Standard Scores and SDs in the 0-Back Condition of the N-Back Task. 
 
a) Correlation between Full-scale IQ  
and 0-Back SDs 
b) Correlation between Verbal IQ  
and 0-Back SDs 
c) Correlation between Performance IQ  







Vertical line indicates the median of FIQ standard 
scores at 104.  
Horizontal line indicates median of individual 
mean SDs scores in the 0-Back at 101.21ms. 
Vertical line indicates the median of Verbal IQ 
standard scores at 99. 
Horizontal line indicates median of individual 
mean SDs scores in the 0-Back at 101.21ms. 
Vertical line indicates the median of Performance IQ 
at 105. 
Horizontal line indicates median of individual mean 
SDs scores in the 0-Back at 101.21ms. 
rho = -.461, n=25, p = .021 rho = -.512, n=25, p = .009 rho = -.244, n=25, p = .240 
 
  






Figure 3. 15   Correlations between Estimated IQ Standard Scores and Performance on the Continuous Performance Task 
(MCCB) 
 
a) Correlation between Full-scale IQ and 
CPT-IP Scores 
b) Correlation between Verbal IQ and 
CPT-IP Scores 
c) Correlation between Performance IQ 







Vertical line indicates mean CPT score at 2.34. 
Horizontal line indicates mean Full-scale IQ at 103. 
Vertical line indicates mean CPT score at 2.34.  
Horizontal line indicates mean Verbal IQ at 102.5 
Vertical line indicates mean CPT score at 2.34.  
Horizontal line indicates mean PIQ at 103. 











- Scatterplots concerning asymmetry between the WASI subscales and estimated IQ in Table 3. 18 
Figure 3. 16   Correlations involving Asymmetry between WASI subscales and estimated IQ Scores  
(a) Full-scale IQ and Asymmetry between 
WASI subscales 
(b) Verbal IQ and Asymmetry between 
WASI subscales 
(c) Performance IQ and Asymmetry 
between WASI subscales 
   
rho = .281, n=25, p = .174 rho = .576, n=25, p = .003 rho = -.202, n=25, p = -.333 
 





  166 
 
3.7.3 Correlations concerning asymmetry between the WASI subscales 
The final row of Table 3. 18 reports the correlations with the IQ Asymmetry variable which 
is the difference between participants’ individual scores on the VIQ and PIQ subscales 
(where positive scores indicate higher VIQ scores and negative scores indicate higher PIQ 
scores).  This was generated because in section 3.3 substantial differences between the 
WASI subscales were reported affecting 52% of the TRS group raising concerns that the 
small VIQ>PIQ subgrouping might represent a confound in the data, particularly as they 
were distinctive in other respects. 
 
Of note, in correlations between IQ Asymmetry and other “attentional” variables, there was 
a correlation with negative symptoms indicating VIQ>PIQ scores were associated with 
fewer negative symptoms. However, a correlation in the same direction, between total 
PANSS scores and IQ Asymmetry (not shown in the table) did not reach significance (rho = 
-.348, n = 25, p = .089).  There was also a significant correlation between IQ Asymmetry 
and 0-Back SDs , but not with CPT-IP scores.  There was a correlation between IQ 
Asymmetry and VIQ (again, favouring the VIQ>PIQ individuals), however, the correlations 
with PIQ and FIQ were not significant.  The corresponding scatterplots for correlations with 
asymmetry are shown in Figure 3. 16. 
 
3.7.4   Correlations with Positive Symptoms 
Not every individual with a higher level of negative symptoms also had more positive 
symptoms:  three participants had positive symptom scores above the median for positive 
symptoms and negative symptom scores below the median for negative symptoms; while 
four participants showed the opposite pattern.  However, there was strong positive 
correlation between negative and positive symptoms:  rho = .595, n=25, p = .002.  
Another correlation was conducted between positive symptoms and RTs in the 0-Back 
condition in case higher scores might be associated with arousal but this was non-significant 
(rho = .327 n=25, p = .111).   
 
Further correlations were conducted between positive symptoms and the same seven 
variables as for negative symptoms in sections 3.7.1, 3.7.2.  However, none approached 
significance apart from one between positive symptoms and 0-Back SDs, in Figure 3. 17. 
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Figure 3. 17   Correlation between positive symptoms and 0-Back SDs 
 
Vertical line indicates median of 0-Back SDs at 101.21ms 
Horizontal line indicates the median score of positive symptoms at 11 (the 
minimum score for positive symptoms is 7). Scores of 12 and above are indicated 
as “Higher POS” in the scatterplot. Bonferroni for 8 correlations with positive 
symptoms alpha = .006 
 




Considered alongside the corresponding correlation for negative symptoms, this scatterplot 
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3.7.5   Post Hoc Analyses based on a Reduced Set of Participants without the 
Superior VIQ Grouping (VIQ>PIQ)  
The four individuals exhibiting intellectual asymmetry were distinguished in other ways: 
 
Table 3. 19   Distinctive Characteristics of Individuals with Higher VIQ than PIQ 
• Distinguished by their rarity, only 16% of the TRS group had superior estimated 
verbal IQ scores relative to performance IQ scores.  
 
• VIQ>PIQ individuals had low negative symptom scores (mean = 9.75, SD: 1.5, 
8-11, n=4).  Seven indicates no pathology, also see “floor effect” in Figure 3. 3. 
 
• The mean difference between the VIQ and PIQ subscales was marked at 22 
standard points (Table 3. 6). 
 
• Median estimated FIQ was higher in the VIQ>PIQ grouping (111.5 compared to 
103 in the no asymmetry grouping and 99 in PIQ>VIQ grouping). 
 
• They progressed to a trial of clozapine more quickly than most TRS individuals 
in this study (mean = 2.5 years, SD=2.18, 1-5, n=4 compared with mean = 7.7 
years, SD=5.3, 0.5-21, n=22). 
 
• Mean standard deviations in the 0-Back condition at 78.71ms (SD: 21.78) were 
highly similar to those in the control group at 79.74ms (SD: 91.20). 
 
• Mean RTs in the 0-Back condition at 469.66ms were intermediate between the 
control and reduced TRS groups at 412.66ms and 540.54ms respectively. 
 
• While error rates increased with increasing load, VIQ>PIQ participants exhibited 
a lower percentage of omission errors than the control group at higher levels of 
cognitive load in the 2-Back and 3-Back conditions (Figure Appx. 5. 3).    
 
• As depicted in Figure Appx. 5. 2, RTs for VIQ>PIQ participants increased 
sharply in the 3-Back condition, along with standard deviations, to approximate 
and exceed those for the TRS group, even though error rates were lower.   
 
• The median MCCB profile for VIQ>PIQ participants differed markedly from 
other TRS.  Performance on category fluency and the CPT-IP exceeded the 50th 
percentile (Figure Appx. 5. 1).  However, performance on planning and reasoning 
(NAB Mazes) was depressed, consistent with lower PIQ/fluid intelligence scores. 
 
• Social cognition was superior with a median score at the 21st percentile 
compared to the rest of the TRS group at 2.4.   
 
• Visual learning and verbal learning scores were superior, although the latter 
seemed low in the context of average to good VIQ scores.  Behaviourally, none 
recalled any item from the last three positions upon first recall of the HVLT-R 
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Consequently, as described in Methods (at the end of section 2.7.1) some of the 
correlational analyses (shown in Tables 3.17 and 3.18) were repeated in a reduced set which 
excluded scores from VIQ>PIQ participants and are reported in corresponding tables in 
Appendix 5 (Table Appx. 5. 1 and Table Appx. 5. 2).  The correlations mostly survived the 
exclusion of 4 participants, however, the highly significant correlation between negative 
symptoms and CPT-IP scores was abolished.  This was arguably restored (with modest 
significance) after an outlier was removed (Figure Appx. 5. 4).  The inverse correlation 
between 0-Back SDs and CPT-IP also remained moderately significant.  In addition, the 
highly significant inverse correlation between negative symptoms and the proposed proxy 
for sustained attention (0-Back SDs) was not weakened in the reduced set, while the positive 
correlation between  0-Back SDs and the percentage of omission errors in the n-back task as 
a whole assumed significance having been at trend in the full set.   
 
In contrast to most of the attentional variables, the removal of the four VIQ>PIQ individuals 
abolished the significant correlations between negative symptoms and FIQ and VIQ, while 
the correlation between negative symptoms and PIQ remained nonsignificant. Also, the 
correlation between CPT-IP and VIQ scores was markedly less significant.  In this reduced 
set, however, the previously non-significant correlation between PIQ and CPT-IP 
performance became highly significant (r = .586, n=19, p = .008).  
 
Associations between the MCCB and estimated IQ scores in the full and reduced sets are 
reported in Table Appx. 5. 4.  The colour coding of significance levels in that table 
highlights that little changed in the reduced set.  Notable exceptions concern the weakening 
of correlations to “trend” levels between VIQ and visual learning, also between VIQ and 
category fluency. While the previously nonsignificant correlation between reasoning and 
problem solving (NAB Mazes) and PIQ, and between Trail Making and PIQ become 
significant.  As both variables are likely correlates of fluid intelligence, this may be 
consistent with the newly significant correlation between CPT-IP and PIQ (above), after the 
removal of 4 PIQ scores which were markedly depressed relative to VIQ scores.   
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Results Part:  II Functional MRI 
 
3.8   Functional MRI Results of the N-Back Verbal Working Memory Task 
As described in section 2.12, it is worth restating that unlike many other approaches, 
significant contrasts observed with XBAM methodology do not require adjustment for 
multiple comparisons because it compares the statistical significance of the median SSQ 
values for the group at each voxel by permutation sampling against a null distribution 
generated from the randomised time series.  This is an important advantage. 
 
The main effect of the task, defined as progressive linear increases and decreases in the 
haemodynamic response with increasing cognitive load in the TRS and control groups 
separately will be shown in the following section. In addition, Appendix 2 contains tables 
showing significant within-group changes in the haemodynamic response relative to 
baseline at each level of cognitive load (as opposed to linear changes reported in the trend 
analyses, i.e. 1-back vs. 2-back vs. 3-back).  
 
3.9   Trend Analysis 
It was hypothesised there would be linear increases and decreases in the haemodynamic 
response with increasing cognitive load in a fronto-parietal network that is usually engaged 
by the verbal n-back task.  However, as this study is largely exploratory, further predictions 
were not made. The statistical activation maps for the positive and negative linear trends are 
shown in Table 3. 20 and Table 3. 21 for the control group and Table 3. 22 and Table 3. 23 
for the TRS group.  There were 21 significant clusters for each group with respect to areas 
exhibiting a positive linear trend, while 11 significant clusters of relative decreases in the 
haemodynamic response/ “deactivations” were observed in each table reporting a negative 
linear trend.  
 
- Description of Positive Linear Trends 
As can be seen from Tables 3.21 and 3.23 below for the control and TRS groups 
respectively, there were significant linear trend increases in the haemodynamic response 
associated with increasing cognitive load (1-Back < 2-Back < 3-Back) across 21 brain areas 
including several loci, bilaterally, in the prefrontal cortex (BA9 and BA10 in both groups, 
extending to the right BA8 in the TRS group).  Linear trend increases were also observed in 
parietal cortex in both groups, notably the left inferior parietal lobe in the TRS group and 
bilaterally in the control group;  however, in the TRS group there were moderate large 
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clusters with peak loci in the right precuneus (BA19, cluster size 95mm3) and left precuneus 
(BA 7, cluster size 207mm3,with the peak medially), while there was a large area of 
activation only in left precuneus (BA19, cluster size 364mm3) in the control group, although 
the peak was described as being 10mm away).  Bilateral activations were observed in the 
cerebellum, however, in the control group these involved the posterior lobe (left 173mm3, 
right 32mm3), while in the TRS group, peak loci were ascribed to the anterior lobe (left 
124mm3, right 109mm3). 
 
There was a significant cluster of 80 mm3 in the left posterior cingulate (BA30) in the 
control group which was not present in the TRS group.   Another difference concerned a 
large cluster of 240 mm3, anteriorly, in the left claustrum for the control group which was 
not observed in the TRS group; also, in the control group, the thalamus, bilaterally (186mm3 
in the left hemisphere and, more specifically, in the right hemisphere, the ventral anterior 
nucleus, cluster size 202mm3).  These exhibited linear trend increases.  Further, there was a 
linear trend increase in the middle temporal gyrus, (left BA21, right BA20 at 186mm3 and 
231mm3 respectively) in the control group which was not present in the TRS group.   
 
On the other hand, there appeared to be linear trend increases in areas associated with visual 
processing in the TRS group (left fusiform gyrus, BA36, 44mm3 and right cuneus, BA19, 
28mm3) which were not present in the control group.  Another difference concerned a linear 
trend increase in the left caudate (cluster size 75 mm3), which was present in the TRS group 
but absent in the control group.  
 
- Description of Negative Linear Trends 
Tables 3.22 and 3.24 list a smaller number of areas (11 in each group) exhibiting significant 
decreases in the haemodynamic response relative to group baselines as cognitive load 
increased in the control and TRS groups respectively.   
 
As might be expected, in these tables, structures associated with the default mode network 
are more prominent in the negative trend analyses.  In particular, there was a large cluster of 
455mm3 in the left medial frontal gyrus (BA10) in the control group which was also 
proximal to sizeable cluster of 550mm3 in the left superior frontal gyrus (BA 9) which had a 
peak co-ordinate in a medial position.  While, in the TRS group, the corresponding 
activation was much more circumscribed at 122mm3 in the left medial frontal gyrus albeit 
with a different Brodmann label (BA8).  There were also proximal areas exhibiting trend 
deactivation not seen in the control group in the left middle frontal gyrus (BA8, 110mm3) 
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and large cluster posteriorly, with a peak medially, in the cingulate gyrus (left BA24, cluster 
size 708mm3) which raises the possibility these areas might have performed a similar 
function or compensatory function to that observed in the control group. 
 
More posteriorly in the control group, a very large cluster of deactivation of 1704mm3 was 
observed in the parietal lobe with a peak medially in the left paracentral lobule (BA31); 
also, one of 643mm3 in the left postcentral gyrus (BA3).  In the TRS group, there was a 
sizeable cluster of 615mm3 in the cingulate gyrus (BA31) in the right hemisphere, along 
with clusters of 382mm3 the right precuneus (BA 7) and 262mm3 in right posterior cingulate 
(BA30).  Linear trend decreases were not observed in the right hemisphere for these last 
three areas in the control group. 
 
However, linear trend decreases were observed in both groups in the occipital lobe: in the 
left cuneus, BA23 medially (262mm3) and right middle occipital gyrus BA18 (85mm3) in 
the control group and in the right cuneus, BA17 medially (197mm3) in the TRS group.   
 
More laterally, linear trend decreases were also observed in both groups in the precentral 
gyrus, in the right BA44 (135 mm3) in the control group and in the left BA6 (51mm3) and 
left BA4 (736 mm3) in the TRS group. 
 
Both groups also showed linear trend decreases in the right transverse temporal gyrus 
(BA41) in sizeable clusters of 585mm3 and 393mm3 in the control and TRS groups 
respectively.  However, bilateral linear trend increases in the middle temporal gyrus (right 
BA20 (231mm3), left BA21 (186mm3), left BA39 (454mm3) and trend decreases in the left 
middle temporal gyrus BA21 (193mm3) and the right superior temporal gyrus, BA38 (102 
mm3) were only observed in the control group.   
 
Finally, the control group exhibited a linear trend increase in the right insula (BA13, 
270mm3) and a decrease in the left insula, (BA13, 442mm3), while a trend decrease was not 
was not observed in the TRS group.  However, a linear trend increase was observed in the 
right insula (BA13, 270mm3) with a peak at an identical set of co-ordinates (Talairach = 33, 
22, 10), along with another cluster in the left insula BA13 in a homologous cluster 
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3.9.1   Trend Analysis within the Control Group 
Table 3. 20   Within Control Group:  areas exhibiting a significant positive linear trend 
in activity with increasing cognitive load 




Cluster   p-Value  
size  
(mm3) 
 Talairach  
co-ordinates*  
   x       y       z 
Superior Frontal Gyrus BA 10 R 311 0.00292  -36  56  13 
Middle Frontal Gyrus 
(6 mm away) 
BA 10 L 405 0.00289  -31  48    9 
Middle Frontal Gyrus BA 9  R 330 0.00193   40  33  33 
Middle Frontal Gyrus BA 9 L 355 0.00271  -36  22  33 
Insula BA 13 R 270 0.00241   33  22  10 
Claustrum   - L 240 0.00194  -25  22   6 
Medial Frontal Gyrus BA 6 R 341 0.00049     0  11  46 
Inferior Frontal Gyrus 
(5.2 mm away) 
BA 9 R 132 0.00733   46  10  29 
Frontal Lobe, Sub-Gyral BA 6 R 422 0.00020   25    0  53 
Frontal Lobe, Sub-Gyral,  BA 6 L 369 0.00064  -25    0  53 
Thalamus, Ventral Anterior 
Nucleus 
  -  R 202 0.00702   11   -4   7 
Thalamus  - L 186 0.00792  -11   -4  -3 
Middle Temporal Gyrus 
5.2 mm away 
BA 21 L 186 0.00931  -51 -30   0 
Middle Temporal Gyrus BA 20 R 231 0.00827   54 -41 -13 
Inferior Parietal Lobe BA 40 L 153 0.00176  -40 -48  40 
Inferior Parietal Lobe BA 40 R 389 0.00056   36 -48  40 
Cerebellum, Posterior 
Lobe, Cerebellar Tonsil 
- L 173 0.00782  -33 -56 -33 
Middle Temporal Gyrus 
(6.0 mm away) 
BA 39 L 454 0.00120  -33 -57  27 
Precuneus, (10.0 mm away) BA 19 L 364 0.00265  -31 -62  39 
Cerebellum, Posterior 
Lobe, Uvula 
- R   32 0.01167     4 -70 -30 
Posterior Cingulate BA 30 L   80 0.00376  -29 -70  13 
21 clusters ordered from an anterior to posterior in the coronal plane. 
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Table 3. 21   Within Control Group:  areas exhibiting a significant negative linear 
trend in activity with increasing cognitive load. 




Cluster   p-Value  
size  
(mm3) 
 Talairach  
co-ordinates*  
   x     y     z 
Medial Frontal Gyrus BA 10 L   455 0.00495  -4  59     7 
Superior Frontal Gyrus BA 9 L   550 0.00138  -4  52   30 
Superior Temporal Gyrus BA 38 R   102 0.00727  36    7  -30 
Middle Temporal Gyrus BA 21 L   193 0.00635 -43    0  -30 
Precentral Gyrus, Frontal BA 44 R   135 0.00505  51    0     7 
Insula BA 13 L   442 0.00493 -36 -14   14 
Paracentral Lobule BA 31 L 1704 0.00033   -4 -15   43 
Transverse Temporal Gyrus BA 41 R   585 0.00191  51 -19   13 
Postcentral Gyrus, Parietal BA 3 L   643 0.00185 -22 -30   59 
Cuneus, Occipital Lobe BA 23 L   262 0.00984   -4 -74   13 
Middle Occipital Gyrus BA 18 R     85 0.00938  18 -85   13 
11 clusters ordered from an anterior to posterior in the coronal plane. 










Figure 3. 18  Brain areas showing significant changes in the haemodynamic response with increasing cognitive load in the 
Control Group:  (a)  Positive Linear Trend and (b) Negative Linear Trend 
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3.9.2   Trend Analysis within the TRS Group 
 
Table 3. 22   Within TRS Group:  areas exhibiting a significant positive linear trend in 
activity with increasing cognitive load 




Cluster   p-Value  
size  
(mm3) 
 Talairach  
co-ordinates*  
   x     y     z 
Middle Frontal Gyrus BA 10 R  183 0.00166   25  56  10 
Middle Frontal Gyrus BA 10 L  236 0.00115  -36  48  13 
Middle Frontal Gyrus BA 9 R  180 0.00195   36  33  33 
Middle Frontal Gyrus BA 9  L  153 0.00216  -40  30  30 
Superior Frontal Gyrus BA 8 R    40 0.00898   25  26  50 
Insula, Sub-lobar BA 13 R  199 0.00274   33  22  10 
Caudate    - L   75 0.00546  -31  21   9 
Insula BA 13 L  213 0.00269  -29  19   7 
Medial Frontal Gyrus BA 6 L  259 0.00031     0  15  43 
Middle Frontal Gyrus 
(5.2 mm away) 
BA 9 R  116 0.00276   50  14  26 
Middle Frontal Gyrus BA 6 R  204 0.00079   33   4  50 
Precentral Gyrus BA 6 L  135 0.00391  -36   0  30 
Frontal Lobe, Sub-Gyral 
(5.2 mm away) 
BA 6 L  264 0.00128  -19   -1  53 
Supramarginal Gyrus 
(6.9 mm away) 
BA 40 R  133 0.00232   44 -44  34 
Fusiform Gyrus, Temporal 
Lobe 
BA 36 L   44 0.01083  -51 -45 -20 
Inferior Parietal Lobe BA 40 L  291 0.00341  -44 -48  36 
Cerebellum, Anterior Lobe - L 124 0.00512  -30 -52 -30 
Cerebellum, Anterior Lobe, 
Culmen 
- R 109 0.00698   22 -56 -26 
Precuneus BA 19 R    95 0.00599   33 -67  40 
Precuneus BA 7 L  207 0.00515    -4 -70  43 
Cuneus, Occipital Lobe BA 19 R    28 0.00735     4 -89  33 
 
21 clusters ordered from anterior to posterior in the coronal plane. 









Table 3. 23   Within TRS Group:  areas exhibiting a significant negative linear trend in 
activity with increasing cognitive load 




Cluster   p-Value  
size  
(mm3) 
 Talairach  
co-ordinates*  
   x     y     z 
Precentral Gyrus, Frontal BA 4 R 450 0.00249  43  -15  36 
Medial Frontal Gyrus BA 8 L 122 0.00751  -7   38  40 
Middle Frontal Gyrus BA 8 L 110 0.00598 -20  27  38 
Precentral Gyrus 
(6.4 mm away) 
BA 6 L 51 0.00707 -61     0  36 
Cingulate Gyrus BA 24 L 708 
 
 
0.00077 -4 -15 40 
Precentral Gyrus, Frontal 
(5.7 mm away) 
BA 4 L 736 0.00225 -36  -20  40 
Transverse Temporal Gyrus BA 41 R 393 0.00819  36 -26  10 
Cingulate Gyrus BA 31 R 615 0.00137  20 -28  38 
Precuneus BA 7 R 382 0.00361  14 -44  53 
Posterior Cingulate BA 30 R 262 0.00818  18 -67   7 
Cuneus, Occipital Lobe BA 17 R 197 0.01166    4  -81   7 
 
11 clusters ordered from an anterior to posterior in the coronal plane. 
Age was used as covariate; voxel-wise p-value = <0.05, cluster-wise p= 0.01. 
 
 






-  Statistical Maps 
Figure 3. 19   Brain areas showing significant changes in the haemodynamic response with increasing cognitive load in the TRS 
Group:  (a)  Positive Linear Trend and (b) Negative Linear Trend 
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3.10   Factorial Analysis Comparing TRS and Control Groups 
-  The initial ANCOVA results 
After adjusting the thresholds to minimise the risk of type one error and repeating the 
analysis, the result of the initial ANCOVA between the TRS and control groups, indicated 5 
clusters of significant differential activation.  The peak co-ordinates for these were in the 
left medial frontal gyrus (BA 8), right frontal lobe sub-gyral (BA 6), left posterior cingulate 
(BA 31) nearest grey 6.9mm away, and right precuneus (BA 7) in the parietal lobe and left 
lingual gyrus in the occipital lobe.  These were all highly significant - the cluster for the 
lingual gyrus was the least significant at p = 0.007.  However, the clusters in the medial 
frontal gyrus and precuneus were very large at 815 and 997 voxels respectively. 
 
Therefore, a more stringent analysis was conducted by raising the voxel p-value to 0.01 
(from a default value at 0.5).  This had the desired effect of reducing cluster sizes and 
demonstrated the “robustness” of the clusters that were still significant.  However, the 
lingual gyrus was no longer significant which highlighted the risk of type 2 error had been 
increased.   (This exploratory analysis is supplied for reference in Appendix 3).  
 
-  The main ANCOVA results declustered 
For the factorial analyses, interpretation of the figures in the following pages is helped 
considerably by the presence of a consistent pattern that emerges with increasing levels of 
cognitive load:  namely, an attenuation in the increases and decreases in the haemodynamic 
response relative to group baselines in the TRS group relative to controls.  A similar pattern 
is observed in the higher PANSS group compared to the lower PANSS group (section 3.11), 
thereby indicating the haemodynamic response is influenced by the level of pathology.  This 
over-arching pattern in the factorial analyses was without exception: in no instances were 
greater increases or decreases observed in the group with a higher level of pathology.  
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Table 3. 24   Factorial Analysis comparing TRS Participants with Controls across 
Three Levels of Cognitive Load in the Working Memory Task   




Cluster   p-Value  
size  
(mm3) 
 Talairach  
co-ordinates*  
   x     y     z 
Medial Frontal Gyrus BA 10 L 305 0.00309   -4  59  17 
Medial Frontal Gyrus BA 8 L 226 0.00370   -4  52  40 
Superior Frontal Gyrus BA 10 L   12 0.01208  -25  48  26 
Anterior Cingulate BA 24 L 159 0.01301   -7  30  -3 
Superior Frontal Gyrus BA 6 L   85 0.00718   -7  30  56 
Middle Frontal Gyrus BA 9 R   87 0.00897  43  19  33 
Putamen - R   16 0.01239  22  19  -7 
Superior Frontal Gyrus BA 6 L 119 0.00437    0   4 50 
Frontal Lobe, Sub-Gyral BA 6 L 109 0.00386 -25   4 53 
Frontal Lobe, Sub-Gyral BA 6 R 245 0.00463  29   0 53 
Thalamus - R 128 0.01084  11  -4   3 
Cingulate Gyrus  BA 24 L 172 0.00375  -4 -15 33 
Parahippocampal Gyrus 
(nearest grey 5.8 mm away) 
BA 36 R 176 0.01237  40 -30 -11 
Cingulate Gyrus 
(nearest grey 6.9mm away) 
BA 31 
 
L 285 0.00448  -3 -26  37 
Middle Temporal Gyrus BA 21 L   78 0.01211 -47 -33    0 
Parietal Lobe, Sub-Gyral BA 40 R 302 0.00505  36 -44  33 
Paracentral Lobule BA 5 L   56 0.01385 -10 -44  59 
Limbic Lobe, Sub-Gyral 
(nearest grey 9.4mm away) 
BA 31 L 174 0.00869 -19 -46  37 
Parahippocampal Gyrus BA 30 L   57 0.01404 -29 -48    3 
Precuneus BA 7 R 365 0.00721  22 -59  26 
Lingual Gyrus - L   78 0.01211 -29 -70    0 
 
21 areas ordered from anterior to posterior in the coronal plane. 
Age was used as covariate; voxel-wise p-value = <0.05, cluster-wise p= 0.01. 
One participant was excluded from analyses for the 3-back condition as they scored 0/9 












Figure 3. 20   Haemodynamic response as cognitive load increased in TRS participants and controls in the left Medial Frontal 
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Control 
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Figure 3. 21  Haemodynamic response as cognitive load increased in TRS participants and controls in the left Anterior 






 1-Back 2-Back 3-Back  1-Back 2-Back 3-Back 
TRS Group -0.01225  0.00236 -0.00130 TRS Group -0.00525 -0.05296 -0.03237 
Control Group -0.01554 -0.04821 -0.03087 Control Group -0.04701 -0.16794 -0.15823 
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Figure 3. 22   Haemodynamic response as cognitive load increased in TRS participants and controls in the right Middle and left 
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Figure 3. 23  Haemodynamic response as cognitive load increased in TRS participants and controls in the right and left 






 1-Back 2-Back 3-Back  1-Back 2-Back 3-Back 
Control Group -0.00176  0.00280  0.00076 Control Group -0.00449 0.01135 0.00711 
TRS Group -0.00538 -0.02095 -0.02288 TRS Group -0.00140 0.00996 0.00931 
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TRS Group
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 1-Back 2-Back 3-Back  1-Back 2-Back 3-Back 
Control Group 0.03831 0.08190 0.08725 Control Group 0.00832 0.01005 0.00849 
TRS Group 0.00535 0.02939 0.01978 TRS Group 0.00507 0.02913 0.01416 
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Figure 3. 25  Haemodynamic response as cognitive load increased in TRS participants and controls in the Parahippocampal 







 1-Back 2-Back 3-Back  1-Back 2-Back 3-Back  1-Back 2-Back 3-Back 
Control 
Group  0.01987  0.06328  0.04884 
Control 
Group 0.03630 0.04798 0.06790 
Control 
Group -0.00517  0.02927  0.00608 
TRS 
Group -0.01670 -0.00130 -0.00229 
TRS 
Group 0.00162 0.01399 0.01214 
TRS 
Group -0.00323 -0.01543 -0.02303 
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Figure 3. 26   Haemodynamic response as cognitive load increased in TRS participants and controls in the left Cingulate Gyrus 





 1-Back 2-Back 3-Back  1-Back 2-Back 3-Back 
TRS Group -0.02445 -0.07498 -0.04491 TRS Group  0.00659 -0.00102  0.00218 
Control Group -0.04412 -0.11562 -0.16391 Control Group -0.01530 -0.02891 -0.05269 
* Significant at p = 0.00448 * Significant at p = 0.01385 
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Figure 3. 27   Haemodynamic response as cognitive load increased in TRS participants and Controls in the right Parietal Lobe, 








 1-Back 2-Back 3-Back  1-Back 2-Back 3-Back  1-Back 2-Back 3-Back 
Control 
Group 0.06997 0.15356 0.18375 
Control 
Group 0.05284 0.15967 0.13115 
Control  
Group  0.00794  0.02230  0.03506 
TRS Group 0.02800 0.07691 0.06899 TRS Group 0.02883 0.04474 0.03282 TRS Group -0.00297  0.00100 -0.02589 
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-  Statistical Maps 
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3.11   Factorial Analysis Comparing TRS Individuals Grouped by Symptom 
Severity (Lower vs. Higher PANSS) 
Table 3. 25   Differences in the haemodynamic response between with higher and lower 
symptom groups (Lower versus Higher PANSS) 




Cluster   p-Value  
size  
(mm3) 
 Talairach  
co-ordinates*  
   x     y     z 
Superior Frontal Gyrus, BA 9 L    57 0.00753   -7  56  26 
Medial Frontal Gyrus BA 9 R    50 0.00966    7  48   26 
Middle Frontal Gyrus BA 9 L    76 0.00279 -36  26  30 
Claustrum - L  111 0.00542 -25  22  13 
Inferior Frontal Gyrus BA 9 L  100 0.00669 -43    4  23 
Postcentral Gyrus BA 3 R  482 0.00587  43 -19  43 
Supramarginal Gyrus BA 40 L    89 0.00303 -41 -46  33 
 
 
Figure 3. 29   Haemodynamic response in the left Claustrum at different levels of 





 1-Back 2-Back 3-Back 
Higher PANSS -0.008391  0.000504 -0.018727 
Lower PANSS  0.028348  0.054817  0.090098 
Control Group  0.022842  0.035109  0.031020 
* Significant between Higher and Lower PANSS Groups at p = 0.00542 
Note:  Activation in the control group is shown for comparison. The difference with the TRS 
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Figure 3. 30   Haemodynamic response in the left Superior Frontal Gyrus (BA 9), right Medial Frontal Gyrus (BA 9) and the 







 1-Back 2-Back 3-Back  1-Back 2-Back 3-Back  1-Back 2-Back 3-Back 
Higher 
PANSS 
-0.02126 -0.03342 -0.03002 
Higher 
PANSS 
-0.00099 -0.02431 -0.00135 
Higher 
PANSS 
-0.01677 -0.00038 -0.01879 
Lower  
PANSS 
-0.03105 -0.07128 -0.06750 
Lower  
PANSS 
-0.03337 -0.06913 -0.04733 
Lower  
PANSS 
-0.01728 -0.04107 -0.08186 
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Figure 3. 31   Haemodynamic response in the left Superior Frontal Gyrus (BA 9), right Medial Frontal Gyrus (BA 9) and the 
right Postcentral Gyrus (BA3) at different levels of cognitive load in TRS individuals grouped by symptom severity 
 
   
 1-Back 2-Back 3-Back  1-Back 2-Back 3-Back  1-Back 2-Back 3-Back 
Higher 
PANSS 
0.00023 0.01815 0.01627 
Higher 
PANSS 
0.02025 0.03571 0.06136 
Higher 
PANSS 
0.02474 0.10343 0.05899 
Lower  
PANSS 
0.04226 0.09275 0.10627 
Lower  
PANSS 
0.03313 0.05850 0.11267 
Lower  
PANSS 
0.06894 0.18283 0.12024 


















Left Middle Frontal Gyrus, BA9
(x = -36, y = 26, z = 30)*

















Left Inferior Frontal Gyrus, BA 9
(x = -43, y = 4, z = 23)*

















Left Supramarginal Gyrus, BA 40
(x = -43, y = -48, z = 33)*
TRS Higher PANSS TRS Lower PANSS






-  Statistical Maps 
Figure 3. 32    Statistical Maps of the Factorial Interaction between TRS Participants Grouped According to Symptom Severity (Lower and 











3.12 Correlational Analyses of the Haemodynamic Response at different levels 
of Cognitive Load and Symptom Severity in the TRS Group 
The following analyses were conducted in XBAM (using the correlational option, BBAM) 
to explore relationships between the haemodynamic response and positive and negative 
symptoms in TRS group. 
 
3.12.1   With Positive Symptoms 
-  positive correlations 
Table 3. 26   Brain areas showing significant positive correlation between positive 
symptom scores and the haemodynamic response in the TRS group 




Cluster   p-Value  
size  
(mm3) 
 Talairach  
co-ordinates*  
   x     y     z 
1-BACK        
Left Medial Frontal Gyrus BA 6 L 119 0.00217 -18 30 33 
2-BACK        
Non-significant.        
3-BACK        
Non-significant.        
 
Voxel-wise p-value = <0.05, cluster-wise p= 0.01. 
Note: Age and reaction times in the baseline condition of the n-back task were covariates. 
 
  
Figure 3. 33    Statistical Map showing a significant positive correlation between 
positive symptoms scores and the haemodynamic response in the left Medial Frontal 




Positive correlation between the level of positive symptoms and the haemodynamic 











Figure 3. 34  Positive correlation between positive symptom scores and the 
haemodynamic response in the left Medial Frontal Gyrus (BA 6) during the 1-Back 
condition in the TRS Group 
 
 
Notes: Vertical line indicates the median number of positive symptoms at 11. 
Lines of best fit shown for lower and higher PANSS subgroups, n = 14, n = 11. 
 
 
There were no significant negative correlations between the haemodynamic response and 
positive symptoms at any level of cognitive load with both age and mean RTs in the 0-Back 





3.12.2   With Negative Symptoms 
-  positive correlations 
Table 3. 27    Brain areas showing significant positive correlation between negative 
symptoms and the haemodynamic response at different levels of cognitive load in the 
TRS Group 




Cluster   p-Value  
size  
(mm3) 
 Talairach  
co-ordinates*  
   x     y     z 
1-BACK        
Non-significant        
2-BACK        
Medial Frontal Gyrus  BA 6 R 155 0.00256   4 -26  53 
3-BACK        
Postcentral Gyrus  BA 40 L 210 0.00239 -33 -37  50 
 
Voxel-wise p-value = <0.05, cluster-wise p= 0.01. 
Note: Age and reaction times in the baseline condition of the n-back task were covariates. 
 
 
Figure 3. 35    Statistical Map showing a significant positive correlation between 
negative symptom scores and the haemodynamic response in the right Medial Frontal 




Positive correlation between the level of negative symptoms and haemodynamic response in 
the medial frontal gyrus (BA 6).  (Note: the precuneus is prominent in this cluster although 






Figure 3. 36   Correlation between negative symptom scores and the haemodynamic 




Notes: Vertical line indicates the median number of negative symptoms at 14. 







Figure 3. 37   Statistical Map showing a significant positive correlation between 
negative symptom scores and the haemodynamic response in the left Postcentral Gyrus 








Figure 3. 38   Correlation between negative symptom scores and the haemodynamic 




Notes: Vertical line indicates the median number of negative symptoms at 14. 




-  negative correlations 
Table 3. 28    Brain areas showing significant negative correlation between negative 
symptom scores and the haemodynamic response at different levels of cognitive load in 
the TRS Group 




Cluster   p-Value  
size  
(mm3) 
 Talairach  
co-ordinates*  
   x     y     z 
1-BACK        
Non-significant.        
2-BACK        
Non-significant.        
3-BACK        
Anterior Cingulate Cortex 24 R  107 0.00259   4  33  17 
Parahippocampal Gyrus 
(Nearest gray 5.4mm away) 
30 R    74 0.00377  11 -40    5 
 
Voxel-wise p-value = <0.05, cluster-wise p= 0.01. 
Note: Age and reaction times in the baseline condition of the n-back task were covariates. 
 
Figure 3. 39   Statistical Map showing significant negative correlation between negative 
symptom scores and the haemodynamic response in the right Anterior Cingulate 
Cortex (BA 24) and right Parahippocampal Gyrus (BA 30) during the 3-Back 





Negative correlation between negative symptoms and the right Anterior Cingulate Cortex 









Figure 3. 40   Negative correlations between negative symptom scores and the haemodynamic response and in the right Anterior 
Cingulate Cortex (BA 24) and right Parahippocampal Gyrus (BA 30) during the 3-Back condition in the TRS group 
 
 





Notes:  Vertical line shows median for negative symptoms at 14.  Lines of best fit shown for lower and higher PANSS subgroups, n = 14, n = 11.  
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CHAPTER IV - DISCUSSION  
 
4.1   Overview and Organisation of the Discussion 
TRS is a category which is currently not recognised by the main psychiatric classification 
systems, which has suffered from the lack of a consistent definition in the literature and has 
been relatively under-researched.  Therefore, the nature of this study is inevitably largely 
exploratory.  Moreover, this enquiry is set within the over-arching question as to whether 
TRS might represent a distinctive aetiopathological subgroup of schizophrenia, or is simply 
a more severe form of the disorder?  The epidemiological evidence of Wimberley et al. 
(2016), which observed a lack of sex difference in TRS, along with an earlier age of onset, 
together with observations of normal presynaptic dopamine capacity in the associative  
striatum (Demjaha et al., 2012; Kim et al., 2017) provide a biological basis for a distinctive 
subtype.  Nonetheless, the question cannot be settled without further evidence since 
understanding schizophrenia more generally remains one of the great challenges of 
neuroscience, but it is in the background prompting and guiding, nonetheless.   
  
The main hypothesis of the current body of work was that TRS participants would, during 
the performance of a verbal n-back task, show attenuated engagement of an “executive” 
fronto-parietal network similar to that described for healthy controls in an earlier meta-
analysis of n-back fMRI studies by Owen et al. (2005), and meta-analyses of studies 
comparing individuals with schizophrenia and healthy controls (Glahn et al., 2005;  
Minzenberg et al., 2009).  
 
None of these studies specifically addressed TRS.  The results of this thesis supported this 
hypothesis as the groups with the higher level of pathology (TRS participants relative to 
controls) displayed attenuated haemodynamic responses with increasing cognitive load in 
the frontal and parahippocampal gyri bilaterally, the right thalamus, right parietal lobe, right 
precuneus and left lingual gyrus compared to the control group.  They also showed 
increased haemodynamic response in the right putamen, left medial/superior frontal gyri, 
left cingulate gyrus and left paracentral lobule. 
 
Similarly, the higher PANSS group exhibited an attenuated haemodynamic response with 
increasing cognitive load in the left claustrum and left frontal gyrus, relative to the lower 
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PANSS group, as well as increased haemodynamic response in left superior frontal, right 
medial frontal and right postcentral gyri. 
 
The behavioural and neuropsychological analyses in the TRS group revealed estimated IQ 
scores clustered around the peak of the normal distribution yet scores on the MCCB 
domains were consistently depressed relative to standardisation norms for the general 
population. Also, scores were superior in the lower PANSS group on the speed of 
processing composite, the test of visual learning, and for attention and vigilance, all at trend 
level significance.  Further, exploratory correlations revealed negative symptoms were 
strongly associated with decrements in attention and also with estimated full-scale IQ and 
verbal IQ scores.  However, the presence of intellectual asymmetries between the WASI 
subscales in 52% of TRS participants, with two polarised groups, complicates interpretation.    
 
The results of this thesis contribute to the search for further biomarkers to distinguish TRS 
from FLRS. These results suggest the involvement of a common circuitry which has a 
rostral focus in the striatal-thalamocortical loops and ACC (see Weinstein et al., 2017 in 
relation to dopamine pathways), including the motor cortex and DLPFC, extending to the 
parietal and temporal association cortices.  Important to efficient function, the large-scale 
networks of the salience network and DMN are implicated as well.  However, the primary 
pathology may start in different areas in TRS and FLRS, but with the progression of 
pathophysiological processes they may increasingly resemble each other, for example, 
exhibiting deficits in GABAergic interneurons and GAD enzymes, grey and white matter 
abnormalities along with behaviours and clinical symptoms.  Also, dopaminergic and 
glutamatergic neurotransmitter systems interact, for example, where receptors are present on 
the same neuron.  It follows that the most distinctive biomarkers for both TRS and FLRS 
may be present early on in the disease and might also be found in unaffected first-degree 
relatives. 
 
Further, in the light of evidence in this study that verbal and visual learning may deteriorate 
during episodes of acute psychosis before a trial of clozapine is tried, it is proposed that 
metabolically overactive brain areas (possibly consequent upon decrements in GABAergic 
inhibition), might become underactive as chronicity progresses, perhaps through 
degenerative changes or deficits in neural transmission and synaptic plasticity.  Further, as 
proposed in section 1.7.3, ultra-TRS might reflect a more advanced form of TRS with 
possible support in the lower perfusion values of non-responders to clozapine in the SPECT 
studies of Rodriguez et al. (1997; 1998) where there might be a relative loss of function 
from which recovery is more difficult.  By contrast, the therapeutic response to clozapine 
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appears to have involved reductions in perfusion values irrespective of whether an area was 
hyperactive or relatively hypoactive in relation to the values in a normative database (in the 
thalamus, basal ganglia bilaterally, superior DLPFC and anterior PFC bilaterally).  The only 
region of interest where treatment with clozapine did not significantly lower perfusion 
values in responders was in the inferior DLPFC bilaterally).  A significant decrease in the 
anterior prefrontal area in responders may also be consistent with hyperactivity in the ACC 
in some TRS individuals, at least, before clozapine treatment is initiated (Demjaha et al., 
2014; Mouchlianitis et al., 2016 (a).  Of course, other explanations could apply to ultra-
TRS, not least a history of chronicity and different treatments, also, a loss of function might 
be predicted to be associated with greater atrophy in related areas. 
 
This discussion will start with the clinical, neuropsychological and behavioural aspects, 
followed by the main results of the neuroimaging study which are to be found in the 
factorial analyses, along with a brief discussion of some of the “hub” areas and networks 
that are implicated in this study.  This is intended to provide further perspective on the 
results of the trend analyses and correlations between the haemodynamic response and 
behaviour which follow. The main findings will be summarised in a model which 
characterises TRS along with pertinent observations in the wider literature (section 5.1).  
Some limitations will then be highlighted, followed by some ideas for further research. 
 
4.2   Clinical, Neuropsychological and Behavioural aspects 
4.2.1   Participant characteristics 
-  A low level of symptoms 
In view of their TRS status, it was striking that many participants presented with low levels 
of clinical symptoms, indeed the median total PANSS scores for the group as a whole was 
only 45 (min-max:  37-90, n=26), on a measure where the minimum score is 30 (one point is 
given for an absence of pathology) and the maximum possible PANSS score is 210, but may 
be rarely achieved.  A better reference point might be found in studies of chronically unwell 
individuals, partially or wholly refractory to treatment, for example, in Zink et al., (2009) at 
84 (SD=11.2) or Honer et al., (2006) at 102.5 (SD=15.8).   A 20% reduction in symptoms 
defines the clinical response for in some drug trials (e.g. Cipriani et al., 2009), while a 50% 
reduction in these studies (yielding 42 and 51) would be closer to scores in this study.   
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The low scores are surely indicative of the efficacy of clozapine however, they might also 
be a function of participant selection.  While it is often the case that participants may not be 
representative of their peers, it is wondered if this might be particularly true of the clinical 
participants in this study as recruitment proved very difficult.  Several people, to whom I am 
indebted, became involved, often making fruitless visits to clinics.  Samanaite et al., (2018) 
commented “patients who are about to start clozapine can be difficult to recruit to research 
involving neuroimaging or invasive procedures because they are often very unwell and may 
lack capacity to consent.” (p.24)  However, in the light of the experience here, perhaps, the 
persistence of some negative or cognitive symptoms undermine motivation despite an 
overall reduction in symptom scores?  Fatigue might be a further or exacerbating reason as 
clozapine can have sedative effects (Thompson et al., 2014).51  Sometimes an individual 
may be reluctant to participate if they feel they have been let down as patients.52 
 
4.2.3   Cessation of Smoking – a sign of clinical improvement? 
A high prevalence of smoking has often been observed in schizophrenia and 92% of the 
TRS group indicated they had been nicotine dependent at some point.  However, there was a 
reduction in the lower PANSS group compared with the higher PANSS group, even though 
smoking was still highly prevalent in the lower PANSS group at 65.3%. The lower PANSS 
group had been attending clozapine clinics for a longer period and there is considerable 
incentive to reduce smoking because this may permit the lowering of the clozapine dose due 
to metabolic factors, therefore, the lower PANSS group had a longer time to respond to this 
message.  However, this could be over-stated since the median period of clozapine treatment 
was 4.5 years in the higher PANSS group.  An alternative possibility is that some 
individuals in the lower PANSS group felt well enough to stop smoking . 
 
There is evidence on both sides of the “self-medication” hypothesis, e.g. Boggs et al. (2017) 
recently disputed it (although it may be relevant their participants had few negative 
symptoms and only one was taking clozapine, so perhaps they did not have deficits which 
could be further relieved by nicotine).  However, substantive evidence points to nicotine 
having neuromodulatory effects with amelioration of negative symptoms.  Smucny et al., 
(2017) observed hypoconnectivity between the ACC and ventrolateral PFC during a placebo 
(no nicotine) condition in their PSZ group relative to healthy controls; also, 
 
51 One participant told me about their “bad days” when they just sit all day. 
 
52 One person approached me to say they wouldn’t be taking part in the study but wanted to say they 
were angry that trial of clozapine hadn’t been tried earlier. 
 
  
  205 
 
hyperconnectivity between nodes of the salience network (the insula and middle cingulate 
cortex). The latter also correlated with the severity of negative symptoms (anhedonia and 
asociality) during the placebo condition when nicotine was not administered to individuals 
with schizophrenia (all participants had not smoked for a minimum of 3 months).  It was 
further observed nicotine affected connectivity between the ACC and the CEN and also 
“betweenness centrality” in the ACC where the high betweenness centrality of the salience 
network may help it “to integrate information and process salience.” (p.86)  Similarly, 
Smucny et al. (2017) have observed:   
 
The hypothesized role of the salience network in switching between task-positive and task-
negative network dominant states as a function of cognitive demands (Menon, 2011; 
Palaniyappan and Liddle, 2012) suggests that nicotine may improve cognition in 
schizophrenia (Barr et al., 2008; Harris et al., 2004) via its ability to increase the integrative 
capacity of the network. (p.94) 
 
In their study, short term abstinence increased omission errors to targets on a CPT task for 
both PSZ and controls who smoked and it was suggested this may have been mediated by 
tobacco cravings, however, spatial working memory performance was impaired only in the 
schizophrenia group and improved upon resumption of smoking. 
 
It was also interesting that Smucny et al. (2017) chose to highlight the role of von Economo 
neurons (VENs): 
 
The ability of nicotine to affect betweenness centrality of the ACC may be related to the 
presence of specialized neurons in the area called von Economo or “spindle” neurons. Von 
Economo neurons are unusually long (160-200 mm or more) neurons that are exclusively 
present in the ACC and insular cortices...... The unique morphology of these cells is thought 
to enable these brain areas to communicate with distal sites, facilitating their ability to 
integrate information from many sources to aid in complex computations associated with 
high-level cognitive functions, e.g. social behavior (Butti et al., 2013).  (p.94) 
 
Decrements in VENs had been observed in early onset schizophrenia (Brune et al., 2010) 
and their presence has now been established in the ACC, Insula and DLPFC in humans and 
if TRS is characterised by impairments in global connectivity then this could be an 
important area of enquiry (also see:  Allman et al., 2010, 2011;  Nimchinksy et al., 1995, 
1999;  Hakeem et al., 2009;  Stevens et al., 2011).  Certainly, rapid and accurate assessment 
of social situations would have survival value and it is noted that the social cognition had 
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the lowest scores on any individual test, just below the 3rd percentile for both lower and 
higher PANSS groups.   
 
Interestingly, smoking status was observed to affect emotional recognition scores in the 
study comparing cognitive profiles in TRS, FLRS, U-TRS and healthy controls in the study 
by Anderson et al. (2015,b) to the extent it was entered as a covariate in their analyses.  
Performance on this task also correlated with negative symptoms in their FLRS group and 
both with verbal memory and verbal fluency in their TRS group.   However, the task which 
involved judgements based on faces had fewer individuals exhibiting deficits than the FLRS 
or U-TRS groups and appeared more similar to the controls.  While, in this study scores may 
have been affected by some unfamiliar American vocabulary (e.g. “tractor-trailer truck”).  
Also, the reading skills of the group were not tested and a printed sheet of the scenarios 
being described may have been unhelpful to some participants. 
 
4.2.4   Other Substance Use 
Table 3. 4 indicated there were no significant differences between the higher and lower 
PANSS groups on the prevalence of drug use prior to the first episode of psychosis.  While 
doubt should be cast on the accuracy of recall concerning distant events, a high prevalence 
of drug use is not unusual in schizophrenia populations although it may be under- 
reported (Bahorik et al., 2014, a; Bahorik et al., 2014, b), so it would be unsurprising if 
drugs were also taken in the prodrome (among the participants this would have been 
approximately between 1985 and 2003).  A link between psychosis and cannabis which has 
dopaminergic effects has been established (Marconi et al., 2016), although earlier types of 
cannabis may have been less potent.  Also, the use of ecstasy which has serotonergic, 
dopaminergic and cholinergic actions (Annenken et al., 2013) may have been less common 
than today.  However, the use of LSD reported by 40% of the group was particularly 
concerning and, apparently, is becoming fashionable again (Pollan 2018).    
 
4.2.5   Time to Access Clozapine 
Recent statistics for England and Wales, indicate 23.7% of individuals with schizophrenia 
are receiving clozapine but it could not be ascertained why a trial of clozapine had not been 
tried in some individuals with TRS (Patel et al., 2014).  In this study, the median average 
time to access clozapine in the higher PANSS group was 7 years and the median delay in 
the lower PANSS group was 4-years (Table 3. 3).  The latter is like Taylor et al. (2003), 
whose study of antipsychotic prescribing in the South London and Maudsley NHS 
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Foundation Trust in a temporally overlapping cohort, observed a mean delay of nearly 4 
years in individuals who commenced clozapine between 1.1.2006 and 15.4.2010.  National 
Institute of Clinical Excellence guidelines recommend a trial of clozapine should be initiated 
as soon as possible for TRS (Howes et al., 2012; Taylor, et al., 2003). 
 
Among those in the higher PANSS group, were three individuals who had only started 
clozapine in the previous year.  In a further case, there had been earlier concerns about 
adherence, so the duration of treatment may have been an over-estimate.  As clozapine can 
take 6-12 months before the benefit is more fully apparent (Lieberman et al., 1994; Fabrazzo 
et al., 2002), shorter treatment duration might help to explain a higher level of symptoms.  
Estimates indicate the higher PANSS group had received clozapine for around half the 
period of the lower PANSS (p = 0.016) so delays in accessing clozapine and a shorter 
duration of treatment might contribute to greater pathology. 
 
Earlier studies on the duration of untreated psychosis in the prodrome have been mixed in 
PSZ.  However, relapse in the first year appears to be a predictor of cognitive outcomes 
(Rund et al., 2016), which could be pertinent to TRS.  Exploratory correlations were 
conducted on access and duration of treatment with clozapine and are reported in section 
3.1.2 (and Table Appx. 4. 7 where they were mostly non-significant).  However, it is 
interesting to note those who had waited the shortest time before their first trial of clozapine 
were among the more recently diagnosed, which is consistent with the prescribing 
guidelines above being applied.  There were no significant correlations with the duration of 
treatment with clozapine, however, if most benefit accrues within  two years this sample 
cannot address this.  
 
Relatively few of the selected correlations with the time to access to clozapine were 
significant, however, there was a highly significant (albeit unadjusted) negative correlation 
between the MCCB overall composite score and the time to access clozapine  
(p = .007, Table Appx. 4. 7, b).  This is difficult to interpret since the overall composite 
score reflects many variables.  Indeed, so does the WASI yet neither FIQ nor the subscales 
correlated with the elapse of time before clozapine, notwithstanding these were strongly and 
very significantly correlated with the overall composite score (Table 3. 9).  Also, the overall 
composite scores were extremely low in this study, with a group median percentile of 2.3 
(Table 3. 7), so it should be considered whether sufficient data informed the extremes of the 
distribution in the MCCB standardisation study: in a reply to Siu (2008), the authors (Kern 
et al., 2008) agreed that the values at the lower end of the distribution had been inferred 
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since “few subjects in the community normative sample scored at extremely low levels”, 
however, their sample met the assumptions of normality. 
 
There was, however, a significant negative partial correlation where age at the time of the 
study was controlled, between the time to access a trial of clozapine and verbal learning 
(Figure 3. 5).  Similarly, with free recall on the first trial of the HVLT-R (Table Appx 4. 7, 
b).  There was also a significant negative partial correlation (again with age as a covariate) 
between the time to access a trial of clozapine and visual learning scores (Figure 3. 6).  
These significant partial correlations indicate that untreated acute psychosis may be 
neurotoxic with respect to processes associated with short term learning in both the visual 
and verbal domains.  Possibly relevant to this, was the apparent lack of a recency effect 
during free recall on the first trial of the HVLT-R discussed in relation to the phonological 
short-term store below. 
 
Further, the lack of correlation between the time to access clozapine variable with 
performance IQ might indicate fluid intelligence and the overlapping concepts of executive 
performance and working memory are less susceptible to illness progression during this 
period.  However, the above observations could be consistent with the view that both verbal 
and visual learning could be affected by progressive deficits in synaptic plasticity (Friston et 
al., 2016; Stephan et al., 2009).  A mediating factor might be the vulnerability of associated 
areas to glutamate excitotoxicity, which may be more likely to arise with acute psychosis. 
Similarly, this might help to explain the apparent lack of recency in free recall, although, 
alternative explanations are advanced (in Chapter 5).  As previously discussed, vulnerability 
of myelin is one aspect; another is subunit composition at the NMDAR in the prefrontal 
cortex where the NR2B subunit may enhance learning but also increase the risk of damaging 
influxes of calcium ions (the “double-edged sword” described by Monaco et al., 2015). 
 
4.2.6   Performance on the WASI 
Estimated IQ in TRS participants was normal to good normal:  median FIQ in the lower 
PANSS group at the 66th percentile was greater than the median score for the higher PANSS 
at the 39th percentile (p = .04 with a large effect size).  Median statistics which minimise the 
effects of outliers also indicated PIQ scores across the entire TRS group were higher than 
VIQ scores (63rd percentile compared with the 47th;  Figure 3. 1).  This was also apparent in 
the depiction of differences between the subscales for individual participants (Figure 3. 2), 
which also revealed that for a minority (4 individuals) there was an asymmetry of 10 or 
more standard scores in the opposite direction where VIQ scores were higher than PIQ 
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(VIQ>PIQ grouping).  In Figure 3. 3 which plots the level of negative symptoms against 
asymmetry between the scales, it was apparent that all the VIQ>PIQ individuals had very 
low levels of negative symptoms and so, as previously stated, might represent a confound in 
the data. 
 
The evidence of intact intellectual performance on the WASI contrasts with a literature 
review by Ohi et al., 2017 (b) where 70% PSZ exhibited a marked decline of 30 points 
relative to premorbid IQ.  However, higher WASI scores may be a function of participant 
recruitment rather being representative of TRS.  Further, relatively high IQ may help to 
explain some excellent responses to clozapine: “High IQ can be a protective factor in that it 
is likely to be associated with better overall level of functioning and with better outcomes in 
schizophrenia” (Kremen et al., 2001 p.453). 
 
4.2.7   Intellectual Asymmetry 
Examination of the WASI subscales indicated around half the TRS group had an 
asymmetry.  In 36% of TRS participants scores were higher on the PIQ whereas in 16% 
they were higher on the VIQ, while 48% exhibited less asymmetry, if at all.  The verbal IQ 
subscales reflects crystallised intelligence or declarative knowledge such as vocabulary 
which can be extended through education and learning (including previous encounters with 
the WASI!), however, the performance subscale measure fluid intelligence is a relatively 
fixed attribute, so the relative superiority is harder to explain. Therefore, the observation of 
superior performance IQ in TRS individuals is intriguing and may be a rare observation.   It 
was difficult to find reports of intellectual asymmetry in schizophrenia, however, they 
typically favour VIQ (Amminger et al., 2000).53  Kremen et al. (2001), for example, using 
the Wechsler Adult Intelligence Scale-Revised (WAIS-R; Wechsler 1981), observed 
intellectual asymmetry favouring VIQ over PIQ in their sample of 36 PSZ which was 
present irrespective of whether IQ was in the low average (81-94) or average (95- 109) 
range, whereas performance between the subscales was more even in the control group. 
 
In this study, a minimum difference of 10 points was considered to be meaningful in a 
distribution that clustered around the 50th percentile.   This difference was also greater than 
those considered to be of clinical interest in a review of 12 studies on IQ asymmetry in brain 
injury by Hawkins et al., 2002, who observed VIQ is typically spared relative to PIQ in 
brain injury and the differences recede as individuals recover.  Using the above criteria, 52% 
 
53 Kremen et al. (2001) citing Heaton and Drexler 1987: “higher verbal than performance IQ is the 
predominant pattern in schizophrenia,” p.453. 
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of the sample in this study exhibited superior PIQ.  By contrast, previous reports on 
intellectual asymmetry in schizophrenia have usually favoured verbal IQ over performance 
IQ.  In Amminger et al. 2000, these were present premorbidly during adolescence (mean age 
13.1 years, SD 3.2) and again at follow up about 18 years later (mean age 30.9, SD. 3.9).   
 
However, the findings in this study could be a consequence of using the WASI to estimate 
IQ.  Axelrod (2002) directly compared the accuracy of the WASI in estimating the FIQ and 
subscales of the WAIS-III with 72 clinical participants (66 had psychiatric or neurological 
diagnoses) and reported that WASI PIQ and FSIQ scores were higher than analogous 
WAIS-III scores, and that WASI VIQ was lower than WAIS-III VIQ (p.19).  Such 
discrepancy bias may be important when interpreting the results of the current study, which 
showed higher PIQ compared to VIQ scores (the dominant asymmetry in Axelrod, 2002).  It 
was concluded “the utility of estimating VIQ and PIQ with the WASI is difficult to endorse 
when less than one half of the clinical cases obtained scores within 6 points of their WAIS-
III VIQ and PIQ scores.” (p.22).  This imbalance accords with the observations in this study 
where the 52% of the participants exhibited an asymmetry of 10 or more standard points.   
 
Yet, the possibility of asymmetry raises some interesting questions.  For example, whether 
this could reflect the incomplete lateralisation of language involving Broca’s territory (in the 
vicinity of the inferior frontal gyrus) and Wernicke’s territory (proximal to the superior 
temporal gyrus) which were reported (e.g. Bleich-Cohen et al. 2009; Chou et al., 2017).   
Neurological soft signs relating to motor function have also be attributed to atypical 
lateralisation (Niethammer et  al. 2000), which might also be related to mistiming and 
related disruption to higher cognition, embodied in the concept of “cognitive dysmetria” 
(Andreasen et al., 1998; Varambally et al. 2006; Matsuo et al., 2013). 
 
Recent advances in tractography have made it possible able to infer the strength of 
connections based on volumetric measures and found considerable variation in healthy 
populations. Taking the example of the long segment of the arcuate fasciculus54 Catani et al. 
(2007), observed this had little or no presence in the right hemisphere in approximately 60% 
of right-handed healthy participants.  While in the remaining 40%, this tract was bilaterally 
 
54 This perisylvian pathway runs medially, connecting the temporal and frontal cortex around the 
temporo-parietal junction.  The pathway runs proximal to the inferior parietal cortex (angular gyrus 
BA39 and supramarginal gyrus, BA40), where parallel anterior and posterior segments ascend more 
laterally into the inferior parietal cortex of Geschwind’s territory.  In the dominant left hemisphere, 
the long segment connects Wernicke’s territory (in the middle temporal gyrus posteriorly /temporo-
parietal junction) and Broca’s territory in the inferior precentral gyrus and posterior parts of the 
middle frontal gyrus; thereby implicating it in language function. 
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distributed with about half showing some leftward distribution.  In addition, consistent with 
the view that hemispheric organisation increases with development, they commented that 
myelin organisation in this tract, as measured by fractional anisotropy, increases between 
the age 5 and 30 years.  Variation in lateralisation has also been reported in sensory-motor 
pathways. 
 
It is suggested here that PIQ tasks may typically involve activity that is more distributed 
across brain areas than VIQ ones, so efficient processing may involve greater reliance upon 
dynamic interactions with the default mode network and between the hemispheres involving 
major tracts such as the dorsomedial cingulum and parts of the corpus callosum.  While 
representing a potential vulnerability as decrements in interhemispheric communication 
have been observed in schizophrenia (Hoptman et al., 2012), a more distributed system may 
be less vulnerable to local damage (for example, if it is possible for there to be local 
concentrations of excitoxocity).  Also, there may also be greater opportunities for 
compensatory connections and mitigation through the redundancy available in rich club 
organisation, for example in bilateral hubs in the superior frontal and superiorparietal cortex, 
precuneus, putamen, thalamus and hippocampus identified by van den Heuvel and Sporns 
(2011);  therefore, PIQ may be more spared from the consequences of “leftward pathology” 
which has been commented in studies of schizophrenia:  for example, a systematic review of 
46 studies by Sun et al. (2009) presented evidence of associations between the development 
of thought disorder and auditory hallucinations with volumetric reductions in the superior 
teral gyrus, particularly in the left hemisphere;  also, a consortium study of 1985 individuals 
with schizophrenia reported in Walton et al. (2017) observed a significant association 
between negative symptoms and reductions in cortical grey matter and only in the left 
hemisphere.  They further commented that atypical lateralisation in the schizophrenia 
literature may reflect “greater involvement of the right hemisphere, which may relate to a 
broader, more diffuse semantic network (Grabner et al., 2007).”  p.8 
 
The possibility of superior PIQ in some instances makes an opposite asymmetry reported by 
Kravariti et al. (2006) concerning 108 unaffected first-degree relatives all the more 
interesting.  That study was consistent with earlier reports on intellectual asymmetry in 
schizophrenia which have usually favoured verbal IQ over performance, for example, 
Amminger et al. (2000) compared IQ premorbidly during adolescence (mean age 13.1 years, 
SD 3.2) and again at follow up about 18 years later (mean age 30.9, SD. 3.9) and observed 
relative decrements in PIQ preceded the onset of psychosis.  Kravariti et al. (2006) proposed 
an intellectual VIQ>PIQ asymmetry might be endophenotype of schizophrenia.  
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4.2.8   A Comparison of scores on the MCCB relative to the WASI 
The MCCB is relatively new and was designed to measure improvement in drug trials and 
there is still large a gap in the literature concerning how performance on the MCCB relates 
to IQ scores (August et al., 2012).  However, it is a reasonable assumption that percentile 
scores on the MCCB may be predictive of scores on the WASI.  Mohn et al. (2014) set out 
to address this and observed a high degree of correlation in their sample of 250 healthy 
participants.  The strongest correlation was observed between FIQ and the composite score  
r =.60, which is also in agreement with this study: rho = .681, n=24, p = .001. 
  
Mohn et al. (2014) further proposed that in the light of this some measures on the MCCB 
could be used to predict IQ, in order to reduce assessment times.  All the domain scores, 
except for social cognition, correlated with FIQ.  Certainly, in principle, this might be an 
efficient approach, for example, Ohi et al., 2017 have developed a WAIS-Short Form 
assessment involving a combination of “Similarities” from the verbal subscale of the WAIS-
III and Symbol Search from the Performance subscale.  However, in the case of the TRS 
participants in this study, further transformation of MCCB scores would be required as 
percentile scores on the MCCB were lower than those on the WASI.  Also, there were some 
clear differences in correlations with the subscales (Table Appx. 4. 5), where neither symbol 
coding, spatial span nor NAB mazes scores correlated with VIQ.  Moreover, social 
cognition did not correlate with PIQ scores and the speed of processing composite did not 
correlate with any of the WASI measures.  The latter, being one of the four domains (along 
with working memory, visual and verbal learning) proposed by Mohn et al., (2014, p.100) 
that could be used to infer IQ level.  However, this could be misleading in TRS if there is 
uneven deterioration with disease progression, as might be the case for visual and verbal 
learning.  Also, some adjustment would be necessary as scores were depressed relative to 
the 50th percentile. 
 
Nonetheless it is striking that MCCB scores in this study, unlike those in the WASI, were 
consistently below the 50th percentile, indeed, most were below the 16th percentile which 
approximates to 1 SD below the mean in a normal distribution.  The best performance on an 
individual test was for the category fluency word generation task (animal names), which 
might suggest semantic organisation and processing post-encoding were relatively 
preserved.  The worst score was for social cognition which approached 2SDs below the 
mean.  In both tests, there was no difference in the median scores for the lower and higher 
PANSS subgroups.  Indeed, there were no significant differences between these symptom 
groups for any of the tests (Table 3. 7). 
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Moreover, in direct comparison of FLRS, TRS and U-TRS, Anderson et al. (2015, b) 
concluded “treatment-resistant patients may not be more neurocognitively impaired than 
responders to first-line anti-psychotics and that patients with ultra-treatment-resistant 
schizophrenia perform similarly.” (p.817)  However, the mean age of their participants was 
in their early 30’s so it seems likely that most had an established course of schizophrenia; 
also, TRS participants were on clozapine monotherapy which may have brought about some 
cognitive improvement so it is quite possible there had been a convergence in scores (as 
proposed in the preliminary comments to this discussion that different groups may 
increasingly resemble each other).  It should also be noted that Anderson et al. (2015, b) did 
not use the MCCB, so their results are not necessarily equivalent, for example, their test of 
visual memory appears to have conflated visual learning and visual working memory.                 
 
Contrary to what may have been predicted on the basis of the wider schizophrenia literature, 
the performance on the working memory tests (letter-number span and spatial span at the 
26th and 24th percentiles respectively) ranked only behind category fluency.  This is in 
agreement with Lystad et al.’s (2014) study of 131 individuals with psychotic disorders 
(88.5% PSZ), who commented “A relatively unexpected result” of their Norwegian MCCB 
study of schizophrenia “was that working memory emerged as the least impaired domain in 
the patient group.” (p.1098)  It was also the case that working memory was far less impaired 
than verbal memory recall and recognition in Anderson et al. (2015, b). 
 
Performance on the remaining tests drops towards and below the 10th percentile. (The next 
best performance for the TRS group as a whole, concerned the composite score of 
processing speed at the 10th percentile, although this was elevated by the inclusion of the 
category naming task as one of the 3 tasks).  There was also a marked discrepancy in 
percentiles between the lower and higher PANSS groups for visual learning but this failed to 
reach significance.  However, observation that scores in the lower PANSS group were 
generally higher was supported by the overall composite score (Table 3. 7) based on the ten 
tests which reached significance, p = 0.024, but would not survive Bonferroni correction.  
This score was markedly below the rest at 2.3 percentiles, which is also two standard-
deviations below the mean.  This is lower than might be expected on basis of the other 
scores, however, the designers of the MCCB acknowledge “a form of measurement bias can 
occur when comparisons are made with domains assessed by a single test” resulting from a 
renormalisation process that enables domain scores to have the same metric regardless of 
the number of tests:  
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The group difference in the domain score is adjusted by a factor that increases as a) the 
correlations between the component tests decrease and b) the number of tests increases.  
Intuitively, this is because when the correlations are imperfect, each test contributes 
additional unique variance in defining between group differences.  (Kern et al., 2011, p.6) 
 
4.2.9   A deficit in the phonological short-term store? 
A Post Hoc Analysis of Serial Position in Free Recall (HVLT-R) 
The apparent attenuation or absence of the recency effect would seem a rare observation in 
schizophrenia research, for example, one study compared performance by 62 first-episode 
participants who were antipsychotic- naïve with 67 healthy controls matched for IQ, age and 
other variables, on the extensive California Verbal Learning Test (Kristian Hill et al., 2004):  
deficits were apparent in the schizophrenia group relating to verbal learning, memory, 
attention and recognition memory; however, no deficits were apparent relating to serial 
order, i.e. in the primacy, middle or recency portions of the list.   Interestingly, the level of 
negative symptoms was associated with consistency in the recall of items but no other 
variables and there were no differences between the groups for the rate of forgetting 
following a 20-minute delay or proactive and retroactive interference arising from the 
learning of different lists.  It was further observed their findings were consistent with other 
studies with medicated participants with chronic schizophrenia. 
 
A deficit in recency therefore might possibly yield a biomarker of TRS. It may also indicate 
“an impairment of the phonological short-term store”  (see Vallar, 2006 below at p.216).  
Moreover, on the basis of preclinical studies with rodents (Olney and Farber, 1995; Olney et 
al., 1999), it is the kind of damage that might be expected to arise from relatively focal 
damage to the parietal lobe caused by glutamate excitotoxicity, which can arise by various 
means, but would be also consistent with NMDA receptor hypofunction hypothesis of 
schizophrenia.  It might also offer one explanation of intellectual superiority favouring PIQ 
in some participants.  However, this might conflict with the evident sparing of language 
comprehension and speech production in the TRS group, as demonstrated by normal 
performance on the category fluency task, as this might be predicted to be impaired if there 
is damage in the vicinity of the inferior parietal cortex, including the posterior cingulate and 
areas proximal to temporo-parietal junction and fibre tracts of the arcuate fasciculus with its 
different segments (described in Catani and de Schotten, 2010).  However, on the basis of 
DTI and fMRI analysis, it was recently proposed there is a ventral route involving the 
extreme capsule that connects the middle temporal area with the ventrolateral prefrontal 
cortex and enables the mapping of meaning to sound, complementing the dorsal route which 
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might be at greater risk under this scenario (Saur et al., 2008; Hickok and Poeppel, 2004; 
Makris et al., 2009).  The dorsal route may specialise in conveying “sub-lexical” 
information, “mapping sound to articulation” and complete disconnection of this pathway 
may result in conduction aphasia where it is not possible to repeat words but is possible to 
produce unintended utterances and meaningless sounds (i.e. paraphasias and “word salads”), 
however, it is proposed here that more subtle phonological impairment might be possible 
including defective or inefficient phonological encoding or storage which would undermine 
the usefulness of recency.   
  
Yet the HVLT-R was not designed to examine recency and it is necessary to consider 
alternative explanations, one possibility might be that participants exhibited behavioural 
inflexibility or inefficient strategies, which Kristian Hill et al. (2004) noted has been 
observed in the schizophrenia literature.  For example, some participants may have preferred 
to learn and reproduce list items in the same order as they were presented, despite the 
instruction that items could be recalled (consistent with this, there is a hint of a recency 
effect around the fifth item in Figure 3. 7, a typical limit for STM capacity, e.g. Miller, 
1956;  Cowan, 2001).  Moreover, they did not change strategy when the list was repeated.    
However, the summary of frequencies with which the first three words were recalled in the 
order of their list positions in Table 3. 10 indicates serial recall was not a common strategy.   
 
Possibly a more effective challenge to the proposal that the recency effect was attenuated in 
the TRS participants, may come with the characteristics of the words in the test list. In 
particular, it begins with the low frequency word ‘Lion’, however, this is also acquired early 
in the childhood lexicon and so is more likely to be recalled (Morrison et al., 1992).  The 
majority of individuals (66.7%) started recall with this word, so perhaps, primacy plus early 
age of acquisition were sufficiently salient to focus attention upon the start of the list, 
although, this is not necessarily a refutation of the lack of recency as the last two or three 
words should still have been available in a transient auditory store. 
 
The area associated with phonological store in the inferior parietal lobe and left temporo-
parietal area (Baddeley, 2007; Warrington, Logue, and Pratt, 1971) is also proximal to the 
posterior cingulate cortex, an area revealed in preclinical rodent studies to be exceptionally 
vulnerable to glutamatergic damage.  Applying a glutamatergic hypothesis, such a deficit 
might have been predicted in TRS because of preclinical studies which helped to inform the 
second hypothesis that cingulate gyrus may be implicated, for example, damage was 
demonstrated to occur in the posterior cingulate at a lower dose of NMDA receptor 
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antagonist than other areas affected by “a neuron-necrotizing reaction” (Olney and Farber, 
1995). Further, in Olney et al. (1999):  
 
Multipolar and pyramidal neurons in the occipital cortex were also susceptible to 
degeneration, along with “At risk populations” which included “pyramidal and multipolar 
neurons in the prefrontal, posterior cingulate and retrosplenial, occipital, temporal, parietal, 
entorhinal, perirhinal and piriform cortices and in the anterior olfactory nucleus, taenia tecta, 
amygdala and hippocampus. (p.525) 
 
In a “festschrift for cognitive neuropsychology”, Vallar (2006) observed “A defective 
recency in free recall of auditory-verbal lists is a hallmark of the impairment of the 
phonological short-term store” (p.141)  Auditory presentation might have been expected to 
“load” the phonological loop/ store automatically (Baddeley and Hitch 1974), but just as 
Vallar (2006) also observed “There may be no advantage in rehearsing items held in a 
damaged store”, recency might not have been used as a strategy because it was not generally 
helpful.  This could have something to do with the quality of encoding in this modality.  
Selective impairments in auditory verbal short-term memory (Warrington, Logue, and Pratt, 
1971) may be rare but more subtle auditory perceptual deficits could be associated with 
damage to the parietal lobe.  Alternatively, deficient sensory gating, possibly linked to 
abnormal GABA levels, might offer an explanation for subtle perceptual deficits and 
inefficient encoding.  
 
4.2.10  Might visual learning/short-term visual memory involve “activated LTM”? 
The proposal that the short term retention of words and morphemes can rely upon the 
temporary represented crystallised knowledge might be regarded as “activated LTM”.   
There was corresponding correlation between spatial span scores (a putative measure of the 
visuo-spatial sketch-pad).  However, this may be more difficult to understand with the 
abstract visual stimuli in the BVMT. 
 
Certainly, a verbal strategy might be applied to some stimuli as they are composed of 
geometric shapes which could be associated with spatial locations, or perhaps, given labels 
according to passing resemblance to objects, however, the test was presumably designed to 
minimise these strategies.  One possibility that the association between visual learning and 
verbal learning is mediated by fluid intelligence (which seems quite possible given the 
strength of correlations between PIQ and verbal span, between visual learning and verbal 
span and between visual learning and PIQ (Table 3. 9).   
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Alternatively, it is suggested here, short term visual learning could be related to “activated 
LTM” at the level of “elements” of “micro-features” possibly represented in connections 
between assemblies of cells in the visual association cortex. 
 
4.2.11  Testing the correlations: were negative symptoms associated with 
correlates of attention rather than higher cognition? 
Figure 3. 3 and Table 3. 19 indicate the presence of a small group of VIQ>PIQ individuals 
could act as a confound in the data.  (This was also evident in Figure Appx. 5. 5 depicting 
correlations involving asymmetry between WASI subscales and proposed markers of 
attention (CPT-IP and 0-Back SDs) where it can be seen on the right-hand side the four 
VIQ>PIQ individuals are acting as a polarising influence.  (Also see Table Appx. 5.2). 
 
Some post hoc correlations were explored on a reduced set of participants that excluded the 
four VIQ>PIQ individuals.  The overall observation was that the removal of this group 
weakened some correlations and strengthened others, however, they mostly remained 
significant or acquired significance.  A signficant negative correlation between negative 
symptoms and VIQ disappeared in the reduced set, possibly because the VIQ>PIQ group 
had been a polarising influence since they had a low level of negative symptoms and high 
VIQ scores.  The weakening of correlations in the reduced set in several instances (see 
Table Appx. 5. 2) might be explained by reduced power.  However, some correlations were 
considerably more significant in the reduced set, for example, symbol coding and verbal 
learning which correlated positively with PIQ, while the percentage of omission errors 
correlated negatively with VIQ only in the reduced set.  Similarly, a negative correlation 
between trail making and PIQ was significant only in the reduced set.   
 
The most striking correlation to newly acquire significance in the reduced set was a strong 
positive correlation between the CPT-IP and PIQ, with a large effect size so that better 
performance on this measure of sustained attention/vigilance was associated with higher 
PIQ scores (VIQ>PIQ individuals had marked decrements in their PIQ scores).  Similarly, 
an inverse correlation between another putative marker of sustained attention, 0-Back SDs 
with PIQ was significant only in the reduced set, again with a large effect size.  Therefore, 
correlations between the attentional markers of CPT-IP score and 0-Back SDs with PIQ 
appear to have been confounded by the presence of 4 VIQ>PIQ individuals who performed 
well on attentional measures yet had relatively poor performance IQ.  As noted above, the 
inverse correlation between negative symptoms and VIQ was only significant in the full set 
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(Table 3. 18, p.161 compared with Table Appx. 5. 2, p.360), while there were no significant 
correlations between negative symptoms and PIQ in the full or reduced set of participants. 
From this it might be inferred higher PIQ scores (and, perhaps, by extension fluid 
intelligence) were associated with the better application of attention;  however, the absence 
of a correlation between PIQ and negative symptoms which correlated with other variables 
associated with attention (Table 3. 17, Figure 3. 11) is worth noting.  Apart from the inverse 
correlation between negative symptoms and VIQ which depended on the presence of the 
VIQ>PIQ group, it would seem that negative symptoms were generally associated with 
putative markers of attention rather than higher cognitive functions.  This was supported by 
a lack of significant correlation between negative symptoms and the tests on the MCCB, 
whether in the full or reduced sets.   
 
Consistent with this interpretation, the only exception was a strong negative correlation 
between negative symptoms and performance on the test of sustained attention/vigilance 
(CPT-IP).  While there was the very strong correlation been CPT-IP with PIQ that emerged 
in the reduced set, negative symptoms and 0-Back SDs still did not correlate with PIQ.  
These associations may be mediated by different biological factors as it is observed that the 
CPT-IP is a test of selective attention as well as sustained attention (whereas, it is proposed 
that the simpler 0-Back condition may be a purer test of sustained attention).  As selective 
attention requires the inhibition of distractors (which may be perceptual or occurring at 
higher levels of representation), neuromodulators such as dopamine and GABA could be 
more effective in the 0-Back condition as there is less perceptual load and the pace of 
presentation is slower than in the CPT-IP. 
 
However, to consign negative symptoms to an attentional factor that has little bearing on 
higher cognitive function could be a mistake, since the presence of negative symptoms are 
associated with worse functional outcomes (Rabinowitz et al., 2012), also they may have 
been generally too low in this group to have an influence.  Moreover, an association 
between negative symptoms and the sensory gating of visual information has been observed 
in studies using backward masking where it has been observed that longer periods may be 
required for the processing of early visual information in schizophrenia (Herzog and Brand, 
2015; Greene, 2007; Shaqiri et al., 2015).  Interestingly, in the latter study, nicotine was 
observed to ameliorate age-related deterioration in backward masking.  It has been further 
proposed an imbalance in the GABAergic system might underlie these “gamma oscillations 
in the somatosensory cortices may be associated with the SG [sensory gating] ability and 
behavioral performance of response inhibition” although the evidence base is currently 
weak (Cheng et al., 2016, p.20437).  However, it would seem clozapine has the potential to 
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improve this through actions at D4 receptors which are highly concentrated in the 
hippocampus (Andersson et al., 2012). 
 
However, it should be considered that the CPT-IP was not tested on a TRS population, 
along with the incidental observation that some participants complained they felt 
uncomfortable (one mentioned “flickering”).  Clozapine has been reported to improve 
sensory gating deficits (Micoulaud-Franchi et al. 2015) but the difficulty observed in this 
study could indicate problems may persist even after clozapine treatment has commenced. 
Alternative explanations include undetected problems concerning the computerised display 
or lighting conditions, however, as observed in the introduction, perceptual deficits have 
been frequently observed in schizophrenia yet appear to be routinely overlooked.  It is 
proposed that early sensory deficits could have a profound effect on signal detection and the 
quality of subsequent encoding.  This is turn might affect the trade-offs between processing 
and capacity. This is a different kind of hypothesis (although not a mutually exclusive one) 
from the initial one that proposed hyperactivity in the DMN (or a preoccupation with the 
“inner world”) might be related to negative symptoms which, in turn, might cause 
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4.3   The Neuroimaging Study  
4.3.1   Hypotheses 
The main hypothesis of the fMRI study was that TRS participants would, during the 
performance of a verbal n-back task, show attenuated activation in a fronto-parietal network 
similar to that described for healthy controls in previous studies. The second hypothesis was 
that brain areas exhibiting altered haemodynamic response would include the cingulate 
gyrus and would be associated with task performance and symptom severity.  That 
hypothesis was informed by emerging evidence that a dopaminergic theory involving 
hyperactivity in the striatum may be an unlikely candidate for the aetiopathology of TRS, 
rather a glutamatergic hypothesis might provide a better account.  The early seminal papers 
in this area are based on preclinical studies by Olney and colleagues which were specifically 
motivated by the problem of persistent negative and cognitive symptoms after more florid 
positive symptoms have resolved and therefore seem particularly pertinent to TRS.  
 
These highlighted the physical vulnerability of various areas in the rodent brain to glutamate 
excitotoxicity consequent upon antagonism at the NMDA glutamate receptor causing 
transient reactions or more permanent cell loss but without pathological hallmarks such as 
glial scarring (see Najjar & Pearlman, 2015; Vostrikov et al., 2007, 2008).   The most 
vulnerable areas appeared to involve midline structures including the cingulum, but perhaps 
especially the posterior cingulate.  Further, clozapine was demonstrated to prevent these 
effects (Olney and Farber, 1994, 1995; Olney et al., 1999).  While there are profound 
differences between the rodent and human brain, if demonstrated in the human brain, a 
pathological focus involving the cingulum and perhaps the corpus callosum inferiorly may 
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4.3.2   Results of factorial analysis 
The results of factorial analysis revealed that the group with the higher level of pathology 
(TRS participants relative to controls) displayed attenuated haemodynamic responses with 
increasing cognitive load.  In the factorial analysis concerning the TRS and control 
participants, these were observed in the in the right middle frontal gyrus, left superior frontal 
gyrus, right thalamus, left middle temporal gyrus and parahippocampal gyri bilaterally, the 
right parietal lobe, right precuneus and left lingual gyrus (Figures 3.22, 3.24, 3.25, 3.27). 
  
A consistent pattern of attenuation was also observed concerning decreases in the 
haemodynamic response with increasing cognitive load in the TRS group.  These decreases 
are described as increases in the haemodynamic response as this is relative to the control 
group which exhibits progressive decreases in the haemodynamic response with increasing 
cognitive load.  Significant contrasts were observed in in the left medial frontal gyrus, and 
left superior frontal gyrus, the left anterior cingulate, right putamen, left cingulate gyrus 
(posteriorly), left paracentral lobule.  In the figures depicting these, there often appears to be 
little or no change from the baseline as cognitive load increases in the TRS group (Figures 
3.20, 3.21, 3.23, 3.26).   These contrast with the progressive reductions in the 
haemodynamic response observed in the control group in the same figures.   
 
Similarly, in the factorial analysis concerning the higher PANSS and lower PANSS groups, 
the higher PANSS group exhibited an attenuated increase in the haemodynamic response 
with increasing cognitive load in the left claustrum, left middle frontal gyrus, left inferior 
frontal gyrus and left supramarginal gyrus (Figures 3.29, 3.31).  While an increased 
haemodynamic response was observed in the left superior frontal and right medial frontal 
and right postcentral gryi, where, a marked attenuation relative to the baseline task, was 
again observed in higher PANSS group (Figure 3. 30). The right postcentral gyrus in the 
parietal lobe exhibited the largest cluster size (482 mm3) in this factorial analysis and so 
might be implicated in DMN activity (Table 3. 25).  While the relatively smaller clusters (57 
mm3 and 50 mm3) in the left superior and right medial frontal cortex might be described as 
the DLPFC (BA 9), the medial location of the clusters suggest they are part of the medial 
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4.3.3   The implication of connector hubs in large-scale networks 
In addition to the consistency of the pattern and widespread nature of the foci, a further 
striking aspect of the contrasts between control and TRS participants is that all the areas  
(at the subcortical as well as cortical level) appear to be important hubs for information 
processing that have been identified through graph theoretical approaches applied to 
structural data (e.g. from DTI) and functional MRI.  Hub areas are characterised by having a 
high number of connections with other highly connected hubs (forming “rich clubs”) and 
other nodes in the network. They also exhibit high “betweenness centrality” and shorter path 
length.   As summarised by Bullmore and Sporns (2012), an important aspect of this 
topological organisation is to facilitate communication between areas in a parsimonious way 
which minimises “wiring costs” as from a metabolic perspective, long range connections 
between nodes whether structural or functional, are expensive to build and maintain. They 
are also likely to be heavily myelinated in the mature brain as maintaining ion gradients 
across membranes involves a high degree of energy expenditure.   
 
Moreover, at the cortical level, there is also very considerable agreement between the areas 
of differential activation in this study with those areas identified by Fornito et al. (2011), in 
a twin study of resting state connectivity, as areas having a high degree of heritability.   
Long range connections enable integration across specialised modules, as typically required 
by higher cognitive function, but in view of their “wiring cost” it is hypothesised that 
evolution will only favour connections which have proven adaptive value.  These arguments 
are presented in Bullmore and Sporns (2012), who also present an image from Fornito et al. 
(2011) showing areas of high heritability.   
 
The TRS group exhibited heightened activity in the default mode network, and the resulting 
dominance might present an ongoing source of distraction during the performance of the  
n-back task, resulting in microlapses in attention and contributing to longer and more 
variable latencies in the clinical group.  This idea is highly similar to one about behaviour 
between networks advanced by Kelly et al., (2008).  Such a habitual state might also weaken 
some connections while strengthening others making it more difficult to disengage the 
DMN and possibly to avoid an impasse, it may be necessary to be able to shift attention 
between networks by various mechanisms (apart from the usual desirability of having 
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The default mode network was identified only fairly recently, first using PET (Raichle et al., 
2001) and then resting state methodologies (Greicius et al., 2003) and is defined as a set of 
areas that are more active when an individual is resting with eyes closed or engaged in 
inwardly oriented activities such as planning or day-dreaming.  This has lead to a pardigm 
shift, closely followed by theories about communication across and between large-scale 
networks through oscillatory rhythms (Raichle, 2009; Buzsaki and Freeman 2015). 
 
Subcortically, the thalamus has long been recognised as an important relay hub in striatal 
circuitry.  Not only does it relay information from cortical areas, but it also sends 
information from the cerebellum, brainstem, autonomic and endocrine systems.  As part of 
the striatum, the right putamen also has an important role in relaying information (van den 
Heuvel, & Sporns, 2011). 
 
Helpfully, in this study all but one TRS participant, successfully performed the n-back task 
at the highest level of cognitive load.  Also, significant differences between the TRS and the 
control group only emerged when factorial analysis included the highest level of cognitive 
load.  This may help to explain the continued dearth of studies on TRS, as previously 
mentioned, Nakajima et al., (2015) found only 5 studies comparing TRS and with healthy 
controls, of which only one was an fMRI study (by Fitzgerald et., 2007, involving 3 
participants described as having treatment resistant auditory verbal hallucinations).     
 
This study further highlighted significant differences between the lower and higher PANSS 
groups even though the range of symptom scores was fairly limited.  Important connector 
hubs areas were again apparent. The higher PANSS group exhibited an attenuated 
haemodynamic response with increasing cognitive load in the left claustrum and left frontal 
gyrus relative to the lower PANSS group (Figures 3.29, 3.31), as well as an increased 
haemodynamic response in left superior frontal, right medial frontal and right postcentral 
gyri (Figure 3. 30). These results show a common pattern in the haemodynamic response in 
all the contrasts – that of stronger activation or deactivation relative to within group 
baselines in the control group relative to the TRS group and, similarly, in the lower PANSS 
group relative to the higher PANSS group.  This is interpreted as indicating pathology or 
higher pathology may result in an attenuated response.   
 
Of particular interest is the left claustrum with a peak which appears near fibres of the 
anterior limb of the internal capsule.  This has extensive long-range functional connections 
with virtually every part of the brain, however, it rarely appears as an area of differential 
activation in the literature, possibly, because it may be difficult to distinguish from other 
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structures with which it may co-activate and also by virtue of its long, thin shape.  The 
extensive connectivity and proximity to the key nodes of the salience network (insula and 
anterior cingulate cortex) could provide an important compensatory function in the lower 
PANSS group by helping to support activity in other areas (also see 4.3.5 below). 
 
With respect to networks, it is apparent that apart from areas associated with particular task 
positive activities such as the premotor area BA 6, and the cognitive control network 
characterised by interactions between frontal and parietal areas, the major nodes of the 
DMN, including the medial temporal lobe network appear to be present (Andrews-Hannah 
et al. 2010;  2014). 
 
The pattern of attenuation has many potential explanations, some of which are compatible 
with the literature in schizophrenia such as impaired connectivity and glutamatergic 
theories.  However, simpler explanations may also apply involving artefacts or side effects 
of medication with clozapine.  However, as there is a dearth of literature in this area and a 
virtual absence of peer-reviewed neuroimaging studies, this study is largely exploratory and 
perhaps its value may lie in the generation of hypotheses of which there are several.   
 
One explanation for the observed haemodynamic patterns could lie with glutamate NMDA 
receptor hypofunction on GABAergic interneurons as Anticevic et al. (2012) observed 
similar attenuation in selected areas following the administration of the glutamate receptor 
antagonist, ketamine, in healthy volunteers.  As previously mentioned (section 1.5.2) 
ketamine may exacerbate or reinstate symptoms in schizophrenia (Krystal et al., 1994).  
Also, in Honey et al. (2008) a high dose of ketamine induced negative symptoms in healthy 
individuals.  Further, marked alterations in the fMRI response in fronto-thalamic circuity 
were observed when ketamine was administered at a lower dose: with an increase in activity 
in the thalamus, bilateral caudate and right putamen. 
 
There may be further compatibility here with a resting state connectivity study of 250 
healthy individuals by Manza et al. (2015) who observed the putamen, along with the 
pallidum exhibits negative connectivity with key nodes in of the DMN (posterior cingulate 
and ventromedial prefrontal cortex), and so anticorrelation which was interpreted as 
supporting the “task positive network” (which includes the somatomotor cortex), which 
declined with age.  (This is reminiscent of Marsman et al.’s (2013) meta-analysis on 
glutamate deficits in PSZ which exhibited acceleration with age). 
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Observations of abnormal glutamate function in TRS individuals do, of course, invite 
consideration of TRS in terms of glutamatergic theories, perhaps, especially when the case 
for a dopaminergic one is unclear (although of course, shared or inter-related circuitry may 
be involved).  Convergent evidence of potential glutamatergic damage within this study, 
might be found in the observation of a lack of a recency effect in immediate free recall in 
the post hoc analysis of performance by TRS group in the HVLTR, as discussed in section 
4.2.9 above.  This theorising around glutamatergic theories is highly speculative, however, 
further indirect support could come from functional connectivity resting state studies 
(possibly the only ones of TRS to date) by Wang et al. (2015) and Ganella et al. (2017, 
2018).   Both observed decrements in connectivity in TRS individuals relative to controls 
and Wang observed some unique connections that were specific to unaffected first-degree 
relatives that were not present in the control or TRS group and so were proposed to be 
potentially compensatory.  However, it was the increases in local efficiency which were 
interpreted as a possible compensatory strategy by Ganella et al. (2018) that might be 
deployed in a different argument as it was accompanied by decrease in global efficiency:  
the local increase would be predicted to arise in the event of disruptions to large scale 
networks as a result of topological reorganisations to optimise the organisation of the brain 
with respect to the brain’s “energy budget.”   
 
However, there are other explanations for the observed pattern of attenuation.  Energy 
deficits of another kind, for example, arising from a thyroid hormone deficiency (not 
uncommon in psychiatric populations).  A more likely factor in this context might be the 
development of a degree of insulin resistance as a side effect of clozapine (hyperglycaemia 
is a common side effect).  Hyperactivity in the DMN has been observed in the context of 
metabolic disorders e.g. Cha et al. (2015).  Similarly, anything else that might compromise 
energy might be expected to affect core hubs and attenuate activity, for example, drowsiness 
can be caused by clozapine.  Moving on to the realm of potential artefacts that might give 
the appearance of attenuation, the groups were not matched for IQ and so, while the TRS 
individuals exhibited normal estimated IQ scores overall and included some very high 
functioning individuals, this data was not collected for the control group. 
 
A further possible limitation is that errors were not modelled in the analysis in the interests 
of conserving data, nor were d’prime values used.  Fortunately, the error rates were very low 
in the control group and also in the TRS group with most errors occurring on the second 
trial of the 3-Back condition, which is interpreted as indicating participants were trying to 
perform the 3-Back task although their strategy was less successful at that point.  A more 
detailed consideration of all the above will follow.
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4.3.4   The Insula and Anterior Cingulate Cortices 
Maintaining a rostral focus, linear trend increases were observed with increasing cognitive 
load in the insula (BA13) in the right hemisphere in the control group, and in the TRS group 
bilaterally (the co-ordinates of the peak maxima in the left insula were highly similar to 
those for the left caudate body).  The insula which is recognised for a role in interoception is 
also a key node of the salience network along with the anterior cingulate cortex.  However, 
an increase in the ACC with increasing cognitive load was not observed in either group, 
although a sizeable area of deactivation (708 voxels) was observed in the TRS group (Table 
3. 23) but not in the control group.  This could potentially reflect a failure in the monitoring 
function of the ACC at more difficult levels of load in the TRS group.   
 
It would be wrong to assume the ACC is not activated during performance of the baseline 
task as there are still speed/accuracy trade-offs to be made, so decreasing activity with 
increasing cognitive load could reflect a fatigue effect or, possibly, the irrelevance of ACC 
activity at more difficult levels of the task in TRS individuals, so it might fall away on the 
basis this is an ineffective use of resources.  A similar argument was used by Callicott et al., 
(2003), when they observed an inverted-U of activity in the DLPFC as the capacity of 
working memory was exceeded.  Consistent with this, individuals with schizophrenia who 
exhibited superior performance also demonstrated increasing activity in the DLPFC like 
controls rather than exhibiting “hypofrontality” that had been widely described.  However, 
there are no significant within group activations above baseline in either group in the tables 
of Appendix 2, so the “falling away” argument seems unlikely in this instance.  
 
An alternative idea to this last proposal is that there is a deliberate suppression of activity in 
the ACC with increasing cognitive load because this provides a source of distraction, 
perhaps, even more so if it is bilateral.  This seems possible given the “alerting role” 
ascribed to the salience network as proposed by Menon and Uddin (2010) who proposed the 
networks responds to the “bottom-up” detection of salient events and facilitates the efficient 
allocation of cognitive control and attention.  This may involve rapid switching between 
large-scale networks (e.g. between “task positive” and DMN activity).  It may also require 
the rapid mobilisation of motor responses as reflected in a strong functional coupling 
between the ACC and motor cortex.  Therefore, it seems plausible, if there were a lack of  
selectivity in the salience network this might interfere with the efficient deployment of 
attention and processing resources.  This could be consistent with observations of 
hyperactivity in the ACC in TRS (Mouchlianitis et al., 2016 (a), except that most of the TRS 
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participants in this study had been medicated with clozapine for a long period and it is 
proposed elsewhere in this thesis this may have helped to “normalise” neural activity.   
 
4.3.5   The Claustrum 
A linear trend of increasing activation with cognitive load was observed in the left claustrum 
(anteriorly) in the control group, but not in the TRS group.  The rostral locus of this cluster 
suggests a proximity to other structures engaged in higher cognitive processing as, in the 
“economy” of the brain’s organisation, such relationships may not be coincidental 
(Bullmore and Sporns, 2012).  
The claustrum is a subcortical structure that is connected with virtually every part of the 
cortex.  It is packed with GABAergic parvalbumin-positive interneurons and claustral 
projection neurons.  However, synaptic connections between the latter are rare, suggesting it 
may be unsuited to integrating multisensory information within the claustrum (Kim et al., 
2016, p.781).  Rather, they suggest this architecture may be sensitive to correlated inputs 
and so may respond to novelty.  It may also amplify activity.  This is consistent with 
proposals that the claustrum may detect fairly non-specific but salient changes in the 
external environment (Remedios, Logothetis and Kayser 2014);  also see Goll et al. (2015), 
who observed claustral neurons appear especially responsive to step-wise changes in 
sensory inputs.  Goll et al. (2015) further proposed the claustrum could help to “decide” 
between competing activations in different cell groups, possibly in different modalities, that 
are demanding attention.  It is suggested here that all these features may enable the 
claustrum to modulate the signal, for example, by decreasing interference and possibly 
enhancing other aspects during the performance of the n-back task (also see correlation with 
0-Back SDs, Figure Appx. 6. 4).  Therefore, it might help the integration of information but 
through activities beyond the structure of the claustrum itself.  This is compatible with 
Meletti et al. (2015) that the claustrum is a “highly relevant hub centre in neural 
synchronization of several (and distant) cortical areas” (p.1230)  As such it can “potentially 
bind together and modulate neural activity”.  However, the lack of significant activity in the 
claustrum in trend analysis for the TRS group might suggest that either participants could 
not perform the highest level of the task (it is suggested the error data does not support this 
interpretation), or perhaps, the long-range connections intercepted by the claustrum are less 
effective.  This may be consistent with the proposal that the communication and integration 
of information across long range connections may be compromised in TRS, although, as 
explored in the introduction there may be numerous ways this might arise. 
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4.3.6   Other Middle and Superior Frontal Areas 
In the TRS group, apart from BA9, clusters of significant linear activation were also 
observed in middle frontal gyrus bilaterally, described as Brodmann area 10. A further 
cluster was observed in BA8 in the superior frontal gyrus in the right hemisphere. All these 
areas are considered to be part of the prefrontal cortex.  Increasing activation was also 
observed more posteriorly in the premotor cortex in the right BA6 (middle frontal gyrus), 
and left BA6 (precentral gyrus and in a proximal sub-gyral location).  These latter 
activations may have been related to motor activity, for example, even a simple action might 
require more cognitive effort because of the need to inhibit responses to distractor stimuli 
held in working memory; or perhaps, because of more general depletion of resources 
associated with meeting demands associated with higher levels of cognitive load.   
 
In both groups, sizeable clusters, also in BA6, were observed with peak maxima in the 
longitudinal fissure and described as the medial frontal gyrus, which is an important hub in 
the DMN.  In the control group, this was ascribed to the right hemisphere, and in the TRS 
group to the left hemisphere.  However, a linear increase in activity in the medial prefrontal 
cortex with increasing cognitive load is at odds with classical descriptions of DMN activity 
(Fox et al., 2005), so this activation is perhaps more compatible with the BA6 designation, 
but it might also reflect the supplementary motor area (SMA) which has a more medial 
location within BA6 and is superior to the dorsal ACC.  The reliability of activation in the 
right SMA (regardless of the sensory modality of a stimulus) with co-activations in the right 
temporal parietal junction, the inferior frontal gyrus, anterior insula and anterior cingulate 
led Corbetta and Shulman (2002) to propose a ventral-fronto-parietal attentional system 
based in the right hemisphere which processes “bottom up” information and has an alerting 
role which may interrupt processing under the control of more consciously directed 
attention.  However, evidence from intrinsically defined networks has since indicated the 
SMA may be involved in the bilateral “top-down” dorsal attention system (Fox et al., 2006).  
What is clear, however, is that the premotor cortex and SMA (BA6), the dorsal ACC and 
DLPFC have been shown to be typically activated in the within group analyses of executive 
tasks, including the n-back (Minzenberg et al., 2009). 
 
4.3.7   The Medial Prefrontal Cortex (“proper”) 
While the labelling of clusters in BA6 has been questioned above, this is not the case for 
those described as the medial prefrontal cortex showing a negative linear trend in activation 
in the left BA8 (Table 3. 23) and left BA10 (Table 3. 21) in the TRS and control groups 
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respectively.  These relative deactivations are consistent with classic descriptions of DMN 
nodes (Raichle et al., 2001; Andrews-Hanna et al., 2010);  for example Fox et al. (2005), 
classically described the DMN as involving decreasing activity in a “set of regions, 
including posterior cingulate, medial and lateral parietal and medial prefrontal cortex” 
(p.9673) during cognitive tasks which are demanding of attention. 
 
4.3 8   Broca’s Territory 
As sub-vocal articulatory rehearsal might be expected to support successful performance in 
the n-back task, it might be predicted that trend analysis would also reveal increasing 
activation in Broca’s area (BA44, and BA45, in the dominant (left) inferior frontal gyrus).  
However, neither area was significant in the TRS group, while activity in a relatively small 
cluster with a peak maxima lateralised in the right inferior gyrus (BA 9) in the control group 
seemed an unsuitable candidate as the participants were right-handed.  However, the lack of 
significance in the trend analysis may not be anomalous because in meta-analyses of 
executive function involving healthy individuals, or those with schizophrenia (Owen et al., 
2005; Minzenberg et al., 2009), Broca’s area rarely achieves prominence, although this may 
be present in individual studies e.g. Chen and Desmond (2005).   
 
4.3.9   Wernicke’s Territory 
Similarly, Becker et al., (1999) questioned the assumption that a phonological store 
supporting working memory might be localised to the supramarginal gyrus (BA 40) in the 
vicinity of Wernicke’s area and the angular gyrus (BA 39) in the dominant hemisphere.  
Inconsistent or weak observations might in part be explained by difficulties in localising 
activity in areas subsumed by large clusters;  also more recently, tractography studies have 
shown fibre tracts with terminations outside the language areas they classically link, which 
is why Catani and Thiebaut de Schotten (2012), prefer to use the term “territory” when 
referring to Broca’s and Wernicke’s areas.  Further elucidation of the circuitry has been 
provided by Fegen et al., (2015) who concluded the middle frontal cortex and the superior 
parietal lobe respond to load in verbal working memory (observations which hold for both 
groups in this study).  Additionally, they identified activity in a circuit involving a parietal-
temporal area around the Sylvian fissure which showed linear load effects but was also 
affected by rehearsal rate.  The nodes in this circuitry included the inferior frontal gyrus,  
possibly corresponding to Broca’s area, the premotor cortex and parietal areas - superior 
parietal lobule and BA7.  
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In these analyses, linear increases in activity with increasing cognitive load were observed 
in both groups in the right supramarginal gyrus (BA40), the right precuneus (BA19), the left 
inferior parietal lobe (BA40) and left precuneus (BA7).  These areas may be linked with the 
area of activation in the temporal lobe inferiorly by the arcuate fasciculus which has a rising 
middle segment. According to Catani and de Schotten (2012) p.241, the terminals of this 
pathway (which is also bundled with a long segment) extend beyond the classical language 
areas, including tracts within the middle temporal gyrus, i.e. beyond the confines of  BA 22 
which is traditionally attributed to Wernicke’s area, also beyond BA 44 and BA 45 which 
form Broca’s area, with terminations in the posterior middle frontal gyrus and inferior 
precentral gyrus.  Accordingly, increasing activity in these areas may reflect the engagement 
of circuitry associated with language processing and memory.  
 
Possibly consistent with the above, trend analysis also revealed linear decreases in 
activation in with increasing cognitive load in the right transverse gyrus (BA 41) in both 
groups.  This is primary auditory cortex, also known as Heschl’s gyrus.  As all participants 
were right handed this increased the likelihood that language would be left lateralised, 
However, arguments based on lateralisation may be confounded through enrichment by 
other sensory associations: from lip-reading to orthography; also, by the level of processing: 
from syntactic analysis of the “speech envelope” to the fine discriminations required for 
phoneme analysis.  All that will be ventured here, is that the progressive diminuation of 
activity in the contralateral hemisphere might decrease interference during phonological 
processing. 
 
4.3.10  The Precuneus 
The role of the precuneus is far from understood and as with its neighbour, the PCC, it is 
likely to be very important because of its position in a highly protected area within the 
medial fissure and towards the back of skull (where it slopes) so is less likely to suffer 
damage during a fall.  Consequently, there has been a death of neuropsychological case 
studies to advance understanding.  However, there appears to be broad agreement the 
precuneus has a high degree of connectivity with another highly protected area, the posterior 
cingulate cortex (Leech and Sharp, 2014).  This has led Andrews-Hanna et al., (2014) to 
describe this area as “the broader PCC” which they propose is an important zone of 
integration supporting bottom-up attention to behaviourally relevant sources of information 
drawn from memory and/or perception).”  While Fransson et al. (2008) observed “the 
precuneus/posterior cingulate is the only node in the default mode network that directly 
interacted with virtually all other nodes.”   
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The precuneus is known to be a projection target for serotonergic neurons and highly 
interconnected with other brain areas (Castellanos et al., 2008) and is accepted by many as 
an important node in the default mode network along with the adjacent posterior cingulate 
cortex inferiorly and the medial prefrontal cortex which is also a notable target of serotonin 
innervation.  The precuneus and the posterior cingulate cortex are linked by long range 
connections to the anterior cingulate cortex (Castellanos et al., 2008).  All these areas are 
implicated in the pathophysiology of schizophrenia. 
 
The precuneus also emerged as an area that correlated with the haemodynamic response in 
some BBAMs, for example, in the TRS group (Table Appx. 6.3) there were negative 
correlations between the haemodynamic response in the right precuneus (BA 31 and BA 7)55 
and the proxy variable of attention (SDs in the 0-Back condition), with greater activation in 
the 2-Back and 3-Back conditions being associated with better attention (indicated by lower 
mean standard deviations, as depicted in Figures Appx. 6.6 and 6.9).  Only three higher 
PANSS participants had values below the TRS group median 0-Back SDs.  In this analysis 
it was also interesting a negative correlation was observed in the claustrum in the 1-Back 
condition, another highly connected structure, that may have been performing a similar role 
to the precuneus.   At the highest level of cognitive load, a further negative correlation was 
observed with the medial frontal gyrus (BA 10), an important node of the DMN and, as 
mentioned above, a target for serotonergic innervation.  Taken together, these results 
suggest better attention/ cognitive control was associated with increases in the 
haemodynamic response relative to baseline in these important areas of the DMN.  
Similarly, in the corresponding BBAM correlation for the control group , there was a 
significant negative correlation in the haemodynamic response involving the right precuneus 
(BA7) in the 2-back condition with 0-Back SDs.  However, this was not significant at the 3-
Back level (Table Appx. 6. 4).    
 
 
55 This variation in labelling may not be troubling as this area lacks a distinctive cytoarchitectural 
boundary between the the mesial precuneus of BA7 and BA 31 - the latter being described by Cauda 
et al., (2010) as a transition area between BA 7m and BA23c.  Cavanna and Trimble (2006) elaborate 
further, describing a gradually changing gradient (in a rostro-caudal direction):  the medial surface of 
the precuneus has fully differentiated isocortex with prominent layers 11, 1V, V and V1 and a 
columnar organisation, whereas the precuneus more mesially, the retrosplenial and posterior 
cingulate cortices are thinner. The resulting diversity of the cytoarchitecture may also reflected by 
extensive cortical and subcortical connections, accompanied by the fractionation of this area into 
several subdivisions.  
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To summarise, negative correlations were observed between activity in the right precuneus 
in the control group during the 2-back condition and in the clinical group in the 2-back and 
3-back with a proxy measure of attention.  Less responding variability in the baseline task 
was associated with greater activation in these areas.   
 
There may be some hazard related to using a proxy variable that will also correlate 
indirectly with the neural activation in the experimental condition because it is likely to be 
related to the baseline neural activations from which the experimental activations are 
subtracted.  However, an investigation of standard deviations and/or reaction times may also 
be warranted because responses in the TRS group were slower overall and this could impact 
upon the fMRI BOLD signal markedly.  Parasuraman and Jiang (2012), for example, 
observed less neural activation in executive function paradigms in healthy individuals who 
were fast and accurate compared to those with slower and made more errors.  In one 
comparison between individual participants, increased activity could be partly explained by 
the further engagement of areas associated with conflict monitoring (the anterior cingulate), 
default mode activity (posterior cingulate) and areas associated with emotional regulation 
(subcortical limbic areas).  In another experiment with 30 healthy participants, they 
observed less activity in the precuneus in participants with superior performance - a result 
which contrasted with heightened activity in the precuneus that has been observed in clinical 
populations (Buckner, Andrews-Hanna and Schacter, 2008).  This pattern is consistent with 
an interpretation that equates slower and more erroneous performance with distraction, or, 
alternatively, weaker application to “task positive activity” due to hyperactivity in the 
default mode network.  It may also find some resonance with the observations in Honey et 
al. (2000) who observed in a verbal n-back study that healthy participants with slower 
reaction times also activated areas in the posterior parietal cortex bilaterally (although the  
Talairach co-ordinates were not similar to those reported here).  The co-ordinates for the 
precuneus in the TRS and controls in the correlational analyses with 0-Back SDs in the 2-
Back condition were more similar at x = 25, y = -67, z = 20 in the TRS group and x = 25, y 
= -59 and z = 30 in the control group, even though they were labelled as BA 31 and BA 7 
respectively (Tables Appx. 6. 2 and 6. 4). 
 
The replication between groups and across task levels of the negative correlation between 
activity in the right precuneus and mean SDs in the baseline task suggests it is robust and its 
presence at the more difficult task levels could indicate it is related to bringing more 
processing resources to the task or, perhaps, suppressing other areas of the DMN.  An 
alternative explanation for the absence of this correlation from the 1-Back condition, might 
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be due to a higher indirect correlation between this proxy variable (which may index 
inattention) and baseline activity in the 1-Back condition which is subtracted from the  
0-Back condition to produce the SSQ values.  However, this seems less likely as there is 
another significant negative correlation 1-Back condition in the control group (where 
reaction times and standard deviations in the baseline task had identical ranks):  the left 
transverse temporal gyrus (primary auditory cortex, Heschl’s gyrus) which, at first sight, has 
a more tenuous relationship with attention or default mode activity.  This correlation could 
reflect individuals in the control group responding to the phonological aspects of stimuli, 
either as an epiphenomenon (possibly detected because the signal is more discernible in this 
group), or as a verbally mediated strategy in the 1-Back task that assists performance. 
 
If the negative correlations between the right precuneus and average of standard deviations 
in the baseline task are not artefactual, this is actually in the opposite direction to what 
might be predicted as default mode activity generally anti-correlates with tasks which 
require engagement with the outer world and decreases further with increased task demands 
(Greicius et al., 2003; Ceko et al., 2015).  It is also contrary to the pattern described above 
by Parasuraman and Jiang (2012), and Buckner et al. (2008).  
 
A potential explanation may lie with this activity being related to an area of the precuneus 
(treated by Leech et al., 2011, as part of the PCC), which by virtue of its connectivity acts in 
a contrary way, has been described by several researchers.  Using resting state fMRI, Leech 
et al. (2011) showed complex interactions involving different parts of the PCC and other 
intrinsic connectivity networks, for example, the anterior (dorsal) PCC exhibited increased 
functional connectivity within the DMN and stronger anti-correlation with the frontal 
parietal attention network with increased task demands.  Whereas the posterior (ventral) 
PCC showed increased connectivity within the DMN when attention was internally directed.  
In other words, the anterior aspect of the PCC may be involved in suppressing the DMN 
while requiring it to be active in order to be suppress it, i.e. the DMN may have a role in 
suppressing itself.   The precuneus seemed to be involved in both functions 
 
These observations find considerable resonance with Utevsky 2014, who observed increased 
connectivity between the precuneus and the right frontoparietal (executive) network during 
task performance, and heightened connectivity between the precuneus and the DMN during 
rest.  This organisation is also recognised by Cauda et al., (2010) in their rsfcMRI study 
concerning four areas of the posteromedial cortex:  “The dorsal portion [of the anterior 
precuneus in BA 31 and the PCC in BA23] seems to be functionally associated with the 
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TPN, whereas the ventral portion, along with the retrosplenial cortex (BA 29 and BA 30), is 
selectively interlinked with the TNN” (p. e13107) 
 
Utevsky et al. (2014) describe Leech et al., 2011 as offering a “unifying” resolution of 
competing results, “by acknowledging that the precuneus is functionally variable, exhibiting 
connectivity with different neural networks according to task state or level of engagement 
with one’s surroundings and demonstrating that connectivity between the precuneus and the 
DMN reflects this level of engagement” (p.937) 
 
4.3.11  The Temporal Lobes 
Areas of increasing activation with cognitive load were observed in the temporal lobes with 
peak maxima in the middle temporal gyrus (left BA 21 and right BA20) in the control group 
and in the fusiform gyrus (left BA 36) in the TRS group (Table 3. 20).  In the trend analysis 
for the TRS group, the labelling of BA36 as the fusiform gyrus is slightly problematic as it 
is more usual to ascribe this label to BA37 (which is recognised for involvement in 
processing facial information), whereas BA36 is an area of dysgranular cortex (lacking layer 
IV cells), sometimes described as the ectorhinal area and part of the perirhinal cortex.  
 
BA36 (shown in Figure 3. 41 below) appears to be involved in coding recency or familiarity 
- as discussed by Davachi (2004) who cited studies which have observed a correlation 
between activation in the perirhinal cortex with item recognition or item familiarity - 
distinguishing it from activity in the hippocampus which is associated with conjunctive 
memory (or, “source recollection”).  The coding of recency or use of familiarity might also 
be a more apt considering the nature of the n-back, particularly as performance comes under 
pressure.  On the other hand, a case for the role of the fusiform gyrus in processing aspects 
of language has been advanced by Mechelli et al., (2000) who proposed the fusiform gyrus 
may specialise in the processing of local features of visual inputs, while the lingual gyrus 
(especially, the right medial posterior lingual gyrus) may be involved in the processing of 
the global features of words and objects, as demonstrated by greater activation during the 
processing of degraded stimuli such as might be found with reduced contrast).  Activation in 
either area might be expected to support processing during the performance of the n-back.  
Although the activity was only significant in the TRS group, this could reflect greater 
reliance on the processing of orthographic features rather than verbal mediation using 
articulatory rehearsal per se as cognitive load increases (a view that is reinforced by 
suspicions concerning the usefulness of the phonological store raised in the discussion of the 
recency effect in free recall (section 4.2.9).   By contrast, it may be relevant to note there 
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was a negative correlation for the control group in the left transverse temporal gyrus (BA 
41, Figure Appx. 6. 14) where greater variability in  0-Back SDs was associated with less 
activation in this area of primary auditory cortex during the 1-Back condition. While there 
was an opposite positive correlation in the right superior temporal gyrus (BA 38) which is 
located in the temporal pole (Figure Appx. 6. 11).  Its function remains obscure although a 
meta-analysis of 11 connectivity studies indicated in may be involved in language 
production and comprehension (Ardila et al., 2014). 
 
The reason for the increasing engagement of the BA19, in the right hemisphere in the TRS 
group and the left hemisphere in the control group is unclear (Tables 3. 22 and 3. 20).  In the 
analyses it was labelled as the precuneus within the parietal cortex, although BA19 is 
usually classified as part of the occipital cortex.  As can be seen in Figure 3. 41 on the 
medial surface BA19 is anterior to the cuneus and superior to the lingual gyrus - both areas 
are involved with visual processing.  However, consistent with the peak maxima and the 
parietal designation, activity in this cluster could related to multimodal integration.  On the 
other hand, the cluster in the control group might be discounted as an artefact as the peak 
maxima was 10mm away from the nearest gray matter, although this doesn’t explain the 
peak activation in the opposite hemisphere for the TRS group at similar co-ordinates. 
 
Figure 3. 41    Brodmann Areas 19 and 36 
 
  
By Brodmann - File:Brodmann_Cytoarchitectonics.PNG, 
Public Domain, https://commons.wikimedia.org/ 
w/index.php?curid=8284855 
By Brodmann - File:Brodmann_Cytoarchitectonics.PNG, 
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4.3.12  The Cerebellum 
In the trend analysis, increasing activation with increasing cognitive load was also observed 
in the cerebellum bilaterally for both groups.  Even though the cerebellum is well-known for 
its role in movement, it has been implicated in higher cognition for a long time because of 
neuropsychological studies concerning the effects of focal cerebellar lesions (Ravizza et al., 
2006).  More recently neuroimaging studies with healthy participants have demonstrated the 
cerebellum is reliably activated in verbal working memory tasks and this is also seen in the 
within-group activations at every level for both the control and TRS groups (Appendix 2).  
Increased activation with increasing cognitive load could simply reflect a greater rate of 
articulation or phonological mediation.  However, a model proposed by Desmond (1998), 
which found favour with Kirschen et al., (2005), distinguished between processing of 
articulatory control and phonological storage in superior and inferior cerebellar regions 
respectively in a WM task.  In addition to increases in cerebro-cerebellar activation with 
increases with cognitive load, they observed increased activity with practice (involving the 
right inferior cerebellum and left inferior parietal lobe), which might instantiate 
improvements in attention/ attentional control/ application of attention.  Therefore, it does 
seem likely that not only does the cerebellum support higher cognition, but function may 
also segregate with different areas.  Certainly, different parts of the cerebellum are 
associated with significant activations in these analyses but as the cerebellum has numerous 
divisions, this won’t be pursued further. 
 
4.3.13  The Posterior Cingulate (BA 30) 
The identification in the linear trend analysis of a significant positive cluster in the left 
posterior cingulate (BA 30) in the control group (Table 3. 20) was problematic for 
interpretation as this area, as part of the DMN, would have been expected to correlate 
negatively with increasing cognitive load.  However, inspection of the Talairach co-
ordinates of the peak maxima (x = -29, y = -70, z = 13) indicated a position in the 
retrosplenial area, proximal to the optic radiations and Brodmann areas 17 and 18.  This part 
of the posterior cingulate, posterior and inferior to the splenium of the corpus callosum, is 
also proximal numerous other fibre tracts.  Cauda et al. (2010), who conducted a systematic 
and extensive mapping of connectivity of the posteromedial cortex (PMC) in the resting 
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state56  affirmed correlations with a “task negative network” (equating to the DMN)57.  
However, their results also revealed a more nuanced pattern:  A high degree of 
interconnectivity was observed within the PMC, although the posterior part correlated more 
with BA 30 than BA 23;  however, BA 30, 31 and part of BA 23 were all “prevalently 
involved” with the DMN.  This was not invariably the case as indicated below: 
 
In our study, the retrosplenial cortex (BA 29 and BA 30) was characterized by selective 
functional correlations with the medial aspect of the temporal lobe and a number of 
subcortical structures, including the amygdala, the left nucleus accumbens, the left 
claustrum, and the caudate (left: positive correlation; right: negative correlation), and the 
dorsomedial thalamus (both positive and negative correlations).  Again, these results 
replicate with fair accuracy the connectivity patterns observed in the primate brain. (Cauda 
et al., 2010, p.9). 
 
Therefore, the increasing activation the left posterior cingulate cortex in a relatively small 
cluster (80 voxels) in the control group, could be explained by such variation in the 
connectivity of BA30 rather than being an anomalous observation.  It might also have arisen 
in relation to the significant clusters exhibiting a positive linear trend in the left claustrum 
and left thalamus because of the correlations uncovered in their analysis. 
 
4.3.14  Some correlations with the haemodynamic response 
Correlational analyses were conducted between the haemodynamic response and positive 
and negative symptoms.  These are reported in section 3.12.  As strategies and performance 
may tend to diverge among participants with increasing cognitive load, the correlations are 
likely to vary and lessen accordingly. 
 
Correlations between haemodynamic response and 0-Back SDs are discussed above in the 
section on the precuneus and wider posteromedial cortex (these are shown in Appendix 6).  
At first sight the unexpected observation of greater activation in the DMN nodes being 
associated with lower mean 0-Back SDs (suggestive of better attention) required 
explanation, however a reconciliation has been suggested by observations of increased 
activity in the DMN network while other areas are suppressed (section 4.3.10). 
 
56 Cauda et al., employed two different techniques which systematically explored the intrinsic 
connections of the posteromedial cortex with 10 “equispaced” regions of interest. 
 
57 The term was probably used instead of DMN as TTN activity anticorrelates with a “task positive 
network” (TPN) and is also discernible in spontaneous activations in the resting state. 
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Only one correlation was observed with positive symptoms, this indicated that greater 
suppression of the medial frontal gyrus in the 1-Back condition was associated with fewer 
positive symptoms.  This might indicate that positive symptoms are more likely to interfere 
with suppression of network activity. 
 
With respect to correlations with negative symptoms, a greater suppression of the medial 
frontal gyrus in the 2-Back condition and postcentral gyrus in the 3-Back was associated 
with a lower level of negative symptoms.  Both areas are associated with the DMN.  In 
addition, greater activation of the ACC and parahippocampal gyrus in the 3-Back condition 
was associated with fewer negative symptoms.  The involvement of the latter possibly 
suggests the involvement of memory processes, while the engagement of ACC would be 
predicted to facilitate performance.  Collectively, this suggests that better suppression of 
DMN areas is accompanied by greater activation in task positive networks, however, this 
may be weaker in the presence of a higher level of negative symptoms. 
 
Finally, significant correlations were observed in the core nodes of the salience network 
were observed in relation to estimated FIQ (Tables Appx. 6.5, 6.6).  
 
4.3.15  A General Conclusion  
It is tentatively proposed, the implication of highly metabolically active hubs may be 
suggestive of a general impairment affecting large scale networks. Further, the negative 
correlation in verbal and visual learning with increasing time to access a trial of clozapine 
from the point of diagnosis, could be compatible with progressive deficits in synaptic 
plasticity as proposed by Friston et al., (2016) and Stephan et al. (2009). Further, this might 
be consistent with a glutamatergic hypothesis/ cortical disinhibition model in the 
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4.4   Some Limitations 
Possibly the chief limitation of this study is the lack of a FLRS group for comparison with 
the TRS group.  However, given the heterogeneity of schizophrenia it may have been 
difficult to ensure they were appropriately matched.  In addition to age and gender, for 
example, it may have been helpful to match them on a primary characteristic like processing 
speed or estimated IQ.  The reason for the absence of inclusion of a clinical comparison 
group e.g. schizophrenia patients responding to first line antipsychotics, was a limited 
availability of funds to perform fMRI.  The absence of such a group represents a main 
limitation of the study, as our results were unable to account for clinical status and thus to 
address the question whether TRS might represent a distinctive aetiopathological subgroup 
of schizophrenia or is simply a more severe form of the disorder. What the study was able to 
investigate, however, were cognitive and neuroanatomical differences between the TRS 
symptomatology groups, highlighting haemodynamic changes associated with potentially 
therapeutic effects (and with lack of treatment response). 
 
A larger sample would have also been desirable, particularly in view of the presence of 
participants with marked asymmetries between the WASI subscales.  Also, there may have 
been a wider range of psychopathology.  In the light of difficulties in recruitment, it is not 
possible to infer, for example, how exceptional the individuals with distinctive profiles in 
the VIQ>PIQ subgroup were, or indeed whether the proportion of the group with an 
asymmetry favouring PIQ (PIQ>VIQ) would have increased had there been a higher 
prevalence of negative symptoms.  A larger sample may have also been helpful for 
comparisons between the lower and higher PANSS groups since these may have been 
under-powered; similarly, between male and female participants (an aspect which was not 
investigated for this study). 
 
Similarly, a larger number of participants would have augmented the neuropsychological 
and behavioural measures, where corrections for multiple comparisons were not applied 
even though the Bonferroni statistic was usually supplied.  To do so, would have been 
against the exploratory nature of the study in a rarely studied population.  Instead, exact  
p-values were cited and effect sizes were considered during interpretation.  However, it 
seems quite possible (in the light of normal to good estimated IQ scores), a more 
homogeneous and higher “functioning” group may have been recruited than would have 
been otherwise the case without the difficulties in recruitment. 
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It may have better to have a slightly longer version of n-back, but scanner time was limited.  
Nonetheless, it was remarkable that the proposed proxy variable of sustained attention based 
on average SDs in the 0-Back condition was so robust when this was based on just 9 
responses per participant.  Also, a shorter duration minimised the risk of fatigue arising 
during the task.  (Trial by trial analysis of the data raises this possibility as accuracy 
decreased in the TRS group, relative to the control group, on the last two trials: Figure 3. 9). 
 
As proposed in this thesis, hyperglycaemia is a very common side-effect of treatment with 
clozapine so developing insulin resistance could provide an explanation for the attenuated 
changes in the haemodynamic response in this study;  it would have been good to control for 
this by administering the oral glucose tolerance test since this is a more sensitive measure 
than tests of free glucose, hip-waist measurements or the body mass index.   
 
A further possible limitation is that errors were not modelled in the analysis in the interests 
of conserving data, nor were d’prime values used.  Fortunately, the error rates were very low 
in the control group and in the TRS group with most errors occurring on the second trial of 
the 3-Back condition, which is interpreted as indicating participants were trying to perform 
the 3-Back although their strategy was less successful at that point. 
 




5.1    A Summary Model Characterising TRS based on the Literature and Results of this Study 
 


















Verbal and visual learning scores were significantly 
depressed in the TRS group, unlike working memory 
performance.  
The haemodynamic response was attenuated during the  
n-back task with increasing cognitive load in the group with 
a higher level of pathology, i.e. TRS relative to controls and 
the higher PANSS relative to the lower PANSS.  This 
affected many areas corresponding to “connector hubs”.   
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                  This characterisation of TRS appears compatible with a cortical disinhibition model involving GABAergic deficits and excessive 
glutamatergic transmission with progressive pathology.  There may be further impacts on subcortical circuits and oscillatory rhythms. 






5.1.1  Notes on the Characterisation of TRS in the Summary Model 
Figure 5. 1 shows a summary model that characterises TRS and includes contributions from 
the literature on the left-hand side, proposed features relating to the aetiopathology of TRS 
in the middle and possible contributions from the current study on the right-hand side. 
 
- Contributions from the literature 
The published literature suggests that TRS may represent a distinct aetiopathological 
subgroup of schizophrenia comprising around 21% of all PSZ and is characterised by 
several biological features. (As such the group may represent a potential confound in some 
studies).  Some of these may indicate a neurodevelopmental basis including an earlier age of 
onset and a lack of sex difference in prevalence (Wimberley et al., 2016).  It is proposed the 
latter might reflect an onset before possible protection or benefit afforded by mature levels 
of female sex hormones.  Compatible with an earlier onset, TRS is present at the first 
episode of psychosis in 70-84%  (Lally et al., 2016;  Demjaha et al., 2017).  TRS individuals 
also exhibit normal synthetic capacity of striatal presynaptic dopamine in contrast to FLRS 
(Demjaha et al., 2012;  Kim et al., 2017).  However, elevations in glutamate/glutamine in 
the ACC have been observed in individuals unresponsive to initial antipsychotic treatment 
(Egerton et al., 2012); and TRS not on clozapine (Mouchlianitis et al., 2016, a) which might 
lead to damaging pathophysiological processes as well as cognitive dysfunction. 
 
Various lines of evidence suggest TRS may be characterised by deficits in long-range 
communication, for example, it is associated with more neurological soft-signs  
(de Bartolomeis et al., 2018).  Also, weaker connectivity relative to controls between the 
frontal lobe and primary auditory cortex, the frontal lobe and cuneus, between the 
paracentral lobule and the occipital lobe (Ganella et al., 2017).  Some connections were 
weaker in TRS participants relative to controls and stronger in unaffected siblings so 
potentially compensatory (Wang et al. 2015).  Decreased global efficiency and increased 
local efficiency were observed in TRS and UFMs relative to healthy controls which were 
significant in cerebellar and visual modules (Ganella et al., 2018).  It is suggested here, this 
might reflect an efficient trade-off which maximises resources if global connectivity has 
been compromised (Bullmore and Sporns, 2012). 
 
One environmental feature associated with TRS which contrasted with FLRS individuals, 
was a higher incidence of living in provincial or rural environments at the time of initial 
diagnosis  (Wimberley et al., 2016).   
243 
 
- Potential contributions from this study 
Results in the current study show some support for the proposed mechanisms that have been 
discussed in the published literature, and these will be briefly discussed below: 
 
The TRS participants who took part in this study had a group median estimated IQ at the 
61st percentile norm, while working memory performance (verbal and visual) and category 
fluency appeared depressed in relation to this but were relatively intact compared to 
standardised norms.  (Category fluency is associated with executive function as well as 
processing speed, for example, Shao et al., 2014).  By contrast, verbal and visual learning 
scores were significantly below those for category fluency.  Moreover, partial correlations 
with age as a covariate indicated verbal and visual learning may deteriorate with delays in 
accessing clozapine.  These latter observations are suggestive of deficits in synaptic 
plasticity and progressive deterioration during periods of acute psychosis. 
 
In the fMRI study, the haemodynamic response was attenuated during the n-back task with 
increasing cognitive load in the group with a higher level of pathology, i.e. TRS relative to 
controls and the higher PANSS group relative to the lower PANSS.  This was reminiscent 
of the attenuation observed in selected areas following the administration of the NMDAR 
antagonist ketamine to healthy volunteers (Anticevic et al., 2012).  In this study, the 
attenuation involved many areas - all of which might  correspond to “connector hubs”.   
These enhance long-range communication and minimise “wiring costs” (Fornito et al., 
2011;  Bullmore and Sporns, 2012).  This converges with other evidence indicating 
impaired global connectivity; however alternative explanations should be considered,  
particularly the possibility of developing insulin resistance as side-effect of clozapine.   
 
As so many hubs were implicated, it is perhaps unsurprising there was evidence of 
hyperactivity related to major nodes of the DMN (reflected in attenuated “deactivations”). 
Further support might be found in the intercorrelations between responding variability  
(0-Back SDs), the measure of sustained attention (CPT-IP), estimated FIQ and negative 
symptoms.  The latter might be expected to be a feature of DMN hyperactivity which might 
also cause microlapses in attention affecting cognitive performance. 
 
Finally, two incidental observations arose during testing which might point to deficits in 
early sensory processing.  One was that the CPT-IP test appeared poorly tolerated by some 
participants even though it had been standardised with a PSZ population.  Moreover, there 
was no recency effect on the first trial of verbal free recall (HVLT-R) with the auditory 
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presentation of a supra-span list.  This could be an artefact of list construction as other 
detailed studies with PSZ have not observed this.   
 
- Interpreting current evidence within a broader model based on cortical 
disinhibition 
Specific observations in this study when set within the wider context of schizophrenia 
research may be compatible with a cortical disinhibition model where there is excessive 
glutamatergic activity which clozapine appears to prevent or ameliorate.  There are several 
ways in which disinhibition might arise, for example, hypofunction of NMDA receptors on 
GABAergic interneurons (Olney et al. 1995, 1999), or perhaps at GABA-A receptors where 
PV+ interneurons synapse with cortical pyramidal neurons (Grace, 2016;  Marx et al., 2011; 
2014), or reduced numbers of GABAergic interneurons in the ACC (Benes et al., 1991).  An 
NMDA receptor antagonist might model any of these because the circuitry is inter-related.  
In view of the learning deficits observed in this study, it is also interesting to note that 
healthy male volunteers exhibited dose-dependent deficits in verbal learning following the 
administration of  ketamine in Newcomer et al. (1999).   
 
Evidence from the literature also supports “windows of vulnerability” across the lifespan 
(Keshavan, 1999).  For example: early influences on the immune and endocrine systems;  
the vulnerability of interneurons which are the last to migrate (Grace, 2016).  Adolescence 
provides another window (Monaco et al., 2015;  Selemon et al., 2013).  Neurodegenerative 
processes could also arise, for example, oligodendrocytes appear to be particularly 
vulnerable to glutamate excitotoxicity (Matute et al., 2006).  It is further pondered whether 
thinly myelinated areas within association cortices might be at increased risk58.  However, 
the transition to psychosis may not be inevitable but precipitated by a “hit”, probably 
environmental (Abi-Dargham, 2017), which overwhelms protection and repair. 
 
A cortical disinhibition theory would be consistent with observations of increased activity in 
the ACC in TRS individuals not medicated with clozapine (Mouchlianitis et al. 2016 (a); 
also,  Egerton et al. 2012, as above).  Further, it might be compatible with the evidence of 
the prospective SPECT studies of Molina Rodriguez et al., (1997, 1998) where responders 
to clozapine exhibited higher levels of perfusion when on conventional antipsychotics than 
non-responders:  in the thalamus, basal ganglia bilaterally, left inferior DLPFC and in the 
 
58 “The regions with high areal expansion tend to be lightly myelinated, including prefrontal, inferior 
parietal, lateral temporal, and anterior cingulate cortices.” (Glasser et al., 2010, p.1162).  While 
Flechsig (1901) determined that the inferior parietal lobule is one of the last areas to complete 
myelination (Catani and Thiebaut de Schotten, 2012, p.241).   
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right superior DLPFC.  Further, all these values were significantly higher than those in a 
normative database, as was the value for the left superior DLPFC for responders.  Following 
treatment with clozapine significant reductions were observed in responders in the thalamus, 
basal ganglia and superior DLPFC.  Similarly, a [18F] Fluoro-deoxy-glucose PET study by 
Molina et al. (2005), reported reduced metabolism in the basal ganglia and PFC in TRS 
participants after 6 months of treatment with clozapine.  However, interestingly, metabolism 
in primary visual cortex increased and was associated with an improvement in positive 
symptoms.  Molina et al. (2005) proposed this might be related to thalamic dysfunction and 
its excitatory projections to the occipital cortex.  It is suggested here, an increase in 
metabolism might reflect improved function following increased inhibition.  Concentrations 
of GABA are higher in the occipital cortex than more anterior areas in healthy individuals 
(Hoftman et al. 2018 ) and so may play a prominent role in early visual processing, for 
example, mediating orientation-specific surround inhibition (Yoon et al., 2010).  
An alternative model of cortical disinhibition has been proposed by Hoftman et al. (2017), 
who suggested a homeostatic downregulation of GABAergic activity in response to a 
decrease in glutamatergic transmission. As with the pathophysiological effects of increased 
glutamatergic activity, it was proposed GABAergic downregulation might lead to the 
collapse of the ability to generate oscillatory rhythms which support working memory.   
 
 
5.2   Ideas for further research 
This exploratory study, with a relatively small number of participants, has generated 
numerous ideas.  They are not ranked according to importance, as this varies according to 
how they are evaluated, for example, from an academic perspective, pressing need or 
practicality.  Given the lack of studies comparing TRS and FLRS in the literature, it may be 
useful to revisit several areas of previous exploration in schizophrenia research - this time, 
honouring this distinction and using the consensus definition of TRS as proposed by Howes 
et al. (2017), in which case, the list may be extensive, but the suggestions made here will 
take as their starting point observations arising within this study.  
 
5.2.1  Insulin Resistance as an alternative explanation for the attenuated fMRI 
BOLD signal 
An alternative interpretation is offered for the attenuation in the haemodynamic response in 
TRS and higher PANSS participants during the n-back as the involvement of highly active 
“hubs”, might indicate metabolic failures and stress with associated weakening in functional 
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connectivity, even myelin deficits.  As proposed above, this could involve developing 
insulin resistance related to the high metabolic liability of clozapine itself (Ahmed et al., 
2008) and also be consistent with a recent review by Cha et al. (2015) of studies which have 
pointed to associations between relative hyperactivity in the DMN and metabolic disorders. 
It is proposed in this thesis (section 4.3.3) insulin resistance might compromise energy at 
highly active hubs.  It has also been  associated with white matter abnormalities in type 2 
diabetes (T2DM), for example, in a study of 46 individuals with T2DM, Yau, et al. (2014) 
found extensive abnormalities indicated by increases in medial diffusivity (MD): ten were in 
the temporal lobe, including bilateral changes in the auditory cortex of Heschl’s gyrus, the 
fusiform gyrus, the hippocampal areas and arcuate fasciculus), further MD increases were 
observed in the right insula, in the occipital cortex bilaterally (particularly around the 
calcarine sulcus), also in the frontal and parietal cortices.  In addition, reductions in white 
matter integrity were observed: in the temporal lobe (including the arcuate fasciculus 
bilaterally, the left superior temporal and right middle temporal gyri), while the largest 
cluster of reduction was in the parietal lobe.  The widespread nature of these changes 
associated with T2DM bears some similarity with the deficits in grey matter in TRS 
observed by Anderson et al. (2015, a), and, perhaps, also with the many areas of differential 
alterations in the haemodynamic response in this study, for example, an attenuation of the 
haemodynamic response was observed in the left parahippocampal gyrus (Figure 3. 25).   
 
Metabolic aspects, e.g. hip-waist ratios, might have been informative in this study as they 
are a marker of metabolic syndrome.  However, the oral glucose tolerance test would be 
more sensitive: evidence from the longitudinal Hisayama study of elderly Japanese observed 
an association between the development of mild cognitive impairment and the failure of 
insulin levels to normalise within 2 hours of glucose challenge.  Whereas blood glucose 
levels were not a useful predictor (Ohara et al., 2011).  Also, consideration should be paid to 
the diurnal rhythm, for example, it might be better to consistently measure insulin resistance 
and conduct neuroimaging studies in the morning, or at least a similar time of day. 
 
5.2.2  Reductions in Global Efficiency – a biomarker of TRS? 
The implication of widespread attenuations in the haemodynamic response at connector 
hubs in this n-back study could be consistent with observations on resting state functional 
connectivity by Ganella et al. (2017), who observed widespread reductions in the strength of 
functional connections in TRS individuals relative to healthy controls affecting 3.4% of the 
connections identified using their methodology.  It was further inferred that the disorder 
might be characterised a disorder of “hub to hub” connectivity because of reductions in 
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global connectivity.  Certainly, a failure to integrate information across different brain areas 
might help to explain some symptoms and is consistent with the implication of connector 
hubs in this study.  
 
Since the observation of reduced global connectivity and increased local efficiency might 
provide a useful biomarker of TRS, particularly in the early stages (before further 
progression of pathology in FLRS), it is quite possible, a study has been recently been 
completed or is currently under way comparing FLRS individuals with TRS individuals 
who have been recently diagnosed.  Better still, a prospective study before a trial of 
clozapine is tried, since clozapine may help to improve global network connectivity and 
potentially reduce differences with FLRS individuals who have also been acutely unwell.  
There may also be confounds in relation to delays in accessing clozapine, particularly from 
time of the first episode   However, reductions in global efficiency with corresponding 
increases in local efficiency were also observed in unaffected siblings by Ganella et al. 
(2018), which may indicate this is an endophenotype of TRS, consistent with proposed 
trade-offs between local and global efficiency to optimise metabolic costs (Bullmore and 
Sporns, 2012). 
 
If this pattern is distinctive to TRS (and first-degree relatives) and as seems likely, is present 
in the early stages, it may be possible to identify individuals at risk of TRS before they 
become unwell and perhaps treat proactively, if for example, elevations in immune, 
endocrine or other markers suggest possible transition to psychosis is imminent.  Progress 
has been made by Sabine Bahn and colleagues using proteomic and metabolomic markers in 
relation to PSZ (referenced under Diagnostic Profiling below).  However, the simple 
hypothesis in the first instances could be that at time of diagnosis TRS individuals will 
exhibit reductions in global efficiency and increases in local efficiency relative to healthy 
control and FLRS individuals, because TRS can be characterised as a disorder of impaired 
global connectivity. 
 
5.2.3  A case register study of outcomes and speed in accessing Clozapine  
To determine if delays in accessing clozapine from the point of a first admission or 
diagnosis might be associated with worse outcomes.  These might be indicated by the 
number of hospital admissions and days in hospital.  Also, whether greater benefit accrues 
with longer periods of treatment with clozapine (although the results of this study would 




5.2.4  A comparison of recency effect in TRS and FLRS groups in supra-span 
lists, with further tests of auditory acuity for verbal and nonverbal stimuli 
             (and corresponding tests in the visual domain e.g. with backward masking) 
 
The meta-analysis of 19 studies involving 1188 individuals at clinical high risk of psychosis 
by Fusar-Poli et al., 2012 (section 1.5.1) observed the greatest decrements in performance 
on tests of short-term verbal and visual memory, in addition to lower scores of general 
intelligence and cognition.  Therefore, both TRS and FLRS individuals might show this.  
However, the decrement might be greater in TRS individuals and this study indicates further 
deterioration may arise during the period from diagnosis until treatment with clozapine 
which might reverse or interrupt decline. 
 
An unusual and potentially important observation, which may be related to this and which 
will need replication was the apparent lack of recency effect in free recall on the first trial of 
the Hopkins Verbal Learning Test.  However, the list began with the word ‘lion’ which is 
acquired early in a child’s lexicon so it is proposed this may have evoked a powerful 
representation which might have distracted attention away from the items in the recency 
portion.  Therefore, careful consideration should be given to the construction of word lists 
concerning factors such as age of acquisition, frequency, ease of articulation, concreteness, 
salience, list position and other factors which might affect recall.  If replicated this would 
suggest a selective deficit of the phonological store which could contribute to impairment in 
the free recall of auditorily presented words (Vallar, 2006).  As discussed in section 4.2.9, 
this might be predicted on the basis of preclinical studies which have highlighted potential 
vulnerability of the inferior parietal cortex/posterior cingulate to glutamatergic excitotoxity 
consequent to the operation of disease or, perhaps, NMDAR antagonism with ketamine or 
PCP (Olney et al., 1999).  Importantly, not only might this provide an index of illness 
severity, but a deficit in recency might provide a specific biomarker of TRS. 
 
Related to this (on the basis of neuropsychological observations on acquired damage 
(Warrington et al., 1971) degenerative changes might be localised to deformations of the 
posteromedial surface observable in sMRI data or abnormal connectivity in aspects of the 
superior longitudinal fasciculus which includes the arcuate fasciculus and has terminal 
projections in the PFC.  The corpus callosum might also be affected posteriorly.  A 
relationship might be found between aspects of recall and perceptual tests of auditory acuity 
for verbal and nonverbal stimuli (as in Bruder et al., 2004 – although, their word lists were 




Perceptual problems can arise for a variety of reasons, for example, “glue ear” during early 
childhood, but in schizophrenia these might arise from a lack of specificity in the signal at 
the encoding stage which might be related to deficits in selective attention (Engle et al., 
1999; Gandal et al., 2012, figure 3).  The introduction indicated ways these might arise, for 
example, a lack of inhibition arising from low GABA in the visual cortex, or perhaps 
dopamine dysregulation in the prefrontal cortex at a later stage of processing, or difficulties 
in integrating information in the striatal-thalamo-cortical loops.  (Also, various 
neuromodulators could give rise to imbalances at different stages).   
 
It is further predicted that TRS individuals might be more likely to have perceptual deficits 
than FLRS individuals.  Also, their short-term learning deficits are more likely to be related 
to a glutamatergic aetiology, whereas FLRS may be more likely to have deficits in learning 
and verbal working memory related to dopamine dysregulation in the prefrontal cortex.  On 
the basis of the evidence in this study with TRS individuals, negative symptoms might be 
more likely to be associated with perceptual and sensory gating deficits than higher 
cognition, although it is possible, clinical symptoms across the group were insufficient to 
show the latter.  Finally, it would be interesting to see if unaffected first-degree relatives 
have perceptual deficits and exhibit an attenuated recency effect in the free recall of 
auditory-verbal lists.  This could indicate encoding problems may be related to perception 
rather than arising during the course of the disease.  It is an empirical question whether there 
might be corresponding deficits in the visual domain mediated by similar factors. 
 
5.2.5  A study of intellectual asymmetry in unaffected first-degree relatives of 
TRS and FLRS individuals 
It is apparent the WASI subscales may be prone to asymmetry, yet intellectual asymmetry 
has been observed in PSZ with other measures.  A simple search of the PubMed data base 
using the terms “IQ OR “intellectual” AND asymmetry AND schizophrenia” conducted 
31.7.19 yielded only 18 results. Many of these concerned differences in the lateralisation of 
fibre tracts, which could provide a related line of enquiry.   
 
It might be helpful to repeat the design of Kravariti et al. (2006), who observed intellectual 
superiority in the VIQ scale over the PIQ in unaffected first-degree relatives of 
schizophrenia.  A short version of the Wechsler Adult Intelligence Scale - Revised (WAIS-
R, Wechsler, 1981) was administered which may be less prone to  variations in scores 
between the subscales than the WASI (section 4.2.7).  Its purpose would be to assess and 
compare intellectual asymmetry between the first-degree relatives of individuals with TRS 
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and FLRS to ascertain whether these might reflect contrasting endophenotypes for 
schizophrenia.  This has several advantages, not least because it may be easier to recruit 
participants who have not endured a major mental illness or taken psychotropic medication.  
This would also permit the examination potential sex differences where pre-menopausal 
women might be afforded some protection against glutamate excitotoxicity by ovarian 
hormones. A further hypothesis is that that a more distributed organisation of fibre tracts, as 
might be associated with fluid intelligence could offer some protection against excitotoxic 
and oxidative events in local circuits. 
 
Certainly, genetic factors could underlie asymmetries in performance, for example, in a 
study of healthy twins by Budisavljevic et al. (2016), a significant and asymmetric familial 
effect in the volume of the dorsomedial cingulum was observed that accounted for 51% of 
the variance in the left hemisphere while in the right hemisphere this contribution at 34% 
was nonsignificant.  However, other tractography measures (medial diffusivity and 
fractional anisotropy) indicated major genetic effects in both hemispheres.  They further 
observed FA of the cingulum has been observed to be positively correlated with FIQ and 
PIQ (Chiang et al., 2009). This was also consistent with Luders et al. (2007) who found the 
volume of the isthmus of the corpus callosum correlated positively with IQ and that FIQ and 
PIQ had the largest effect sizes.  
 
5.2.6  A comparison of TRS and FLRS participants on sensory gating 
Worse performance on memory tests have been associated with decrements in auditory 
perception (e.g. Bruder et al, 2004), or when artificially caused through manipulations such 
as the word length effect or acoustic similarity effect.  It might be predicted TRS may be 
unaffected by phonological similarities between words (Conrad, 1964), or word length 
(Baddeley, Thomson and Buchanan, 1975) since they may already have poor phoneme 
discrimination.  Such deficits could be related to sensory gating deficits and also contribute 
to deficits in short-term verbal and visual learning on the basis of a worse signal to noise 
ratio, and/or because encoding requires more processing capacity to make representations 
more distinctive.   
 
Even though clozapine appears to have some efficacy with sensory gating (Micoulaud-
Franchi et al. 2015).  One clue to the possibility of greater sensory gating deficits may have 
come from the observation that the CPT-IP was poorly tolerated in some participants in this 
study, indicating possibility that the test stressed selective attention when perceptual 
capacities were under strain.  This would be more likely to occur with longer letter stimuli 
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where different letter representations in memory may compete for identification 
(McClelland and Rumelhart, 1981). A more rapid rate of presentation (one item per second) 
with infrequent breaks could also make it harder to recover between trials.  In a recent 
multicentre study of schizophrenia using a visually degraded form of the CPT (DS-CPT), 
worse performance was observed in individuals with a higher level of symptoms, however, 
this was statistically inconclusive because of insufficient numbers of participants with 
higher PANSS at some centres;  also, this kind of study is vulnerable to poor inter-rater 
reliability (Nuechterlein et al., 2015).  It should also be calibrated to avoid floor and ceiling 
effects.  An easier approach might be to compare TRS and FLRS participants on a 
perceptual task involving backward masking to see how much time participants require to 
process the information (consciously and pre-consciously). 
 
5.2.7  Further explorations of myelin deficits in TRS and FLRS including areas 
corresponding to the distribution of Von Economo Neurons 
Following the proposal by Smucny et al. (2017) that VENs could be compromised, it might 
be worthwhile to follow the example of Cauda et al. (2013) and apply a mask to a DTI 
dataset comparing TRS, FLRS and HC to see if white matter decrements are concentrated in 
areas where VENs have been found (e.g. ACC, DLPFC and anterior insula) in an attempt to 
rule out a selective deficits.  VENs enable rapid communication at distance and a deficit 
would be consistent with the implication of the connector hubs in this study.  It might also 
help to explain the low scores on social cognition as VENs have been proposed to support 
this (Butti et al., 2013);  or indeed any task that requires the rapid processing of information 
across large-scale networks.  Moreover, a deficit in VENs could also increase demands upon 
connector hubs and increase the likelihood of damage. 
 
From a TRS perspective, regions of interest may include thinly myelinated areas which may 
be particularly vulnerable to various form for damage (excitotoxic, oxidative, redox).  These 
include the prefrontal, insular, cingulate, temporal and parietal association cortices.  In the 
interesting study by Vanes et al., 2018, no differences were observed between TRS and PSZ 
groups with respect to myelin abnormalities, however, it is suggested that any difference in 
thinly myelinated areas could be relatively small and perhaps the signal might be obscured 




5.2.8  Histology studies in TRS and FLRS concerning the density of VENs and 
GABAergic interneurons  
While Benes et al. (1991), provided a seminal observation concerning depletions in 
GABAergic interneurons these are so numerous decrements may be difficult to quantify but 
it might be predicted there are deficits in PV+ GABAergic interneurons relative to control 
samples and these could be greater in TRS than FLRS.  By contrast, VENs are less 
numerous, rare in evolution and may still to be reported in some areas of the human brain.  
However, they are large, myelinated and have a distinctive spindle or corkscrew shape with 
an absence of collaterals along the main length and so might be easier to quantify.  Again, 
they might be less numerous or smaller in TRS than FLRS and healthy controls, perhaps 
especially in the ACC where chronic hyperactivity (Mouchlianitis et al., 2016, a) might have 
resulted in sustained myelin damage, neuronal atrophy or loss. 
 
5.2.9  The Claustrum in TRS and FLRS 
Another ROI which may reward study is the claustrum where significant differences were 
observed in the haemodynamic response between the lower and higher PANSS groups in 
this study.  This has the potential to provide compensatory support to the salience network 
and selective attention through its widespread connectivity, however, it might also be 
vulnerable to widespread deficits in myelin and related deficits in connectivity.  Either way 
individuals with a higher level of symptoms might be predicted to have smaller grey matter 
claustral volumes than those with a lower level of symptoms.  However, a comparison with 
matched healthy controls might help to indicate whether differences in the claustrum might 
be compensatory or due to pathophysiological processes.  Given the topographical 
organisation of the fibres, any changes might be predicted to affect the anterior claustrum.  
Further, this may be a point of difference between TRS and FLRS participants although 
perhaps this is less likely after Vanes et al. (2018). 
 
5.2.10   fMRI BOLD Studies 
It is expected the literature will continue to expand and further support may be found for the 
idea that one source of attention deficit may arise from DMN dominance (hyperactivity of 
some areas).  This may not be a feature that is unique to TRS, for example, Fryer et al. 
(2013) made similar observations in their study of individuals at high risk of psychosis or 
with early psychosis.  Hyperactivity was also observed in the medial prefrontal cortex 
during the encoding phase of a working memory task  in unaffected siblings of PSZ (de 
Leeuw et al., 2013).  However, as suggested above, hyperglycaemia/insulin resistance may 
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possibly cause this kind of dysfunction (for example, see Cha et al., 2015).  Indeed, as this 
was not controlled in this study, it is possible the observations might be attributed to this 
rather than pathology directly related to TRS.  Therefore, it could be informative if a future 
BOLD fMRI study controls for this.   
 
It would also be advantageous to include a group of carefully matched FLRS participants in 
a future study. Another lesson learned concerning participant selection - from this study and 
research using molecular neuroimaging (e.g. Goldstein et al., 2015 vs, Mouchlianitis et al., 
2016, a) is that clozapine treatment may “normalise” observable function in some 
individuals, so medication is an important consideration.  I also agree with So et al. (2018) 
that group homogeneity may be important, as significant differences in this study appeared 
to depend on increasing cognitive load to a high level.  It is therefore important participants 
are able to perform the task across all levels and helpful to ascertain when performance 
starts to degrade whether this is for similar reasons, or if there is a divergence in strategy.  
So et al. (2018) suggested group homogeneity was improved by a screening process which 
resulted in the selection of a “high-performing” schizophrenia participants (something that 
may have been inadvertently achieved in the demanding nature of this study).   
 
5.2.11   sMRI investigations of the Hippocampus, ACC, Insula and Posteromedial 
Cortices 
The structural data has been collected and could be correlated with neuropsychological 
variables. While the hippocampus has been extensively studied and schizophrenia research, 
it would be remiss not to look at the hippocampal volumes in TRS, given its importance to 
memory function and because the hippocampus has been proposed as, possibly, the primary 
site of pathology in schizophrenia (e.g. Grace, 2012, 2017).  Many lines of evidence 
implicate stress in the genesis of schizophrenia and the hippocampus, which a site of 
feedback for glucocorticoids as it is involved in regulating the HPA axis, and  particularly 
vulnerable to an excess (Mondelli et al., 2010), perhaps especially in the context of another 
pathology that compromises energy (e.g. Armanini et al., 1990; Herbert et al., 2006; 
Jacobson and Sapolsky, 1991).  It therefore seems highly likely hippocampal volumes will 
also be reduced in TRS (although there may be regional variations). Attempts have been 
made in this thesis to consider alternative loci for primary pathology in TRS, however, all 
roads of enquiry may lead back to the hippocampus as it has a population of fast-spiking 
parvalbumin positive interneurons (e.g. Zaletel et al., 2016), which are vulnerable to chronic 
stress and quite possibly other insults. The vulnerability of PVIs to damage and their 
important role in putting inhibition onto excitatory networks is elaborated upon by Grace 
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2016, whose argument was not specifically directed towards TRS but which might apply 
very well (also relevant, section 1.5.5). 
 
5.2.12   Investigations of Oscillatory Rhythms  
Emerging evidence suggests neural synchrony is important for the integration of 
information across large scale distributed networks (e.g. Uhlhass and Singer 2006, 2008; 
Sirota et al., 2008) and several studies have observed weaker long-range gamma phase 
synchrony during working memory tasks in schizophrenia (e.g. Chen et al., 2014;  So et al., 
2018;  Haenschel et al., 2009).  Given the conclusion of this research is that TRS could be 
well-characterised by deficits in long-range communication (possibly distinguishing it from 
FLRS), electrophysiological methods might be particularly suited to the study of TRS and 
might be used with other approaches.  However, it is also possible to measure the amplitude 
of low-frequency fluctuations (ALFF) in the rsfMRI BOLD signal as demonstrated by Fryer 
et al. (2015)  who observed an association between a neuropsychological measure of 
sustained attention and reduced ALFF values in the bilateral posterior parietal areas, 
posterior and dorsal anterior cingulate and right DLPFC in participants with schizophrenia 
relative to controls (n=168 and n=166 respectively). 
 
5.2.13   Historic Drug Use 
While recent evidence suggests TRS is present in the majority from the first episode of 
psychosis, it now generally accepted there may be many paths to psychosis (Murray, 2017) 
and even though TRS has been generally disregarded as a separate category, it is quite 
possible this may also be true of TRS.  Premorbid drug abuse might be one vulnerability 
factor and it is estimated (Appendix 1) that 72% of the TRS participants may have tried 
drugs which increase striatal dopamine.  The majority had tried drugs with serotonergic 
effects or had serotonergic and dopaminergic effects combined.  Current illicit drug taking 
was not considered in this study and drug screening tests are rare except for molecular 
imaging studies, however, concurrent use appears common if widely under-reported 
(Bahorik et al., 2014,b).   
 
The diversity of drugs available today and polydrug use pose a problem for surveys which 
might seek associations between exposures to particular kinds of drug and mental illness.  
However, the participants in this study were from a generation who had access to a more 
restricted choice. There are concerns about data which relies upon subjective recall, 
particularly in participants who may have cognitive deficits;  however, it is suggested “first 
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ever” experiences might be better retained on the basis of their novelty and also the 
“primacy effect” (Baddeley, 1986).  Also, while a considerable mismatch between self-
report and the drug-screening results was observed in a study of more than 1000 individuals 
(Bahorik et al., 2014,b), individuals may be more willing to share “historic” information. 
 
The potential value of research into possible pharmacological antecedents of FLRS and TRS 
partly arises from concern that psychedelics are being commonly used.  An interesting case 
is also building for their use in therapy, possibly in relation to anxiety, depression and OCD 
(Carhart-Harris, 2016;  Pollan, 2018), but the hazards are far from understood.  The 
responses to few demographic questions and cross-tabulation with the date of diagnosis 
demonstrated this might be feasible and recruitment for the purpose of a short interview 
should be far easier than for a neuroimaging study. 
 
5.2.14  Adjunctive Treatments in TRS 
These suggestions are based on the alternative explanations for the widespread attenuations 
in the haemodynamic response observed in this study.   
 
- Metformin 
With respect to the hypothesis, this might be related to transient deficits in energy 
metabolism, it is proposed that the early use metformin to improve insulin uptake might be 
particularly helpful in TRS.  Not least, in helping guard against developing insulin 
resistance given the high risk of hyperglycaemia associated with clozapine treatment.  The 
use of metformin as an adjunct to clozapine has already shown promise (Hebrani et al., 
2015; Wu et al., 2008). 
 
It is the development of occult insulin resistance, as well as diabetes which are both linked 
with neurodegeneration that is particularly concerning (Ohara et al., 2011, Chen et al., 2016) 
in the light of clozapine’s adverse profile for metabolic side effects.  As mentioned in 
section 1.5.8, there is some limited evidence that suggests glucose dysregulation may be a 
premorbid feature (Guest et al., 2011), with a heighted prevalence in first-degree relatives 
(e.g. Thakore et al., 2002; Henderson, et al., 2005)59.  Identifying the prevalence of this 
 
59 In an interesting convergence, insulin in the hippocampus may have a role in promoting the 
expression of extra-synaptic GABA A receptors by trafficking them to the cell surface.  This affects 
membrane properties such as the resting membrane potential and firing patterns and was 
demonstrated to decrease the excitability of neurons in layers 5-6 of the prefrontal cortex (Trujeque-
Ramos et al., 2018). 
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potential problem would be a valuable step and not a counsel of despair (clozapine remains 
the “gold standard” and perhaps only effective treatment of TRS) because, as above, there is 
evidence that adjunctive treatment with metformin may lead to weight loss and improve 
insulin sensitivity.  Insulin resistance is widely underdiagnosed or not controlled properly in 
the general population and, excess body fat which is often associated with this is itself a 
source of inflammatory cytokines.  Given observations of a generally higher rate of 
morbidity from all causes in schizophrenia, considerable benefit might be gained by 
controlling insulin resistance which affects so many systems. 
 
Similarly, to minimise challenges to energy metabolism thyroid function should be carefully 
evaluated by checking free thyroxine and not just thyroid stimulating hormone.  Further 
improvements may be made by ensuring a good quality of sleep but without sedation during 
the day.  It follows, good sleep habits and the timing, as well as the dose of clozapine may 
be important factors in optimising adherence and treatment. 
 
- D-serine 
If TRS is well characterised by a glutamatergic hypothesis, then the use of an adjunctive that 
facilitates transmission at the NMDA receptor might be beneficial.  However, it may have 
less benefit if clozapine already facilitates this (Farber et al., 1998;  Tanahashi et al., 2012).  
The use of D-serine as an adjunctive has also shown some promise and, perhaps, might be 
used with all FEP cases to prevent excitotoxicity associated with NMDAR hypofunction? 
 
- Modulation of Nicotinic Receptor Agonism as an Adjunctive Treatment? 
Koukouli et al, 2017 have suggested a therapeutic role for nicotine in schizophrenia, for 
example, Shaqiri et al., 2016 observed nicotine helped to reverse deficits in visual backward 
masking which increase with age and also in first-degree relatives of individuals with 
schizophrenia.  In a study of performance on the CPT-IP and a degraded stimulus version of 
the CPT (DS-CPT) by 1140 participants with schizophrenia, Nuechterlein et al. (2015) 
observed that current and past smoking were associated with slower responses to targets, 
and current smoking was also associated with worse accuracy.  Perhaps, those participants 
were more likely to smoke because they have greater need of stimulation?  Ettinger et al., 
2107, observed nicotine had general arousing effects in their healthy participants but may 
lack specific effects on selective attention.  However, another study indicated nicotine may 
improve selective attention in PSZ, also nicotine improved working memory in the PSZ 
group while worsening that in the control. (Jacobsen et al, 2004).  Consequently, it is 
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observed individual differences and also nicotine dependency may be important variables.  
Moreover, in explaining contrasting observations on connectivity between executive 
networks and the ACC, where it was reduced in the control group and increased in the PSZ 
group, Smucny et al., (2017) observed this could reflect an inverted-U function whereby 
sensitivity to agonism at nicotine receptors may be enhanced in individuals who have 
relatively low levels of receptors, whereas, signalling might become sensitised in healthy 
individuals who had normal levels before nicotine administration.  In a preclinical study, 
clozapine was observed to induce acetylcholine release in the rodent PFC, striatum and 
nucleus accumbens without the development of tolerance (Parada et al., 1998). 
 
As discussed in relation to the different prevalence of smoking in the lower and higher 
PANSS groups, a large body of evidence suggests nicotine may improve cognition in 
schizophrenia and help to ameliorate negative symptoms, which may make this of particular 
interest to TRS research (Patkar et al., 2002).  Also, the anterior cingulate (including the 
dorsal cingulate cortex) and striatum are regions of interest in TRS research that are 
modulated by nicotine.  Empirical work has been conducted in healthy and PSZ populations 
which indicates nicotine may affect the connectivity of networks and particularly the 
salience network involved adaptive behaviours and switching across networks (Hong et al., 
2009).  Smucny et al., 2017, suggested nicotine or other stimulants could be used to improve 
connectivity in large scale networks.  Nicotine may also help to decrease DMN activity 
when attention is oriented towards task positive activity (Tanabe et al. 2011).  The cognitive 
effects of nicotine appear to involve “cholinergic projections to the neocortex, and 
hippocampus, influencing inter alia glutamatergic and GABAergic neurons” (Kumari et al., 
2003, p.1002).  It is therefore unsurprising that nicotine has been observed to improve 
attention, accuracy and working memory performance (Kumari et al., 2003).  
 
When viewed from network perspective it seems possible that stimulants which increase 
processing speed, may also alter resting state connectivity (e.g. Jacobsen et al. (2004) and 
affect networks (e.g. Hong et al., 2009; Tanabe et al., 2011).  Moran et al. (2018) reported 
nicotine increased activation in the right caudate following task errors in participants with 
schizophrenia compared with controls, while both activation in the dorsal and rostral ACC 
was increased in both groups.  Behaviourally, nicotine appeared to improve adaptive 
performance in the schizophrenia group, providing further evidence of improved cognitive 
control and a shift in attention away from consuming default-mode activity towards more 
task positive activity.  Tanabe et al., 2011 may have observed a similar change following the 
administration of a nicotine patch in a rsMRI study of healthy non-smoking individuals 
where DMN activity was attenuated while an increase in activity in extra-striate areas was 
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observed, which was interpreted as a shift from the DMN towards networks involved in the 
processing external information.  Phenomenologically, such a shift might help to “keep the 
demons at bay”60 in schizophrenia and help to explain the high prevalence of nicotine 
dependency.  Better understanding of these aspects could inform therapy directed at 
emotional regulation and smoking cessation.  
 
- Alternatives to Clozapine? 
Where individuals are unwilling to try clozapine or it is not suitable for another reason, 
promising research indicates pregnenolone or one of its metabolites may be a useful 
treatment.  As with clozapine, the reasons for potential efficacy are unclear but their actions 
may overlap (for example, if they both have modulatory actions at the same GABA-A 
receptor).  This could make it less likely they would be more effective in combination; 
however, they could be useful as alternatives.  
 
5.2.15  Immunological and Endocrine Investigations 
Recently, there has been growing interest in associations between immune factors and 
schizophrenia, for example, with observations of vitamin D deficiency which affect the 
immune system (Lally et al., 2016);  also, associations involving stress and childhood 
trauma (Mondelli et al., 2011).  It has been observed in thesis that the persistence of certain 
negative symptoms bears some similarity with “sickness behaviour” in animals when they 
become unwell (section 1.10.4).  This observation has been made by others and an 
immunological perspective has been advanced by Bullmore (2018).  Given the persistence 
of negative symptoms is a feature of TRS and may already present at the first episode of 
illness, TRS individuals may be more likely to have increased levels of inflammatory 
markers than FLRS (at least before Clozapine treatment has started).  Indeed, these might be 
a suitable biomarker for TRS when used in combination with other features (next section).   
 
Further, TRS individuals and their UFMs may be more suitable candidates for 
immunological treatment compared with FLRS, because the persistence of negative 
symptoms is a feature of TRS.  According to a review by Zhang and Zhou (2014), 
minocycline inhibits microglia activation and has been effective in treating negative 
symptoms in several trials and mitigates the effects of glutamate excitotoxicity (e.g. Monte 
et al., 2013).  Also, higher levels of inflammatory cytokines in FEP individuals predicted 
less improvement in clinical symptoms (Mondelli et al., 2015).  Further, inflammation may 
 
60 This was how a non-participant described the effects of smoking on their schizophrenia. 
259 
 
be localised as well as systemic, for example, there have been case reports of hyperperfusion 
in the posterior cingulate being reduced with a combination of minocycline and 
antipsychotic treatment (Miyaoka et al., 2007; Chavez et al., 2010).  As one of the most 
metabolically active areas in the brain, the posterior cingulate may be suitable target for this 
therapy. 
  
It was with considerable expectation a prospective RCT was conducted with minocycline as 
an adjunctive medication administered to FEP individuals for a year (Deakin et al., 2018; 
Lisiecka et al., 2015). Unfortunately, there were no significant differences between the 
placebo and minocycline group with respect to the outcome measures (grey matter volume 
in the mPFC and DLPFC activation in the n-back task) and it was concluded that the drug 
should not be administered unless there are signs of active inflammation.  Yet it is possible, 
this course of treatment is more likely to be effective in TRS participants, in which case the 
trial would have lacked power to detect a significant effect.  Also, it is suggested here the 
outcome measure used in the BeneMin study of grey matter volumes might be less suitable 
for use with TRS individuals in the light of a report by observations by Ahmed et al. (2015) 
that these may continue to decrease during the year after commencement of treatment with 
clozapine.  As clinical improvement was seen during this period, it was observed 
progressive decrements in grey matter might not be pathological, for example, it might be 
consistent with the pruning of aberrant connections.  Kishimoto et. al. (2018) observed it 
may be premature to terminate research on immunotherapy, while Deakin et al., (2018) 
acknowledged other subgroups might be suitable candidates.   
 
Abnormal endocrine activity may also be linked with TRS:  in a study by Mondelli et al. 
(2015), a blunted cortisol awakening response (CAR) was also predictive of a poor 
treatment response, possibly indicative of long-standing overactivity in the HPA, which may 
have implications for other systems (section 1.10.5). Consistent with this, larger pituitary 
volumes (reflecting, in part, greater activity in the corticotroph cells) have predicted a poor 
treatment response (Garner et al, 2009), and blunted CAR has been observed in individuals 
at ultra-high risk of developing psychosis (Day et al, 2014), while larger pituitary volumes 
have been observed in unaffected relatives, suggesting there may be a “genetic susceptibility 




5.2.16  Diagnostic Profiling of TRS using Multiple Biomarkers 
A combination of biomarkers which need not be from the same category could progress the 
identification and treatment of TRS.  Mondelli et al. (2015), for example, recommended 
cytokines could provide a marker of treatment responsiveness.  Pattern recognition 
techniques using artificial intelligence (for example, the support vector machine), can 
accommodate a diverse range of measures (at least to begin with, until their utility is 
determined).  This approach, taken by Sabine Bahn’s team, involving the molecular 
analyses of CSF, has shown considerable promise (e.g. Holmes et al., 2006;  Huang et al., 
2006;  Huang et al., 2007;  Guest et al., 2013;  Schwarz et al., 2010), but this might prove 
even more useful if the distinction between TRS and FLRS is observed and a wider range of 
measures is incorporated.  A search of the literature in molecular biology (encompassing 
genetics and neuroimaging) and preclinical studies can provide more e.g. a screening study 
by Malik (2011) indicated treatment with clozapine increases neurotropins such as BDNF, 
NGF, also TTR (thyroid hormone and retinol carrier which sequesters B-amyloid in the 
CSF).  Clozapine was also observed to upregulate transthyretin (TTR) in the rat 
hippocampus after 4 weeks of treatment by Chen and Chen, 2007. 
 
Subject to practical considerations, other biomarkers might include measures relating to 
CAR and other endocrine information relating to sex hormones and insulin resistance 
which, as previously suggested (5.2.10), might be an important factor to control considering 
the relative hypometabolism reflected in attenuated responses in this fMRI study.  Also, 
because cognitive impairment may arise in association with hyperglycaemia and developing 
or occult insulin resistance.  The posterior cingulate may be particularly vulnerable to 
hyperglycaemia and is one of the first areas to develop pathology in Alzheimer’s disease 
(Buckner et al., 2005;  Vlassenko et al., 2010).  Genetic information, molecules in plasma, 
vitamin D, inflammatory cytokines, d-serine might also provide biomarkers, as might 
neuroimaging measures such as resting state connectivity and proton magnetic resonance 
spectroscopy (1H-MRS), for example to measure GABA.  Also, white matter, for example, 
in a prospective study of 63 FEP participants, non-responders exhibited lower fractional 
anisotropy than responders and control participants, mostly in the cingulum and corpus 
callosum, also the uncinate.  This improved in both responders and non-responders after 12 
weeks of antipsychotic treatment (Reis Marques et al., 2014). 
 
Some putative biomarkers suggested by this study include the possibility that TRS 
individuals might have worse sensory gating deficits and need more time to assimilate early 
perceptual information, so a backward masking technique could be used to explore this and 
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perhaps also drug responsiveness.  Simple standard deviations might be obtained in the 
baseline task of a CPT-X paradigm (similar to the ‘Is it X’ condition of the n-back task) 
which might provide a measure of variability in responding and usefully index sustained 
attention.  However, the main problem may lie not with cognitive control but with the 
ability to resist interference (i.e. selective attention), which Engle et al. (1999) described as 
“the critical factor common to measures of WM capacity and higher level cognitive tasks” 
(p.312)  Indeed, it will be interesting to learn more about the relationship of GABA as well 
as dopamine as potential modulators of selective attention.   
 
In the inexpensive category of ideas for further research, as already suggested above 
(section 5.2.4), the recency effect in TRS individuals may reward further investigation if it 
transpires it is abolished and is usually specific to TRS.  Further, it might be useful to 
explore whether post-error slowing (which appeared to be abolished in the behavioural data 
for TRS participants), might form the basis of a test which indexes of ACC behavioural 
monitoring function.  This might be expected to improve with treatment response.  
However, at the outset, it might be predicted that this function may be more compromised in 
TRS compared with FLRS. 
 
Finally, in view of the increasing numbers of studies which are finding shared 
endophenotypic characteristics in unaffected first-degree relatives, it should perhaps be 
considered that, free from antipsychotic medication, they too might provide a source of 
useful biomarker information.   
 
5.2.17  Proton magnetic resonance spectroscopy (1H-MRS) 
Finally, it is important to revisit what has already been learned.  An example of project that 
might fall within a “moonshot” category - where the evidence base that it might work is 
limited but the potential reward is great, may be offered through the advent of 1H-MRS 
which has clear advantages over studies which have had to rely upon analysis of CSF to 
explore certain questions.  One potentially interesting biomarker of TRS (or rather the 
converse, FLRS) identified through CSF studies, concerns the elevation of homovanillic 
acid (HVA), a metabolite of dopamine (Pickar, 1992).  This was subsequently replicated by 
Risch and Lewine (1993) and is compatible with a dopaminergic hypothesis of FLRS.  
Moreover it might yield a biomarker should it be possible to measure central HVA 
accurately and non-invasively, e.g. using 1H-MRS, or in plasma (possibly, the ratio of 
plasma HVA and 3-methoxy-4-hydroxyphenylglycol (MHPG). 
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When reviewing predictors of the clozapine response, Samanaite et al. (2018) also found 
these studies.  In addition, they found a small study by Szymanski et al. (1993).  Of the three 
studies, Samanaite et al. (2018) observed: 
 
“lower HVA/5-HIAA concentration ratios before clozapine were associated with a greater 
degree of subsequent symptomatic improvement, both in the short- and longer-term (47, 48, 
64). This suggests that the balance between dopamine and serotonin metabolism before 
clozapine administration may be predictive of clozapine response, with lower levels of 
dopamine metabolism relative to higher levels of serotonin metabolism being associated 
with better outcomes.” (p.332-333) 
 
The use of 1H-MRS to measure other biomarkers of TRS has been demonstrated with 
respect to elevations in glutamate in the anterior cingulate of unmedicated individuals (e.g. 
Mouchlianitis et al., 2016, a).   This technology has also indicated an association between 
baseline GABA levels and working memory performance in healthy individuals (Yoon et 
al., 2016).  An integrative view of the emerging literature on GABA and gamma oscillations 
suggests this may lead to the development of biomarkers which may help diagnose TRS and 
evaluate responses to therapy.  Also, if a fundamental problem arises from a lack of 
inhibition in cognitive processing, for example, through a failure of entrainment of cell 
populations downstream and deficits in oscillatory rhythms (e.g. Kwon et al., 1999), then 
this could pave the way for diverse therapeutic approaches.  Therefore, the measurement of 
GABA levels could be informative if  TRS is principally characterised by a glutamatergic 
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APPENDICES   
These appendices contain some extensive tables which are only briefly referred to in the 
main text, or where there is a fair degree of overlap with other information contained there.  
Further, as this study concerns a rare group of participants, some data is included which 
might be relevant, or of potential interest, to other researchers.   
 
APPENDIX 1:   
 
Historic Drug Exposure before the First Episode of Psychosis (1978 - 2003) 
As part of the demographic assessment referred to in sections 2.5 and 3.1, exposure to 
“recreational” drugs prior to the onset of psychosis was considered.  All participants had 
“passed” an initial screening question concerning their history of drug use and whether they 
had received treatment for addiction.  They were reminded it was not necessary to answer 
questions and were asked if they had ever tried a drug (from a list) and if they could recall 
the approximate age of “first ever” use.  This was subsequently related to age of first 
admission for psychosis from medical records (a question not asked of participants).  Setting 
reservations aside concerning the accuracy of self-reports about distant events, the purpose 
was to establish whether drug use could have been a factor in the development of TRS.   
 
Figure Appx. 1. 1 depicts the estimates that arose from this cross-tabulation and the 
corresponding data is found in Table Appx. 1. 1.  From these, it would appear the majority 
of individuals, had tried “recreational drugs’ before the onset of psychosis and around a 
third indicated they had tried at least 4 different kinds of drug.  The differences between the 
individuals grouped according to symptom levels (PANSS scores) appears minimal, but the 
relatively small group sizes and the questionable quality of the data is not strong enough to 
make firm inferences. 
 
When considered from the perspective of the pharmacological actions and psychotomimetic 
effects of the drugs (Figure Appx. 1. 2), the potential relevance to schizophrenia becomes 
clearer as all are agents which might alter or, otherwise, interact with a pre-existing 
vulnerability in circuitry associated with schizophrenia.  As previously observed, certain 
drugs have been associated with the development of psychosis, for example, cannabis, 
cocaine and amphetamine are known to increase dopamine availability in the striatal 
synapse and the risk concerning cannabis is now well-established (Murray et al., 2017; Rapp 
et al., 2013).  Cannabis appears to have been the most commonly used drug with 64% of 
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“first ever” experiences reported prior to diagnosis (one participant estimated they had been 
a regular user of cannabis since the age of 10 years and several may have continued or 
extended drug taking after diagnosis).  As indicated in Figure Appx. 1. 2, 72% of TRS 
participants may have taken drugs which boost dopamine availability before their FEP. 
Figure Appx. 1. 1   Estimated Variety of Drugs tried in the TRS Group Prior to 




Table Appx 1. 1   Types of Drug Experienced by TRS Participants Before a 
First Episode of Psychosis - Grouped by Level of Symptoms and Combined* 
 Lower PANSS % Higher PANSS % Groups Combined % 
No Drug Use 12 0 12 
Polydrug Use** 20 12 32 
Alcohol*** 24 12 36 
Cannabis 36 28 64 
Cocaine¬ 8 12 20 
Amphetamine 20 16 36 
Ecstasy (MDMA) 20 8 28 
LSD 16 24 40 
Magic Mushrooms 8 8 16 
Opiates 4 4 8 
Heroin (intravenous) 4 8 12 
Solvents 8 4 12 
* Percentages all shown in relation to entire whole group (n = 25) 
**Polydrug Use - tried four or more different kinds of drug 
*** Alcohol Use - only noted if binge drinking (28% of all TRS) or sustained use (8%). 


















*Polydrug Use = had tried  > 3 different drugs     
**Alcohol = "binge" or sustained in 28% (n=25)
Lower PANSS (n = 14)
Higher PANSS (n = 11)
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Figure Appx. 1. 2   Estimated Pharmacological Exposure by Drug Type   to 
TRS Participants Before the First Episode of Psychosis 
 
 
  NB:  Numbers inside the columns indicate percentage out of group (n=25) per class; 
The data in each column represents pharmacological exposure, and was counted only 
once for an individual, irrespective of the number of different drugs that may have been 
tried within a particular class.   
 
* Ecstasy has notable serotonergic and dopaminergic effects. 
 
Alcohol = glutamatergic; Cannabis, Cocaine and Amphetamine = dopaminergic; LSD 
and “magic mushrooms” (Psilocybin) = serotonergic; Ecstasy (MDMA) = 




The high level of serotonergic agents tried by 48% of the clinical participants is also 
interesting as during a period when LSD use was legal on both sides of the Atlantic, many 
cases of psychosis were associated with its use (Grof 1975).  Clozapine has been 
demonstrated to have antagonistic effects at certain serotonin receptors and treatment might 
even lead to a downregulation (e.g. Hietala et al. (1992). Further, 28% of TRS participants 
indicated the use of ecstasy (3,4-Methylenedioxymethamphetamine, or MDMA), which has 
notable effects on both dopamine and serotonin systems.  Alcohol, which has glutamatergic 
effects, can be highly excitotoxic, particularly, during vulnerable periods, as observed in 
offspring with foetal alcohol syndrome.  Of those who had age of alcohol use had predated 
the first onset of illness, 28% of the group (i.e. 7/9 participants) described periods of “binge” 




































Estimated Pharmacological Exposure by Drug Type Prior to a 
First Episode of Psychosis
Lower PANSS (n = 14) Higher PANSS (n = 11)
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Some clues as to LSD’s biological and psychotropic effects comes from research by 
Muthukumaraswamy et al. (2013) with a related drug, psilocybin, a nonselective agonist at a 
serotonin (5HT2A) receptor.  In healthy individuals, this was observed to reduce the power 
of intrinsic oscillations in frontal association cortices, posterior association cortices and the 
default mode network.  Further, through dynamic causal modelling of cell populations it 
was determined that an increase in the excitability of deep-layer neurons which have a high 
density of 5HT2A receptors in the cingulate cortex explained desynchronization in a major 
hub of the DMN, the posterior cingulate cortex. This was consistent with previous work in 
the area by this group, who concluded “breakdown of brain networks may be a fundamental 
feature of the psychedelic state.” 
  
The use of MDMA (“ecstasy”) is also concerning, as a pure substance, for example, 
dopaminergic terminals in striosomes of the mouse striatum were observed to be vulnerable 
to loss after MDMA administration (Granado et al., 2008)  In a further study, Granado et al. 
(2010) observed depletions in tyrosine hydroxylase following metamphetamine, particularly 
in the striosomes rather than the matrix of the basal ganglia, commenting this pattern is 
similar to the effects of neurotoxins used in models of PD and early Huntingdon’s.     
In addition to the dopaminergic and serotonergic effects, cheaper drugs have often been 
mixed in during manufacture to dilute the drug (e.g. one study which analysed 25 ecstasy 
tablets from around the UK found high doses of ketamine in 2 tablets.61     
Therefore “ecstasy” either as pure MDMA, or combined with other substances and, perhaps, 
in the context of potentiated release of very high levels of cortisol on the dance-floor 
(Parrott, 2008, 2009), could surely be neurotoxic?    
 
These observations may not be unusual in schizophrenia research although illicit drug use 
may be under-reported:  for example, in the US-based multi-centre CATIE study of 1042  
individuals, 38% tested positive for at least one of three drug types (cannabis, cocaine and 
metamphetamine), although 58% of these did not disclose this in self-rated assessments 
(Bahorik et al., 2014).  In a further study of 974 individuals, Bahorik et al. (2014) observed 
there were no improvements in cognition associated with positive drug screening tests, 
indeed quite the reverse for cocaine, which was associated with reduced processing speed, 
while amphetamine at low dose increased it moderately.  However, generally, no significant 
differences in cognition were observed between individuals with schizophrenia who tested 
 
61 Other contaminants found in some tablets were the stimulants caffeine, amphetamine, 
amphetamine and ephedrine.  Paracetamol had also been used as “cutting agent” although “not 
present in concentrations likely to cause harm, even if individuals took several tablets in one 
evening.”  Sherlock et al., 1999, p.196.   
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positive for drug use (cannabis, cocaine and methamphetamine) and those who tested 
negatively; however, this does not exclude the possibility of impairment with other types of 
drug such as ketamine or PCP (both NMDA antagonists) or LSD (serotonergic).   
 
This data may reflect drug taking patterns in S.E. London generally and, what was available 
over a 25-year period from around 1978-2003 (the earliest first diagnosis in the cohort was 
in 1985 and last was in 2003).  The NMDA antagonist ketamine which can induce 
schizophrenia-like symptoms was not on the list asked of participants but may have become 




62  Ketamine was described in one memoir as “the new kid on the block” in 2003 ... Ecstasy had been 
the drug of choice in the ’90s, LSD felt like a relic from the ’60s, and mushrooms were as old as the 




APPENDIX 2  
Tables of Within Group Activations Relative to the Baseline (‘Is it X?’) 
-  Within Control Group Significant Increases 
Table Appx. 2. 1.1   Within Control Group:  areas exhibiting significant 
increases in activation relative to the baseline task (‘Is it X?’) during the 1-Back 
condition 









 Talairach  
co-ordinates*  
  x        y       z 
Inferior Frontal Gyrus - R  155 0.0030  40 52    0 
Middle Frontal Gyrus BA 10 L    96 0.0041 -33 44  17 
Middle Frontal Gyrus BA 10 R  384 0.0015  36 37  23 
Precentral Gyrus BA 9 L  117 0.0036 -43 22  36 
Insula BA 13 L  129 0.0036 -33 15  10 
Middle Frontal Gyrus BA 6 R  461 0.0005  28  9  55 
Inferior Frontal Gyrus BA 9 R  205 0.0012  43  4  26 
Middle Frontal Gyrus BA 6  L  268 0.0015 -28  0  50 
Thalamus - R  193 0.0041  11 -7    3 
Thalamus -    87 0.0055 -18 -15  10 
Midbrain, Substantia Nigra 
(10.0mm away) 
- R   19 0.0071  10 -20 -10 
Superior Temporal Gyrus BA 22 L    37 0.0045 -51 -37  10 
Temporal Lobe, Sub-Gyral - R 324 0.0030  47 -41  -7 
Parietal lobe, subgyral BA 7 R 313 0.0002  37 -44  33 
(Posterior) Cingulate Gyrus BA 31 L 214 0.0021 -19 -44  37 
Parahippocampal Gyrus BA 19 L 142 0.0036 -40 -44   -7 
Cerebellum, Anterior Lobe, 
Culmen 
- L 104 0.0061 -40 -48 -20 
Cerebellum, Anterior Lobe, 
Culmen 
- L   24 0.0066    0 -52 -13 
Temporal Lobe, Fusiform 
Gyrus 
BA 37 R 266 0.0016  40 -59 -10 
Precuneus  BA 7 R   35 0.0004  23 -63  30 
Temporal Lobe, Fusiform 
Gyrus  
BA 37 L 223 0.0021 -40 -63 -11 
Posterior Cingulate BA 18 L 185 0.0013 -25 -67  16 
Superior Parietal Lobule BA 7 L   37 0.0047 -22 -74  44 
Occipital Lobe, Lingual 
Gyrus 
BA 18 R 201 0.0023   25 -74 -10 
 






Table Appx. 2. 1.2   Within Control Group:  areas exhibiting significant 
increases in activation relative to the baseline task (‘Is it X?’) during the 2-Back 
condition 
Anatomical Location             Brodmann  






p-Value  Talairach  
co-ordinates*  
  x        y       z 
Middle Frontal Gyrus BA 10 R 408 0.00000  40  59  13 
Superior Frontal Gyrus BA 10 L 385 0.00001 -36  48  20 
Superior Frontal Gyrus BA 9 R 432 0.00000  40  37  30 
Inferior Frontal Gyrus BA 13 R 350 0.00002  33  22    7 
Claustrum - L 276 0.00001 -25  22    7 
Middle Frontal Gyrus BA46 L 460 0.00000 -40  19  23 
Superior Frontal Gyrus BA 6  L 310 0.00000    0    7  50 
Inferior Frontal Gyrus BA 9 R 279 0.00000  43    4  23 
Superior Frontal Gyrus BA 6 L 410 0.00000 -25    4  50 
Frontal Lobe, Sub-Gyral BA 6 R 529 0.00000  25    4  53 
Thalamus, Anterior Nucleus BA  L 399 0.00014 -11   -4    7 
Thalamus - R 412 0.00015  11   -4    3 
Brainstem: Substantia Nigra 
(9.8mm away) 
- R 147 0.00121  12 -16 -10 
Superior Temporal Gyrus BA 22 R 542 0.00019  43 -26   -3 
Temporal Lobe, Fusiform Gyrus BA 37 L 859 0.00014 -40 -44 -10 
Cerebellum, Anterior Lobe, 
Cerebellar Lingual 
- R 163 0.00082   0  -44 -17 
Inferior Parietal Lobule 
(6.4 mm away) 
BA 40 R 585 0.00000  36 -45  40 
Cerebellum, Anterior Lobe - R 208 0.00008  29 -56 -30 
Middle Temporal Gyrus 
(10.0 mm away from grey) 
BA 39 L 421 0.00001 -31 -57  29 
Cerebellum, Posterior Lobe, 
Cerebellar Tonsil 
- L 402 0.00008 -36 -59 -33 
Posterior Cingulate 
(5.8 mm away) 
BA 31 R 536 0.00000  21 -62  17 
Precuneus BA 7 L 533 0.00000 -21 -63  33 
Cerebellum, Posterior Lobe, 
Uvula, 
- L 161 0.00107 -11 -63 -33 
Occipital Lobe, Lingual Gyrus, BA 19 R 291 0.00027  29 -63    0 
Cerebellum, Posterior Lobe, 
Declive 
- R 213 0.00301   4 -67 -20 
Cerebellum, Posterior Lobe, 
Declive 
- R 214 0.00024  33 -67 -17 
 







Table Appx. 2. 1.3   Within Control Group:  areas exhibiting significant 
increases in activation relative to the baseline task (‘Is it X?’) during the 3-Back 
condition 
Anatomical Location           Brodmann  






p-Value  Talairach  
co-ordinates*  
   x        y       z 
Middle Frontal Gyrus BA 10 R 390 0.00000  40  56  13 
Middle Frontal Gyrus BA 10  L 511 0.00001 -36  37  23 
Middle Frontal Gyrus BA 9 R 399 0.00000  36  37  33 
Inferior Frontal Gyrus BA 45 R 505 0.00001  29  30   7 
Claustrum - L 455 0.00001 -25  26   3 
Middle Frontal Gyrus BA 9 L 343 0.00000 -47  19 36 
Inferior Frontal Gyrus,  
(5.2 mm away) 
BA 9 R 331 0.00001  46  10 26 
Superior Frontal Gyrus BA 6 L 374 0.00000   -4    4 53 
Frontal Lobe, Sub-Gyral BA 6 L 337 0.00000 -25    0 53 
Frontal Lobe, Sub-Gyral BA 6 R 495 0.00000  27   -1 55 
Thalamus -  R 518 0.00003  11   -4   3 
Thalamus, Ventral Lateral 
Nucleus 
- L 456 0.00022 -11 -11 10 
Brainstem: Substantia Nigra 
(10.0 mm away) 
- R 190 0.00061  10 -16 -10 
Middle Temporal Gyrus BA 20 R 538 0.00021  51 -37 -10 
Parietal Lobe, Sub-Gyral BA 40 R 911 0.00000  36 -44  33 
Parahippocampal Gyrus 
(7.3 mm away) 
BA 19 L 496 0.00027 -37 -44  -3 
Cerebellum, Anterior Lobe, 
Cerebellar Lingual 
- R 164 0.00084   0 -45 -17 
Fusiform Gyrus BA 37 L 329 0.00044 -40 -48 -17 
Cerebellum, Posterior Lobe, 
Cerebellar Tonsil 
- R 197 0.00086  33 -52 -33 
Cerebellum, Posterior Lobe, 
Cerebellar Tonsil 
- L 258 0.00023 -33 -56 -33 
Middle Temporal Gyrus 
(6.7 mm away) 
BA 37 R 481 0.00073  40 -56   0 
Precuneus, (10.0 mm away) BA 19 L 694 0.00002 -31 -62  42 
Cerebellum, Posterior Lobe, 
Uvula 
- L 369 0.00100 -11 -63 -30 
Posterior Cingulate BA 30 L 328 0.00022 -29 -70  13 
 











-  Within Control Group Significant Decreases 
Table Appx. 2. 1.4   Within Control Group:  areas exhibiting significant 
decreases in activation relative to the baseline task (‘Is it X?’) during the 1-
Back condition 







p-Value  Talairach  
co-ordinates*  
   x        y       z 
Medial Frontal Gyrus BA 10 L  122 0.00432 -14  33 -6 
Superior Frontal Gyrus BA 9 R 543 0.00013    4  56 23 
Superior Frontal Gyrus BA 9 L  421 0.00013 -11  52 36 
Anterior Cingulate - R 147 0.00224    4  48  0 
Superior Frontal Gyrus BA 6 L  415 0.00131 -11  30 56 
Superior Temporal Gyrus BA 38 L  175 0.00150 -40  19 -30 
Sub-lobar Extra-Nuclear BA 13 L    65 0.00522 -25  19 -10 
Superior Temporal Gyrus BA 22 R   39 0.00331  54  11  0 
Superior Temporal Gyrus BA 22 L    10 0.00720 -61  11  -3 
Middle Temporal Gyrus BA 21 R 289 0.00263  43  7 -30 
Cingulate Gyrus BA 24  R 259 0.00117    7  7 33 
Superior Temporal Gyrus BA 21 L    28 0.00752 -54 -4  3 
Cingulate Gyrus BA 24 L  265 0.00007    0 -11 40 
Parahippocampal Gyrus BA 28 L    82 0.00718 -18 -15 -13 
Postcentral Gyrus  
(nearest grey 5.2mm away) 
BA 2 R 224 0.00315  58 -22 23 
Postcentral Gyrus BA 1 L    24 0.00440 -65 -22 23 
Insula BA 13 R 127 0.00340  43 -22 17 
Postcentral Gyrus BA 2 L  122 0.00517 -44 -22 30 
Posterior Cingulate Gyrus BA 31 L  254 0.00032   -7 -30 40 
Inferior Parietal Lobule BA 40 L  134 0.00501 -36 -37 50 
Postcentral Gyrus BA 5 R   24 0.00341  40 -41 63 
Posterior Cingulate Gyrus BA 31 L  661 0.00030   -7 -44 33 
Precuneus BA 7 L  143 0.00402   -7 -48 59 
Precuneus, BA 19 L  113  0.00371 -43 -74 36 
Middle Temporal Gyrus BA 39 L  118 0.00189  43 -59 10 
Inferior Parietal Lobule BA 40  L    59 0.00420  -58 -59 40 
Middle Occipital Gyrus 
(BA 18 is sometimes described 
as the Posterior Cingulate) 
BA 18 R   51 0.00389  14 -92 17 
 
27 clusters ordered from an anterior to posterior in the coronal plane. 






Table Appx. 2. 1.5   Within Control Group:  areas exhibiting significant 
decreases in activation relative to the baseline task (‘Is it X?’) during the 2-
Back condition 









 Talairach  
co-ordinates*  
  x        y       z 
Superior Frontal Gyrus BA 10 R 1260 0.00000    4 59  26 
Superior Frontal Gyrus BA 8 L   730 0.00000 -15 30  46 
Superior Temporal Gyrus BA 38 L   599 0.00008 -36 15 -23 
Superior Temporal Gyrus BA 38 R   415 0.00011  43 11 -30 
Cingulate Gyrus BA 24 R   387 0.00004   7 7  33 
Putamen - L   578 0.00055 -18 4 -10 
Precentral Gyrus BA 43 R   338 0.00006  51  -4  10 
Claustrum - R   543 0.00051  36  -4 -7 
Precentral Gyrus BA 6 L   221 0.00054 -51  -7  7 
Superior Temporal Gyrus BA 22 L   251 0.00134 -51  -7 -7 
Claustrum - L   344 0.00014 -33 -11 13 
Cingulate Gyrus  BA 24 L   599 0.00000  -4 -15 33 
Insula BA 13 R   809 0.00000  47 -26 23 
Cingulate Gyrus  BA 31 L 2233 0.00000   -7 -33 36 
Middle Temporal Gyrus BA 39 L   676 0.00033 -43 -56 10 
Cerebellum, Posterior Lobe, 
Inferior Semi-Lunar Lobule 
- R   261 0.00032   29 -74 40 
 







Table Appx. 2. 1.6   Within Control Group:  areas exhibiting significant 
decreases in activation relative to the baseline task (‘Is it X?’) during the 3-
Back condition 









 Talairach  
co-ordinates*  
  x        y       z 
Superior Frontal Gyrus BA 9 L 2191 0.00000   -4 48  30 
Superior Temporal Gyrus BA 38 L   812 0.00015 -33 11 -30 
Middle Temporal Gyrus BA 21 R   696 0.00089  36  4 -30 
Claustrum - L   720 0.00039 -33 -7  13 
Precentral Gyrus BA 4 R   618 0.00000  47 -15  43 
Parahippocampal Gyrus BA 28 L   529 0.00101 -22 -15 -13 
Cingulate Gyrus BA 24 R 1687 0.00000   4 -19  40 
Insula BA 13 R   769 0.00001  47 -22  20 
Precentral Gyrus 
(8.1 mm away) 
BA 4 L   728 0.00000 -25 -28  48 
Postcentral Gyrus BA 3 L   544 0.00000 -22 -33  59 
Cerebellum, Anterior Lobe, 
Culmen 
- R   304 0.00131  22 -37 -17 
Parietal Lobe, Supramarginal 
Gyrus 
BA 40 L   172 0.00301 -61 -48  33 
Middle Temporal Gyrus BA 39 L   201 0.00062 -43 -56  10 
Cuneus BA 17 R   733 0.00025  11 -85   7 
 







Tables of Within TRS Group Activations Relative to the Baseline (‘Is it X?’) 
-  Within TRS Group Significant Increases 
Table Appx. 2. 2.1   Within TRS Group: areas exhibiting significant increases 
in activation relative to the baseline task (‘Is it X?’) during the 1-Back 
condition 




Cluster   p-Value  
size  
(mm3) 
 Talairach  
co-ordinates*  
 x       y       z 
Middle Frontal Gyrus 
(nearest grey 6.9mm away) 
BA 10 R 296 0.00075  36   45  11 
Middle Frontal Gyrus BA 10 L 331 0.00108 -36  41  13 
Middle Frontal Gyrus BA 46 R 104 0.00193  43  33  23 
Middle Frontal Gyrus BA 9 L 111 0.00380  -40  26  33 
Precentral Gyrus BA 44 R   64 0.00395  51  15    7 
Middle Frontal Gyrus BA 9 R   86 0.00305   43  11  33 
Superior Frontal Gyrus BA 6 L 207 0.00164   -4   7  56 
Precentral Gyrus BA  6 L 166 0.00118 -40   0  30 
Middle Frontal Gyrus BA 6 L   99 0.00435 -29   0  56 
Frontal Lobe, Sub-Gyral BA 6 R 164 0.00109  29  -4  53 
Thalamus - L   59 0.00471 -11  -7    0 
Thalamus, Ventral Lateral 
Nucleus 
- R 121 0.00664  14 -11  10 
Thalamus, Medial Dorsal 
Nucleus 
- L   44 0.00692   -7 -22  10 
Middle Temporal Gyrus 
(nearest grey 5.7 mm away) 
BA  20 R   94 0.00339   51 -37 -11 
Inferior Parietal Lobule BA 40 R 265 0.00022  40 -44  40 
Fusiform Gyrus BA 37 R 126 0.00266  47 -48 -17 
Cerebellum, Posterior Lobe, 
Declive 
- L 137 0.00334 -51 -52 -20 
Cerebellum, Posterior Lobe, 
Cerebellar Tonsil 
- R   91 0.00459  36 -56 -36 
Middle Temporal Gyrus 
(nearest grey 5.2 mm away) 
BA 39 L 516 0.00016  -31 -57  29 
Precuneus BA 7 R 176 0.00140  14 -67  46 
 








Table Appx. 2. 2.2   Within TRS Group: areas exhibiting significant increases 
in activation relative to the baseline task (‘Is it X?’) during the 2-Back 
condition. 




Cluster   p-Value  
size  
(mm3) 
 Talairach  
co-ordinates*  
   x      y      z 
Middle Frontal Gyrus 
(nearest grey 5.2 mm away) 
BA 10 R 338 0.00001  39  47  10 
Temporal Lobe, Sub-Gyral  
(nearest grey 6.4 mm away) 
BA 37 R 405 0.00006  47  45  -7 
Middle Frontal Gyrus BA 10 L 550 0.00001 -36  41  13 
Middle Frontal Gyrus 
 
BA 10 R 209 0.00003  33  41  20 
Middle Frontal Gyrus BA 9 R 163 0.00001  41  33  34 
Middle Frontal Gyrus BA 9 L 227 0.00003 -40  30  30 
Insula BA 45  R 414 0.00006  29  26    7 
Insula BA 13 L 333 0.00002 -36  20    8 
Medial Frontal Gyrus BA 6 R 263 0.00001    6  16  44 
Inferior Frontal Gyrus BA 9 R 248 0.00007  40    7  26 
Putamen - L 289 0.00050 -14    3    7 
Precentral Gyrus BA 6 L 280 0.00001 -40    0  30 
Frontal Lobe, Sub-Gyral BA 6 L 380 0.00000 -22    0  56 
Medial Globus Pallidus, - R 379 0.00138  11   -4    0 
Middle Frontal Gyrus BA 6 R 259 0.00000  25   -7  50 
Inferior Parietal Lobule 
(nearest grey 7.7 mm away) 
BA 40 L 461 0.00000 -35 -47  38 
Angular Gyrus BA 39 R 585 0.00000  33 -56  36 
Cerebellum, Posterior Lobe, 
Declive 
- L 463 0.00077 -40 -56 -20 
Cerebellar Tonsil - L 199 0.00033 -40 -59 -33 




R 330 0.00015  36 -63 -33 
Precuneus BA 7 L 385 0.00004 -14 -67  43 
Cerebellum, Posterior Lobe, 
Uvula 
- L 290 0.00068   -7 -74 -33 
Fusiform Gyrus BA 19 R 184 0.00233  33 -78 -13 
 











Table Appx. 2. 2.3   Within TRS Group: areas exhibiting significant increases 
in activation relative to the baseline task (‘Is it X?’) during the 3-Back 
condition 







p-Value  Talairach  
co-ordinates*  
   x        y       z 
Middle Frontal Gyrus BA 10 R   66 0.00001  25  56  10 
Superior Frontal Gyrus BA 11 R   46 0.00696  11  48 -13 
Middle Frontal Gyrus BA 10 L 411 0.00001 -36  41  13 
Middle Frontal Gyrus BA 9 R 276 0.00002   40  33  30 
Middle Frontal Gyrus BA 9 L 216 0.00001 -40  30  30 
Insula BA 13 R 445 0.00005   33  22    3 
Insula BA 13 L 378 0.00007  -33  19    7 
Middle Frontal Gyrus BA 9 R 207 0.00008   50  14  26 
Medial Frontal Gyrus BA 6 R 345 0.00000     4  14  46 
Inferior Frontal Gyrus BA 9 L 270 0.00001 -40    4  30 
Caudate Body - L 243 0.00034 -14    4  13 
Frontal Lobe, Sub-Gyral BA 6 R 249 0.00000  29    0  53 
Middle Frontal Gyrus BA 6 L 298 0.00002  -25   -4  46 
Hypothalamus - R 487 0.00143    7   -7   -3 
Middle Temporal Gyrus BA 21 L   64 0.00440 -58 -19   -7 
Middle Temporal Gyrus BA  21 R 235 0.00114   58 -26 -10 
Superior Temporal Gyrus BA 22 L   85 0.00250  -58 -41  10 
Inferior Parietal Lobule BA 40 R 435 0.00001  36 -48  36 
Inferior Parietal Lobule BA 40 L 276 0.00000  -47 -48  36  
Fusiform Gyrus BA 37 L 328 0.00040 -51 -48 -20 
Precuneus BA 7 L 529 0.00006  -14 -67  43 
Cerebellum, Posterior Lobe, 
Tuber 
- R 374 0.00040  36 -67 -26 
Cerebellum, Posterior Lobe, 
Uvula 
- L 216 0.00089    -7 -78 -33 
 








-  Within TRS Group Significant Decreases 
Table Appx. 2. 2.4   Within TRS Group: areas exhibiting significant decreases 
in activation relative to the baseline task (‘Is it X?’) during the 1-Back 
condition 









 Talairach  
co-ordinates*  
   x        y       z 
Superior Frontal Gyrus BA 9 R   94 0.00155    7  56  28 
Superior Frontal Gyrus BA 9 L 117 0.00168   -7  56  26 
Medial Frontal Gyrus BA  R 208 0.00248    7  52   13 
Superior Frontal Gyrus BA 8 R   17 0.00591  13  47  47 
Superior Frontal Gyrus BA 8 L 204 0.00184 -10  37  43 
Cingulate Gyrus   BA 24  L 449 0.00083 -15  36  -0 
Superior Frontal Gyrus BA 8 R   93 0.00262  22  33  43 
Inferior Frontal Gyrus 
(nearest grey 6.9mm away) 
BA 47 R   48 0.00322  57  23  -3 
Superior Temporal Gyrus BA 38 L   65 0.00566 -43   11 -26 
Middle Temporal Gyrus BA 21 L   47 0.00151 -58    4  13 
Middle Temporal Gyrus BA 21 R   82 0.00381  54    0 -17 
Precentral Gyrus 
(nearest grey 6.9mm away) 
BA 6 R 212 0.00445  47 -11  30 
Superior Temporal Gyrus BA 42 R   38 0.00221  69 -30  17 
Precentral Gyrus BA 4 L 292 0.00162 -29 -30  59 
Cerebellum, Anterior Lobe, 
Culmen 
- L   50 0.00830 -25 -33 -30 
Parahippocampal Gyrus BA 36 L   79 0.00686 -22 -33 -13 
Cerebellum, Anterior Lobe -  R   82 0.00530  22 -33 -26 
Cingulate Gyrus  BA 31 L 330 0.00045 -11 -41  30 
Posterior Cingulate BA 23 R 411 0.00058    7 -44  26 
Parahippocampal Gyrus BA 30 L 151 0.00211 -11 -45    3 
Cerebellum, Anterior Lobe, 
Culmen 
- R 176 0.00277  11 -48    0 
Middle Temporal Gyrus BA 22 R 129 0.00557  54 -48    3 
Cerebellum, Anterior Lobe - R   70 0.00917    4 -52 -26 
Middle Temporal Gyrus BA 39 L 107 0.00288 -47 -67  23 
Lingual Gyrus BA 18 R 117 0.00533  11 -78  -3 
Lingual Gyrus BA 18 R   90 0.00434  18 -78   0 
 








Table Appx. 2. 2.5   Within TRS Group: areas exhibiting significant decreases 
in activation relative to the baseline task (‘Is it X?’) during the 2-Back 
condition 







p-Value  Talairach  
co-ordinates*  
   x        y       z 
Medial Frontal Gyrus BA 9 R   586 0.00002    0  52  13 
Cingulate Gyrus (Dorsal 
PCC) 
BA 31 R 1136 0.00000  11 -40  30 
Medial Frontal Gyrus BA 8 L   585 0.00009 -14  33  43 
Inferior Frontal Gyrus BA 9 R     93 0.00033   65  19  30 
Superior Temporal Gyrus BA 38 R   192 0.00248  47  15 -23 
Middle Temporal Gyrus BA 21 L   236 0.00226  -43   4 -23 
Middle Temporal Gyrus BA 21 L   130 0.00137 -58   4 -13 
Cingulate Gyrus (Anterior) BA 24 R   951 0.00000    0 -11  40 
Postcentral Gyrus,   BA 3 L   261 0.00006 -51 -19  36 
Precentral Gyrus BA 4 L   549 0.00000 -36 -20  40 
Insula BA 13 L   367 0.00026  -43 -26  13 
Superior Temporal Gyrus BA 42 R   183 0.00101   69 -30  17 
Hippocampus - L   187 0.00093 -29 -30   -7 
Cerebellum, Anterior Lobe, 
Culmen 
- L   109 0.00210 -22 -30 -26 
Cerebellum, Anterior Lobe - R   254 0.00084  22 -37 -26 
Precuneus BA 31 L   639 0.00000 -14 -48  30 
Parahippocampal Gyrus BA 30 L   823 0.00005 -11 -48    3 
Cerebellum, Anterior Lobe, 
Dentate 
- L    78 0.00126 -14 -48 -23 
Cerebellum, Anterior Lobe - L   229 0.00064   -7 -48   -0 
Middle Temporal Gyrus BA 39 L   173 0.00101 -47 -70  13 
 







Table Appx. 2. 2.6   Within TRS Group: areas exhibiting significant decreases 
in activation relative to the baseline task (‘Is it X?’) during the 3-Back 
condition 









 Talairach  
co-ordinates*  
   x        y       z 
Medial Frontal Gyrus BA 9 L   767 0.00021    -7  52 33 
Superior Frontal Gyrus BA 8 R   321 0.00051   17  44 46 
Superior Temporal Gyrus BA 38 R     36 0.00304   33  22 26 
Superior Temporal Gyrus BA 38 R     68 0.00216   47  11 23 
Middle Temporal Gyrus BA 38 L   218 0.00185  -43   7 23 
Middle Temporal Gyrus BA 21 R     19 0.00303   61   0 20 
Cingulate Gyrus (Anterior) BA 24 L   916 0.00000   -5 -17 42 
Postcentral Gyrus BA 3 R   565 0.00000   40 -22 40 
Superior Temporal Gyrus BA 41 R 1247 0.00017   47 -26 17 
Transverse Temporal Gyrus BA 41 L   843 0.00025 -36 -26 13 
Cingulate Gyrus (Posterior) BA 31 R 1036 0.00000  18 -30 43 
Cingulate Gyrus (Posterior) BA 31 L 1032 0.00000 -14 -37 36 
Parahippocampal Gyrus BA 36 L   144 0.00409 -25 -37 13 
Cerebellum, Anterior Lobe, 
Culmen 
- R   549 0.00113  11 -44 13 
Cerebellum, Posterior Lobe, 
Tonsil, (6.9 mm away) 
- L   126 0.00590 -11 -45 32 
Lingual Gyrus BA 18 L   563 0.00001 -14 -52  3 
Cerebellum, Posterior Lobe, 
Declive 
- L   102 0.00372 -14  -59 13 
Middle Temporal Gyrus BA 39 L   199 0.00082 -47 -70 17 
Lingual Gyrus - L   671 0.00013   -7 -78   0 
 








Factorial Analysis (TRS and Controls) using the voxel p-Value of 0.01 
 
Table Appx. 3. 1    Factorial ANCOVAs comparing the haemodynamic 
response in TRS and Control Groups using a voxel p-Value of 0.01  









 Talairach  
co-ordinates*  
   x        y       z 
Superior Frontal Gyrus BA 6 L    93 0.00594    0    4 50 
Precuneus BA 7 R  172 0.00264  22 -59 26 
 











p-Value  Talairach  
co-ordinates*  
   x        y       z 
Medial Frontal Gyrus BA 8 L  271 0.00064   -4  52  40 
Cingulate Gyrus 
(6.9mm away from nearest grey) 
BA 31  L  195 0.00128 
 
  -7 -30  33 
 







Figure Appx 3. 1   Haemodynamic response in the right Precuneus (BA 7) at 
different levels of cognitive load in TRS individuals compared with Controls 
 
 
R Precuneus, BA7 1-Back 2-Back 3-Back 
TRS Group 0.012699 0.038963 0.010952 
Control Group 0.035352 0.111436 0.140326 
* Significant at p =   0.00594 
 
 
Figure Appx 3. 2   Haemodynamic response in the left Superior Frontal Gyrus 




 1-Back 2-Back 3-Back 
TRS Group 0.01881 0.05745 0.04568 
Control Group 0.03695 0.12027 0.15800 















Right Precuneus, BA 7

















Left Superior Frontal Gyrus, BA 6




Figure Appx 3. 3   Haemodynamic response in the left Medial Frontal Gyrus 




 1-Back 2-Back 3-Back 
TRS Group -0.01418 -0.04640 -0.02808 
Control Group -0.05127 -0.16462 -0.14883 
* Significant at p = 0.00064 
 
 
Figure Appx 3. 4   Haemodynamic response in the left Medial Frontal Gyrus 




 1-Back 2-Back 3-Back 
TRS Group -0.01912 -0.06601 -0.05857 
Control Group -0.04316 -0.15532 -0.17532 












Left Medial Frontal Gyrus, BA 8












Left Cingulate Gyrus, BA 31

















Factorial Analysis (Lower and Higher PANSS) using the voxel p-Value of 0.01 
 
Table Appx. 3. 2   Factorial ANCOVAs comparing the haemodynamic response 
in the Lower and Higher PANSS Groups using a voxel p-Value of 0.01 
 









 Talairach  
co-ordinates*  
   x        y       z 
Paracentral Lobule BA 31 L  101 0.0016   0 -33 43 
 
NB:  Age was a covariate; threshold used voxel p value = 0.1 
 
 









 Talairach  
co-ordinates*  
   x        y       z 
Supramarginal Gyrus BA 40 L   43 0.00342 -43 -48 33 
Middle Frontal Gyrus BA 9 L   65 0.00137 -36  26 30 
Middle Frontal Gyrus BA 6 R   34 0.00343  29   -4 50 
 
NB:  Activation clusters ordered from anterior to posterior 























Figure Appx. 3. 6    Haemodynamic response in right Middle Frontal Gyrus 




 1-Back 2-Back 3-Back 
TRS Higher PANSS -0.04098 -0.08382 -0.09355 
TRS Lower PANSS -0.01764 -0.03462 -0.05182 
* Significant at p = 0.001552 
 
Figure Appx. 3. 7    Haemodynamic response in the left Supramarginal Gyrus 




 1-Back 2-Back 3-Back 
TRS Higher PANSS 0.05316 0.10351 0.09271 
TRS Lower PANSS 0.02246 0.03015 0.03074 













Left Paracentral Lobule, BA 31 
(x = -1, y = -31, z = 45)













Left Supramarginal Gyrus, BA 40
(x = -41, y = -46, z = 35) 
TRS Lower PANSS TRS Higher PANSS
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Figure Appx. 3. 8    Haemodynamic response in left Middle Frontal Gyrus (BA 




 1-Back 2-Back 3-Back 
TRS Higher PANSS 0.03449 0.07644 0.09248 
TRS Lower PANSS 0.00669 0.03146 0.02461 
* Significant at p = 0.001371 
 
Figure Appx. 3. 9    Haemodynamic response in right Middle Frontal Gyrus 




 1-Back 2-Back 3-Back 
TRS Higher PANSS 0.01930 0.08033 0.10363 
TRS Lower PANSS 0.01307 0.03119 0.02640 












Left Middle Frontal Gyrus, BA 9
(x = -35, y = 25, z =31)













Right Middle Frontal Gyrus, BA 6
(x = 29, y = -4, z = 50)







Figure Appx. 3. 10   Statistical Maps in the factorial analysis (Lower vs Higher PANSS) at the voxel p-value threshold of 0.01 
Statistical Maps of the Factorial Interaction between TRS Participants Grouped According to Symptom Severity (Lower and Higher 









APPENDIX 4:  
Supplementary Data - Verbal Learning using the HVLT-R 
Table Appx. 4. 1   Attenuated Recency Effect in the Recall of Auditorily 
Presented Word Lists in TRS?  
 
 1st Presentation 2nd Presentation 3rd Presentation 
Lower PANSS Number of items 
recalled at the last 3 
positions in the list 
Number of items 
recalled at the last 3 
positions in the list 
Number of items 
recalled at the last 3 
positions in the list 
ID09* 2  3 = recency effect? 3 = recency effect? 
ID 10 2 2 2 
ID 11 2 2  3 = recency effect? 
ID 38* 2 2 3 = recency effect? 
ID 13 2 1  2 
ID 23 1 3 = recency effect? 2  
ID 25 1 3 = recency effect? 3 = recency effect? 
ID 14 1 2 2 
ID 18 1 2 3 = recency effect? 
ID 15 0 2 2 
ID 17* 0 2 2  
ID 24 0 2 2  
ID 43 0 0 0 
Higher PANSS    
ID 48** 3 = recency effect? 3 = recency effect? 3 = recency effect? 
ID 08*** 3 = recency effect? 2 3 = recency effect? 
ID 22 2 2 2  
ID 26 2 2 2 
ID 15 1 2 2 
ID 19 1 2 1  
ID 45* 1 3 = recency effect? 3 = recency effect? 
ID 46 1 3 = recency effect? 3 = recency effect? 
ID 27 1 1 2 
ID 41 0 0 2 
ID 44 0 1 0 
Mean recall at last 3 position 1.21 1.96 2.17 
No. individuals who recalled 







No. individuals who recalled 







N = 24 
 
Behaviourally, it is noted that on the first trial:  
Ninety-two percent (22/24) of TRS participants did not begin recall with the last item from the list.  
* VIQ>PIQ individuals.  Despite superior verbal IQ, none who showed this asymmetry started their 
recall on the first trial with any item from the last 3 positions in the list. 
** The last three items were recalled at the end, in reverse order starting with “hut”. 
*** None achieved the classic pattern of starting recall with the last three items in reverse order, 




Supplementary Data - Some Inter-correlations between the MCCB Scores and 
other Neuropsychological, Behavioural and Clinical Measures  
 
The correlations in Table Appx. 4. 2 below are mostly between MCCB domains and the 
MCCB overall composite scores using the standardised percentile scores, except for total 
negative and positive symptom scores, also RTs and SDs in the 0-Back condition of the  
N-Back task (proposed as proxy measures of processing speed and sustained attention, 
respectively). 
 
The correlations with the MCCB overall composite involving verbal and visual learning, 
PIQ and VIQ are also shown in Table 3. 11, section 3.5, but are repeated here so all the 
composite correlations are in one place and because the presence of p-values at .001 and 












MCCB Speed of Processing Composite    TRS  (PSZ)   
- MCCB Overall Composite    .750   ¬ .91     24    .0005*** 
- Symbol Coding (BAC SC)    .712 24    .0005*** 
- Trail Making Test (TMT)    .373 24    .073 
- Category Fluency    .305 24    .147 
- Reaction Times in the 0-Back Condition   -.405 24    .050* 
MCCB Working Memory Composite    
- MCCB Overall Composite    .718   ¬ .83    24    .0005*** 
- Verbal Span    .633        .001*** 
- Spatial Span    .504 24    .012* 
Learning correlated with the MCCB 
Overall Composite 
   
- Verbal Learning    .415   ¬ .8        24    .043* 
- Visual Learning    .818   ¬ .79 24    .0005*** 
Attention correlated with the MCCB 
Overall Composite 
   
- Sustained Attention/Vigilance (CPT-IP)    .485  ¬ .86   24    .016* 
- Standard Deviations in the 0-Back      -.373 24    .073 
Reasoning and Problem Solving 
correlated with the MCCB Composite 
   
- NAB Mazes    .713   ¬ .64 24    .001*** 
Social Cognition    
- MCCB Overall Composite    .262   ¬ .65     24    .216 
Estimated IQ (WASI) correlated with 
the MCCB Overall Composite 
   
- Full-Scale IQ    .681 24   .0005*** 
- Performance IQ    .689 24   .0005*** 
- Verbal IQ    .536 24   .007*** 
Symptoms (PANSS) correlated with the 
MCCB Overall Composite 
   
- Total Negative Symptoms Scores   -.455 23   .029* 
- Total Positive Symptoms Scores    -.314 23   .144 
- Total PANSS Score   -.493 24   .014* 
 
Correlations based on percentile scores, apart from PANSS symptoms, 0-Back RTs and 0-Back SDs. 
* = significant at p = .05;  ** = significant at p = .01;  
*** = significant after Bonferroni correction for family of 22 comparisons at p = .002.      
P-values of .0005 used in this table to differentiate SPSS output of p = .000 from p = 001 
¬   coefficient from study with 47 PSZ participants by Sui et al., 2015. 
 
General Note:  Cohen (1988), pp. 79-81 proposed the strength of a correlation coefficient is small if  










Table Appx. 4. 3   Descriptive Statistics for Estimated IQ Scores in the TRS group 
 
Mean Estimated IQ in the TRS Group (n=25) 
 Full Scale IQ  Verbal IQ  Performance IQ   
Mean (SD) 101.68 (14.63) 100.24 (17.42) 102.28 (12.75) 
N (Min-Max) 25 (61-124) 25 (55-130) 25 (70-127) 
Mean (SD) of reduced set 100.00 (14.64) 96.00 (14.93) 103.33 (12.79) 
N (Min-Max) 21 (61-124) 21 (55-120) 21 (70-127) 
 
Median Estimated IQ in the TRS Group (n=25) 
 Full Scale IQ  Verbal IQ  Performance IQ   
Median 104.00  99.00  105.00  
N (Interquartile range) 25 (92-111.5) 25 (89.5-110) 25 (94.5-105) 
Median of reduced set 100.00  99.00  105.00  













Table Appx. 4. 4   Correlations involving Crystallised and Fluid Intelligence (VIQ and PIQ) with Performance on the MCCB by TRS 
Participants (full set) 
 WM 
Composite 
Verbal WM Visuospatial 
WM 
TMT BAC SC Verbal 
Fluency 
NAB Mazes HVLT-R BVMT Managing 
Emotions 




       .409*       .593***                    .098     ¬     .017           .154         .246            .276        578***       .449*  ¬   .370 
Sig. (2-
tailed) 
       .047        .002               .648            .937           .473         .247            .191          .003        .028        .075 





      .699***        688***            .475*    ¬   - .312           .454*          .532**         .564**          .392        598***        .001 
Sig. (2-
tailed) 
       .001        .001            .019            .138           .026         .007            .004          .058        .002   ¬   .997 
N           24             24               24              24              24            24               24             24           24           24 
 
¬   indicates Spearman’s rho  
**   Correlation is significant at the 0.01 level. 
*     Correlation is significant at the 0.05 level.   







Table Appx. 4. 5   MCCB Associations with Estimated IQ in the Full and Reduced TRS Set (excluding VIQ>PIQ individuals)  
 






Trail Making Test (TMT-A) Pearson Correlation -.305 -.466* .011 -.256 -.133 -.357 
Sig. (2-tailed) .147 .039 .960 .276 .536 .122 
N 24 20 24 20 24 20 
Symbol Coding (BAC SC) Pearson Correlation .454* .525* .154 .272 .308 .398 
Sig. (2-tailed) .026 .018 .473 .247 .143 .082 
N 24 20 24 20 24 20 
Verbal Learning (HVLT-R) Pearson Correlation .392 .459* .578** .442 .552** .452* 
Sig. (2-tailed) .058 .042 .003 .051 .005 .045 
N 24 20 24 20 24 20 
Spatial Span (WMS-III) Pearson Correlation .475* .451* .098 .311 .298 .395 
Sig. (2-tailed) .019 .046 .648 .182 .158 .085 
N 24 20 24 20 24 20 
Letter Number Sequence (LNS) Pearson Correlation .688*** .651** .593** .782*** .721*** .740*** 
Sig. (2-tailed) .001 .002 .002 .001 .001 .001 
N 24 20 24 20 24 20 
Reasoning and Problem Solving 
(NAB Mazes) 
Pearson Correlation .564** .628** .276 .440 .463* .566** 
Sig. (2-tailed) .004 .003 .191 .052 .023 .009 
N 24 20 24 20 24 20 
*   Correlation is significant at the 0.05 level.                                                                                                                                        Table continued on next page ………. 
** Correlation is significant at the 0.01 level. 
Uncorrected for multiple comparisons.  Colour coded to indicate general pattern:  green indicates possible “trend” significance (p < .09),  






Table Appx. 4. 5 continued:  MCCB Associations with Estimated IQ in the Full and Reduced TRS Set (excluding VIQ>PIQ individuals) 
 






Visual Learning (BVMT-R) Pearson Correlation .598** .585** .449* .418 .586** .511* 
Sig. (2-tailed) .002 .007 .028 .066 .003 .021 
N 24 20 24 20 24 20 
Category Fluency  
(animal names) 
Pearson Correlation .532** .609** .246 .474* .395 .529* 
Sig. (2-tailed) .007 .004 .247 .035 .056 .016 
N 24 20 24 20 24 20 
Social Cognition (MSCEIT 
ME) 
Pearson Correlation .148 .277 .408* .445* .340 .404 
Sig. (2-tailed) .489 .238 .048 .050 .104 .077 




Pearson Correlation .315 .586** .546** .497* .543** .578** 
Sig. (2-tailed) .143 .008 .007 .031 .007 .009 
N 23 19 23 19 23 19 
Speed of Processing 
Composite 
(TMT+BACS+Fluency) 
Pearson Correlation .243 .240 .206 .177 .242 .207 
Sig. (2-tailed) .252 .308 .333 .454 .254 .381 
N 24 20 24 20 24 20 
Working Memory 
Composite (LNS+WMS-III) 
Pearson Correlation .699** .649** .409* .634** .608** .664** 
Sig. (2-tailed) .000 .002 .047 .003 .002 .001 
 N 24 20 24 20 24 20 
*   Correlation is significant at the 0.05 level.  ** Correlation is significant at the 0.01 level. 
Note:  The speed of processing composite was normally distributed, although the component TMT test was positively skewed. 
Uncorrected for multiple comparisons.  Colour coded to indicate general pattern:  green indicates possible “trend” significance (p < .09),  
pale yellow * (significant at p = .05); deep yellow ** (significant at p = .01). 
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Trail Making Test 
(TMT-A) 
Coefficient .263 .362 .024 .114 
Significance  .215 .117 .912 .643 
N 24 20 23 19 
Symbol Coding (BAC 
SC) 
Coefficient -.231 -.289 -.129 -.194 
Significance.  .278 .216 .557 .427 
N 24 20 23 19 
Verbal Learning 
(HVLT-R) 
Coefficient .058 .133 -.135 .001 
Significance  .786 .576 .540 .997 
N 24 20 23 19 
Spatial Span  
(WMS-III) 
Coefficient -.145 -.307 .121 -.044 
Significance  .499 .188 .581 .858 
N 24 20 23 19 
Letter Number 
Sequence (LNS)  
Coefficient -.274 -.295 -.258 -.331 
Significance  .194 .207 .235 .167 
N 24 20 23 19 
Reasoning and Problem 
Solving (NAB Mazes) 
Coefficient -.263 -.282 -.147 -.157 
Significance  .215 .228 .504 .521 
N 24 20 23 19 
Visual Learning 
(BVMT-R) 
Coefficient -.346 -.378 -.296 -.344 
Significance  .097 .101 .171 .150 
N 24 20 23 19 
Category Fluency Coefficient -.077 .103 -.072 .015 
Significance  .721 .664 .744 .950 
N 24 20 23 19 
Social Cognition  
(MSCEIT ME) 
Coefficient -.172 -.152 -.354 -.275 
Significance  .422 .523 .098 .255 
N 24 20 23 19 
Sustained Attention/  
Vigilance (CPT-IP) 
Coefficient -.477* -.311 -.564** -.364 
Significance  .021 .196 .006 .137 
N 23 19 22 18 
Speed of Processing 
(TMT+BACS+Fluency) 
Coefficient .188 .256 .101 .109 
Significance  .379 .275 .648 .657 
N 24 20 23 19 
Working Memory 
(LNS+SpSp) 
Coefficient -.332 -.426 -.122 -.244 
Significance  .114 .061 .580 .314 
N 24 20 23 19 
* Correlation is significant at the 0.05 level. 
** Correlation is significant at the 0.01 level. 







Table Appx. 4. 7 (a) Correlations concerning Time to access Clozapine and 








Spearman's rho Time between 




Sig. (2-tailed) .  
N 25  
Time on clozapine Correlation 
Coefficient 
-.403* 1.000 
Sig. (2-tailed) .046 . 
N 25 25 
PANSS Score Correlation 
Coefficient 
.242 -.319 
Sig. (2-tailed) .244 .120 
N 25 25 
Negative Symptoms Correlation 
Coefficient 
.242 -.293 
Sig. (2-tailed) .255 .165 
N 24 24 
Zero-Back RTs Correlation 
Coefficient 
.145 .039 
Sig. (2-tailed) .488 .852 
N 25 25 
Zero-Back SDs Correlation 
Coefficient 
.192 -.129 
Sig. (2-tailed) .358 .539 
N 25 25 
Percentage of Omission 
Errors (to 36 targets 





Sig. (2-tailed) .746 .697 
N 25 25 
Category Fluency 
(animal names)  
Correlation 
Coefficient 
-.089 ¬    .272 
Sig. (2-tailed) .687 .209 





-.289 ¬   -.115 
Sig. (2-tailed) .191 .610 
N 22 22 
Table continues on next page ...... 
¬   indicates Pearson Product Moment Coefficient 
*   Correlation is significant at the 0.05 level. 
** Correlation is significant at the 0.01 level. 





Table Appx. 4. 7 continued (b)   Correlations concerning Time to access Clozapine and 
Duration of Treatment with Clozapine 
 




Spearman's rho Time between 
diagnosis and clozapine 
Correlation 
Coefficient 
1.000 ¬  -.397* 
Sig. (2-tailed) . .049 
N 25 25 
Time on clozapine Correlation 
Coefficient 
¬  -.397* 1.000 
Sig. (2-tailed) .049 . 
N 25 25 




¬  -.474* ¬   .419* 
Sig. (2-tailed) .022 .047 
N 23 23 




¬  -.438* ¬   .382 
Sig. (2-tailed) .037 .072 





¬  -.521* ¬    .225 
Sig. (2-tailed) .011 .302 
N 23 23 
Full Scale IQ Correlation 
Coefficient 
¬  -.234 ¬   .184 
Sig. (2-tailed) .271   .389 
N 24 24 
Verbal IQ Correlation 
Coefficient 
¬  -.207 ¬   .147 
Sig. (2-tailed) .333 .492 





¬  -.209 ¬   .201 
Sig. (2-tailed) .327 .347 







Sig. (2-tailed) .007 .195 
N 23 23 
 
¬   indicates Pearson Product Moment Coefficient 
*    Correlation is significant at the 0.05 level. 
**  Correlation is significant at the 0.01 level. 
After Bonferroni correction for a family of 30 comparisons adjusted alpha = .002 
 
It is noted there was a significant negative correlation between time to access clozapine and 
the duration of treatment with clozapine, indicating that the longer the wait, the shorter the 
duration of treatment.  None of the other correlations with duration of treatment with 






Comparison of TRS Domain Profiles with other Studies of Schizophrenia (not identified as TRS) 
These were conducted out of curiosity in case of clear disparity with the TRS group, but the main inference is to be beware of perceived 
similarities.  However, the scores for the control group in Johnson et al. (2017) around the 50th percentile in Figure Appx. 4. 1 support the 
standardisation study. 
  




Sui et al., 
2015 
(PSZ=47) 
August et al., 
2012 
(PSZ=117) 






MCCB Overall Composite 31.52 31.3 30 30.7 52.55 
Processing Speed 37.71 35.3 35 34.85 54.38 
Working Memory 42.25 37.1 38 38.67 53.14 
Verbal Learning 39.79 38 38 38.81 51.42 
Visual Learning 37.75 36.6 34              34.1 42.46 
Reasoning and Problem Solving 41.17 46.1 42 42.46 52.95 
Social Cognition 33.29   40.5 38 38.76 51.68 
Attention/Vigilance              40.00 36 38 39.43 52.25 
 PSZ = participants with schizophrenia (not identified as TRS). 
HC = healthy controls. 








Figure Appx. 4. 1   Comparison of MCCB Domain Profiles with other Studies 
 
 
PSZ = participants with schizophrenia.  HC = healthy control participants (the T-score at 50 also represents the 50th percentile of the standardisation study 
by Kern et al., 2011).  













TRS participants (n=24) Sui et al., 2015 (PSZ=47)
August et al., 2012 (PSZ=117) Johnson et al., 2013 (PSZ=99)




Descriptive characterisation of the superior VIQ grouping (VIQ>PIQ), n=4 
Figure Appx. 5. 1   Comparison of Median Scores on the MCCB in the Superior 
VIQ and Reduced TRS Groupings 
 









Trail Making Test (TMT-A)  3.4 0.1 - 19.7 17.0 5.1 - 34 
Symbol Coding (BACS SC)   4.95 2.5 - 17.7 12.0 2.7 - 48 
Verbal Learning (HVLT-R) 29.7 11.3 - 66.6 10.0  5.5 - 25.5 
Spatial Span (WMS-III) 15.95 6.2 - 29.8 29.1  18 - 68.3 
Letter-Number Span (LNS) 25.05 4.7 - 62.3 26.0 16.5 - 41.1 
Reasoning and Problem Solving 
(NAB Mazes) 
       4.75 
 
1.4 - 47.6 13.8 8.5 - 26.3 
Visual learning (BVMT-R) 27.3 0.4 - 85.8  7.4 1.4 - 37 
Category Fluency        52 12.9 - 71 38.0 19.5 - 64.6 
Social Cognition (MSCEIT ME) 20.6 0.8 - 68.7  2.4 0.4 - 4.3 




























Figure Appx. 5. 2    Descriptive data for mean reaction times and standard deviations in the reduced set of TRS participants, 





Note: Full descriptive data available in Table Appx. 5. 3      
0-Back 1- Back 2-Back 3-Back
Controls (n=21) 412.66 458.07 558.35 644.07
TRS (n=22) 540.54 572.32 675.83 735.34
TRS (VIQ>PIQ,
n=4)





















Mean Reaction Times in the N-Back Task
Controls (n=21) TRS (n=22) TRS (VIQ>PIQ, n=4)
0-Back 1- Back 2-Back 3-Back
Controls (n=21) 79.74 112.14 191.21 216.72
TRS (n=22) 153.19 142.69 198.14 227.13
TRS (VIQ>PIQ,
n=4)























Mean Standard Deviations in the N-Back 
Task 
Controls (n=21) TRS (n=22) TRS (VIQ>PIQ, n=4)
355 
 
Figure Appx. 5. 3    Descriptive data for omission errors in the reduced set of 
TRS participants, superior VIQ asymmetry grouping and control group 
 
 
The four VIQ>PIQ participants were distinguished in various ways, as above.  As 
summarised in Table 3. 20, these included a higher  median estimated FIQ standard score (at 
111.5, compared with 103 in the ‘no asymmetry’ group and 99 in the ‘superior PIQ’ group); 
a low level of negative and positive symptoms (although one participant was classified as 
“higher PANSS” on the basis of their scores on the general scale).  Visual inspection of 
median percentile scores on the MCCB tests (adjusted for age and gender) depicted in 
Figure Appx. 5. 1, indicated that their scores were markedly depressed compared to the 
standardisation norm represented at the 50th percentile, with the exception of category 
fluency and scores on the measure of sustained attention/vigilance (CPT-IP) which 
surpassed the reduced set of TRS participants, indeed, passed the 50th percentile.  
Moreover, as can be seen in descriptive data of differences in mean RTs and SDs shown in 
Table Appx. 5.3, the mean of 0-Back SDs was virtually identical to that of the control 
group, and almost half that of the reduced set of 20 TRS participants, thereby, possibly 
providing some convergent support for superior CPT-IP scores in Figure Appx. 5.1.   
 
Reaction times in the 0-Back condition in the VIQ>PIQ group were intermediate - between 
those of the control group and the other TRS participants.  Figure Appx. 5. 2 depicts this 
data for every condition, where it can be seen performance of the VIQ>PIQ grouping 
slowed remarkably at the highest level of cognitive load.  This could be related to the 
increase in omission errors during the 3-Back condition by the VIQ>PIQ group, depicted in 
Figure Appx. 5. 3.  One possible explanation is that these participants were better able to 
detect their errors and tried to adjust their responses following error detection (e.g. a 
0-Back 1-Back 2-Back 3-Back
Control Group, n=21 1.06 0.53 8.46 15.34
Superior VIQ (VIQ>PIQ), n=4 0.00 2.78 5.55 11.11























Control Group, n=21 Superior VIQ (VIQ>PIQ), n=4 Reduced set of TRS, n=22
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speed/accuracy trade-off), thereby exhibiting post error slowing.  This might also indicate a 
relative sparing of the monitoring function and use of prediction error, which is associated 
with the ACC. By contrast, RTs in the rest of the TRS group did not increase as much as 
might have been expected given the higher rate of errors in the 3-Back condition.  Indeed, 
they might have been expected to diverge with the control group which had a lower error 
rate (Figure Appx. 5. 2) by responding more cautiously after making errors.  However, the 
pattern is consistent with the faulty use of prediction error and a failure to notice or, perhaps, 
act on errors by the main TRS group. 
 
Explorations with a reduced dataset (without the VIQ>PIQ grouping) 
Correlational analyses with the reduced data set, n=18-22 
The exclusion of data from participants on the basis they might be outliers in some way, 
increases the risk of losing aspects of data which may be important to interpretation.  
However, in the case of asymmetries between the WASI subscales, 48% exhibited little or 
no asymmetry, while there were two polarised populations exhibiting sizeable asymmetries 
which behaved differently in other respects as summarised above.  In the scatterplots of 
correlations between WASI Asymmetry and CPT-IP scores, also 0-Back SDs (Figure Appx. 
5. 5) the four VIQ>PIQ participants are identifiable on the positive side of the horizontal 
axis forming clusters (loosely in the plot with CPT-IP scores and more closely in the plot for 
0-Back SDs).  Therefore, some of the correlations in Table 3. 17 and  3.18 were repeated 
without the four VIQ>PIQ participants.  These are shown in Appendix 5 (Table Appx. 5. 1 
and Table Appx. 5. 2).  
 
Briefly, the analyses confirmed these participants had had a polarising effect in some 
correlations:  their removal abolished the highly significant correlation between negative 
symptoms and performance on the CPT-IP (rho = -.364, n=18, p = .137), which was not 
unexpected as the four (VIQ>PIQ) participants had a low level of negative symptoms and 
relatively good scores on the CPT-IP.  Also, the correlation between negative symptoms and 
omission errors on the n-Back task was no longer significant (rho = .096, n= 21, p = .096).   
While the correlation between CPT-IP scores and omission errors (previously at trend 
significance, p = 0.063) remained nonsignificant (rho = .308, p = .199, n=19).   However, 
the correlation between negative symptoms and mean standard deviations in the 0-Back 
condition remained highly significant (rho = .750, n=21, p = .001) and would survive 
Bonferroni correction in a family of 24 comparisons.  Further, the correlation of medium 
strength between mean standard deviations in the 0-Back task and CPT-IP scores remained 
significant and was slightly stronger in the reduced set (rho = -.484, n=19, p = .036).  
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Moreover, the correlation between mean standard deviations in the 0-Back condition and the 
percentage of omission errors in the n-Back task was now significant (rho = .473, p = .026, 
n=22).  
 
The survival of the correlation between negative symptoms and mean standard deviations in 
the 0-Back conditions merits further consideration and as previously suggested, the CPT-IP 
might make notable demands upon selective attention as well as sustained attention.  This 
could help to account for the latter’s nonsignificant correlation with negative symptoms.  
However, inspection of the scatterplot for the now non-significant correlation (not depicted) 
revealed the influence of a single outlier where a participant had a high level of negative 
symptoms but also performed well on the CPT-IP task.  Also, they were not typical with 
superior estimated IQ scores (FIQ =121, PIQ = 127, VIQ = 111).  Uniquely for this study, 
the correlation was repeated without the scores of the participant which resulted in a 
significant correlation shown in Figure Appx. 5. 4 below.  Arguably, this restores the 
relationship between negative symptoms and CPT-IP scores observed in the full TRS set 
(Table 3. 17).  Collectively, this set of observations indicates that even in the reduced set, 




Figure Appx. 5. 4   Correlation between Negative Symptoms and Performance 
on the CPT-IP task in a reduced set of TRS participants*  
 
* Correlation excluded 4 participants showing a marked asymmetry between WASI 
subscales (VIQ>PIQ).  This correlation also excluded an outlier exhibiting a high level of 




Correlations with a Reduced Set of TRS Participants (excluding VIQ>PIQ) 
 
This section contains tables of correlations between neuropsychological and behavioural 
variables based on a reduced set of participants after the removal of small subset of 
participants with an asymmetry between WASI subscales that favoured the VIQ.  They also 
had markedly higher estimated FIQ scores than the other participants along with very low 
level of negative symptoms.  As such they might represent a confound in the data.   
 
Table Appx. 5. 1   Inter-correlations between Variables Proposed to be 
Associated with Attention in a reduced set of 20 TRS participants excluding 




















1.000    
Sig. (2-tailed)     .    






    .750** 1.000   
Sig. (2-tailed)     001     .   






¬-.364 -.484* 1.000  
Sig. (2-tailed) .137 .036     .  
N        18 19      19  
 Percentage of 
Omission Errors 
in the N-Back 
task (to 36 targets) 
Correlation 
Coefficient 
      .373 .473*   -.308 1.000 
Sig. (2-tailed)       .096 026    .199     . 
N        21 22 19     22 
 
* Correlation is significant at the 0.05 level. 
** Correlation is significant at the 0.001 level. 
Bonferroni correction for 24 comparisons sets alpha at .002, Tables Appx. 5.1, Appx. 5.2. 
 
¬ Correlation became significant again, once the influence of an outlier was removed from the 
computation, as described in Figure Appx 5. 4 above. 
 









Table Appx. 5. 2   Correlations between Variables associated with Attention and WASI Scores including Subscale Asymmetry in 
a reduced set of TRS participants (excluding those with superior VIQ scores relative to PIQ (VIQ>PIQ) 
Spearman’s rho  
(except where ¬ indicates Pearson).  Negative 
Symptoms 
Standard 






















Full-scale IQ Correlation Coefficient -.385 -.537* .578**¬ 1.000    
Sig. (2-tailed) .093 .012 .009 .    
N 20 21 19 25    
Verbal IQ Correlation Coefficient -.375 -.531* .497*¬ .964**¬ 1.000   
Sig. (2-tailed) .103 .013 .031 .000 .   
N 20 21 19 21 25   
Performance 
IQ subscale 
Correlation Coefficient -.294 -.464* .586**¬ .945**¬ .830**¬ 1.000  
Sig. (2-tailed) .208 .034 .008 .001 .001 .  
N 20 21 19 21 21 25  
IQ 
Asymmetry 
Correlation Coefficient -.349 -.384 -.085 .187 .374 -.135 1.000 
Sig. (2-tailed) .132 .085 .730 .417 .095 .559 . 
N 20 21 19 21 21 21 25 
 
* Correlation is significant at the 0.05 level.  ** Correlation is significant at the 0.01 level.  
*** would survive Bonferroni correction with an alpha = .0021 for 24 comparisons (in Tables Appx. 5.1, Appx. 5.2). 
¬ indicates use of the Pearson product moment correlation 
 






Figure Appx. 5. 5   Correlations involving Asymmetry between WASI subscales and Proposed Markers of Attention 
a)  Correlation between CPT-IP scores and IQ Asymmetry  
 
b) Correlation between 0-Back SDs and IQ Asymmetry 
 
Horizontal line indicates mean CPT-IP score at 2.34.  Horizontal line indicates median of  0-Back SDs scores at 101.21ms. 
rho = -.276, n=23, p = .237 rho = -.450, n=25, p = .024 
 
Note:  in both of these plots the four data points on the right side represent individuals in the superior VIQ group. 
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Table Appx. 5. 3   Descriptive Statistics for Mean Reaction Times and Standard 
Deviations at Different Levels of Cognitive Load in the Control Group, 
Superior VIQ (VIQ>PIQ) Group, and the Reduced Set of TRS Participants 
Control 




ZeroBackRTs 21 297.78 630.11 412.66 83.04 
OneBackRTs 21 340.22 638.22 458.07 89.93 
TwoBackRTs 21 402.56 760.86 558.35 105.65 
ThreeBackRTs 21 361.63 1067.83 644.07 159.10 
Standard Deviations 
ZeroBackSDs 21 22.20 455.44 79.74 91.20 
OneBackSDs 21 22.23 386.19 112.14 87.69 
TwoBackSDs 21 85.66 384.63 191.21 88.67 








ZeroBackRTs 4 371.78 525.00 469.66 68.32 
OneBackRTs 4 430.11 570.67 518.58 65.77 
TwoBackRTs 4 461.78 668.22 561.98 84.38 
ThreeBackRTs 4 673.86 845.33 779.62 74.32 
Standard Deviations 
ZeroBackSDs 4 48.33 94.51 78.71 21.78 
OneBackSDs 4 84.65 229.74 160.66 62.12 
TwoBackSDs 4 88.54 201.27 157.31 54.52 
ThreeBackSDs 4 117.46 374.54 265.24 108.78 
 
Reduced set of 
TRS 




ZeroBackRTs 22 370.56 851.38 540.54 132.73 
OneBackRTs 22 372.78 912.00 572.32 137.90 
TwoBackRTs 22 378.67 1204.63 675.83 203.35 
ThreeBackRTs 21 332 1180 735.34 215.20 
Standard Deviations 
ZeroBackSDs 22 32.38 411.82 153.19 111.20 
OneBackSDs 22 27.04 274.34 142.68 64.16 
TwoBackSDs 22 56.10 403.59 198.14 98.15 






Table Appx. 5. 4   Associations between MCCB performance and Estimated IQ in the Full and Reduced TRS Sets 
 






Trail Making Test (TMT-A) Pearson Correlation -.305 -.466* .011 -.256 -.133 -.357 
Sig. (2-tailed) .147 .039 .960 .276 .536 .122 
N 24 20 24 20 24 20 
Symbol Coding (BAC SC) Pearson Correlation .454* .525* .154 .272 .308 .398 
Sig. (2-tailed) .026 .018 .473 .247 .143 .082 
N 24 20 24 20 24 20 
Verbal Learning (HVLT-R) Pearson Correlation .392 .459* .578*** .442 .552*** .452* 
Sig. (2-tailed) .058 .042 .003 .051 .005 .045 
N 24 20 24 20 24 20 
Spatial Span (WMS-III) Pearson Correlation .475* .451* .098 .311 .298 .395 
Sig. (2-tailed) .019 .046 .648 .182 .158 .085 
N 24 20 24 20 24 20 
Letter Number Sequence (LNS) Pearson Correlation .688*** .651*** .593*** .782*** .721*** .740*** 
Sig. (2-tailed) .001 .002 .002 .001 .001 .001 
N 24 20 24 20 24 20 
Reasoning and Problem Solving 
(NAB Mazes) 
Pearson Correlation .564*** .628*** .276 .440 .463* .566*** 
Sig. (2-tailed) .004 .003 .191 .052 .023 .009 
N 24 20 24 20 24 20 
Visual Learning (BVMT-R) Pearson Correlation .598*** .585*** .449* .418 .586*** .511* 
Sig. (2-tailed) .002 .007 .028 .066 .003 .021 
N 24 20 24 20 24 20 
NB “Reduced TRS” set excluded the 4 VIQ>PIQ participants.     
Colour coded to indicate general pattern:  green indicates possible “trend” significance (p < .09), pale yellow * (significant at p = .05);  









Table Appx. 5. 4 continued:   Associations between MCCB performance and Estimated IQ in the Full and Reduced TRS Sets 
  






Category Fluency  
(animal names) 
Pearson Correlation .532** .609** .246 .474* .395 .529* 
Sig. (2-tailed) .007 .004 .247 .035 .056 .016 
N 24 20 24 20 24 20 
Social Cognition (MSCEIT ME) Pearson Correlation .148 .277 .408* .445* .340 .404 
Sig. (2-tailed) .489 .238 .048 .050 .104 .077 
N 24 20 24 20 24 20 
Sustained Attention/ Vigilance 
(CPT-IP) 
Pearson Correlation .315 .586** .546** .497* .543** .578** 
Sig. (2-tailed) .143 .008 .007 .031 .007 .009 
N 23 19 23 19 23 19 
Speed of Processing Composite 
(TMT+BACS+Fluency) 
Pearson Correlation .243 .240 .206 .177 .242 .207 
Sig. (2-tailed) .252 .308 .333 .454 .254 .381 




Pearson Correlation .699** .649** .409* .634** .608** .664** 
Sig. (2-tailed) .000 .002 .047 .003 .002 .001 





Figure Appx. 5. 6   Positive Correlation between Verbal learning (HVLT-R) and the 
Verbal IQ Subscale with participants grouped according to IQ asymmetry 
 
n=4 (16%) superior scores on the verbal IQ subscale;  n=9 (36%) superior scores on the performance 
IQ subscales; n=12 (48%) no asymmetry between the subscales 
 
Note:  Outlier (bottom left) may be distorting line of best fit for PIQ>VIQ grouping.  
 
The prediction that VIQ might correlate with verbal learning (HVLT-R), was also supported 
by a strong positive correlation: r = .578, n=24, p = .003.  Notwithstanding this, the 
correlation may have been undermined by the lack of correlation in the “no asymmetry 
grouping” with no asymmetry between IQ subscales, (n=12) where 5 individuals had good 







Correlational Analyses of the Haemodynamic Response at different levels of 
Cognitive Load with Attention (SDs in the 0-Back condition) in the TRS Group 
-  positive correlations 
Table Appx. 6. 1    Brain areas showing significant positive correlation between SDs in 
the 0-Back condition and the haemodynamic response at different levels of cognitive 
load in the TRS group 
 




Cluster   p-Value  
size  
(mm3) 
 Talairach  
co-ordinates*  
   x     y     z 
1-BACK        
Cingulate Gyrus BA 31 L 133 0.00348 -11 -37 40 
2-BACK        
Non-significant.        
3-BACK        
Non-significant.        
 
Voxel-wise p-value = <0.05, cluster-wise p= 0.01. 
Note: Age and reaction times in the baseline condition of the N-Back task were covariates.  
 
 
Figure Appx. 6. 1  Statistical Map of a significant positive correlation between SDs in 
the 0-Back condition and the haemodynamic response in the left Cingulate Gyrus (BA 












Figure Appx. 6. 2  Positive correlation between and SDs in the 0-Back condition and 
the haemodynamic response in the left Cingulate Gyrus (BA 31) during the 1-Back 
condition in the TRS group 
 
 
Note:     Vertical Line indicates the median value of baseline standard deviations at 101 ms. 




-  negative correlations 
Table  Appx 6. 2   Brain areas showing significant negative correlations between SDs 
in the 0-Back condition and the haemodynamic response at different levels of cognitive 
load in the TRS group 
 




Cluster   p-Value  
size  
(mm3) 
 Talairach  
co-ordinates*  
   x     y     z 
1-BACK        
Claustrum   - L 167 0.00133 -25   4 17 
2-BACK        
Precuneus BA 31 R 143 0.00240  25 -67 20 
3-BACK        
Medial Frontal Gyrus BA 10 R 117 0.00266  14  48 10 
Precuneus BA 7 R 111 0.00324  25 -67 33 
 
Voxel-wise p-value = <0.05, cluster-wise p= 0.01. 
Note: Age and reaction times in the baseline condition of the N-Back task were covariates. 
  
 
Figure Appx. 6. 3  Statistical Map showing a significant negative correlation between 
SDs in the 0-Back condition and the haemodynamic response in the left Claustrum 
during the 1-Back condition in the TRS Group 
1-BACK 
 








Figure Appx. 6. 4  Negative correlation between SDs in the 0-Back condition and the 




Note:     Vertical Line indicates the median value of baseline standard deviations at 101 ms. 





Figure Appx. 6. 5 Statistical Map showing a significant negative correlation between 
SDs in the 0-Back condition and the haemodynamic response in the right Precuneus 




Negative correlation between SDs in the 0-Back condition and the right Precuneus (BA 31) 
 
 
Figure Appx. 6. 6   Negative correlation between SDs in the 0-Back condition and the 
haemodynamic response in the right Precuneus (BA 31) during the 2-Back condition in 
the TRS group 
 
Note:   Vertical Line indicates the median value of baseline standard deviations at 101 ms. 




Figure Appx. 6. 7  Statistical Map showing significant negative correlations between 
SDs in the 0-Back condition and the haemodynamic response in the right Medial 




Negative correlation between SDs in the 0-Back condition and the right Medial Frontal 
Gyrus (BA 10) and right Precuneus (BA 7). 
 
 
Figure Appx. 6. 8  Negative correlation between the haemodynamic response in the 
right Medial Frontal Gyrus (BA 10) in the 3-Back condition and SDs in the 0-Back in 
the TRS group (3-Back). 
 
Note:   Vertical Line indicates the median value of baseline standard deviations at 101 ms. 
Lines of best fit shown for lower and higher PANSS subgroups, n = 14, n = 12.  
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Figure Appx. 6. 9  Negative correlation between SDs in the 0-Back condition and the 
haemodynamic response in the right Precuneus (BA 7) during the 3-Back condition in 
the TRS group 
 
 
Notes:  Vertical line above indicates the median value of the baseline standard deviations at 101ms. 




Correlational Analyses of the Haemodynamic Response at different levels of 
Cognitive Load with Attention (SDs in the 0-Back condition) in the Control Group 
 
-  positive correlations 
Table Appx. 6. 3   Brain areas showing significant positive correlations between SDs in 
the 0-Back condition and the haemodynamic response and at different levels of 
cognitive load in the Control group 
Anatomical Location   Brodmann  
  Area 
Hemis 
-phere 
Cluster   p-Value  
size  
(mm3) 
 Talairach  
co-ordinates*  
   x     y     z 
1-BACK        
Superior Temporal Gyrus BA 38 R 109 0.00269  61 11 -20 
2-BACK        
Non-significant        
3-BACK        
Non-significant        
 
Voxel-wise p-value = <0.05, cluster-wise p= 0.01. 
Note: Age and reaction times in the baseline condition of the N-Back task were covariates. 
  
 
Figure Appx. 6. 10   Statistical Map of a positive correlation between SDs in the 0-Back 
condition and the haemodynamic response in the right Superior Temporal Gyrus (BA 





Positive correlation between SDs in the 0-Back condition and the right Superior Temporal 












Figure Appx. 6. 11  Positive correlation between SDs in the 0-Back condition and the 
haemodynamic response in the right Superior Temporal Gyrus (BA 38) during the 1-
Back condition in the Control group 
 
 
Note:  Vertical line indicates median of SDs in the baseline condition of the N-Back task in the 





-  negative correlations 
Table Appx. 6. 4  Brain areas showing significant negative correlation between SDs in 
the 0-Back condition and the haemodynamic response at different levels of cognitive 
load in the Control group 




Cluster   p-Value  
size  
(mm3) 
 Talairach  
co-ordinates*  
   x     y     z 
1-BACK        
Transverse Temporal Gyrus BA 41 L 151 0.00193 -47 -26 10 
2-BACK        
Precuneus BA 7 R 97 0.00319  25 -59 30 
3-BACK        
Non-significant.        
Voxel-wise p-value = <0.05, cluster-wise p= 0.01. 
Note: Age and reaction times in the baseline condition of the N-Back task were covariates. 
 
 
Figure Appx. 6. 12   Statistical Map showing significant negative correlation between 
SDs in the 0-Back condition and the haemodynamic response in the left Transverse 
Temporal Gyrus (BA 41) during the 1-Back condition in the Control Group 
1-BACK 
 
Negative correlation between SDs in the 0-Back condition and the left Transverse Temporal 
Gyrus (BA 41). 
 
 
Figure Appx. 6. 13   Statistical Map showing a significant negative correlation between 
SDs in the 0-Back condition and the haemodynamic response in the right Precuneus 
(BA7) during the 2-Back condition in the Control group 
2-BACK 
 
Negative correlation between SDs in the 0-Back condition and the haemodynamic response 









Figure Appx. 6. 14  Negative correlations between SDs in the 0-Back condition and the haemodynamic response in the left 
Transverse Temporal Gyrus during the 1-Back condition and the right Precuneus during the 2-Back in the Control Group 







Notes:  Vertical line = median of SDs in the baseline condition of the N-Back task at 54.03ms, n=21.    
The graphs are based on n=20 after an outlier was removed for depiction purposes. 
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Correlational Analyses of the Haemodynamic Response at different levels of 
Cognitive Load with Estimated Full-Scale IQ and Subscales in the TRS Group 
-  positive correlations 
Table Appx. 6. 5  Brain areas showing significant positive correlation between FIQ 
scores and the haemodynamic response at different levels of cognitive load in the TRS 
group 




Cluster   p-Value  
size  
(mm3) 
 Talairach  
co-ordinates*  
   x     y     z 
1-BACK        
Insula BA 13 L    88 0.00377 -33 15 17 
Insula BA 13 R  210 0.00068  43   7 10 
2-BACK        
Non-significant.        
3-BACK        
Non-significant.        
Correlation with scores on the Verbal IQ Subscale in the 1-Back Condition: 
Inferior Frontal Gyrus BA 13 L 196 0.00102 -43 26 10 
 
Voxel-wise p-value = <0.05, cluster-wise p= 0.01. 
Note: Age and mean reaction times in the baseline N-Back condition were covariates. 
  
Figure Appx. 6. 15  Statistical map showing significant positive correlation between 
FIQ scores and the haemodynamic response in the Insula bilaterally during the 1-Back 
condition in TRS Group, also between VIQ and the left Inferior Frontal Gyrus (BA 13) 
1-BACK 
 




A positive correlation was also observed between Verbal IQ subscale scores and the 








Figure Appx. 6. 16  Positive Correlations between FIQ scores and the haemodynamic response in the Insula (BA 13) bilaterally 
during the 1-Back Condition 









Figure Appx. 6. 17  Positive Correlation between Verbal IQ subscale scores and the 












-  negative correlations 
Table Appx. 6. 6   Brain areas showing significant negative correlations between FIQ 
scores and the haemodynamic response at different levels of cognitive load in the TRS 
group 




Cluster   p-Value  
size  
(mm3) 
 Talairach  
co-ordinates*  
   x     y     z 
1-BACK 
Non-significant        
2-BACK 
Non-significant        
3-BACK 
Anterior Cingulate BA 32 L 129 0.00294 -18 37 10 
Anterior Cingulate  BA 32 R 136 0.00348   8 29 22 
Inferior Frontal Gyrus BA 44 L 171 0.00163 -54 11 17 
 
Voxel-wise p-value = <0.05, cluster-wise p= 0.01. 
Note: Age and reaction times in the baseline condition of the N-Back task were covariates. 
 
 
Figure Appx. 6. 18  Statistical Map showing significant negative correlations between 
FIQ and the haemodynamic response in the Anterior Cingulate (BA 32) bilaterally and 
in the left Inferior Frontal Gyrus (BA44) during the 3-Back condition 
3-BACK 
 
Negative correlations between FIQ scores in the TRS Group and the haemodynamic 
response in the Anterior Cingulate Gyrus, BA 32 bilaterally and the left Inferior Frontal 









Figure Appx. 6. 19  Negative correlations between FIQ scores and the haemodynamic response in the Anterior Cingulate (BA 32) 
bilaterally and the 3-Back Condition 






Notes:  Vertical line = median of estimated Full-scale IQ at 104 in the TRS group, n = 25.  Lines of best fit show lower and higher PANSS subgroups, n=13, n=12. 
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Figure Appx. 6. 20  Negative correlation between FIQ scores and the haemodynamic 





Notes:  Vertical line = median of estimated Full-scale IQ at 104 in the TRS group, n=25.   





Sample Participant Information Sheet and Consent Forms 
 








We are inviting you to take part in a research study.  Before you decide it is important 
for you to understand why the research is being done and what it will involve.  Please 
take time to read the following information carefully and talk to others about the study 
if you wish.  Thank you for considering taking part. 
 
• Part 1 outlines the purpose of this study and your role in it if you take part.   
• Part 2 gives you more detailed information about the conduct of the study.  
Please ask us if there is anything that is not clear or if you would like more 
information.  Take time to decide whether or not you wish to take part. 
 
•Purpose of the Study: 
The purpose of this research is to investigate the way the medication you are taking 
works.  This study will look specifically at which brain areas are involved in certain 
memory tasks. It will involve a structural magnetic resonance imaging (sMRI) scan 
and two functional MRI brain scans (fMRI).   
 
•Why have I been chosen?: 
Because you are attending an Outpatient Clinic. 
 
•Do I have to take part?:’ 
No.  It is up to you to decide whether or not to take part.  If you do, you will be given this 
information sheet to keep and be asked to sign a consent form. You will still be free to 
withdraw from the study at any time and without giving a reason. 
 
•What will happen if I take part? 
You will be invited to spend about half a day at the Institute of Psychiatry where you will be 
met in the main reception and taken to a more private area where you will be given a brief 
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overview of the schedule of activities and asked to sign a consent form (remembering, of 
course, that you can withdraw at any time without giving a reason).  You will also be asked 
some general background questions, for example, about your age and current occupation.  
 
During your time at the Institute you will be asked to complete a series of short 
psychological tasks. Some of these tasks with be presented to you by a researcher who will 
ask you for instance to copy geometric patterns using small building blocks, to find 
similarities between words, and to give the meaning of individual words as if you were a 
dictionary, for example, “what is a crocodile?”.  Some other tasks will involve pressing 
buttons or clicking on a computer screen with a cursor, for example, to indicate the location 
of a dot that was displayed previously. 
 
Before accompanying you to the MRI scanner the researcher will give you the opportunity 
to practice on a couple of tasks which we will then ask you to perform while having a 
functional brain scan (which will take about one hour).  These tasks are computer-based and 
involve memory and attention.  For example, you will be asked to indicate if you recognize 
a letter on a computer screen as having occurred shortly beforehand; also to tap out patterns 
using three fingers.  You will have plenty of practice at these tasks before you go into the 
scanner. The scanner consists of a large magnet which does not emit radiation and you will 
not be asked to take any drugs. During the scan we will make an image of the structure of 
your brain, as well as collecting lots of images of your brain as you perform the tasks 
described in this paragraph. A structural MRI scan lasting 7 minutes will be also collected, 
during which we’ll ask you to rest and even sleep if you feel like. 
 
Lastly, you’ll be asked to give a blood sample in order to collect genetic information which 
we will investigate in relation to your brain scan. This will help us to investigate whether 
certain genetic variations are associated with the way the brain works and responds to the 
antipsychotic medication you are taking.  
 
•Expenses and payments:  
Each participant will receive £30 for taking part in the study. We’ll also cover your travel 
expenses if necessary.  
 
•What do I have to do?: 
You will have the opportunity to ask the radiographer any questions you may have before 
you enter the scanner. When you are in the scanner you will be asked to keep as still as 
possible. Some people find the scanner noisy or uncomfortable as you go into a small space. 
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As the scanner is a magnet it may attract certain metallic objects. Therefore you must not 
have a scan if you have received metal injuries to the eye, had metallic objects (including 
clips) inserted in your body during an operation, or you have received a shotgun injury, or 
have a heart pacemaker. During your scan we can talk to you and you can talk to us and you 
can be brought out of the scanner if you wish. While you are in the scanner the psychologist 
conducting the study will be on the other side of the screen making sure that everything runs 
smoothly. You can ask her any question that you may have at any time. 
 
•What is the device or procedure that is being tested?: 
The scanner consists of a large magnet, it does not emit radiation and you will not be asked 
to take any drugs. Use of that device will allow us to monitor the activity in your brain during 
performance of the mental operations (tasks) mentioned above. 
 
•What are the alternatives for diagnosis and treatment?: 
We do not expect to find anything of concern in your scan. However, if we do we will 
contact your GP with your permission.  
 
•What are the side effects of any treatment received when taking part?: 
Magnetic Resonance imaging (MRI) is an absolutely safe method which does not contain any 
radiation or cause any side effect. 
 
•What are the other possible disadvantages and risks of taking part?: 
You might experience some discomfort in the scanner as you will have to remain still in a 
small enclosed space and periodically it will be very noisy. You can leave the scanner at any 
time if you cannot tolerate it. 
 
•What are the possible benefits of taking part?: 
By taking part in the study you may help in the future other client users with problems similar 
to those you are a experiencing. We are hoping this investigation will help us to predict which 
individuals with schizophrenia may not benefit from certain drugs and enable them to access 
more suitable treatment.   
 
•What happens when the research study stops?: 






•What if there is a problem?: 
Any complaint about the way you have been dealt with during the study or any possible harm 
you might suffer will be addressed. Contact number for complaints: Dr Chiara Nosarti, 0207 
848 0133. 
 
•Will my taking part in the study be kept confidential?  
Yes. All the information about your participation in this study will be kept confidential 
(Details included in part 2). 
 
•Contact Details: 
For further information about the study please do not hesitate to contact Mrs Hazel Sparey on 
07850 985588 or  0207 848 0516; or Tracey Collier on 0207 848 0029.    If you would like to 
receive independent information or advice about your rights as research subject or about being 
involved in this particular research study you could also contact the Patients Advice and 
Liaison Service (PALS) at SLaM on 0800 7312864. 
 
This completes Part 1 of the Information Sheet. If the information in Part 1 has 
interested you and you are considering participation, please continue to read the 




•What will happen if I don’t want to carry on with the study?: 
As it has been already mentioned you can withdraw from the study at any time. If you 
do so we will use the data collected up until your withdrawal. 
 
•What if there is a problem?: 
If you have a concern about any aspect of this study, you should ask to speak with the 
researchers who will do their best to answer your questions (Contact number is given 
in part 1). If you remain unhappy and wish to complain formally, you can do this 
through the Institute of Psychiatry.  King’s College London, indemnity arrangements 
will apply.  
 
•Will my taking part in the study be kept confidential?: 
Information about the participants will be held in confidence and numerical codes will 






•Will genetic tests be done?: 
A blood sample will be drawn by trained staff for genetic testing.  This will enable the 
influence of hereditary traits in psychotic conditions to be assessed and hence 
potentially improve treatment. 
 
•Are there any other blood tests? 
Not directly, but Researchers will need access to periodic reports on plasma levels 
related to drug treatment regimes and screening for other substances which could have 
an influence on how patients respond to their drug therapy. 
 
•What will happen to the results of the study?: 
The results of the research will be published e.g. Peer reviewed scientific journals, 
internal reports, and conference presentations. You will not be identified in any 
report/publication. 
 
•Who is organising and funding the research? 
The National Institute for Health Research Biomedical Research Centre for Mental 
Health. 
 
•Who has reviewed this study?: 
This study was given a favourable ethical opinion by Wandsworth Research Ethics 
Committee.  
 
Each participant will be given a copy of the information sheet and a signed consent 
form to keep. 
 








































Participants did not see this list of “pro forma” questions.  Some questions were not 
routinely asked, for example, participants were not expected to know dates relating to illness 
onset or medication details which, in any case, would be checked.  A question about 




Safety Questionnaire for MRI 
 
 
